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Abstract 
 
Streptococcus pneumoniae has a highly adaptable genome due at least in part to its 
natural transformability and its ability to recombine with other pneumococci and 
related species.  The emergence of antibiotic resistant clones of S. pneumoniae 
presents an opportunity to investigate how the genome has altered, spread and 
diversified within a defined time frame.  We postulated that the genomes of epidemic, 
resistant isolates of S. pneumoniae would carry evidence of the genetic mechanisms 
that have shaped their evolution. We investigated this using eight to fifteen isolates 
from each of three S. pneumoniae clones; two multiply resistant clones Spain 9V-3 and 
Taiwan 19F-14 and one clone that has not acquired multiple resistance, England 14-9.   
 
Genome diversity in each of the three clones was investigated using pulsed field gel 
electrophoresis and multilocus sequence typing. Polymorphisms identified as a result 
of changes in the size of restriction fragments were found to be caused mainly by 
genomic rearrangements rather than restriction site mutations.  Several 
deletion/insertion events in addition to one large inversion were identified.  A number 
of polymorphisms correlated with previously known variable regions.  Database 
analysis of multilocus sequence data from all three clones showed that recombination 
leads to sequence divergence more frequently than de novo mutation, but was 
significantly less common in England 14-9. The lower frequency of recombination 
events in England14-9 was in line with a transformation deficiency observed in vitro, 
and may explain the rare occurrence of penicillin resistance in this clone. Analysis of 
competence and recombination gene sequences available from databases revealed a 
potential cause of transformation deficiency: a four amino acid deletion in CelA, 
involved in DNA uptake and transport.  
 
Recombination can act as a DNA repair mechanism, but the significantly low 
occurrence in England14-9 suggests other mechanisms act to repair severe damage. 
Although S. pneumoniae does not have a typical SOS response it does possess DNA 
polymerase IV, encoded by dinB, which is predicted to be involved in error-prone 
DNA replication and repair of double strand breaks.  DinB knockout mutants were 
created to investigate the effect in isogenic backgrounds.  DinB mutants presented a 
lower frequency of spontaneous rifampicin resistance mutations than wild type 
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isolates.  DinB mutants were more sensitive to killing by three different DNA 
damaging agents as well as by hydrogen peroxide.  Isolates of the natural dinB mutant 
clone Spain 9V-3 were also shown to be more sensitive to DNA damaging agents than  
clones England 14-9 and Taiwan 19F-14.   
 
It is concluded that genetic differences between the three clones investigated do 
influence their patterns of evolution, and may account for differences in their 
antibiotic resistance profiles. Furthermore DNA polymerase IV does function as an 
error prone repair polymerase capable of protecting pneumococci from DNA damage 
despite the lack of a coordinated SOS response in pneumococci, and the absence of 
the gene in one successful multi-resistant clone. 
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1.1 Streptococcus pneumoniae 
 
S. pneumoniae is a Gram-positive, catalase-negative, facultative anaerobic bacteria 
which normally presents in clusters of diplococci.  It is a member of the 
Lactobacillaceae family which includes the Enterococcus, Lactococcus and 
Streptococcus species.  
 
S. pneumoniae has been vital in our understanding of bacterial resistance to drugs and 
natural transformation as a way of exchanging genetic material.  
 
1.1.1 Genus Streptococcus  
The genus Streptococcus is a relatively large genus and contains a number of 
clinically significant microorganisms that are responsible for a wide variety of 
infections.  Genus Streptococcus can be divided taxonomically into six major clusters 
based on 16s RNA gene sequence analysis (Kawamura et al., 1995).  The six major 
clusters are shown in figure 1.1.1.  Identification and classification is often associated 
with their haemolytic properties on blood agar.  Three different reactions may occur 
all of which are based on the ability of haemolysis to break down the red blood cells 
in blood agar; α- haemolysis (partial haemolysis), β-haemolysis (complete 
haemolysis) and γ-haemolysis (no haemolysis).  
 
Streptococcus pneumoniae is categorised under the mitis group (Hardie and Whiley, 
1997). This group is generally considered commensal, however S. pneumoniae is a 
major pathogen.  It is responsible annually for over 1 million infant deaths (Bogaert et 
al., 2004a) and is likely to be much higher in individuals that are immunocomprimised 
and the elderly  (van der Poll and Opal, 2009). The case-fatality rate of pneumococcal 
meningitis is high at 20% and can even reach 50% in undeveloped countries (Bogaert 
et al., 2000).  Furthermore, individuals that survive face the possibility of long term 
effects such as neurological deficiencies, loss of hearing, neuropsychological 
impairment and seizures (http://www.meningitis.org).                                                                                                                                                                                                                                                              
 
Although S. pneumoniae is clinically very different from other members of the mitis 
group, 16S rRNA sequence homology revealed that two members, S. mitis and S. 
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oralis, shared 99% 16S rRNA sequence homology to S. pneumoniae.  Mitis group 
members in general display 40 – 60% sequence similarity in addition to presenting 
over 90% homology with 16S rRNA sequences (Kawamura et al., 1995).  
Categorising by 16S rRNA alone is therefore an insufficient method for species 
discrimination (Itoh et al., 2006).   
 
Figure 1.1.1: Genus Streptococcus. S. pneumoniae is classed under the Streptococcus 
mitis group (underlined in red). Adapted from Kawamura et al (Kawamura et al., 
1995). 
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1.1.2 Carriage and Disease 
The paradoxal nature of S. pneumoniae allows it to exist as both a commensal and 
pathogenic organism.  Although an important pathogen, its principal ecological niche 
is in the upper respiratory tract.  Here it colonises the mucosal linings of the 
nasopharynx (Austrian, 1986).  Colonisation can occur simultaneously with multiple 
strains being carried for weeks to months on average before clearance (Weiser, 2009).  
The rates of carriage are dependent on a number of factors such as age, respiratory 
illness, siblings, geographic location and genetic background and are found to be the 
highest within the first two years of life.  Although often carried asymptomatically, S. 
pneumoniae are opportunistic pathogens and therefore have the potential to colonise 
and cause infection at a number of sites (table 1.1.2). It is thought that colonisation is 
the initial stage of disease where inhabitant pneumococci gain entry to different areas 
of the body (Weiser, 2009).  
 
Table 1.1.2:  Infections caused by S. pneumoniae.  
 
Pneumococcal disease progresses as a result of disruption to cells that line the 
respiratory tract.  This causes congestion of various components including the nose, 
nasopharynx, eustachian tube and middle ear. Otitis media can subsequently result 
from accumulation of pathogenic bacteria in the middle ear.  Pneumococcal 
pneumonia occurs when bacteria invade and persist in the lungs.  Failure to control 
the infection may lead to further complications where pneumococci can extend from 
the lungs to the hilar lymph nodes, enter the circulatory system and cause 
bacteraemia.   If pneumococci are able to cross the blood brain barrier then meningitis 
may arise (reviewed in Bogaert et al (Bogaert et al., 2004a)). 
 
Infection caused Site of Infection 
Conjunctivitis Eye 
Otitis media Inner ear 
Sinusitis Sinuses 
Pneumonia Lungs 
Bacteraemia Blood 
Meningitis CNS/meninges 
Chapter 1 
 
 27 
Various factors are known to predispose individuals to pneumococcal infection 
including damage to the spleen, alcoholism, age, connective tissue disease, multiple 
myeloma, diabetes mellitus, steroid and intravenous drug use (Taylor and Sanders, 
1999). Immunocomprimised individuals such as those with HIV infections are also 
predisposed to pneumococcal disease (Janoff et al., 1992).  Murine studies have also 
identified viral infection as a predisposing factor; those infected with the influenza 
virus had an increased mortality rate when compared to non-infected mice (van der 
Sluijs et al., 2004).  Seasonal fluctuation is another factor observed to affect the 
frequency of pneumococcal infection with increased prevalence in winter months.  
Viral infection, mainly influenza and respiratory infection, also tend to correlate with 
a higher incidence of pneumococcal disease (Talbot et al., 2005). 
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1.1.3 Pneumococcal energy metabolism 
S. pneumoniae, like all members of the genus Streptococcus are homofermenters and 
produce lactic acid from sugars (Hardie and Whiley, 1997).  Despite their frequent 
presence in oxygen rich environments, they lack the proteins necessary for aerobic 
respiration and protection from oxidative damage. 
 
Pneumococci use various carbohydrates as a source of energy, including sugars, 
which are catabolised via the glycolysis pathway and penitols which are catabolised 
via the pentose phosphate pathway (Tettelin et al., 2001).  Pyruvate and NADH are 
formed as a result and the NADH is reoxidised (Neijssel et al., 1997).  This can occur 
via three different mechanisms. The conversion of pyruvate to lactate is dependent on 
fructose concentration and is catalysed by lactate dehydrogenase  (Wolin, 1964).  
Under strictly anaerobic conditions, formate and acetyl-CoA are produced as a result 
of another pathway catalysed by pyruvate formate lyase.  The presence of oxygen 
shifts carbon metabolism from homolactic to mixed acid fermentation, resulting in 
increased ATP production (Spellerberg et al., 1996).  Some pyruvate is still converted 
to lactate, however, NADH oxidase (nox) reduces O2 to H2O which alleviates some of 
the damaging effects of oxidative stress (Echenique and Trombe, 2001, Auzat et al., 
1999).  Pyruvate oxidase facilitates the reduction of O2 which thus forms H2O2 
(Spellerberg et al., 1996).  The Fenton reaction can then lead to the reduction of H2O2 
to reactive hydroxyl radicals. 
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1.1.4 Pneumococcal virulence factors 
A great deal of research has been conducted over the decades to identify 
pneumococcal virulence factors that facilitate disease, a variety of which have been 
determined.  Pneumococcal virulence factors include the polysaccharide capsule, cell-
surface proteins and extracellular toxins.  Table 1.1.4 presents a summary of 
pneumococcal virulence factors, most of which were identified due to reduced 
virulence in murine knock out models. The polysaccharide capsule and hydrogen 
peroxide are discussed in more detail as they are of particular interest to this project.  
 
Also interesting to this project are results obtained from comparative genomic 
analysis, which showed that numerous pneumococcal virulence factors are found 
among closely related oral streptococci (Kilian et al., 2008).  It has now been 
suggested that S. pneumoniae once evolved from an ancestral S. mitis progenitor 
(Denapaite et al., 2010).  Although a number of genes are shared between the two 
closely related species, many genes are exclusive to the pneumococcal genome.  
Comparative genomic analysis studies have also revealed that pneumococcal isolates 
thought to be highly related can present differences in genomic regions of virulence 
(Silva et al., 2006). 
 
1.1.4.1 The polysaccharide capsule 
The polysaccharide capsule is one of the most important pneumococcal virulence 
factors and is essential in evasion of the host immune response. All clinical isolates 
express a capsule, those that are avirulent however are unencapsulated.  There are 
currently 93 different capsule types, referred to as serotypes (Park et al., 2007, 
Bratcher et al., 2010). The capsule is vital in colonisation, invasion and respiratory 
tract dissemination due to its ability to avoid opsonophagocytosis which involves 
recognition by complement and/or antibody leading to phagocytosis (Nelson et al., 
2007).  The capsule is also able to reduce exposure to antibiotics and restrict autolysis 
(Fernebro et al., 2004).  Murine studies using isolates with capsule locus mutations 
revealed the importance of the capsule in colonisation, in addition to showing an 
increased access of complement and antibodies to the surface of  S. pneumoniae  
(Magee and Yother, 2001).   
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Table 1.1.4: S. pneumoniae virulence factors. The main virulence factors in s. pneumonia are shown with examples of each and mode of action. 
 
Virulence factor Examples Mode of action Reference 
The polysaccharide capsule 93 capsule types 
exist 
e.g. 9V, 14 and 19F 
Antiphagocytic properties, prevents mucosal clearing, reduces exposure 
to antibiotics and restricts autolysis 
(Avery and Dubos, 1931) 
(Black et al., 2000) 
LytA Releases virulence factors and components of the cell wall following 
degradation of peptidoglycan backbone 
(Rogers H. J., 1980) 
 
Choline binding proteins 
PspA Protection against host complement system 
 
(Yother and Briles, 1992) 
(Yother and White, 1994) 
Pneumolysin Lytic to host cells, slows down ciliary beating in epithelial cells, 
impairs respiratory burst, activates CD4+ T cells, activates 
inflammation 
(Hirst et al., 2004) Extracellular toxins and 
enzymes 
IgA1 protease proteolytic enzyme that degrades human IgA1 
 
(Plaut, 1983) 
 
Pili Aids colonisation of upper respiratory tract, antiphagocytic 
 
(Hava et al., 2003) 
(Rosch et al., 2008) 
Metal binding transporters 
PiaA/PiuA Required for iron uptake 
 
(Brown et al., 2001) 
 
Surface adhesins NanA Cleaves N-acetylneuraminic acid on host glycoproteins, glycolipis and 
mucin which exposes binding sites 
(Kelly and Greiff, 1970) 
Hydrogen peroxide Hydrogen peroxide Cytotoxic to human epithelial cells, involved in interspecies 
competition 
(Duane et al., 1993) 
Regions of genome diversity 41 RDs have been 
identified 
Specific genomic regions are associated with virulence in certain clones 
or serotypes 
(Obert et al., 2006) 
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The significance of the pneumococcal capsule has also been observed in virulence 
differences between variants of serotype 6 (Hausdorff et al., 2000b, Robinson et al., 
2002).  Serotype 6B is significantly more virulent than 6A (Hausdorff et al., 2000b, 
Robinson et al., 2002) but in terms of the capsule differs only in the nature of linkage 
between two sugars; rhamnose and ribitol (Kamerling, 2000).  Although the capsular 
difference is small, the resulting distinction in virulence is significant.  Disease 
potential for certain serotypes can vary as the level of virulence caused by the capsule 
correlates with capsule thickness, which differs between serotypes or clones 
(MacLEOD and KRAUS, 1950).  Moreover, only a relatively small number of 
capsule types are associated with invasive pneumococcal disease (IPD) (discussed 
further in section 1.3.1). 
 
The pneumococcal capsule is interesting to this project due to the high degree of 
genetic variation observed.  Genetic variation has led to the evolution of 93 different 
serotypes (Park et al., 2007, Bratcher et al., 2010) and some can be further sub-
categorised, forming part of a serogroup.  Isolates that are identified to be extremely 
similar or clonal by typing methods such as multilocus sequence typing (MLST) and 
pulsed field gel electrophoresis (PFGE) (see section 1.3.2) can express different 
capsule types due to their ability to recombine capsule genes with other pneumococci, 
a process known as capsule switching (Coffey et al., 1991, Barnes et al., 1995b). 
Similarly, isolates that express the same capsule type may be very different in 
genomic content.  Capsule switching has also allowed some isolates to escape the 
effects of the pneumococcal conjugate vaccine (the PCV is discussed further in 
section 1.1.5) (Brueggemann et al., 2007).  This phenomenon has contributed to the 
evolution and genome plasticity of S. pneumoniae. 
 
The general organisation of capsule loci appears to be shared. Type specific regions 
contain genes unique to a certain serotype or group and encode proteins needed to 
synthesise serotype specific sugars, such as polymerases or glycotransferases (Dillard 
and Yother, 1994, Kolkman et al., 1998).  Serotype specific capsule genes are flanked 
by genes common to all serotypes (Dillard and Yother, 1994, Kolkman et al., 1998).  
The common regions are homologous in isolates of different serotypes and thus 
facilitate a means for recombination.   All genes involved in the synthesis of the 
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polysaccharide capsule are located between the 5’ dexB gene and 3’ plpA gene, in all 
but serotype 37 (Llull et al., 1999). 
 
Figure 1.1.4.1:  General organisation of pneumococcal capsule loci. (A) Genes 
common to most pneumococcal isolates are shown with type specific regions. An 
example of the serotype 9V capsule loci organisation is shown (B).  Adapted from 
van Selm et al, 2002 (van Selm et al., 2002). 
 
The 5’ region common to most serotypes includes genes cpsA, cpsB, cpsC and cpsD 
and encode proteins involved in regulation and modulation of post-translational 
synthesis (Bentley et al., 2006, Morona et al., 2006, Morona et al., 2003).  They do 
not however, appear to be involved in synthesis directly (Guidolin et al., 1994).  
Figure 1.1.4.1 illustrates the general organisation of capsule loci in addition to 
providing a specific example of serotype 9V (figure 1.1.4.1b).  With the exception of 
serotypes 3 and 37 capsular synthesis follows the wzy polymerase dependent pathway 
(Llull et al., 1999, Dillard and Yother, 1994). 
 
1.1.4.2 Hydrogen peroxide 
Hydrogen peroxide is considered to be an important pneumococcal virulence factor. 
Studies have shown H2O2 to have a cytotoxic effect on human epithelial cells 
(Gabrielson et al., 1994) and co-culture experiments have identified the potential of 
H2O2 in eliminating competitive pathogens which reside in the upper respiratory tract. 
These include Neisseria meningitidis, Haemophilus influenzae and Moraxella 
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catarrhalis (Pericone et al., 2000).  Of particular clinical significance may be the 
interspecies competition between Streptococcus pneumoniae and Staphylococcus 
aureus (Regev-Yochay et al., 2004).  Here, it is common to find a negative 
association between carriage of S. pneumoniae and S. aureus (Bogaert et al., 2004b, 
Regev-Yochay et al., 2004) and hydrogen peroxide mediated killing of 
Staphylococcus aureus by S. pneumoniae has been demonstrated (Regev-Yochay et 
al., 2006).  Of clinical significance is the concern that the pneumococcal conjugate 
vaccine will result in increased S. aureus infection.  One study showed a rise in 
colonisation levels of S. aureus, following vaccination for recurring Otitis media in 
children (Bogaert et al., 2004b).  
 
H2O2 is essential to this project as part of the investigation involves looking at the 
effects of DNA damaging agents, including H2O2, on dinB (a gene thought to be 
involved in DNA lesion repair) knock out isogenic mutants.  The effect of oxidative 
damage on DNA is described in section 1.4.3.3. 
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1.1.5 The pneumococcal conjugate vaccine 
The need for a pneumococcal vaccine was apparent from the substantial number of 
associated deaths worldwide in addition to the problem of global multidrug resistance. 
Polysaccharide vaccines function to provide antibodies specific to certain 
pneumococcal capsule types, leading to opsonisation.  In 1977, a 14-valent 
polysaccharide capsule was introduced, which in 1983 was adapted to include a total 
of 23 different capsular types (http://www.cdc.gov/vaccines/vpd-
vac/pneumo/default.htm).  This vaccine (Pneumovax® 23-valent polysaccharide 
vaccine) was identified to present poor immunogenicity in young children (Douglas et 
al., 1983). However, it is currently administered to those over the age of 65.   
 
In 1931, Avery discovered that immunogenicity was increased in rabbits when 
administered with a chemical conjugation of serotype 3 polysaccharide with a protein 
carrier (Avery and Goebel, 1931).  This fuelled the development of a pneumococcal 
conjugate vaccine and a few have been developed since the 23-valent vaccine to 
include a range of protein carriers. The 7-valent pneumococcal conjugate vaccine was 
tested in 2001 and included the seven most common serotypes (4, 6B, 9V, 14, 18C, 
19F and 23F) to affect children under the age of five (Eskola et al., 2001). It was 
introduced in the United States in 2000 and has been shown to reduce IPD of vaccine 
types (Pilishvili et al., 2010).  It was introduced into the UK in 2006 and a reduction 
in IPD was also observed, however, post vaccine studies have highlighted a higher 
incidence of serotype replacement in the UK compared to the United States (Choi et 
al., 2011).  The 7-valent pneumococcal conjugate vaccine was further developed 
following the need to include additional serotypes; in 2009, the 10-valent conjugate 
vaccine was licensed in the United States and more recently, in 2010 the 13-valent 
conjugate vaccine (http://www.cdc.gov/vaccines/vpd-vac/pneumo/default.htm) was 
developed to include serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F 
(Bryant et al., 2010).  
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1.2 Transformation 
 
Transformation is the process by which bacteria acquire exogenous DNA that is 
subsequently incorporated into the host genome. It was discovered in the 
pneumococcus by Griffith in 1928, when he demonstrated that live, unencapsulated 
(and therefore non-pathogenic) S. pneumoniae could transfer the ability to synthesise 
a capsule when injected into mice in conjunction with heat-killed encapsulated 
pneumococci (Griffith, 1928). Natural genetic transformation has since been 
identified to occur in approximately 40 different species (Lorenz and Wackernagel, 
1994).  Transformation is believed to be essential for the genetic plasticity of S. 
pneumoniae (Claverys et al., 2000).   Pneumococci tend to diverge relatively quickly 
as a result of homologous recombination with DNA from a distant strain (Feil et al., 
2000b) (discussed further in section 1.3.5).  Both inter and intraspecies recombination 
has been identified in this organism.  The rise in acquisition of antibiotic resistance 
has also been attributed to this phenomenon (discussed further in section 1.3.5). 
 
1.2.1 Induction of competence 
Natural transformation occurs in organisms that display competence, i.e. the ability to 
incorporate high molecular weight DNA.  In pneumococci, competence is initiated in 
exponentially growing S. pneumoniae cultures.  Other bacteria, for example Neisseria 
gonorrhoeae and Neisseria meningitidis, are continuously in a competent state 
(Biswas et al., 1977).  S. pneumoniae competence induction is controlled by quorum 
sensing.  Quorum sensing controls transcription initiation of genes involved in 
transformation by the amount of pheromone in the surrounding medium (Håvarstein 
et al., 1995).  There are six genes, spread across three operons, involved in this 
process.  Competence stimulating peptide (CSP) in the surrounding medium interacts 
with the CSP receptor comD  (Steinmoen et al., 2002).  ComD then phosphorylates 
comE, a response regulator, which initiates transcription of early transformation 
genes, comX, comE and comAB by binding to the promoter regions.  ComX is 
involved in transcription initiation of late transformation genes needed to induce 
competence. ComE also enhances synthesis of CSP, encoded by comC.  CSP is 
exported by the comAB transporter (Claverys et al., 2000).   
Chapter 1 
 
 36 
1.2.2 Uptake of DNA 
In some species, such as N. gonorrhoeae or H. influenzae, the uptake of DNA will 
only occur if an identifier sequence is present. S. pneumoniae  however is able to take 
up any DNA (Lacks, 1962).  Transformation occurs in competent cells when double 
stranded DNA is irreversibly bound to the cell surface, followed by cleavage of single 
strands at random locations  (Morrison and Guild, 1973).  Subsequently, the nuclease 
EndA allows entry of the bound strand by degrading the complementary strand (Lacks 
and Greenberg, 1976).  There are also four further inducible operons specifically 
associated with DNA uptake in pneumococci.  They contain the genes celAB, cflAB, 
cglABCDEFG and cilC, involved in late competence. 
 
1.2.3 Genetic recombination 
Strand exchange with incoming DNA requires a high level of sequence homology 
between the donor and recipient sequence, however homology is only required in 
regions where recombination takes place.  Novel DNA can thus be inserted into the 
host genome if flanked by regions of homology on either side.  This mechanism is 
dependent on RecA which promotes synapsis, pairing of the two sequences  (Steffen 
and Bryant, 2000).  The donor DNA undergoes repair of any nucleotide mismatches 
following uptake and synapsis with chromosomal DNA, a process known as 
mismatch repair (MMR) (described further in section 1.4.1.3).   
 
The efficiency with which donor sequences transform can vary (Lacks and Hotchkiss, 
1960) depending on how efficiently different types of mutation are repaired by the 
Hex mismatch repair system.  Low efficiency markers result from transitional 
mutations where as high efficiency markers arise from transversions (Claverys et al., 
1983). Mutations in either of the two genes required for MMR, hexA and hexB, lead to 
all markers being integrated with high efficiency (Lacks, 1970). 
 
Following MMR, the recipient DNA that is homologous to the donor DNA is replaced 
and discarded to give a hybrid structure (Fox, 1966).  Finally, chromosomal ligation 
of donor DNA occurs. 
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1.3 Epidemiology and population structure of S. pneumoniae 
 
The first part of this project was based on investigating mechanisms of evolution in 
three internationally recognised pneumococcal antibiotic resistant clones. Section 1.3 
will therefore provide background knowledge on DNA typing methods used in this 
research and elsewhere to genetically characterise pneumococci, mechanisms of 
antibiotic resistance and the spread and genetic diversification of S. pneumoniae 
clones. The vast amount of literature on the worldwide dissemination of invasive 
pneumococci means that the terminology can sometimes be confusing.  For the 
purpose of this thesis the term strain will be used to describe pneumococci that have 
been subject to long term laboratory culture, modification and given a strain 
designation in published literature (e.g. acapsular strain R6) and the term isolate will 
be used to describe pneumococci isolated from clinical samples in the relatively 
recent past.  The term clone will refer to pneumococcal isolates that have identical 
multilocus sequence type (MLST) allelic profiles, known as sequence types (STs) and 
the term clonal complex will refer to pneumococcal isolates that are related to the 
founder ST (MLST is describe further in section 1.3.2.5). 
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1.3.1 Pneumococcal serotypes and disease 
Historically, serotyping has been used to distinguish different types within S. 
pneumoniae.  Recent work has demonstrated that the capsule type has a distinct role 
in relation to virulence (Weinberger et al., 2009).  Of the 93 serotypes that exist, 
worldwide there appears to be 12 dominant serotypes associated with IPD; 1, 3, 4, 6A, 
6B, 7F, 8, 9V, 14, 18C, 19F and 23F (Lynch and Zhanel, 2009, Imöhl et al., 2010, 
Feikin et al., 2005, Liñares et al., 2010).  A smaller number of serotypes account for a 
larger amount of IPD among children (Robinson et al., 2001b) and include serotypes 
6A, 6B, 9V, 14, 15, 18, 19F, 19A and 23F (Lynch and Zhanel, 2009, Imöhl et al., 
2010, Feikin et al., 2005, Liñares et al., 2010).  Geographic location also presents 
differences in serotype distribution which causes difficulty in producing a vaccine 
with worldwide optimal protection.  For example, serotypes 1 and 5 are infrequently 
identified in the USA and Europe although in developing countries tend to be 
dominant in IPD (Lynch and Zhanel, 2009, Brandileone et al., 2003, Hausdorff et al., 
2000a).   
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1.3.2 Antibiotic resistance as a driver for new typing methods 
There is a considerable amount of literature on penicillin resistance in S. pneumoniae 
and the terminology does not always correlate.  Susceptible isolates generally describe 
those that have an MIC ≤0.06g/ml (Jacobs et al., 1998).  Non-susceptible, also 
described as intermediate resistance, describe isolates that have an MIC of 0.1 - 
1g/ml.  These isolates were termed as non-susceptible/intermediate due to 
differences in levels of resistance that lead to treatment failure.  Highly resistant 
isolates usually refer to those with a minimum inhibitory concentration >2g/ml.  For 
the purpose of this thesis however, the term susceptible will be used to describe all 
isolates that have an MIC <0.1g/ml and resistance will be used to describe all 
isolates that have an MIC ≥0.1g/ml. 
 
Penicillin resistant pneumococcal isolates were identified as early as 1965 in the 
United States when 2 out of 200 clinical isolates displayed MICs in the range of 0.1 – 
0.2 g/ml, the researchers however were unaware of the significance of their results 
(Kislak et al., 1965).  The first recognition of penicillin resistance occurred in 
Australia in 1967 where an isolate presented a penicillin MIC of 0.6 g/ml (Hansman, 
1967).  Subsequently in 1974, a study of 518 S. pneumoniae isolates showed that 12% 
were resistant (Hansman et al., 1974).  Resistant isolates were later detected in South 
Africa and Spain (Klugman, 1990, Jacobs et al., 1978, Fenoll et al., 1991, Fenoll et 
al., 1998).  By the early 1990’s, penicillin resistance was documented to have rapidly 
spread worldwide (Lynch and Zhanel, 2005, Hsieh et al., 2004, Doern et al., 2001) 
and included resistance to multiple antimicrobial agents.  The emergence of global 
resistance led to the use and development of new molecular typing techniques to 
further facilitate epidemiological studies.  These techniques have advanced over time 
but all function to delineate genetic relatedness between and within clonal lineages.  
These methods, briefly described below include Multilocus Enzyme Electrophoresis 
(MLEE), BOX-PCR, PBP analysis, pulsed field gel electrophoresis (PFGE), and 
comparatively recently, MLST (http://spneumoniae.mlst.net/). 
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1.3.2.1 Multilocus enzyme electrophoresis (MLEE) 
Initial studies of population structure involved the use of MLEE which employs the 
relative electrophoretic mobilities of housekeeping enzymes to characterise and 
differentiate organisms by generating an electromorph type (ET) (Selander et al., 
1987 , Hall and Duke, 1998, Selander et al., 1986).  MLEE has now been superseded 
by Multilocus Sequence Typing (MLST). 
1.3.2.2 BOX-PCR 
BOX-PCR is a fingerprinting technique which uses single PCR primers to target 
repetitive sequence elements (BOX sequences) in the pneumococcal genome.  The 
resulting fragments can be separated by gel electrophoresis and compared between 
different isolates. 
1.3.2.3 Penicillin binding protein (PBP) analysis 
The heterogeneous nature of PBPs in resistant isolates allowed them to be used in 
typing.  Amplification of the PBP genes followed by restriction enzyme digestion 
allows RFLP profiles to be observed and compared. 
1.3.2.4 Pulsed field gel electrophoresis typing (PFGE) 
PFGE typing involves digesting total genomic DNA with a rare cutting restriction 
enzyme, followed by pulsed field electrophoresis to separate large fragments (5kb – 
6Mb).  This method detects the presence of genomic rearrangements such as 
insertions or deletions, which alter the restriction fragment length pattern. Isolates that 
are identified as having the same PFGE pattern are referred to as clonal (i.e. to have a 
recent common ancestor). 
1.3.2.5 Multilocus sequence typing (MLST) 
MLST directly compares the nucleotide sequence of alleles at seven housekeeping 
genes. The sequence is assigned a specific allele number and an isolate’s allelic 
profile can be obtained when categorising all seven housekeeping allele numbers in 
combination.  Each unique allelic profile is consequently assigned a sequence type 
(ST) and submitted to the database (http://spneumoniae.mlst.net/) to allow 
comparison. The equivalent allelic profile or sequence type is present in clones that 
descend from the founding isolate and initial divergence occurs in variants that differ 
from the founder at a single locus, known as single locus variants (SLVs).  From the 
SLVs further diversity can occur to produce double locus variants (DLVs) and so on.  
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1.3.3 International spread of resistant clones 
The rapid dissemination of resistant clones was associated with the increased use of 
antimicrobial agents.  The international spread of a multi-resistant clone was first 
reported in 1991 when a serotype 23F isolate obtained from a children’s day care 
centre in Cleveland, Ohio, was found to have an indistinguishable PBP, RFLP and 
MLEE profile to isolates that had been analysed in Spain (Muñoz et al., 1991).  The 
importance of clonal spread in antimicrobial resistance was recognised with the rapid 
worldwide dissemination of this multi-resistant clone when it was later identified in a 
variety of locations worldwide; the UK (Coffey et al., 1991), Germany (Reichmann et 
al., 1995), France (Ferroni et al., 1996), Korea (McGee et al., 1997, Tarasi et al., 
1997) Taiwan (Shi et al., 1998), Colombia (Castañeda et al., 1998a), Mexico 
(Echániz-Aviles et al., 1998), Hong Kong (Ip et al., 1999, Bogaert et al., 2000) and 
Greece (Bogaert et al., 2000). Serotype switching is also known to occur in the most 
common antimicrobial resistant serotypes which further enhances diversification of a 
clone (Coffey et al., 1991).  Numerous variants of clone Spain 23F-1 have been 
reported in different geographic locations and include those that express capsular type 
19F (Coffey et al., 1991), 3 (Nesin et al., 1998), 9N (Nesin et al., 1998), 6 (Song et 
al., 2000), 14 (Barnes et al., 1995a) and 19A (Coffey et al., 1998b). 
 
Studies across countries worldwide identified additional cases of global dissemination 
of a pneumococcal clone.  Reports of isolates sharing indistinguishable or similar 
MLEE, BOX-PCR, PBP, PFGE or MLST profiles enabled the geographic success of 
different clones to be documented. The Spanish multi-resistant clone 6B has been 
observed in a number of different countries including Iceland (Soares et al., 1993). 
Fifty seven Icelandic isolates obtained between 1989 and 1992 were investigated by 
PBP analysis, MLEE and PFGE.  All 57 isolates were found to have an 
indistinguishable profile to the Spanish 6B clone (Soares et al., 1993).  In 1995, 28 
penicillin resistant isolates recovered in Toulouse, France were analysed using PFGE.  
Nine of the 28 isolates could be assigned to either of two Spanish clones based on 
their RFLP profile, 6B or 9V (Lefèvre et al., 1995). In 2001 38 S. pneumoniae isolates 
were obtained from day care centres in Portugal (Sá-Leão et al., 2001).  They were 
representative of 6 clones and initially analysed by MLST.  Those that differed in 
MLST allelic profile by more than two alleles were further analysed by PFGE.  Of the 
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38 isolates analysed, 5 DLVs and 3 triple locus variants (TLVs) of the Spanish clone 
6B were detected (Sá-Leão et al., 2001).  This clone has also been identified in 
Finland (Sibold et al., 1992), the UK (Soares et al., 1993), Germany (Reichmann et 
al., 1995) and Taiwan (Shi et al., 1998). 
 
By the mid 1990’s it was well documented that many more pneumococcal clones had 
achieved considerable geographic distribution.  Consequently, in 1997 the 
Pneumococcal Molecular Epidemiology Network (PMEN) was established to monitor 
the spread of the major multi-resistant clones worldwide and establish a 
standardisation of nomenclature of international clones (McGee et al., 2001b).  The 
two Spanish multi-resistant clones described above were subsequently named Spain 
23F-1 and Spain 6B-2, which describes the country of initial detection, the typical 
serotype and the clone number assigned by PMEN.   These are just the first two 
examples of the 43 internationally recognised PMEN clones (table 1.3.3).  Clones in 
the PMEN website were initially included on the basis of their success in global 
dissemination, resistance to antimicrobial agents and coverage in the literature 
(McGee et al., 2001b).    There are now however clones included that are 
antimicrobial susceptible and incorporated due to their wide geographic spread and 
involvement in invasive disease (http://www.sph.emory.edu/PMEN/index.html). 
 
From the 1980’s to the 1990’s, the most successful clones in the rapid increase of 
global antimicrobial resistance (included in the PMEN website) were as follows; 
Spain23F-1 (ST81), Spain6B-2 (ST90), Spain9V-3 (ST156), England14-9 (ST9), 
Taiwan19F-14 (ST236), Taiwan23F-15 (ST242), Poland6B-20 (ST315), Sweden15A-25 
(ST63) and Colombia23F-26 (ST338) (Liñares et al., 2010). 
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Table 1.3.3: PMEN clones. (http://www.sph.emory.edu/PMEN/index.html) (McGee 
et al., 2001b).   ST – MLST sequence type; R – resistant; S – susceptible; PEN – 
penicillin; CTX – cefotaxime; ERY – erythromycin; CLIN – clindamycin; CHL – 
chloramphenicol; TET – tetracycline; SXT – trimethoprim- sulphamethoxazole. 
Clone Sero
type 
ST Antibiotic susceptibilities (Etests) (µg/ml) 
 PEN CTX ERY CLIN CHL TET SXT 
Spain23F-1 23F 81 1 1.5 0.25 0.19 16 64 2 
Spain6B-2 6B 90 0.5 0.75 0.19 0.19 16 48 2 
Spain9V-3 9V 156 1.5 0.75 0.125 0.19 3 0.5 1.5 
Tennessee23F-4 23F 37 0.125 32 32 0.125 3 0.25 2 
Spain14-5 14 18 1.5 1 0.19 0.125 32 24 0.25 
Hungary19A-6 19A 268 1 0.75 >256 >256 24 48 3 
S.Africa19A-7 19A 75 0.19 0.094 0.25 0.19 4 1 4 
S.Africa6B-8 6B 185 0.19 0.125 0.19 0.19 2 0.5 1.5 
England14-9 14 9 0.016 0.016 64 0.125 3 0.5 0.064 
CSR14-10 14 20 8 1 >256 >256 32 48 0.25 
CSR19A-11 19A 175 6 0.5 >256 >256 24 64 2 
Finland6B-12 6B 270 4 0.75 >256 >256 8 64 6 
S.Africa19A-13 19A 41 1.5 0.5 >256 >256 24 48 4 
Taiwan19F-14 19F 236 2 0.75 16 0.25 16 48 2 
Taiwan23F-15 23F 242 0.75 0.75 >256 >256 4 48 0.25 
Poland23F-16 23F 173 8 4 >256 0.25 16 64 1.5 
Maryland6B-17 6B 384 1.5 1 24 0.19 3 0.75 2 
Tennessee14-18 14 67 4 12 >256 >256 3 32 2 
Colombia5-19 5 289 0.003 0.016 0.125 0.125 16 32 0.19 
Poland6B-20 6B 315 0.064 0.032 >256 >256 8 64 0.5 
Portugal19F-21 19F 177 0.032 0.032 >256 >256 4 12 0.047 
Greece6B-22 6B 273 0.023 0.047 >256 >256 16 96 0.25 
N.Carolina6A-23 6A 376 1 0.75 4 0.19 3 0.5 1 
Utah35B-24 35B 377 1 0.75 0.125 0.125 3 0.38 0.38 
Sweden15A-25 15A 63 0.064 0.047 >256 >256 4 0.25 0.094 
Colombia23F-26 23F 338 0.064 0.094 0.19 0.19 4 0.5 0.094 
Sweden1-27 1 217 0.006 0.016 0.19 0.19 4 0.38 0.38 
Sweden1-28 1 306 0.006 0.016 0.19 0.125 2 0.25 0.047 
USA1-29 1 615 0.012 0.016 0.125 0.125 2 0.25 0.125 
Greece21-30 21 193 0.016 0.094 0.25 0.125 3 0.25 0.125 
Netherlands3-31 3 180 0.023 0.023 0.19 0.125 4 0.38 0.047 
Denmark14-32 14 230 1 0.75 0.125 0.125 3 64 1.5 
Netherlands8-33 8 53 0.016 0.023 0.19 0.19 3 0.38 0.032 
Denmark12F-34 12F 218 0.016 0.016 0.19 0.19 3 0.25 0.047 
Netherlands14-35 14 124 0.016 0.023 0.25 0.25 3 0.5 0.094 
Netherlands18C-36 18C 113 0.023 0.023 0.125 0.19 3 0.38 0.064 
Netherlands15B-37 15B 199 0.012 0.023 0.125 0.19 2 0.25 0.094 
Sweden4-38 4 205 0.012 0.016 0.125 0.19 4 0.25 0.094 
Netherlands7F-39 7F 191 0.012 0.016 0.19 0.19 3 0.5 0.094 
Sweden1-40 1 304 0.012 0.012 0.125 0.125 2 0.19 0.125 
Portugal6A-41 6A 327 0.012 0.023 0.125 0.125 3 0.38 0.75 
NorwayNT-42 NT 344 0.094 0.125 4 0.064 2 32 0.38 
USANT-43 NT 448 0.094 0.094 4 0.094 3 32 0.25 
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1.3.4 Mechanisms of resistance 
The genetic mechanism by which S. pneumoniae become resistant is by loss or gain 
of resistance genes within and between different clonal lineages, through horizontal 
gene transfer and DNA recombination, the acquisition of transposable elements that 
contain resistance genes and point mutation events.  The mechanisms of resistance 
vary depending on the antimicrobial agent and a large number of drugs exist.  S. 
pneumoniae are continuing to acquire resistance, in some cases, to relatively new 
drugs (Lynch and Zhanel, 2009, Feng et al., 2009). This section will describe 
mechanisms of resistance to antimicrobial agents that are associated with this project 
(table 1.3.4).  
 
 
Antibiotics used or associated with this project 
 
Antibiotic Antibiotic class Relevance to this project 
 
Penicillin  Β-lactam Resistance in clone Spain9V-3 (chapter 
3) 
Cefotaxime Β-lactam Resistance in clone Spain9V-3 (chapter 
3) 
Sulfonamide Sulfonamide Resistance in clone Spain9V-3 
and clone Taiwan19F-14 (chapter 3) 
Trimethoprin Sulfonamide Resistance in clone Spain9V-3 
and clone Taiwan19F-14 (chapter 3) 
Erythromycin Macrolide Resistance in clone England14-9        
and clone Taiwan19F-14 (chapter 3) 
Tetracycline Tetracycline Resistance in clone Taiwan19F-14 
(chapter 3) 
Chloramphenicol Chloramphenicol Used in mutation assay experiment  
(chapter 4) 
Rifampicin Rifamycins Used in mutation frequency 
experiments  
(chapter 4) 
Table 1.3.4:  Antibiotics associated with this research.  The relevance to the project 
for each antibiotic is noted with chapter reference. 
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1.3.4.1 Mechanisms of penicillin resistance 
Penicillin resistance is acquired through alterations to one or more of the PBPs which 
decreases affinity to the drug. Each bacterial species has a characteristic set of PBPs 
which are involved in peptidoglycan synthesis and S. pneumoniae contain six: three 
high molecular weight (HMW) class A binding proteins (PBP1a, PBP1b and PBP2a), 
two HMW class B proteins (PBPs, PBP2x and PBP2b) and one low molecular weight 
(LMW) PBP (PBP3).  Reduced susceptibility to penicillin may require multiple 
mutations in one or more PBPs  (Hakenbeck et al., 1999).  Alterations to the PBP2x 
gene is one of the principal mechanisms of resistance to penicillin, as the PBP2x 
protein has one of the highest affinities to the drug (Maurer et al., 2008) and a large 
number of PBP2x mutations have been identified.  Mutations in PBP2x as well as 
PBP2b lead to low-level resistance and are required for high level resistance caused 
by mutations in other PBPs (Grebe and Hakenbeck, 1996).  Although point mutations 
lead to resistance (Grebe and Hakenbeck, 1996), clinical isolates generally acquire β-
lactam resistance through horizontal gene transfer of mosaic PBP genes (Hakenbeck, 
2000).  Sequence analysis has shown that these mosaic blocks were attained by 
horizontal gene transfer with closely related oral streptococci (Hakenbeck, 2000).  
 
1.3.4.2 Mechanisms of erythromycin  and tetracycline resistance 
Tetracycline and macrolide resistance are acquired by incorporation of new genes 
carried by transposable elements.  
 
Macrolides such as erythromycin, interfere with the 50S ribosomal subunit in bacteria 
and therefore disrupt the elongation stage of protein synthesis.  Binding causes 
peptidyl-tRNA to dissociate from the ribosome, resulting in early peptide chain 
release  (Weisblum, 1995).  Resistance is acquired through two mechanisms; 
modifications to the 23S rRNA or via an active efflux mechanism. There are four 
different resistance phenotypes M, ML, MSB and MLSB.  This refers to the 
antimicrobial agent resistance has been acquired for and include macrolide (M), 
lincosamide (L) and streptogramins (SB).   
 
The M phenotype (associated with the efflux mechanism) is caused by carriage of 
mefE which encodes a transmembrane protein that acts as an efflux pump (Sutcliffe et 
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al., 1996).  The first mefE carrying structure described was named mega (macrolide 
efflux genetic assembly) (Gay and Stephens, 2001).  Later two more elements were 
described to contain mefE, Tn2009 (Del Grosso et al., 2004) and Tn2010 (Del Grosso 
et al., 2007a). 
 
Modifications to 23S rRNA lead to one of the remaining three phenotypes depending 
on the type of modification.  23S modifications are due to mutation of the rRNA gene 
(Tait-Kamradt et al., 2000a) or post transcriptional methylation of rRNA.  
Methylation caused by the carriage of ermB is the most frequent form of target site 
modification and leads to the reduction of macrolide, lincosamide and streptograminB 
binding  (Weisblum, 1995). This is known as the MLSB phenotype.   Elements that 
carry ermB are described in the next paragraph.  Less common mutations that cause 
resistance have been identified in 23SrRNA and the ribosomal protein L4 (Tait-
Kamradt et al., 2000b). 
 
Tetracycline binds the 30S ribosomal subunit and prevents docking of amino-acylated 
tRNA via an interaction with 16S rRNA.  Resistance occurs following acquisition of 
tetM, or less commonly tetO (Widdowson and Klugman, 1998).  The majority of 
macrolide resistant pneumococci also harbour resistance to tetracycline due to ermB 
insertion into transposons included in the Tn916 family (Tn1545, Tn3872, Tn6002 
and Tn6003) that carry resistance to tetracycline (Varaldo et al., 2009, Cochetti, 
2008).  TetM is also found in elements Tn2009 that contains mefE (Varaldo et al., 
2009, Del Grosso et al., 2004) and Tn2010 that also harbours mefE in addition to an 
ermB element  (Del Grosso et al., 2007b). 
 
1.3.4.3 Mechanism of trimethoprim-sulphamethoxazole resistance 
Trimethoprim and sulphamethoxazole are often used in combination, referred to as 
co-trimoxazole or trimethoprim-sulphamethoxazole.  Resistance is acquired following 
mutation to genes that encode the target proteins of these drugs.  Mutations must 
occur in both genes that encode trimethoprim and sulphonamide target loci for co-
trimoxazole resistance to occur.    
 
Chapter 1 
 
 47 
Sulphonamides work by acting as competitive inhibitors of an enzyme involved in the 
biosynthesis of folic acid, dihydropteroate synthase (DHPS).  Resistance to 
sulphonamide occurs when one or two amino acids in the Arginine-58 to Tyrosine-63 
region (Maskell et al., 1997) or the isoleucine-68 to glutamine-69 (Lopez et al., 1987) 
region are duplicated.  Horizontal gene transfer has also been implicated in the 
acquisition of sulfonamide resistance (Maskell et al., 1997). 
 
Trimethoprim interferes with the enzyme dihydrofolate reductase (DHFR) which is 
also required for folic acid synthesis and resistance is generated through mutation to 
the DHFR locus or HGT.  Substitution of isoleucine-100 for leucine is critical for 
trimethoprim resistance (Adrian and Klugman, 1997). 
 
1.3.4.4 Mechanism of chloramphenicol resistance 
Chloramphenicol targets peptidyl transferase and thus inhibits protein synthesis 
(Shaw and Leslie, 1991).  S. pneumoniae acquires resistance to chloramphenicol by 
acquisition of the chloramphenicol acetyltransferase (Cochetti et al.) gene (Cochetti et 
al.), which is carried on  conjugative transposons such as Tn5253 (Vijayakumar et al., 
1986) and Tn5252 (Ayoubi et al., 1991).  CAT catalyses the conversion of 
chloramphenicol to its derivatives 1-acetoxy, 3-acetoxy and 1,3-diacetoxy.  
Chloramphenicol is thus unable to inhibit peptidyl transferase activity as it can no 
longer bind to the 50S subunit (Vijayakumar et al., 1986). 
 
1.3.4.5 Mechanism of rifampicin resistance 
Rifampicin inhibits RNA polymerase by binding its β-subunit.  This prevents 
transcription and subsequent translation.  The β-subunit of RNA polymerase is 
encoded by the rpoB gene. A number of mutations in this gene can lead to rifampicin 
resistance and previous studies have shown that these mutations localise to one of 
three regions; cluster I, cluster II and cluster III, which are positioned between 
nucleotides 1416 – 1461, 1570 – 1600 and 1750 – 2043, respectively (Padayachee and 
Klugman, 1999). 
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1.3.4.6 The genetic basis for mechanisms of resistance 
It is evident that acquisition of antibiotic resistance can be obtained in a variety of 
ways.  Chromosomal mutation that reduces antibiotic target sensitivity is the primary 
mechanism of resistance to a number of non β-lactam drugs including trimethoprim 
(Adrian and Klugman, 1997), sulphonamide (Maskell et al., 1997, Lopez et al., 1987) 
and rifampicin (Padayachee and Klugman, 1999).  However, mutation in the 
acquisition of antibiotic resistance is generally considered to be rare in the 
pneumococcal population and the spread of resistance determinants into different 
clonal lineages is often due to genetic recombination of genes acquired horizontally 
by transformation (Schrag et al., 2000).  
 
Homologous recombination within and between closely related species can result in 
novel alleles with a mosaic structure as seen with the PBPs (Hakenbeck et al., 2001).  
The same mechanism has been observed in the evolution of tetracycline resistance 
and diversity of tetM has been identified in different clonal lineages with a mosaic 
structure (Oggioni et al., 1996).  Fluoroquinolone resistance has also been reported 
through horizontal gene transfer with viridans group Streptococci, although infrequent 
in comparison to acquisition by point mutation (Bast et al., 2001a).   
 
Conjugative transposons are responsible for dissemination of macrolide, 
chloramphenicol and tetracycline resistance determinants.  Unlike simple transposons, 
conjugative transposons do not duplicate the target sequence when they insert and 
also lack terminal repeats (Norgren and Scott, 1991). These mobile genetic elements 
encode gene products that allow their movement between replicative DNA without 
depending on recombination machinery of the host.  The Tn916 family (section 
1.3.4.2) of transposons is responsible for the majority of erythromycin and 
tetracycline resistance and is present in over fifty different bacterial species   To allow 
dissemination of multiple resistance, the Tn916 family elements are able to insert into 
plasmids and other conjugative transposons intracellularly (Ayoubi et al., 1991).  This 
is observed with composite transposon Tn5253 (section 1.3.4.4) which carries 
chloramphenicol resistance.  Composite transposons are constructed of two insertion 
sequence elements and usually carry one or more genes conferring antibiotic 
resistance.  Tn5253 consists of two transposons, the tetM containing transposon 
Tn5251 inserted into the CAT containing transposon Tn5252 (Ayoubi et al., 1991). 
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Resistance can also be acquired through incorporation of plasmids, although rare in S. 
pneumoniae.  CAT is carried on Tn5253, however sequence analysis of 
chloramphenicol resistant pneumococci has identified sequences homologous to the 
Staphylococcus plasmid pC194 which carries Tn5252 (David et al., 1993).  In some 
cases sequence analysis shows that the entire plasmid has been inserted (Widdowson 
et al., 2000). 
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1.3.5 The evolution of S. pneumoniae 
1.3.5.1 Recombination Vs mutation 
Understanding the relative contributions of recombination versus mutation in the 
evolution of S. pneumoniae as well as other species of bacteria is important in our 
understanding of drug resistance, vaccine development and epidemiology.  All 
bacterial species contain a common ancestor from which genetically related clones 
have emerged. The mechanism of evolution is by mutation or by horizontal gene 
transfer through homologous or non-homologous recombination.  For some species, 
such as M. tuberculosis, mutation appears to be the predominant force in evolution 
and these organisms exhibit a low level of horizontal gene transfer (Cole et al., 1998, 
Dos Vultos et al., 2008).  B. subtilis presents an interesting example of an 
intermediate.  Although only a small proportion of B. subtilis become competent 
(Dubnau, 1991a), like the pneumococcus it is a naturally transformable organism in 
which competence is controlled by quorum sensing. Unlike S. pneumoniae however, 
this is coupled with the occurrence of SOS induced mutagenesis (an error prone repair 
system, the mechanisms of which are discussed in section 1.4.1.4) which implies that 
DNA exchange, in addition to mutation contributes to B. subtilis genome plasticity.  
For S. pneumoniae, recombination is the primary mechanism of evolution (Feil et al., 
2000a) and accounts for the high degree of genomic diversity observed for this 
species. 
 
This may be the primary mechanism of pneumococcal evolution for a number of 
reasons.  Unlike some bacteria, pneumococci are naturally competent organisms 
which can incorporate single stranded native DNA (Lacks 1962).  Mutation can have 
deleterious effects on the cell, where as homologous recombination introduces donor 
sequences that are functional.  Recombination also allows a significantly higher 
degree of diversification as a number of different fragments can be acquired per cell 
(up to 5% of the genome), potentially leading to a variety of new combinations and 
greater evolutionary potential (Claverys et al., 2000).  A relatively rapid rate of 
evolution is further enhanced by horizontal gene transfer of DNA from closely related 
species, as seen with the PBPs (Hakenbeck, 2000).  HGT produces significant 
diversity and facilitates the acquistion of homologous sequences in addition to 
completely new sequences. Regions can be incorporated which contain single 
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nucleotide polymorphisms (SNPs) but can also initiate the insertion/deletion of genes 
and even whole operons. Recombination also mediates capsular switching and a 
number of clinical isolates that express different capsular types have been reported to 
be industuinguishable by typing methods (Coffey et al., 1998a).  
  
Evidence for recombination as the driving force in evolution comes from studies 
using MLST.  As previously described (section 1.3.2.5), MLST involves 
amplification and sequencing of around 450 bp of each of the seven housekeeping 
genes.  Sequences can be compared between isolates of the same clone and used to 
identify single locus variants.  The allele that differs can then be analysed to 
determine whether the variant arose by recombination or mutation; the nucleotide 
change/changes are identified and can be compared to other SLVs entered into the 
database.  Multiple nucleotide changes in the same allele are classified as 
recombination as the likelihood of multiple independent mutational events in a single 
allele is extremely unlikely. A SLV that contains a single nucleotide change is judged 
to have arisen by recombination if the same change is identified in an independent 
isolate in the dataset.  However, a single nucleotide change that produces a novel 
allele (i.e. is not present in the dataset) is classed as mutation. 
 
Feil et al used this method to investigate the relative contributions of recombination 
and mutation in housekeeping genes of 575 pneumococcal isolates (Feil et al., 2000b).  
Of these, 410 were assigned to 28 different clonal complexes with SLVs, 112 were 
from clones that did not contain any SLVs (i.e. were from uniform clones) and the 
remaining 53 had divergent allelic profiles that differed by two or more loci from any 
other isolate.  The SLVs of the 28 clonal complexes were thus selected for analysis.  
In total, 98 SLVs revealed the presence of 9 novel alleles, 8 alleles with the same 
nucleotide change and 81 alleles with multiple nucleotide changes.  As it is extremely 
unlikely that mutation could account for the same single nucleotide change in 
unrelated clones in the MLST database, these variants, as well as those with multiple 
nucleotide changes in one allele were deduced to have resulted from recombination.  
The 9 novel alleles were classed as mutation events.  That gives a recombination to 
mutation ratio in housekeeping alleles of 10:1.  They then analysed the ratio of 
recombination and mutation occuring at any given single nucleotide by comparing the 
total number of nucleotide changes thought to occur as a result of recombination (592 
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nucleotide changes in the 89 alleles) and mutation (9 changes in 9 alleles).  This 
analysis resulted in a 50:1 ratio for recombination to mutation (Feil et al., 2000b).  
 
MLST was also used to examine the extent of recombination and mutation in the 
evolution and virulence of serogroup 6 pneumococci, including isolates of serotype 
6A clones and 6B clones (Robinson et al., 2002, Feil et al., 2000b).   Results showed 
that recombination was predominant in the 212 carriage and invasive isolates 
examined.  Interestingly, there was a significant difference in the relative 
contributions of recombination in 6A and 6B isolates.  Both recombination and 
mutation were prominent in serotype 6A evolution, 6B isolates however were shown 
to evolve mainly through recombination.  An explanation for the difference in 
population structure was suggested to be due to the finding that 6B isolates were more 
frequently derived from invasive disease and 6A were mainly associated with carriage 
(Robinson et al., 2002).  
 
1.3.5.2 Repeated sequences 
In addition to recombination within and between species, genome diversity can arise 
from a number of other factors.  One remarkable feature of S. pneumoniae, relative to 
other species of bacteria, is the genome wide density of repeated sequences (Aras et 
al., 2003, Tettelin et al., 2001).  There are three classifications of repeated sequences 
in the genome; insertion sequences (IS), RUP elements and BOX elements all of 
which constitute around 5% of the genome (Martin et al., 1992, Oggioni and 
Claverys, 1999). Insertion sequences are mobile genetic elements that only encode 
functions necessary for their insertion.  Most are transposase genes that have been 
rendered non-functional as a result of point mutation, insertion or deletion.  Repeat 
unit of the pneumococcus (RUP) elements are of unknown function but are believed 
to be derivatives of insertion sequences and are especially related to the IS630 family.  
They generally span 107bp in length and are thought to still be mobile. It is believed 
that they function to promote genomic rearrangements (Oggioni and Claverys, 1999).  
BOX elements consist of three different subunits; boxA, boxB and boxC.  Around four 
copies of boxB are usually located between boxA and boxC although it has been 
known to contain up to eight boxB copies (Martin et al., 1992).  Genome sequencing 
showed that TIGR4 contains 127 BOX elements (Tettelin et al., 2001, Mrázek et al., 
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2002) and R6 contains 115 (Hoskins et al., 2001). The function of BOX elements is 
also yet to be elucidated although they have been shown to affect expression of 
neighbouring genes and increase genomic diversity (Knutsen et al., 2006). 
 
1.3.5.3 Regions of diversity 
Comparative genome hybridisation (CGH) using DNA microarrays has allowed 
isolates from the same or different clones to be compared. This method has been 
useful in identifying genomic areas which tend to differ in gene content, first referred 
to as regions of diversity (RD) by Tettelin et al (Tettelin, 2004).  
 
Microarrays are constructed by robotic spotting of PCR amplicons onto a slide. The 
amplicons can represent all annotated ORFs present in the test isolate/strain or include 
amplicons represented in more than one isolate/strain.  The DNA from the reference 
isolate/strain is labelled with cyanine 5 (Cy5) dye.     The test isolate/strain is labelled 
with cyanine 3 (Cy3) dye and hybridised to the reference DNA on the microarray 
slide.  As Cy3 and Cy5 dyes emit different colours (green and red, respectively), the 
slide can be scanned and analysed for pixel intensity values to determine regions 
present and absent in reference and test genomes.  Microarrays also come in the form 
of oligonucleotide arrays in which oligonucleotides (usually around 25bp) are spotted 
onto a chip.  Commercial gene chips can be purchased (e.g. from Affymetrix Inc.) that 
include oligonucleotides representative of an entire genome which are exposed to a 
solution containing many copies of the target DNA.  
 
Comparative genome analysis of R6 with TIGR4 has shown that individual 
pneumococcal isolates can differ by up to 10% of their genomic content (Hakenbeck 
et al., 2001, Tettelin et al., 2001). Furthermore, CGH of 13 different isolates showed 
that 13 large loci accounted for over 50% of diversity between isolates (Tettelin, 
2004).  Interestingly, these regions were often indicative of inter/intraspecies gene 
transfer as they were flanked by insertion sequences or contained an atypical GC 
content (Tettelin, 2004).  Silva et al also attempted to characterise S. pneumoniae 
clonal diversity using CGH of thirteen different isolates and the avirulent laboratory 
strain R6.  The thirteen isolates were selected to represent eight MLST types and 
seven serotypes.  These included six serotype 14 strains, a serotype known to be a 
dominant cause of invasive disease (Brueggemann and Spratt, 2003, Hanage et al., 
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2005). CGH results identified 25 regions of diversity (RD) including 248 genes. 
Nineteen of the 25RDs have been previously identified (Hakenbeck et al., 2001) 
which indicates that these RDs are variable between strains.  This study was also 
significant in illustrating that genetic differences can occur between isolates of the 
same ST as one RD was found to differ in content between three serotype 14 strains 
all of ST124.  It is thus evident that although certain typing methods may categorise 
strains as identical, undetected genetic differences can occur between strains.  Other 
studies have used CGH to identify the regions of diversity associated with IPD (Obert 
et al., 2006, Embry et al., 2007).  The results from RD studies covered in the literature 
are summarised in chapter 3, as they relate to this study.  
 
1.3.5.3 The pneumococcal supragenome 
The potential extent of pneumococcal genome diversity was realised when the 
genome sequences of R6 and TIGR4 were compared.  It was remarkable to find that 
the two genomes were highly diverse and even different in size with R6 being 2Mb 
compared to TIGR4 which was 2.16Mb (Brückner et al., 2004, Tettelin, 2006, 
Tettelin et al., 2001, Hoskins et al., 2001).  The two genomes were found to differ in 
10% of their genes and contain regions not present in both genomes.  The R6 genome 
contains six clusters totalling 69kb not present in TIGR4 and the TIGR4 genome 
contains twelve clusters totalling 157kb not present in the R6 genome  (Brückner et 
al., 2004).   
 
Full genome sequence comparative analysis has recently become the principal method 
to identify diversification within and between clones.  At the start of this project, three 
pneumococcal sequences were publicly available; the fully sequenced avirulent lab 
strain R6 (Hoskins et al., 2001), a serotype 4 clinical isolate TIGR4 (Tettelin et al., 
2001) and an incomplete sequence of a serotype 19F clinical isolate, G54. Currently 
(as of January 2012) there are an astonishing 216 genome projects, 23 of which are 
complete and 115 of which are in draft.  In the last three years sequencing technology 
has significantly advanced and it has now become feasible to sequence a large number 
of genomes in a relatively short period of time using new generation sequencing 
technology such as 454 (Margulies et al., 2005) and illumina sequencing technology 
(http://www.illumina.com).  This produces the highest resolution for comparative 
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genomic studies and the more recent literature focuses on the analysis of fully 
sequenced genomes. 
 
Several bacteria display intraspecies and interspecies genetic variation in terms of the 
presence/absence of genes (as opposed to allelic variation).  S. pneumoniae genome 
evolution is affected by the size of the gene pool. Sequence analysis of 16S RNA 
shows that S. pneumoniae along with 11 other species are part of the mitis group 
streptococci. S. pneumoniae is distinct in terms of virulence and pathogenesis yet its 
divergence from other members of the group is no greater than divergence between 
individual lineages of S. mitis (Kilian et al., 2008).  This suggests that the 
pneumococcal gene pool is considerably large and contains a high degree of variation 
(Henriques-Normark et al., 2008). A significant amount of diversification is 
accomplished as a result of naturally transformable strains contributing to and 
withdrawing genes from this gene pool.  
 
The distributed genome hypothesis states that pathogenic bacteria possess a 
supragenome (also referred to in the literature as the pangenome) which describes the 
full complement of genes available to a given species of bacteria and allows 
significant diversity due to its extensive size compared to the genome of any single 
bacterium.  The supragenome can be divided into three components; the core genome, 
which contains genes carried by all isolates of the species, the distributed genome, 
which refers to genes shared by some but not all isolates and the unique genome, in 
which certain genes or clusters are retained by only a single isolate.  
 
The supragenome was first investigated in S. agalactiae (Tettelin et al., 2002) and has 
since been investigated in other organisms such as H. influenza (Hogg et al., 2007).  
Hiller et al investigated the pneumococcal supragenome genome by comparing the 
sequences of seventeen S. pneumoniae genomes (Hiller et al., 2007). Eight genomes 
were sequenced using the 454 Life Sciences GS-20 sequencer (Margulies et al., 2005) 
and combined with the data from nine previously sequenced and publically available 
strains. A variety of different serotypes were included as well as the avirulent 
laboratory strain R6.  A total of 3170 orthologous clusters were identified, of which 
1454 were found to be core (46%), 576 clusters were unique (18%) and 1140 (36%) 
were distributed. In other words, analysis of seventeen pneumococcal genomes 
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revealed that 54% of gene clusters were non-core.  The finite supragenome model 
(based on clustering analysis) was used to estimate the size of the pneumococcal 
supragenome and predicts the presence of around 5100 orthologous clusters, ~1380 
core, ~2100 unique and 1620 distributed clusters.  This data supports the distributed 
genome hypothesis and demonstrates that the pneumococcal supragenome is much 
larger than the genome of any individual isolate.     
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1.3.6 Evolution and diversification within and between pneumococcal 
clones 
 
Studies of bacterial populations can be conducted to elucidate genetic variation within 
a population and identify mechanisms of evolution. As S. pneumoniae are naturally 
transformable there is an increased interest in identifying the genetic events that have 
led to the evolution of drug and multidrug resistance in isolates that cause disease.  
Since multiply resistant S. pneumoniae clones can be assumed not to have existed 
prior to the introduction of antibiotics, they provide a model to observe how 
descendants of clones have diverged within a defined time frame (i.e. since the 
widespread use of antibiotics or first appearance of resistance) as the maximum age of 
the clone can be estimated. Within 20 – 30 years from the extensive use of antibiotics, 
there has been considerable allelic variation of the major resistant clones (Zhou et al., 
2000).   
 
The pneumococcal population contains many clonal complexes in addition to many 
divergent lineages and a single serotype can include numerous different genotypes. A 
number of studies have been conducted to determine relatedness within and between 
different clones and have used various techniques depending on the time of 
investigation.  
 
Earlier studies of clonal diversification used PFGE and MLEE to investigate 
differences between isolates. Highly related isolates were identified by the presence of 
similar PFGE and MLEE profiles. In a study that forms part of the background to this 
thesis, an investigation of 54 isolates from six different serotypes was conducted to 
determine genetic relatedness within and between serotypes identified in the UK (Hall 
et al., 1996).   A total of 30 different MLEE band patterns were observed, 14 of which 
were represented by a single serotype.  Of the 29 different PFGE band patterns 
observed, 22 were found to be represented by a single clone.  Two serotypes were 
found to comprise quite related isolates, 9V and 14. Of the twelve serotype 14 isolates 
investigated, 10 were found to have similar PFGE and MLEE patterns. All the 
serotype 14 isolates were erythromycin resistant.  Seven 9V isolates had very similar 
PFGE patterns and indistinguishable MLEE profiles. Members of this clone were 
generally multidrug resistant although it was intriguing at the time to find that even 
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susceptible 9V isolates were part of the same clone. These results were the first to 
show that S. pneumoniae have an ‘epidemic population structure’ in which 
recognisable and successful clones can arise from a freely recombining background  
(Hall et al., 1996).  Isolates within two major Spanish clones obtained from Lisbon, 
Portugal were also found to be highly related (Caniça et al., 2003).  All presented 
identical PBP profiles and the majority had highly similar PFGE patterns.  
 
Although genetic relatedness has been identified within and between serotypes and 
clones, numerous studies have observed a high degree of genetic diversity.  Clones 
identified as highly related by one technique can demonstrate different types of 
genetic divergence with the use of alternative molecular typing methods. A good 
example of this is with the use of PFGE in conjunction with MLST. Isolates 
indistinguishable or highly related by PFGE may show differences in MLST ST and 
vice versa due to the difference in molecular basis of the two techniques. It is 
therefore constructive to use both techniques in parallel as this increases resolution in 
the investigation of clonal diversity. 
 
Gherardi et al recognised differences within multi-resistant pneumococcal clones 
isolated in Italy (Gherardi et al., 2007).  In total, 105 pneumococcal isolates, 40 of 
which were penicillin resistant and 65 penicillin susceptible, were obtained from 2001 
– 2003.  All isolates were characterised by PFGE and 38 isolates were selected for 
MLST.  Clonal groups were determined by the presence of similar PFGE and MLST 
profiles.  A number of internationally recognised clones were identified and in general 
PFGE patterns correlated well with MLST allelic profiles.  There were however some 
differences.  Fourteen 6B isolates were identified to contain two different PFGE 
types; type 4 (3 isolates) and type 35 (9 isolates).  Three different MLST STs were 
identified among the 9 PFGE type 35 isolates and included isolates that differed by 3 
of the 7 alleles.  In addition, there were serotype 19A and serotype 19F isolates with 
identical MLST STs (ST416) that presented unrelated PFGE patterns.  Diversity was 
also identified within clones.  Clone Spain9V-3 for example were all of PFGE type 1, 
however 11 different subtypes were identified among 16 resistant and 1 susceptible 
isolate in addition to the presence of two different capsular types (9V and 14).  MLST 
results for clone Spain9V-3 were more distinguishable as all resistant isolates were 
identified as the same ST (ST156).  The susceptible isolate was identified as a DLV of 
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ST156, ST664 (Gherardi et al., 2007).  This study highlights the degree of diversity 
that can be observed within different pneumococcal clones and includes drug resistant 
as well as susceptible isolates.  
 
Significant diversity was also identified in clinical isolates collected from 1998 to 
2003 in Poland (Izdebski et al., 2007).  Numerous MLST STs were observed and in 
some cases different PFGE patterns were identified within the same ST. For example, 
three ST236 clone Taiwan19F-14 isolates displayed three different PFGE types (6a, 9a 
and 11a) (Izdebski et al., 2007). Conversely, some studies have identified genetic 
differences in MLST type when thought to be clonal by PFGE. Spain9V-3 isolates 
obtained in Portugal and associated by PFGE type were found in some cases to differ 
by up to three alleles in MLST ST. Although part of the same clonal complex, the 
cluster was identified to contain numerous STs in addition to alternative capsule types 
(Serrano et al., 2005).  It was also astonishing to find that serotype 3 isolates, related 
by PFGE type had in some cases STs that differed in all seven MLST alleles (Serrano 
et al., 2005). 
 
The study already described by Silva et al (section 1.3.5.3) was the first to present 
whole regions of genetic differences within and between clones (Silva et al., 2006).  
Three serotype 14 isolates of the same ST (and therefore part of the same clone) were 
shown to differ in content in two RDs. One RD, named RD17 in the Silva et al study, 
was present entirely in one of the serotype isolates but only partially present in the 
remaining two serotype 14 isolates. In addition, RD23 was completely absent in two 
out of three of the serotype 14 isolates (Silva et al., 2006).    
 
The ability of S. pneumoniae to recombine its genome with other pneumococci and 
closely related species along with the ability to incorporate transposable elements has 
aided the rapid worldwide dissemination of antibiotic resistant clones.  In addition it is 
becoming more apparent that the pneumococcal supragenome is considerably large 
with clonal isolates differing in whole genomic regions.  The methods used to 
investigate genome evolution have increased in resolution since the emergence of 
resistance and differences in divergence can evidently be highlighted by different 
techniques.  The sequencing technology available today allows a vast number of 
sequences to be generated in a relatively short period of time.  A substantial amount 
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of genomes have been sequenced in the duration of this project and studies have 
revealed a high amount of diversity within and between pneumococcal clones.  The 
use of this technology was not feasible at the start of this project.  It was clear 
however that MLST was extremely useful when used in combination with PFGE to 
identify different types of genomic diversification. 
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1.3.7 Clones investigated in this study 
1.3.7.1 Clone Spain9V-3, ST156 
Isolates of clone Spain9V-3 were first identified in Spain in 1991 when a study was 
conducted to investigate PBPs of penicillin resistant isolates (Coffey et al., 1991).  
PBP profiles were obtained for 58 penicillin resistant pneumococcal isolates obtained 
from Spain and the UK.  Of the 58 isolates, 31 of the penicillin resistant isolates had 
identical altered PBP profiles to clone Spain23F-1.  Twelve of these isolates however 
expressed different capsular serotypes, 6 of which expressed serotype 9.  MLEE 
confirmed that all 6 were from the same clone with indistinguishable patterns. This 
study showed that evolution of penicillin resistance in clone Spain9V-3 was probably 
acquired through PBP gene transfer to/from isolates of clone Spain23F-1. Spain23F-1 
isolates and those expressing capsule type 9V were not closely related by MLEE , 
however, both clones were shown to present the exact same three altered PBPs, 
PBP1A, PBP2B and PBP2X (Coffey et al., 1991).  Isolates obtained in Toulouse, 
France between 1991 and 1993 of serotype 9V were also identified to have very 
similar PFGE patterns to the 9V isolates identified in Spain (Lefèvre et al., 1995).  
The significance of serotype 9V isolates as members of an international clone became 
apparent with reports of its geographic spread.  Numerous countries worldwide 
reported the recovery of serotype 9V isolates presenting indistinguishable or very 
similar PFGE, MLEE or PBP patterns;  UK (Coffey et al., 1991), Germany 
(Reichmann et al., 1995), South Korea (McGee et al., 1997), Italy (Marchese et al., 
1998), Sweden (Melander et al., 1998), USA (Corso et al., 1998) and Colombia 
(Castañeda et al., 1998b).  
 
PMEN documented the spread of this clone which was subsequently classified as 
clone Spain9V-3.  It was the third clone to be included in the PMEN international 
collection and is multidrug resistant.  MLST showed that this multidrug resistant 
clone was of ST156.  Clone Spain9V-3 ST156 is believed to have evolved from a SLV 
and penicillin susceptible ST162 isolate (Sjöström et al., 2007). This clone is typically 
resistant to penicillin, cefotaxime and trimethoprim-sulfamethoxazole.  The Spain9V-3 
clone continues to evolve.  It is frequently associated with serotype switches (de la 
Campa et al., 2009) and now includes 95 SLVs in its clonal complex (CC156) 
(http://spneumoniae.mlst.net/). 
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This clone was chosen for investigation as susceptible and resistant 9V isolates form 
part of the same clonal complex.   Resistant ST156 and susceptible ST162 isolates 
differ only at the ddl locus and studies have shown that PFGE patterns can also be 
very similar (Hall et al., 1996).   
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1.3.7.2 Clone England14-9, ST9 
Isolates of clone England14-9 were first identified in 1996 during an investigation of 
genetic relatedness within and between serotypes isolated from the UK (Hall et al., 
1996).   Hall et al identified two major groups that presented a high proportion of 
relatedness in MLEE and PFGE profiles; a clone 9V group in addition to a clone 14 
group (Hall et al., 1996).  The capsule of the serotype 14 is known to be poorly 
immunogenic in young children and in conjunction with its increasing incidence of 
erythromycin resistance contributes to its significance in invasive disease.  It is 
recognised as an internationally successful clone with reports from countries 
worldwide and was the 9th clone to be included in the PMEN dataset; Portugal (Sá-
Leão et al., 2001), Greece (Tsolia et al., 2002), USA(Gherardi et al., 2000), Italy 
(Dicuonzo et al., 2002), Argentina (Sá-Leão et al., 2001), Australia 
(http://spneumoniae.mlst.net/) and Belgium (http://spneumoniae.mlst.net/).  
 
The England14-9, ST9 clone is resistant to erythromycin.  The acquisition of 
erythromycin resistance in this clone was examined in a British general hospital 
(Birtles et al., 2004).  From 2000 – 2001, pneumococcal isolates were obtained from 
56 patients.  Serotypes were determined and isolates were genetically characterised by 
MLST and PFGE.  The mechanism of erythromycin resistance was identified by 
amplification of mefA or ermB.  A total of nineteen serotype 14 isolates were 
identified, fourteen of which displayed erythromycin resistance.  All fourteen isolates 
were characterised as isolates of clone England14-9 by MLST (ST9) and PFGE.  
Results showed that the mechanism of erythromycin resistance for this clone was by 
mefA carriage, associated with efflux resistance (Birtles et al., 2004). 
 
The England14-9, ST9 clone is a SLV of ST15 and part of its clonal complex (CC15). 
This clone continues to evolve and there are now 40 SLVs in CC15.  This clone was 
chosen as although it is erythromycin resistant, unlike most clones it has not acquired 
resistance to multiple antimicrobial agents. 
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1.3.7.3 Clone Taiwan19F-14, ST236 
Isolates of clone Taiwan19F-14 were first identified in an investigation of antibiotic 
resistant pneumococci in Taiwanese hospitals between 1993 and 1997 (Shi et al., 
1998).  A total of 74 penicillin non-susceptible isolates were obtained from patients in 
6 Taiwanese hospitals.  MLST was performed on all 74 isolates and produced 16 
different allelic profiles.  The largest group contained 29 isolates that were all 
serotype 19F and had STs that were either identical or differed at a single locus (Shi et 
al., 1998).  PMEN subsequently included this clone in the collection as Taiwan19F-14 
ST236, the 14th clone to be added.  This clone was present in Taiwan as early as at 
least 1993.  In 1995, two serotype 19F isolates originating in London were identified 
to be indistinguishable by MLST (http://spneumoniae.mlst.net/). Its dissemination 
was also documented in Hong Kong (Ip et al., 2002), Vietnam (Bogaert et al., 2002), 
South Africa (McGee et al., 2001a), USA (Robinson et al., 2001a), New Zealand 
(Bean and Klena, 2005), Greece (http://spneumoniae.mlst.net/) and Australia 
(http://spneumoniae.mlst.net/).   
 
Taiwan19F-14 is multi-drug resistant to sulfamethoxazole-trimethoprim, erythromycin, 
penicillin and tetracycline. The mechanism of macrolide resistance in clone 
Taiwan19F-14 is by carriage of mefE, a transposon of the Tn916 family (Tn2009) 
(McGee et al., 2001b).  Its allelic variant however, ST271, carries mefE in addition to 
ermB as this variant carries Tn2010 which includes both elements.  Chromosomal 
sequence analysis of Taiwan19F-14 and its allelic variant showed that Tn2009 and 
Tn2010 inserted at the same site, respectively (Del Grosso et al., 2007b).  The 
Taiwan19F-14 clone acquired tetracycline resistance through acquisition of Tn2009 as 
this element also contains tetM (Del Grosso et al., 2007b).   
 
This clone is part of the clonal complex 271 (CC271). Taiwan19F-14, ST236 is a SLV 
of ST271.  This clone continues to evolve and there are a total of 57 SLVs currently in 
CC271.  Clone Taiwan19F-14 was chosen following sudden emergence in New 
Zealand (Bean and Klena, 2005) which allowed the possible detection of very recent 
or short term changes.   
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1.4 DNA repair and damaging agents 
 
DNA is subject to continual damage which can lead to spontaneous alteration as a 
result of errors in processes such as replication, recombination and repair itself.  
Damage can also arise from interaction with a number of chemical compounds found 
naturally in the environment.  This damage can lead to the termination of replication 
machinery and therefore affect cell viability.  Although organisms have developed 
systems to deal with DNA lesions, some lesions may persist and the cell is then under 
severe stress.  As a result, specialised translesion synthesis (TLS) polymerases are 
recruited to bypass these lesions, often by introducing mutations, in an attempt to 
rescue the cell. 
 
Various chemicals can be used in the laboratory to produce DNA lesions.  Such 
agents can thus be used experimentally to investigate the response to severe DNA 
damage. The second part of this project was based on investigating the effect of 
alkylating agents and oxidative damage on isogenic S. pneumoniae dinB mutants.  
DinB (described in section 1.4.4) encodes a polymerase, which in E. coli is involved 
in the repair of severe DNA damage. This section will therefore explain the 
mechanisms of DNA repair, the nature of the DNA damaging agents used and the 
presumed role of dinB from studies on E. coli..     
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1.4.1 DNA repair 
Repair of DNA is essential for the preservation and transmission of genetic 
information and a number of mechanisms exist to reduce the amount of mutation 
which becomes permanently fixed in the genome.  Some damage tolerance 
mechanisms however result in a permanent fixture of mutations in the genome.  In 
evolutionary terms, the ability to tolerate DNA damage is as important as the ability 
of eliminating damage.   The type of repair initiated is specific to the type of damage 
caused and each uses particular enzymes in an attempt to reverse damage.  Other 
mechanisms take advantage of natural homologous recombination in the cell.  
 
1.4.1.1 Base excision repair 
Direct reversal repair is limited, however, the most frequently occurring in nature 
involves removal of the incorrect or damaged base by excision from the genome.  
This is achieved by the use of DNA glycosylase which hydrolyses the glycosidic bond 
leaving the sugar-phosphate backbone intact. This creates an apurinic/apyrimidinic 
site, known as the AP site.  Apurinic/apyrimidinic endonucleases then recognise and 
remove the AP site by producing a nick in the duplex DNA.  This is excised by DNA 
deoxyribophosphodiesterase (dRpase).  The remaining gap is filled in during repair 
synthesis and ligated by DNA ligase (reviewed in (Friedberg, 1995)) 
 
Base excision repair is mostly important for the removal of damage caused by 
oxidative stress in which deamination generates highly mutagenic lesions such as 
uracil, hypoxanthine, and xanthine (Kow, 2002). The DNA glycosylases involved in 
their repair recognise and excise specific types of DNA damage.  In both S. 
pneumoniae and E. coli, Uracil for example is repaired by uracil-DNA glycosylase 
(the product of ung) (Chen and Lacks, 1991), while in S. pneumoniae the mutY 
homologue gene product is a DNA glycosylase responsible for the removal of adenine 
from G-A mismatches (Samrakandi and Pasta, 2000).   
 
1.4.1.2 Nucleotide excision repair 
Nucleotide excision repair (NER) is a similar process to BER but involves removal of 
around 12 to 13 nucleotides that include the damaged base caused by UV radiation.  
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The NER system does not recognise specific lesions but instead is able to identify the 
lesion because of the conformational changes that have occurred within the DNA 
molecule (Van Houten, 1990).  
 
Although deficient in photoreactivation and some SOS-like repair functions, S. 
pneumoniae can perform excision repair following exposure to UV light and research 
indicates that the mechanism used to repair such damage may be similar to that seen 
in E. coli (Sicard and Estevenon, 1990). Homologues of the E. coli UvrABC proteins, 
involved in NER, have been identified in the pneumococcus (Sicard and Estevenon, 
1990).  Most research on the mechanism of NER however has been conducted in 
E.coli and the mechanism described is summarised from work carried out in this 
organism; NER is controlled by the UvrABC endonuclease enzyme complex.  This 
complex consists of four Uvr proteins: UvrA, UvrB, UvrC, and DNA helicase II (also 
known as UvrD).  The first step involves DNA scanning by the UvrA-UvrB complex.  
The UvrA subunit recognises and binds the damaged site, while also recruiting UvrB 
to the area.  Following dissociation by UvrA, UvrB then recruits UvrC which makes 
an incision 8 nucleotides away from the distortion on the 5’ end and 4 nucleotides 
away on the 3’ end. DNA helicase II then excises the 12-nucleotide long single-
stranded DNA. The remaining gap is subsequently filled in by DNA polymerase I and 
DNA ligase (Dorson and Moses, 1978).  Larger areas of DNA up to 1500bp have also 
been known to be removed, referred to as long patch excision repair (Kuemmerlt 
1981).  
 
1.4.1.3 Mismatch repair 
Stability of the genome is maintained through the occurrence of replication, 
recombination and repair.  During replication and recombination or through chemical 
modification, insertion, deletion and mis-incorporation of bases can arise.  Mismatch 
repair (MMR) is a repair mechanism similar to BER, involving recognition and repair 
of mismatched nucleotides.  This system was first recognised in S. pneumoniae 
transformation studies where variation in integration efficiencies was observed for 
different genetic markers (Lacks, 1966).  Markers integrated with high efficiency 
(HE) result in yields of one transformant per genome equivalent of donor DNA 
entering the cell.  Transformation efficiencies of other markers, low efficiency (LE) 
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markers, result in a yield typically around 5 to 20-fold lower than HE markers for the 
equivalent quantity of DNA taken up (Tiraby and Fox, 1974) (LE and HE markers 
were also  described in section 1.2.3, genetic recombination). Subsequent to the 
discovery of varying transformation efficiencies, it was proposed that markers 
integrated with low efficiency were excised and repaired from the chromosome 
(Ephrussi-Taylor and Gray, 2005).  This was confirmed when S. pneumoniae hex 
mutants that did not distinguish between high and low efficiency markers were 
identified (Lacks, 1970).  Interestingly, hex mutants were identified to have an 
increased mutation rate, highlighting the importance of hex-dependent MMR in 
mutation evasion.  Transformation experiments have also shown that the Hex MMR 
system recognises frameshift mutations.  Donor DNA that contained +1 frameshifts 
were transformed with similar frequency to low efficiency markers (Gasc and Sicard, 
1986). 
 
Most research into the actual mechanism of this type of repair has been conducted in 
E. coli..  This system is known to be mediated by the mutSLH system.  MutS initially 
recognises the mismatched nucleotides or 1 – 4 unpaired bases and binds at that site 
(Junop et al., 2003). In the presence of ATP, MutS with MutL activates MutH 
endonucleases to cleave unmethylated daughter strand DNA at GATC sequences that 
are hemi-methylated (Hsieh, 2001).  The MutH generated nick initiates entry for 
helicase II, required for unwinding of the cleaved fragment, and exonucleases, for 
degradation.  Re-synthesis is conducted by DNA polymerase III and ligated by DNA 
ligase (Hsieh, 2001).  The S. pneumoniae Hex MMR system is similar to the Mut 
MMR system in E.coli, however, differences between the two mechanisms have been 
identified; strand discrimination is distinguished by strand breaks as opposed to 
methylation (Guild and Shoemaker, 1976) and there does not appear to be a 
pneumococcal mutH homologue (Reenan and Kolodner, 1992) 
 
1.4.1.4 The SOS response system of DNA repair and mutagenesis  
The SOS response has been most widely studied in E. coli. Although S. pneumoniae 
lack key components of this system (Gasc et al., 1980) it is important to outline this 
mechanism in E. coli for comparative purposes.  Replicative DNA polymerases 
function to accurately copy genomic DNA. If a lesion is encountered however, the 
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replication fork stalls as the polymerase is no longer able to progress.  An inhibited 
replication fork affects viability and the cell is therefore in a state of emergency.  As a 
last resort to rescue the cell from severe damage, the SOS response is initiated. This 
damage tolerance mechanism initiates translesion synthesis (TLS) polymerases to 
bypass lesions or errors in DNA, often by introducing mutations.  This allows the 
replicative polymerases to re-initiate and continue through the lesion site.  This 
system involves the use of over 40 genes, the majority of which are involved in 
replication, protection, repair and metabolism of DNA (Janion, 2008).   
 
The first genes identified to be involved in SOS repair were recA and lexA, genes 
previously found to be associated with recombination.  Their involvement in the SOS 
repair pathway was identified as a result of mutations which caused high sensitivity to 
UV irradiation (Clark and Margulies, 1965).  Their role in SOS repair is to maintain 
the down and up regulation of SOS-induced genes. LexA is a transcriptional repressor 
and RecA is involved in the inactivation of the LexA repressor thereby inducing the 
response (Horii et al., 1981, Walker, 1984) Every SOS-induced damage-inducible 
(din) or SOS gene contains a site specific ‘SOS-box’ located near the 
promoter/operator site.  This 20 nucleotide long SOS box binds the LexA repressor 
under normal conditions and thus prevents RNA polymerase binding the promoter 
sequence and initiating gene expression (Walker, 1984, Horii et al., 1981, Schlacher 
et al., 2006, Lewis et al., 1994). SOS gene activation occurs when DNA damage leads 
to the accumulation of single stranded DNA (ssDNA) at replication forks, where 
DNA polymerase is blocked.  This activates RecA coprotease activity, which 
promotes self- cleavage of LexA and thus allows transcription of SOS genes to occur 
(Kim et al., 1997).  
 
Most SOS induced genes are involved in various repair mechanisms such as lesion 
bypass which requires specialised polymerases (Rattray and Strathern, 2003). Five 
polymerases have been isolated in E. coli, DNA polymerase I–V (Pol I–V).  Pol I and 
Pol III are replicative polymerases responsible for lagging strand maturation and 
leading strand replication, respectively.  The remaining three polymerases are all 
involved in TLS. DNA polymerase II is a high-fidelity polymerase (Cai et al., 1995) 
which re-initiates replication of UV-induced lesions in an error free manner.  Most 
lesion replicative bypass involves polymerases from the Y family (Yang, 2003).  
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DNA polymerase IV and V belong to this family. Y family polymerases are found in 
prokaryotes, eukaryotes and archea (Yang, 2003). They are typically low fidelity 
polymerases which lack 3’ – 5’ exonucleases activity (Wagner et al., 1999). DNA 
polymerase IV (encoded by dinB) is a TLS polymerase and has an abundancy in the 
cell which is increased 10-fold by the SOS response (Kim et al., 2001).  The details of 
this polymerase will be discussed further in section 1.4.4.  Pol V is also involved in 
TLS, allowing re-initiation of replication subsequent to arrest by UV damage 
(Hanaoka, 2001).  
 
S. pneumoniae do not appear to have an SOS response typical of E. coli; an increased 
mutation rate following UV exposure was not observed in S. pneumoniae (Gasc et al., 
1980) and there does not appear to be a homologue of LexR, which is vital in SOS 
induction (Little et al., 1981). In E.coli mitomycin C damage is identified by the 
presence of ssDNA as it blocks the replication fork.  This leads to lexA repressor 
cleavage following RecA induction.  As mitomycin C induction of the lysogenic 
phage MMI was found to depend on RecA, it was initially presumed that the SOS 
activity of RecA may also be conserved in S. pneumoniae (Martin et al., 1995).  
However analysis of S. pneumoniae genome sequences did not identify any candidate 
for the SOS regulator that displayed the typical self-cleavage characteristic of the 
LexA family (Claverys et al., 2006).  Interestingly, it has been shown that induction of 
competence in S. pneumoniae is a mechanism of stress response (Claverys and 
Havarstein, 2002).   Prudhomme et al investigated the effect of mitomycin C, a DNA 
damaging agent that initiates the SOS response in E. coli, on the pneumococcal com 
regulon.  Results showed that RecA (fused with luc) was only induced in a comA 
proficient background.  This shows that the pneumococcal com system can be 
initiated in the event of stress (Prudhomme et al., 2006).    
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1.4.2 DNA damaging agents 
1.4.2.1 Chemical agents 
DNA lesions can occur as a result of exposure to a number of different chemical 
agents.  Alkylating agents are highly reactive electrophillic compounds that have an 
affinity for nucleophillic groups in macromolecules (Singer and Kuśmierek, 1982).  
They are widespread in the environment and are also a product of normal cellular 
metabolism.  They include various chemicals that cause mutagenic, carcinogenic, or 
cytotoxic effects. Alkylating agents form O-alkylated or N-alkylated adducts in DNA  
and a number of different sites in each of the four bases have been identified as 
potential sites (Wyatt and Pittman, 2006). 
 
1.4.2.2 EMS, MMS and NQO 
A number of alkylating agents exist, all of which can be used in vitro to study their 
affect on mutagenesis or to investigate repair mechanisms.  The mechanisms of 
different DNA damaging agents vary (Miller, 1983) and this project involves the use 
of three different alkylating agents; ethyl methanesulfonate(Hava et al.), methyl 
methanesulfonate (MMS) and 4-nitroquinoline-1-oxide (NQO). 
 
EMS is a direct mutagen which, although does not incorporate into the DNA itself, 
cause mutation by mispairing templates. EMS typically produces the abnormal base 
O6-alkylguanine. DNA polymerase thus places thymine opposite this abnormal base, 
as opposed to the correct cytosine and subsequent replication rounds lead to the 
presence of A:T in place of G:C (Miller, 1983). 
 
MMS and NQO are referred to as indirect mutagens that damage single or multiple 
nucleotides leading to the formation of adducts or DNA double stranded breaks that 
can stall the replication fork (Miller, 1983, Jarosz et al., 2006b, Williams et al., 2010).  
 
1.4.3.3 Oxidative damage 
Streptococcus pneumoniae produce relatively high amounts of hydrogen peroxide as a 
result of their natural metabolism (refer to section 1.1.3 on pneumococcal 
metabolism).  Although pneumococci have a mainly fermentative metabolism and 
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lack the proteins required for aerobic respiration, they are commonly found to reside 
in oxygen rich environments such as the respiratory tract.  In addition, S. pneumoniae 
do not appear to possess the proteins required for protection against oxidative stress 
that are found in other organisms.  It is therefore intriguing to find that pneumococci 
produce relatively high amounts of hydrogen peroxide, which although can increase 
the rate of mutation, does not appear to be inhibitive of growth (Pericone et al., 2002).   
 
Most of the literature on the effect of hydrogen peroxide (in relation to S. 
pneumoniae) is based on its affect on other organisms following production by 
pneumococci as well as factors that contribute to pneumococcal resistance of 
hydrogen peroxide.  Studies on E. coli as well as other organisms have shown that 
oxidative damage can occur in the form of oxidative DNA lesions, damaged and 
mismatched nucleotides and strand breaks (Farr and Kogoma, 1991, Demple and 
Harrison, 1994).   Like most organisms exposed to oxygen, E. coli possess catalase, 
an enzyme which functions to break down hydrogen peroxide.  Nevertheless, it has 
been shown that the recA gene product, involved in recombination (section 1.2.3) and 
the SOS response (Section 1.4.1.4) is more important with regards to damage 
tolerance (Carlsson and Carpenter, 1980).  Studies have shown that the exposure of E. 
coli cells to relatively small levels of hydrogen peroxide leads to initiation of the SOS 
response (Konola et al., 2000, Goerlich et al., 1989).  This is also true of other 
organisms.  Hydrogen peroxide production by S. pneumoniae has been shown to 
initiate the SOS response in S. aureus leading to resident prophage induction and 
ultimately cell lysis (Selva et al., 2009).  
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1.4.3 DNA polymerase IV 
It is evident that the SOS response is initiated in response to severe DNA damage in 
E. coli. Although the pneumococcus does not display a typical SOS response, its 
genome does include the dinB gene, encoding DNA polymerase IV. It does not 
however include PolV. PolIV is the only Y family polymerase that is evolutionarily 
conserved throughout all domains of life and taxonomically, is the most widespread 
(Ohmori et al., 2001). It was first identified in E. coli functional screening 
experiments to identify genes that have an increased expression following DNA 
damage (Kenyon and Walker, 2005) and subsequent findings have been identified in 
E.coli.   It is an error prone polymerase that allows bypass of lesions in cases where 
DNA damage has caused the polymerase to stall at the replication fork. It has the 
tendency to cause -1 frameshifts at mononucleotide repeats in addition to G to T 
transversions (Tang M et al., 2000)    In vivo, PolIV and its human homologue PolK 
have been shown to preferentially insert the correct nucleotide, dCMP, opposite 
various N2-deoxyguanine lesions (Jarosz et al., 2006a, Choi et al., 2006).  Its 
expression levels compared to PolV are substantial; in uninduced cells western blots 
do not detect the presence of Pol V, compared to Pol IV which is detected at a level of 
250 copies per cell.  Following SOS induction, PolV is detected at a level of 15 copies 
per cell compared to a considerable 2500 molecules per cell for polIV (Fuchs et al., 
2004).  These findings strongly suggest an important metabolic role for DNA 
polymerase IV which is yet to be elucidated.  Over expression of dinB leads to an 
increased mutation frequency (Kim et al., 1997).  Under conditions of stress, polIV 
has been shown to contribute significantly to mutagenesis. An increased mutation rate 
is observed, for example, following carbon source starvation (McKenzie et al., 2001).    
 
Bjedov et al investigated the effect of dinB deletion in different genetic backgrounds 
following exposure to three alkylating agents, EMS, MMS and MNNG. They 
investigated the sensitivity of alkA-  tag- strains that were either polIV proficient or 
polIV deficient (Bjedov et al., 2007).  In E. coli, alkA and tag are DNA glycosylases 
involved in BER, however they also deal with alkylating damage and are responsible 
for the removal of cytotoxic lesions. Bjedov et al inactivated alkA and tag as a number 
of DNA repair enzymes have the potential to act on the same site.  Results, shown in 
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figure 1.4.4 (taken from Bjedov et al., 2007) showed that dinB deficient strains were 
more sensitive to EMS, MMS and MNNG in all cases  (Bjedov et al., 2007).   
 
Figure 1.4.4: The sensitivity of E. coli to DNA damaging agents. Results from the 
Bjedov et al. study are shown (Bjedov et al., 2007).  Serial dilutions of dinB wild type 
(alkA tag) and knock out (alkA tag dinB) E. coli isolates up to 10-6 are spotted onto 
plates containing EMS, MMS and MNNG. Untreated control plates are presented at 
the top of the figure. 
 
 
Correlating results have been observed in additional studies with the use of different 
DNA damaging agents.  DinB mutants displayed increased sensitivity compared to 
dinB wild type isolates when exposed to NQO (Williams et al., 2010, Jarosz et al., 
2006b) and nitrofurazone (NFZ) (Jarosz et al., 2006b).  Evidence for a role of dinB in 
TLS is not limited to E. coli.  Increased sensitivity for dinB mutants was also 
observed when investigating the damaging effect of bile salts in Salmonella 
typhimurium (Prieto et al., 2006).  
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1.5 Aims of this project 
 
The aim of this research was to investigate the mechanisms by which pneumococci 
evolve using three clones that are presumed to have emerged within the last few 
decades: two multiply resistant clones, Spain9V-3 and Taiwan19F-14, and one that has 
not acquired multiple resistance, clone England14-9.   
 
In part one of the project the specific objectives were: 
 To analyse changes underlying polymorphisms of restriction fragments 
generated by a rare cutting restriction enzyme  
 To examine the contribution of recombination and mutation to allelic 
divergence in housekeeping genes in the three clones 
 To explore genetic differences underlying the reduced recombination in 
England14-9 
 
Based on part one findings it appeared that England14-9 would require an alternative 
mechanism to recombination in the repair of DNA breaks. One possible mechanism 
was DNA polymerase IV (encoded by dinB), which was also of interest due a natural 
deletion in the gene in Spain9V-3. The function of this gene had not previously been 
investigated in S. pneumoniae. Specific objectives of part two of the project were: 
 To generate isogenic mutants of dinB in different genetic backgrounds 
 To determine the spontaneous mutation frequency to rifampicin resistance and 
rpoB mutation spectrum in wild type and dinB mutant strains 
 To test the effect of dinB deletion on sensitivity to known DNA damaging 
agents EMS, MMS and NQO. 
 To test the effect of dinB deletion on sensitivity to hydrogen peroxide.  
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2.1 General methods 
General methods used throughout the project are described in this section (section 
2.1) followed by methods specific to chapter 3, diversity within and between clones 
(section 2.2) and chapter 4, investigation of dinB (section 2.3).  A description of all 
buffers and solutions used are included in appendix I.  Abbreviations are listed at the 
beginning of this thesis for reference.  Unless otherwise stated, chemicals and 
antibiotics were purchased from Sigma-Aldrich Ltd. (Gillingham, Dorset, UK).  
Culture media and supplements were obtained from Oxoid Ltd. (Basingstoke, 
Hampshire, UK). 
 
2.1.1 Bacterial strains, culture and stock 
All clinical isolates had originally been isolated from invasive disease specimens and 
stored at -70˚C in Protect Bacterial Preservers containing beads in cryopreservative 
fluid (Technical Service Consultants Ltd, Haywood, Lancashire, UK). 
 
From frozen stock beads, each isolate was plated on Iso-Sensitest agar containing 5% 
defibrinated horse blood.  A single colony of each clinical isolate from overnight 
plates was stored at -70˚C in new Protect Bacterial Preserves (Technical Service 
Consultants Ltd) to make fresh stocks for this project.  From new frozen stock beads, 
isolates were normally plated on Iso-Sensitest agar containing 5% defibrinated horse 
blood.  Cultures were normally grown in Brain Heart Infusion (BHI) broth (Oxoid). 
 
2.1.2 Genomic DNA extraction 
Bacterial strains for DNA extraction were initially grown on Iso-Sensitest agar 
(Oxoid) plates containing 5% defibrinated horse blood, incubated overnight at 37ºC in 
5% atmospheric CO2.  The following day, bacterial growth was collected from agar 
plates, dispersed in 10ml BHI broth (Oxoid) and incubated at 37ºC in 5% atmospheric 
CO2 for approximately 6 hours.  Subsequently, cells were collected by centrifugation 
for 10 minutes, 3000rpm.  The supernatant was discarded and cell pellets were 
resuspended in 0.1ml 1 x Tris-EDTA (TE).  Lysozyme (Sigma) was added to a final 
concentration of 5mg/ml and cell suspensions were subsequently incubated for 30 
minutes at 37ºC in 5% atmospheric CO2.  The following components were then 
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added; 10µl of 10% sodium dodecyl sulphate (SDS), proteinase K (0.5mg/ml), 50µl 
of 5M NaCl and 200µl phenol:chloroform:isoamylalcohol (25:24:1).  Lysates were 
thoroughly mixed before centrifugation at 13,000rpm for 15 minutes.  The top 0.2ml 
of supernatant was subsequently transferred to a fresh Eppendorf tube (Eppendorf UK 
Ltd., Cambridge, UK) and one volume of chloroform was added.  This was followed 
by centrifugation at 13,000rpm for a further 15 minutes.  The top 0.1ml of supernatant 
was then removed and again transferred to a fresh Eppendorf before adding two 
volumes of ethanol.  Samples were then centrifuged for 10 minutes, 13,000rpm.  
Subsequently, all supernatant was discarded and the pellet was dislodged in 0.5ml of 
fresh ethanol before being centrifuged for 5 minutes, 13,000rpm.  All supernatant was 
then discarded and the pellet was allowed to air dry before dissolving in 0.1ml 1 x TE. 
 
A 5µl sample of each genomic DNA extract was separated by electrophoresis in 0.9% 
agarose as described below to check for the presence of high molecular weight DNA.  
All extracts were stored at -20ºC. 
 
2.1.3 Agarose gel electrophoresis 
Agarose was prepared at a concentration of 0.9% by melting in 0.5x Tris-Borate-
EDTA buffer. The agarose was subsequently heated in the microwave until fully 
dissolved and allowed to cool.  The agarose solution was poured into a casting tray 
and left to set.  Solidified gels were then placed in a gel tank containing 0.5x TBE 
buffer. DNA samples (5 - 10µl) were loaded into wells.  Following electrophoresis at 
100V, the gel was placed in ethidium bromide (EtBr) for 10 minutes to allow 
subsequent visualisation of DNA under ultraviolet light (254nm) using GeneSnap 
software (Syngene, Cambridge, UK).   
 
2.1.4  DNA sequencing 
DNA sequencing was conducted from two independent PCR products using forward 
and reverse primers.  Sequencing reactions were conducted by the Queen Mary, 
University of London Genome Centre (Charterhouse Square, London).  Reactions 
were run on a 96 capillary Prism 3700 sequencing apparatus (Applied Biosystems, 
Warrington, UK), using end terminator chemistry BigDye v2.0 from Applied 
Biosystems.  Sequences were returned in the form of a chromatogram on 3700 Data 
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Collection Software v2.0.  The sequences from each reaction were used to form a 
consensus sequence using the BioEdit Sequence Alignment Editor and the ClustalX 
alignment programme. 
 
2.1.5 Polymerase chain reaction (PCR) 
Details of primers used are specified later according to chapter.  Primer stock 
solutions were prepared by adding molecular grade water to a final oligonucleotide 
concentration of 100pmole/µl.  A working dilution was then prepared for each primer 
by adding molecular grade water to a final oligonucleotide concentration of 
10pmole/µl. PCR reactions were set up by adding 5pmoles forward and reverse 
primer to 45 µl ReddyMix 1.1 (ABgene, Epson, Surrey, UK) containing dNTPs, DNA 
polymerase and 1.5mM MgCl2. Template DNA (1 µl) from genomic extracts was also 
added. The reaction was made to 50 µl by adding molecular grade water.  
Amplification was conducted on GeneAmp PCR system 9600 from Applied 
Biosciences (Warrington, UK). The programme cycle used is presented in table 2.1.5. 
 
Temperature (˚C) 
 
Time  Number of cycles 
94 3 1 
94 1 
50 1 
72 1 
 
35 
72 4 1 
4 ∞ 1 
Table 2.1.5: PCR amplification conditions 
 
Following amplification, 10µl of each PCR product was separated on a 0.9% agarose 
gel by electrophoresis and visualised under UV light (254nm) using GeneSnap 
software (Syngene).   
  
2.1.6 Restriction enzyme digestion 
Restriction enzymes were purchased from New England Biolabs (NEB) (New 
England Biolabs Ltd., Ipswich, UK).  Digests were performed in a 10μl reaction 
containing one unit of enzyme, 1μl NEB buffer 4, 5μl PCR product and 3μl molecular 
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grade water.  Digestions were carried out overnight and subsequently analysed on an 
0.9% agarose gel. 
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2.2 Methods:  Mechanisms of evolution in clones Spain9V-3, 
Enlgand14-9 and Taiwan19F-14 
2.2.1 Isolates 
In total, thirty five clinical isolates were selected from three clones recognised by the 
Pneumococcal Molecular Epidemiology Network (PMEN) (McGee et al., 2001b) 
(http://www.sph.emory.edu/PMEN/index.html): clones Spain9V-3; England14-9, and 
Taiwan19F-14. Isolates of Spain9V-3 and England14-9 were from a UK collection of 
invasive S. pneumoniae (isolated from blood or  Cerebrospinal fluid  (CSF)) that had 
been characterised previously in this laboratory (Hall et al., 1996). Isolates of 
Taiwan19F-14 were collected and characterised in New Zealand (Bean et al., 2004) 
and were kindly provided by Dr D. Bean.  Details of the isolates are given in Table 
2.2.1.  These isolates could be categorised as belonging to one of the three clones as 
they displayed the equivalent or very similar PFGE types to the PMEN reference 
clone (McGee et al., 2001b). 
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Table 2.2.1: Origin of Spain9V-3, England14-9 and Taiwan19F-14 isolates used in this 
study.  The serotype, PFGE type, antibiotic resistance profile and year of isolation is 
also Shown. P – Penicillin; CX – Cefotaxime; S/T – Sulfamethoxazole-trimethoprin; 
E – Erythromycin; TET – Tetracycline; Ref clone – PMEN reference clone. 
 
 
Isolate Serotype 
 
Origin 
Resistance 
profile 
PFGE 
type 
Year 
isolated 
PN93/909 9V Avon None 12a 1993 
PN93/917 9V Avon None 12b 1993 
PN93/1029 9V Eire P, CX, S/T 12c 1993 
PN93/1454 9V Hants P, CX, S/T 12d 1993 
PN93/1802 9V Greater London P, CX, S/T 12c 1993 
PN94/661 9V Greater London None 12e 1994 
PN94/812 9V Greater London P, CX, S/T 12f 1994 
PN94/926 9V Cheshire P, CX, S/T 12e 1994 
PN93/637 14 West Yorkshire E 14a 1993 
PN93/872 14 Devon E 14a 1993 
PN93/908 14 South Glamorgan E 14b 1993 
PN93/1565 14 Kent E 14a 1993 
PN93/1719 14 Dyfed E 14a 1993 
PN94/62 14 Worcs E 14b 1994 
PN94/153 14 East Sussex E 14c 1994 
PN94/336 14 West Midlands None 14d 1994 
PN94/469 14 Merseyside E 14d 1994 
PN94/653 14 West Midlands E 14a 1994 
STP002 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP003 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP013 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP022 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP026 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP028 19F Christchurch, NZ E, S/T, TET 1c 1997 
STP031 19F Christchurch, NZ E, S/T, TET 1a 1997 
STP038 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP057 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP110 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP133 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP138 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP194 19F Christchurch, NZ E, S/T, TET 1a 1998 
STP221 19F Christchurch, NZ E, S/T, TET 1d 1998 
STP269 19F Christchurch, NZ E, S/T, TET 1b 1998 
Ref clone 
Spain9V -3 9V 
(Coffey et al., 1991) 
 P, CX, S/T   
Ref clone 
England14-9 14 
(Hall et al., 1996) 
 E   
Ref clone 
Taiwan19F-14 19F 
(Shi et al., 1998) 
 E, S/T, TET   
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2.2.2 Polymerase Chain Reaction (PCR) 
2.2.2.1 MLST 
Internal fragments of the seven housekeeping genes were amplified in each isolate.   
Primer sequences were obtained from the MLST database (www.mlst.net) and are 
specified in table 2.2.2.1 along with associated sequence information.  Cycling 
conditions were as listed in table 2.1.5. 
2.2.2.2 SmaI sites 
The Artemis programme was used to select ~1500bp of sequence surrounding each 
SmaI site to construct a primer set (www.sanger.ac.uk) (Rutherford et al., 2000). 
Primers were then designed to cover the regions surrounding SmaI sites using primer 
3 (http://fokker.wi.mit.edu/primer3/input.htm).   Details of the SmaI primers used are 
shown in table 2.2.2.2.  Cycling conditions were as listed in table 2.1.5. 
Chapter 2 
 
 84 
Table 2.2.2.1: Primers for amplification of the seven MLST housekeeping genes. 
Primer 
Name 
Direction Sequence (5’ to 3’) Length 
(bp) 
Tm 
(˚C) 
GC 
(%) 
 
Product 
Size 
(bp) 
Forward GCCTTTGAGGCGACAGC 17 57.6 64.7 aroE 
Reverse TGCAGTTCA(A/G)AAACAT(A/T)TTCT 23 52.6 28.3 
 
405 
Forward ATGGACAAACCAGC(A/G/C/T)AG(C/T)TT 20 55.3 45 Gdh 
Reverse GCTTGAGGTCCCAT(A/G)CT(A/G/C/T)CC 20 61.4 60 
 
460 
Forward GGCATTGGAATGGGATCACC 20 59.4 55 Gki 
Reverse TCTCCCGCAGCTGACAC 17 57.6 64.7 
 
483 
Forward GCCAACTCAGGTCATCCAGG 20 61.4 60 recP 
Reverse TGCAACCGTAGCATTGTAAC 20 55.3 45 
 
450 
Forward TTATTCCTCCTGATTCTGTC 20 53.2 40 Spi 
Reverse GTGATTGGCCAGAAGCGGAA 20 59.4 55 
 
474 
Forward TTATTAGAAGAGCGCATCCT 20 53.2 40 Xpt 
Reverse AGATCTGCCTCCTTAAATC 20 53.2 40 
 
486 
Forward TGC(C/T)CAAGTTCCTTATGTGG 20 56.3 47.5 Ddl 
Reverse CACTGGGT(A/G)AAACC(A/T)GGCAT 20 58.3 52.5 
 
441 
Chapter 2 
 
 85 
Table 2.2.2.2: Primers used for SmaI site amplification. 
 
 
Primer 
Name 
Direction Sequence (5’ to 3’) Length 
(bp) 
Tm 
(˚C) 
GC 
(%) 
 
Product 
Size 
(bp) 
Forward CCATGTGTAGCGGTGAAATG 20 59.99 50 SmaI_1 
Reverse TTCCCTCACGGTACTGGTTC 20 59.97 55 
1737 
Forward GTGCAGTTGGGAGGGAGATA 20 60.0 55 SmaI_3 
Reverse AGACGGTTATTGGCAACCTG 20 59.9 50 
1936 
Forward TTGACGAGGGAACTTCTGCT 20 57.3 50 SmaI_4 
Reverse CAAGCGCCCTTCCAATACTA 20 57.3 50 
1430 
Forward CAGTGATGGCTGTGCCTAAA 20 57.3 50 SmaI_5 
Reverse TTCTTTTGGCGTGCTTCTTT 20 57.3 50 
1406 
Forward  AGCACAGGTCGATCCAGATT 20 57.3 50 SmaI_6 
Reverse AGCACAGGTCGATCCAGATT 20 57.3 50 
1337 
Forward  GGACACAACTTGCAAGAGCA 20 57.3 50 SmaI_7 
 Reverse GTGCATTTGCTTGAAGACGA 20 55.3 45 
1557 
 
Forward  GTTGGTTCTCGTGGGTCTGT 20 59.4 55 SmaI_8 
Reverse GAGGAACTCTGTCGCCTGAC 20 61.4 60 
1476 
Forward CGCTTTCAACACCAATTCTG 20 55.3 45 SmaI_9 
Reverse GTTATTAGGGGGCACCGTTT 20 57.3 50 
1574 
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Table 2.2.2.2: Primers used for SmaI site amplification 
 
Primer 
Name 
Direction Sequence (5’ to 3’) Length 
(bp) 
Tm 
(˚C) 
GC 
(%) 
 
Product 
Size 
(bp) 
Forward AAATCTAAGGGGCGTGTG 19 56.7 52.6 SmaI_11 
Reverse AAAAGGACTTAGCCTTGTGCA 21 55.9 42.9 
1402 
Forward TGGGAGTAGATGGCAAGA 20 59.4 55 SmaI_12 
Reverse CGTAAAGACATGCCCAAGGT 20 57.3 50 
1398 
Forward GCATTGCCTGGTTTGGTAAT 20 59.8 50 SmaI_13 
Reverse TCAAAACCGCGGAGCTTTACT 20 60.0 50 
1819 
Forward TGCCATTTTCATCACCTCAA 20 53.2 40 SmaI_14 
Reverse GGTGAGACCGAAGGTCGATA 20 59.4 55 
1041 
Forward  CATTTGAGCGAGCTTGGTTT 20 60.3 45 SmaI_15 
Reverse CTCAAGACAGCACTGGGTGA 20 60.0 55 
1560 
Forward  GGGGTGCAGTTCATCATTTC 20 60.3 50 SmaI_16 /_17 
Reverse TCCAGGAACTCCGTCAGCT 20 59.9 50 
3277 
Forward  ACCTGTCACTCGGATGAAGC 20 59.4 55 SmaI_18 
Reverse ACGAGGGTCTGTGACCAATC 20 59.4 55 
1392 
Forward  ACGCTGGACCTTGAAAGAGA 20 59.9 50 SmaI_19 
Reverse TTGCCCTATCGAGAATCAGG 20 60.1 50 
1783 
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Table 2.2.2.2: Primers used for SmaI site amplification 
Primer 
Name 
Direction Sequence (5’ to 3’) Length 
(bp) 
Tm 
(˚C) 
GC 
(%) 
 
Product 
Size 
(bp) 
Forward  CGTCGTCGCTAGGAGAAAAC 20 59.4 55 SmaI_20 
Reverse TGGCAGATGACTCTTGTTGC 20 57.3 50 
1372 
Forward CCAGTTACCCGACCTAACGA 20 59.9 55 SmaI_21 
Reverse ACTCCCAAAGGTCCCGTAGT 20 59.8 55 
1702 
Forward  TGCTCAACATCGACAGTTCC 20 57.3 50 SmaI_24 
 Reverse  TCAATTGCTCACGCTTCAAC 20 55.3 45 
1441 
Forward  TCATTGCGACTGGGGTAAAT 20 60.33 45 SmaI_27 
Reverse  AGACGTCATCGATGTGAACG 20 59.71 50 
1810 
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2.2.3 Pulsed Field Gel Electrophoresis (PFGE) 
2.2.3.1 Preparation of agarose embedded chromosomal DNA 
Isolates were grown overnight on Iso-Sensitest agar containing 5% defibrinated horse 
blood at 37˚C.  Bacterial growth was subsequently collected with a sterile cotton swab 
and suspended in 3ml PETT IV buffer.  This was conducted until a turbidity 
equivalent to a 3.0 McFarland standard was reached.  Cells were then collected by 
centrifugation for 3 minutes, 4˚C at 13,000rpm. The supernatant was discarded and 
the remaining cell pellet was suspended in 125l of PETT IV buffer.  Subsequently, 
1.6% pulsed field certified agarose (Bio-Rad Laboratories Ltd, Hertfordshire, UK) 
was heated until dissolved and sustained at 50˚C in a water bath.  Molten agarose 
(240l) was then mixed rapidly with cell suspensions and immediately injected into 
plug moulds (Bio-Rad) to form agarose plugs.  Plugs were left at room temperature 
for 10 – 15 minutes to allow solidification.   Solidified plugs were placed into sterile 
universal tubes containing 2 ml lysis buffer with lysozyme (final concentration 1 
mg/ml) and heat treated RNase (final concentration 20 g/ml).  Plugs were incubated 
overnight at 37˚C in a shaking water bath. Following overnight incubation, the lysis 
buffer was removed and replaced with 2 ml ESP buffer containing Proteinase K (final 
concentration 0.5 mg/ml). Plugs were incubated overnight at 50C.  Plugs were rinsed 
the following day by soaking in 20ml H20 for 30 minutes at room temperature. Plugs 
were then transferred to sterile universal tubes and washed by soaking in 1x TE buffer 
overnight at 4C. This step was repeated twice and plugs were subsequently cut into 3 
even pieces and stored at 4C in 1 ml of 1x TE until required.  
 
2.2.3.2 Restriction endonuclease digestion of agarose embedded DNA 
A single plug slice for each isolate to be tested was placed in a sterile 1.5ml 
Eppendorf tube. Plug slices were digested using the restriction endonuclease SmaI 
(NEB). For each reaction, 20 units of SmaI, 15 l of 10x buffer 4 (NEB) and 133 l 
of sterile dH2O were added. Reactions were incubated overnight at 25C. 
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2.2.3.3 Electrophoresis of agarose embedded DNA 
A 1% agarose gel was prepared by adding 1g of pulsed field certified agarose (Bio-
Rad) to 100ml 0.5x TBE buffer and heated until dissolved.  The gel was left to set.  
Agarose plugs were subsequently loaded into wells and sealed with 1% agarose to 
prevent plug movement.  The CHEF mapper and CHEF DRII system (Bio-Rad) were 
used for electrophoresis.  Once the gel was secured in the tank, 2L of 0.5x TBE 
running buffer was added and the following conditions were applied; running 
temperature 14˚C, gradient 6.0 V/cm, run time 22 hours, initial switch time 5 seconds, 
final switch time 35 seconds and a linear ramping factor.  Subsequent to 
electrophoresis, gels were stained for 30 minutes in EtBr (05g/ml) and visualised 
UV light (254nm) using GeneSnap software (Syngene).   
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2.2.4 Southern blot 
DNA separated by PFGE was transferred to a positively charged Hybond N+ 
membrane (GE Healthcare Life Sciences Ltd., Buckinghamshire, UK) by the 
following method; the gel was placed in 0.25M HCl for 15 minutes. The gel was then 
treated in denaturation solution for 30 minutes followed by neutralisation solution for 
30 minutes.  The transfer unit was then assembled and the gel was placed on the 
apparatus and covered with a sufficient volume of 20x SSC.  The transfer was then 
conducted for 120 minutes and the gel was subsequently re-stained and examined on 
the UV translluminator to estimate the transfer efficiency.  The membrane was 
removed and the transferred DNA was fixed to the membrane by exposure to 1200 kJ 
UV light for 30 seconds. All Southern hybridisations were conducted with the use of 
the non-radioactive digoxygenin-dUTP (DIG) DNA labelling and detection kit 
(Roche Products Ltd., Welwyn Garden City, Hertfordshire, UK).   
 
2.2.4.1 Probe labelling 
Probes were created using the PCR DIG probe synthesis kit which works by directly 
labelling digoxigenin (DIG) DNA fragments during amplification through direct 
incorporation of DIG-dUTP into the PCR product.  Labelling reactions were prepared 
according to table 2.2.4.1 and cycling conditions were as listed in table 2.1.5. 
 
Table 2.2.4.1: Labelling reactions for PCR DIG probe synthesis. 
 
 
 
Reagents 
 
DIG labelled probe Unlabelled control 
Enzyme mix 0.75 µl 0.75 µl 
PCR DIG labelling mix 2.5 µl - 
PCR buffer with MgCl2 5 µl 5 µl 
dNTP stock solution 2.5 µl 5 µl 
Forward primer 0.5 µl 0.5 µl 
Reverse primer 0.5 µl 0.5 µl 
Molecular grade water 37.25 37.25 
DNA 1 1 
TOTAL 
 
50 50 
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2.2.4.2 Probe hybridisation 
Hybridisations were conducted according to the manufacturer’s instructions.  Briefly, 
an appropriate volume of DIG easy hyb (10ml/100cm2 filter) was preheated to 
hybridization temperature (50ºC).  The membrane was placed in a 50ml Falcon tube 
(BD Biosciences Ltd., Oxford, UK) container and the filter was prehybridised for 30 
minutes with gentle agitation.  Following pre-hybridisation, the buffer was removed 
and replaced with the appropriate amount of pre-warmed DIG easy hyb 
(3.5ml/100cm2 membrane) containing denatured DIG-labelled DNA probe.  The filter 
was incubated overnight at hybridisation temperature (50ºC). 
 
2.2.4.3 Immunological detection 
Following hybridisation, immunological detection was conducted as per 
manufacturer’s instructions.  Briefly, stringency washes were conducted by washing 
the membrane in 2x SSC plus 0.1 % SDS solution for 15 minutes at room temperature, 
and two washes in 0.5x SSC plus 0.1% SDS solution for 15 minutes at 68°C. The 
membrane was subsequently incubated in blocking solution for 30 minutes, followed 
by antibody solution (anti-digoxigenin-alkaline phosphatase conjugate) for 30 
minutes, washing buffer (2 x 15 minutes) and finally equilibrated in detection buffer 
(5 minutes) before incubating the membrane in freshly prepared colour substrate 
solution (as outlined by Roche) until fragments became visible.  The membrane was 
then rinsed in dH2O to cease colour staining and left to dry. 
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2.2.5 SmaI restriction maps of sequenced database genomes 
SmaI restriction maps were constructed for R6, TIGR4, INV200, CGSP14 and T19F-
14 (accession numbers are listed in section 3.5.1) using the genamics expression 
programme. All FASTA sequences except INV200 were obtained from NCBI 
(www.ncbi.nlm.nih.gov/).  INV200 was obtained from the Sanger database 
(www.sanger.ac.uk/).  Each FASTA sequence was copied into genamics expression.  
The sequence surrounding each SmaI site (obtained previously for primer/probe 
design and database restriction digestion analysis) was copied into the genamics ‘find’ 
tab.  Matching SmaI sites were labelled 1 through 29.  SmaI site designated numbers 
correlate throughout all SmaI sequence maps in this document.  The SmaI recognition 
sequence (cccggg) was also searched to identify any new possible sites not previously 
identified in the original devised maps for R6 and TIGR4.  Fragment sizes and band 
order were then determined using the base locations of each SmaI site. 
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2.2.6 Regions of diversity 
A few studies have used microarray technology to identify RDs in the pneumococcal 
genome.  These studies were collectively analysed and summarised.  The sequence of 
TIGR4 and R6 were used to create a RD map.  Both sequences were opened in 
Artemis sequence viewer (http://www.sanger.ac.uk/resources/software/artemis/) 
(Rutherford et al., 2000) and the base location from 5’ to 3’ of each RD was located.  
FASTA sequence of each RD from all studies described (section 3.7.4) was obtained 
and numbered.  These RDs were applied to the previously constructed TIGR4/R6 
SmaI map for comparison and a table was devised to list the RDs and state the 
corresponding RD number in other studies.  RDs that correlated with the location of 
observed PFGE polymorphisms were investigated further. 
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2.3 Methods:  Investigation of dinB 
2.3.1 Isolates 
Three different isolate/strains were used to investigate the role of S. pneumoniae dinB.  
The avirulent laboratory strain R6 was isolated from its direct progenitor, R36A, in 
the 1950’s (Marmur and Hotchkiss, 1955).  These strains are descendents from the 
clinical serotype 2 isolate D39.  R6 was previously provided by Professor Christopher 
Dowson (University of Warwick, Coventry, UK).  CP1015, a mismatch repair 
deficient strain was produced from a cross of Rx, which is also related to R36A, with 
DNA from a streptomycin resistant isolate (Morrison et al., 1983, Hall et al., 1996) 
and was previously provided by Jean-Pierre Claverys. PN94 361 is a clinical isolate 
that has been previously characterised in this laboratory.  This isolate was from a UK 
collection of invasive S. pneumoniae  (Hall et al., 1996).  It is part of clone Greece6B-
22 and was isolated in Northern Ireland in 1994. 
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2.3.2 Polymerase Chain Reaction (PCR) 
Table 2.3.2 presents details of the primers used in the investigation of dinB. The dinB 
gene PCR conditions correlate with those specified in table 2.1.5.   
 
Primer 
Name 
Direction Sequence (5’ to 3’) Length 
(bp) 
Tm 
(˚C) 
GC 
(%) 
 
Product 
Size 
(bp) 
Forward 
 
GGCATGTTGATTTTTCCTTTG 21 54.0 38.1 dinB 
Reverse 
 
AGGCGGACACCTCTTTCTTT 20 57.3 50 
dinB 1017 
dinBΔ 4124 
Forward 
 
TGAAGTGAACGCTCTGTTGG 20 60.0   50 dinB-TET 
Reverse 
 
CCCATTTTCCTAGCATGA 21 59.9   42.8 
1662 
Forward 
 
ATCCTTTCTGGGCTTCCATT 20 55.3 45 TET-dinB 
Reverse 
 
GCCCATTTGATGAAGACGTT 20 55.3 45 
1671 
Forward 
 
CCAGGTGAGCCTAAGACAGC 20 61.4 60 Rifampicin 
Reverse 
 
CGGCAACTACCTGTTTTGGT 20 57.3 50 
1135 
Table 2.3.2: Primers used in the investigation of dinB. DinB – wild type dinB; dinBΔ 
– dinB knock out. 
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2.3.3 Transformation of dinB 
2.3.3.1  Transformation media 
CAT transformation medium was supplemented with 10ml K2HPO4, 3ml glucose, 
1.5ml 0.1 M calcium chloride and 7ml bovine serum albumin (8% solution) to 
produce the final transformation medium (TM). 
 
2.3.3.2 Competence induction 
TM broths were inoculated with a 10-2 dilution of thawed culture and incubated at 
37ºC for 3 hours.  Cultures were then split into 1ml aliquots.  To induce competence, 
0.1mM, NaOH and 1μg competence-stimulating peptide 1 (CSP-1) was added to each 
1ml aliquot culture.  Broths were then incubated at 37ºC for a further 20 minutes 
followed by the addition of donor DNA (dinB with the tetM insert) to the competent 
cultures for transformation.   Controls used in each experiment contained no 
exogenous DNA.   Broths were then incubated at 30ºC for 30 minutes, and then at 
37ºC for 2 hours.   
 
2.3.3.3 Selection of dinB knock out transformants 
0.1ml samples of the neat broth culture were plated on Iso-Sensitest blood agar plates 
containing tetracycline to select for dinB knock out transformants.  All plates were 
incubated at 37ºC for 48 hours.   Transformants that successfully grew on Iso-
Sensitest agar plates (5% defibrinated horse blood) containing tetracycline (8μg/ml) 
were re-plated twice before storing at -80˚C.  Genomic extraction followed by dinB 
PCR confirmed the presence of the mutant dinB gene. 
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2.3.4 Mutation frequency 
2.3.4.1 Preparation of frozen starter culture 
Frozen cultures were prepared from which to inoculate broth cultures, as detailed 
below. The number of cells and frequency of antibiotic resistant mutants present in 
the broth culture innoculum could therefore be determined. From frozen beaded 
stocks, each isolate was grown overnight on Iso-Sensitest Agar containing 5% 
defibrinated horse blood.  Colonies from the overnight plates were emulsified in 
separate 10ml BHI broths. Each 10ml culture was incubated at 37C, until the OD620 
reached around 0.4.  From each culture, a viable count was made by plating 0.1ml of a 
10-6 dilution on three plain Iso-Sensitest agar plates containing 5% horse blood.  To 
identify the number of pre-existing mutants present in the starting innoculum, 0.2ml 
of each culture was plated onto three replica antibiotic selective plates.  Plates were 
incubated at 37C in 5% atmospheric CO2 for 48 hours.  Separate 1ml aliquots of 
culture were frozen at -70C in 300l of glycerol for future mutation frequency 
experiments. 
 
2.3.4.2 Mutation frequency 
For each isolate, a 10-6 dilution of thawed starter culture (containing ~5 x 103 cells/ml) 
was used to inoculate five separate 10ml BHI broth cultures.  Cultures were incubated 
at 37C until OD620 readings reached 0.4. Viable counts were made by plating 0.1ml 
of a 10-6 dilution on three plain Iso-Sensitest agar plates containing 5% horse blood.  
The number of spontaneous resistant mutants was determined by plating 0.2ml 
samples of each neat culture onto three blood Iso-Sensitest plates containing 2mg/L 
rifampicin.  DinB mutant plates also contained tetracycline (8μg/ml). All plates were 
incubated at 37C in 5% atmospheric CO2 for 48 hours.  The mutation frequency of 
each culture was calculated as the fraction of mutants per normal viable cell. 
 
2.3.4.3 Mutation frequency following exposure to 4-Nitroquinoline 1-oxide (NQO) 
For each isolate, a 10-6 dilution of thawed starter culture (containing ~5 x 103 cells/ml) 
was used to inoculate five separate 10ml BHI broth cultures.  Cultures were incubated 
at 37C in 5% atmospheric CO2 until OD620 readings reached 0.2. The culture was 
then split into two separate 5ml broths; one untreated control broth and one broth 
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supplemented with 0.45% NQO.  Both cultures were incubated for a further hour at 
37˚C in 5% atmospheric CO2 and plated as described above. 
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2.3.5 Mutation spectrum 
A single colony from Iso-Sensitest plates (dinB and dinBΔ plates) containing 2mg/L 
rifampicin was selected and re-plated on rifampicin.  Plates were incubated overnight 
in 5% atmospheric CO2 at 37˚C.  The following day, a single colony was inoculated 
in 10ml BHI broth and incubated at 37˚C for 6 hours.  A genomic extraction of each 
culture was conducted as described in section 2.1.2. From each extract, 5μl was 
electrophoresed at 100V on a 0.9% agarose gel.  Following confirmation of genomic 
extraction, the rifampicin resistance gene (rpoB) was amplified in each isolate.  
Samples were run on a 0.9% agarose gel before being prepared for sequencing. 
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2.3.6 DNA damaging agents 
2.3.6.1 EMS, MMS and NQO 
A 10-4 dilution of thawed starter culture of each isolate was used to inoculate separate 
10ml BHI broth cultures. Cultures were incubated at 37C in 5% atmospheric CO2. 
For each concentration of EMS (Sigma), MMS (Sigma) and NQO (Sigma), 100ml of 
agar was made, autoclaved and left to cool in the water bath at 50˚C. When cultures 
reached around OD620 0.3, Iso-Sensitest agar was supplemented with different 
concentrations of DNA damaging agents and 5% horse blood, poured and left to set.  
When OD620 readings reached 0.4, serial 10 fold dilutions of each culture were made. 
A 7μl spot of each dilution was plated onto control plates with no agent and plates 
containing different concentrations of EMS, MMS and NQO.  DinBΔ plates were also 
supplemented with tetracycline (8μg/ml).  Plates were incubated at 37C in 5% 
atmospheric CO2 overnight. 
 
2.3.6.2 Hydrogen peroxide 
A 10-4 dilution of thawed starter culture of each isolate was used to inoculate separate 
20ml BHI broth cultures. Cultures were incubated at 37C in 5% atmospheric CO2 
until they reached OD620 0.3.  Cultures were split into 2ml aliquots and administered 
with different concentrations of H2O2 (Sigma) and control cultures were left untreated.  
All cultures were incubated at 37C in 5% atmospheric CO2 for 30 minutes.  A 10-4 
dilution of each culture was spotted in triplicate (7μl) on Iso-Sensitest agar 
supplemented with 5% horse blood.  DinBΔ plates were also supplemented with 
tetracycline (8μg/ml).  Plates were incubated overnight at 37C in 5% atmospheric 
CO2.  
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2.4 Statistical Methods 
 
2.4.1  Mann-Whitney U-test 
The Mann-Whitney U-test was used to compare rifampicin mutation frequencies 
produced by dinB and dinBΔ isolates in addition to rifampicin mutation frequencies 
following exposure to NQO.  The Mann-Whitney test is a rank sum method that 
compares differences in medians. All Mann-Whitney tests were performed on the 
Graph Prism 4 programme (GraphPad Software Inc., La Jolla, CA, USA) calculating 
the confidence intervals to 95%.   
 
The mutation frequencies produced by all replica cultures within each data set were 
entered into Graph Prism 4.  This calculated a 2-sided P value which indicated the 
presence or absence of a statistically significant difference between the two data sets.  
P values of <0.05 were considered significant, while those of <0.01 were considered 
highly significant. 
 
2.4.2  Chi-squared test 
The chi-squared test was used to compare the mutation to recombination ratios in 
database isolates of clones Spain9V-3, England14-9 and Taiwan19F-14.  Chi2 tests were 
performed on graph prism 4.   
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Chapter 3 
 
Diversity within and between clones of 
S. pneumoniae 
Chapter 3 
 
 103 
3.1 Description of isolates 
 
To investigate the mechanisms by which the pneumococcal genome evolves, we 
selected sets of isolates from three clones recognised by the Pneumococcal Molecular 
Epidemiology Network (PMEN): Spain9V-3; England14-9, and Taiwan19F-14 
(http://www.sph.emory.edu/PMEN/pmen_ww_spread_clones.html). Isolates of 
Spain9V-3 and England14-9 were from a UK collection of invasive S. pneumoniae 
(isolated from blood or CSF) that had been characterised previously in this laboratory 
(Hall et al, 1996). Isolates of Taiwan19F-14 were collected and characterised in New 
Zealand (Bean et al., 2004), and were kindly provided by Dr D. Bean. Details of the 
isolates are provided in the methods section (table 2.2.1).  These isolates could be 
categorised as belonging to one of the three clones, Spain9V-3; England14-9 or 
Taiwan19F-14, as they displayed the equivalent or very similar PFGE types to the 
PMEN reference clone. 
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3.2 MLST 
 
The relatively quick diversification of S. pneumoniae is attributed mainly to the 
occurrence of homologous recombination (Claverys et al., 2000).  Homologous 
recombination is thought to occur via transformation and involves a region of the 
chromosome being replaced by the homologous sequence from another 
pneumococcus (or closely related Streptococcus species). Diversification however 
also occurs less frequently by mutation. At the time of this study, MLST was the best 
established method to determine relatedness of isolates.   The MLST database 
contains over 5000 isolates that can be readily compared 
(http://spneumoniae.mlst.net/misc/info.asp).  An MLST allelic profile had not been 
obtained for all isolates used in this study and would further confirm PFGE evidence 
of belonging to a clone.  Furthermore, MLST allows the proportion of recombination 
and point mutation events in MLST loci to be quantified and compared within and 
between clones.   The aim was to determine whether the relative contributions of 
mutation and recombination differed between the three clones being investigated. 
 
Allelic profiles were obtained for all isolates in this study and most presented 
expected alleles at each locus, i.e. alleles that correlated with those from the PMEN 
reference clone.  A few isolates however have presented a differentiating allelic 
profile (described in sections 3.2.1, 3.2.2 and 3.2.3).  Such isolates represent clonal 
variants that have genetically evolved as a result of mutation/recombination. To 
examine whether the sequence of the divergent allele had changed as a result of 
mutation or recombination, the criteria from Feil et al was followed (Feil et al., 
2000b).  The sequence was initially compared to the allele sequence in the reference 
clone using BLAST align (http://blast.ncbi.nlm.nih.gov/), a programme which aligns 
two nucleotide sequences for comparison.  Once the differences were identified, the 
divergent allele was compared to all alleles of that locus in the MLST database to 
determine if the equivalent change had occurred anywhere else.  As previously 
described (section 1.3.5.1) genetic diversity was said to occur in the form of mutation 
if a single nucleotide change produced a novel allele. Alleles that presented one 
nucleotide change, present in multiple clonal complexes or multiple nucleotide 
changes were classified as recombinants.  
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3.2.1 Divergent allelic profiles for Spain9V-3 
 
Table 3.2.1: Clone Spain9V-3 isolates that presented a divergent sequence type (ST) 
from the MLST expected profile (ST156).  NC; represents number of nucleotide 
changes observed in the divergent allele; ST – sequence type defined by MLST; CC – 
represents the number of clonal complexes observed to contain the divergent allele; 
R/M –due to recombination or mutation. 
 
Three Spain9V-3 isolates were found to have a divergent ST profile compared to the 
expected due to a change in the ddl locus for each (table 3.2.1).  An example of the 
sequence chromatogram from isolate PN94 661 is presented (figure 3.2.1a). 
 
 
Figure 3.2.1a: PN94 661 ddl sequence chromatogram. Sequence change (change 1 
and 2) that resulted in the substitution of allele 1 with allele 14.  A – sequence from 
the ddl locus allele 14; B – Sequence from the ddl locus allele 1. Change 1 – from A 
to C; change 2 – from G to A.  
 
 
Spain9V-3 
 
ST 
 
aroE 
 
gdh 
 
gki 
 
rec P 
 
spi 
 
Xpt 
 
ddl 
 
NC 
 
     CC 
 
R/M 
Expected 
profile 
156 7 11 10 1 6 8 1  
PN93 909 162 7 11 10 1 6 8 14 2 Multiple R 
PN93 917 162 7 11 10 1 6 8 14 2 Multiple R 
PN94 661 162 7 11 10 1 6 8 14 2 Multiple R 
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Figure 3.2.1b: MLST data of allele 14. Allele 14 is confirmed to be present in other 
clonal complexes (this figure shows only seven of the multiple CC’s that contain 
allele 14 at the ddl locus).  
 
It is evident from the sequence read that an allele change from the expected 1 at the 
ddl locus to allele 14 involves two nucleotide changes; A>C at nucleotide 9 and G>A 
at nucleotide 289 (figure 3.2.1a).  This change is considered more likely to have 
occurred as a result of recombination as opposed to mutation for two reasons; firstly, 
it is highly unlikely that independent mutations occurred in all three isolates (i.e. the 
same two mutations in the ddl locus of PN93 909, PN93 917 and PN94 661). 
Secondly, the MLST database contains multiple clonal complexes that contain allele 
14 at the ddl locus (figure 3.2.1b). 
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3.2.2 Divergent allelic profiles for England 14-9 
 
Table 3.2.2: Clone England14 -9 isolates that presented a divergent sequence type (ST) 
from the MLST expected profile (ST9). NC; represents number of nucleotide changes 
observed in the divergent allele; CC – number of clonal complexes observed to 
contain the divergent allele; R/M – recombination or mutation. 
 
Of the ten clone England 14 -9 isolates, two produced a differentiating allelic profile.  
PN93 153 contained a change at the xpt locus.  PN94 336 contained the equivalent 
change at the xpt locus in addition to a change at the aroE locus (table 3.2.2). An 
example of the sequencing chromatogram is shown for isolate PN94 336 (figure 
3.2.2a and 3.2.2c). 
 
Figure 3.2.2a: PN94 336 xpt sequence chromatogram which shows the change from 
allele 1 to allele 3 (caused by a nucleotide change from A to G). A – sequence of the 
expected allele (allele 1); B – forward sequence of xpt allele 3 in PN94 336; C – 
reverse sequence in PN94 336. 
 
 
England14-9 
 
ST 
 
aroE 
 
Gdh 
 
gki 
 
rec P 
 
spi 
 
xpt 
 
ddl 
 
NC 
 
    CC 
 
R/M 
Expected 
profile 
9 1 5 4 5 5 1 8  
PN94 153 15 1 5 4 5 5 3 8 1 Multiple R 
PN94 336 new 14 5 4 5 5 3 8 1 None M/R 
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Figure 3.2.2b: MLST data of xpt allele 3 in other seven other clonal complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2c: PN94 336 aroE Sequence chromatogram showing the allele change 
from allele 1 to allele 14 (due to nucleotide change from C>T). A – Sequence of 
expected allele (allele 1); B – forward sequence of aroE allele 14 in PN94 336. 
 
The change at the xpt locus from allele 1 to allele 3 involved one change from A>G 
(figure 3.2.2a).  The same change occurred in the xpt allele of isolate PN94 153 and is 
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also present in the MLST dataset in multiple clonal complexes (figure 3.2.2b).  It is 
thus probable that recombination is the cause of this allele change.   
 
PN94 336 is a double locus variant and in addition to the xpt allele change, a change 
from allele 1 to 14 at the aroE locus was also observed (figure 3.2.2c).  The change at 
the aroE locus involved only one base change (C>T) and is therefore deducted to be 
the result of a mutation.  The allelic profile of this DLV has not previously been 
established in the MLST database and is therefore considered to be a new ST. 
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3.2.3 Divergent allelic profiles for Taiwan 19F-14 
 
Table 3.2.3: Taiwan19F-14 isolates that presented a divergent sequence type (ST) from 
the MLST expected profile (ST236). NC – nucleotide changes observed in the 
divergent allele; CC – number of clonal complexes observed to contain the divergent 
allele; R/M – recombination or mutation; N – new allele. 
 
 
Of the fifteen Taiwan19F-14 isolates, four produced a divergent MLST allelic profile 
(table 3.2.3).  The allele change at the aroE locus from 15 (ST 236) to 4 (ST 271) was 
present in all but one isolate, but is not considered in this study as an allele change 
(with respect to R/M) as it is a known polymorphism and represents a single locus 
variant of the Taiwan19F-14 clone which was common in New Zealand at the time. 
 
Figure 3.2.3a:  STP 013 spi sequence chromatogram.  The seven nucleotide changes 
(1 – 7) observed in the STP 013 spi locus that caused an allele change from 6 to 5. A 
– spi allele 6 (expected allele sequence); B and C – forward and reverse sequences, 
respectively, of spi allele 5 in STP 013. 
 
Taiwan19F-
14 
 
ST 
 
aroE 
 
gdh 
 
gki 
 
recP 
 
spi 
 
Xpt 
 
Ddl 
 
NC 
 
    CC 
 
R/M 
Expected 
profile 
236 15 16 19 15 6 20 26  
STP 013 new 4 16 19 15 5 21 26 7 Multiple R 
STP 057 new 4 16 19 15 6 21 195 31 Two R 
STP 194 1411 4 16 19 15 6 21 85 28 Two R 
STP 269 new 4 16 19 15 6 N 26 1 None M 
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STP 013 presented a difference from the expected ST at the spi locus and involved 
seven nucleotide changes to convert allele 6 to allele 5 (figure 3.2.3a).  As multiple 
mutations were observed in addition to the identification of these changes in multiple 
clonal complexes, this was accounted for as recombination (figure 3.2.3b).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3b: MLST data of spi allele 5 in six other clonal complexes 
 
 
STP 057 and STP 194 presented a difference at locus ddl.  STP 057 presented an 
allele change from 26 to 195 which involved 31 nucleotide changes and was present 
in one other clonal complex.  As a result, this allele change was said to occur as a 
result of recombination.  This specific sequence type has not been established in the 
MLST database and is thus considered to be a new ST.  The STP 194 ddl allele 
change involved 28 nucleotide changes and is seen in other clonal complexes and 
therefore results from recombination.  This ST has previously been identified as ST 
1411.  
 
Interestingly, a change observed in STP 269 at the xpt locus involving a single 
nucleotide substitution from a C>T had not previously been observed in the MLST 
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database and is therefore considered to be a new allele.  This was likely to have 
occurred from mutation as the single nucleotide change has not been observed in any 
other clonal lineage (figure 3.2.3c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3c: Sequence chromatogram of STP 269 xpt allele. Shows the allele 
change from allele 20 to the new allele not previously observed in the MLST 
database. A – xpt allele 20 sequence; B and C – forward and reverse sequence, 
respectively,  of the new xpt allele sequence which involves a C>T nucleotide change. 
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3.2.4 Summary of MLST data 
 
Table 3.2.4a: Summary of MLST results.  A full allelic profile was obtained for all 
Spain9V-3, England14-9 and Taiwan19F-14 isolates.  Those marked in bold represent 
differences in allele number when compared to the expected. Sequence type (ST) and 
clonal complex (CC) are also included.  
Isolate 
Sero 
-type aroE gdh gki recP spi xpt ddl 
 
ST 
 
CC 
PN93/909 9V 7 11 10 1 6 8 14 162 
PN93/917 9V 7 11 10 1 6 8 14 162 
PN93/1029 9V 7 11 10 1 6 8 1 156 
PN93/1454 9V 7 11 10 1 6 8 1 156 
PN93/1802 9V 7 11 10 1 6 8 1 156 
PN94/661 9V 7 11 10 1 6 8 14 162 
PN94/812 9V 7 11 10 1 6 8 1 156 
PN94/926 9V 7 11 10 1 6 8 1 156 
 
 
 
 
156 
PN93/637 14 1 5 4 5 5 1 8 9 
PN93/872 14 1 5 4 5 5 1 8 9 
PN93/908 14 1 5 4 5 5 1 8 9 
PN93/1565 14 1 5 4 5 5 1 8 9 
PN93/1719 14 1 5 4 5 5 1 8 9 
PN94/62 14 1 5 4 5 5 1 8 9 
PN94/153 14 1 5 4 5 5 3 8 15 
PN94/336 14 14 5 4 5 5 3 8 New 
PN94/469 14 1 5 4 5 5 1 8 9 
PN94/653 14 1 5 4 5 5 1 8 9 
 
 
 
 
 
15 
STP002 19F 4 16 19 15 6 20 8 271 
STP003 19F 4 16 19 15 6 20 26 271 
STP013 19F 4 16 19 15 5 20 26 New 
STP022 19F 4 16 19 15 6 20 26 271 
STP026 19F 4 16 19 15 6 20 26 271 
STP028 19F 4 16 19 15 6 20 26 271 
STP031 19F 4 16 19 15 6 20 26 271 
STP038 19F 4 16 19 15 6 20 26 271 
STP057 19F 4 16 19 15 6 20 195 New 
STP110 19F 4 16 19 15 6 20 26 271 
STP133 19F 4 16 19 15 6 20 26 271 
STP138 19F 4 16 19 15 6 20 26 271 
STP194 19F 4 16 19 15 6 20 85 1411 
STP221 19F 15 16 19 15 6 20 26 236 
STP269 19F 4 16 19 15 6 New 26 New 
 
 
 
 
 
 
 
 
271 
 
 
 
 
 
 
Spain 9V -3 9V 7 11 10 1 6 8 1 156 156 
 England 14 -9 14 1 5 4 5 5 1 8 9 15 
Taiwan 19F 19F 15 16 19 15 6 20 26 236 271 
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MLST results are summarised in table 3.2.4a.  In addition to divergent profiles, this 
table also includes MLST allelic profiles that correlated with the expected STs.  In 
total 11 allelic changes were identified (10 of which were analysed for the occurrence 
of recombination/mutation).  The mutation to recombination ratio for divergent alleles 
are presented in table 3.2.4b. 
 
Table 3.2.4b:  Summary of mutation (M) and recombination (R) events in the 
generation of MLST allelic variants of clones Spain9V-3 (3 variants), England14-9 (3 
variants) and Taiwan19F-14 (4 variants). The resulting percentage mutation is shown. 
 
 
Clone England14-9 presented the highest percentage mutation in the divergent alleles.  
This table however is for summary purposes only as numbers are too small to 
determine whether results are reflective of true R/M differences between the three 
clones.  
 
Clone M:R (total of divergent alleles) % Mutation 
Spain9V-3 0:3 (3) 0% 
England14-9 1:2 (3) 33.3% 
Taiwan19F-14 1:3 (4) 25% 
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3.3 Mutation Vs recombination data analysis 
 
Subsequent to recombination/mutation data analysis with the isolates used in this 
study, the MLST website was analysed to assess the extent of recombination/mutation 
as a means of genetic diversification on a much larger scale. As this study only 
allowed investigation of a small number of isolates from each clone, examination of 
the MLST database was beneficial as a much larger number of representatives that 
have been submitted by numerous laboratories worldwide could be analysed. This 
allowed enough data to be collected to explore whether the clones differ significantly 
in the contribution of recombination and mutation to the diversification of MLST 
alleles. 
 
To examine the extent of recombination/mutation, allelic profiles of all SLVs from 
each clone were compared to the reference ST.  The PMEN reference ST’s of the 
three clones used are presented in table 3.3 for reference. 
 
Clone ST aroE gdh gki recP spi xpt ddl 
Spain9V-3 156 7 11 10 1 6 8 1 
England14-9 9 1 5 4 5 5 1 8 
Taiwan19F-14 236 15 16 19 15 6 20 26 
Table 3.3: PMEN reference STs. Allele numbers for each of the seven housekeeping 
genes are presented, which in combination give the allelic profile or sequence type 
(ST) for the three PMEN reference clones. 
 
The MLST website was used to identify SLVs of each clone and the divergent locus 
was recorded (tables 3.3.1, 3.3.2 and 3.3.3). The occurrence of mutation Vs 
recombination was assessed in the same way as with the isolates used in this study; 
the number of nucleotide differences for each isolate were calculated in addition to 
the number of clonal complexes that contain the divergent alleles (section 3.2). 
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3.3.1 Spain9V-3 MLST dataset analysis for recombination/mutation 
Spain9V-3 aroE gdh gki recP spi xpt ddl 
Locus 
that 
differs CC NC M/R 
ST 156 7 11 10 1 6 8 1  
ST 44 1 11 10 1 6 8 1 aroE multiple 3 R 
ST144 7 5 10 18 6 8 1 recP multiple 1 R 
ST 144 7 5 10 1 6 8 1 gdh multiple 6 R 
ST 157 7 11 10 1 1 8 1 spi multiple 2 R 
ST 158 7 11 10 1 20 8 1 spi two 8 R 
ST 160 7 11 10 1 21 8 1 spi one 3 R 
ST 162 7 11 10 1 6 8 14 ddl multiple 2 R 
ST 164 7 11 10 1 6 34 1 xpt one 1 M 
ST166 7 11 10 1 6 1 1 xpt multiple 2 R 
ST 167 7 11 10 1 4 8 1 spi multiple 16 R 
ST 168 7 11 10 1 6 42 1 xpt one 1 M 
ST 265 7 34 10 1 6 8 1 gdh multiple 6 R 
ST 314 7 11 10 1 6 8 68 ddl multiple 3 R 
ST 333 7 11 4 1 6 8 1 gki multiple 7 R 
ST 334 7 11 10 16 6 8 1 recP multiple 1 R 
ST 355 7 11 10 1 6 8 23 ddl multiple 10 R 
ST 370 7 11 10 1 6 3 1 xpt multiple 1 R 
ST 379 7 11 10 1 10 8 1 spi multiple 6 R 
ST 539 7 11 10 1 9 8 1 spi multiple 14 R 
ST 548 7 11 10 1 36 8 1 spi multiple 1 R 
ST 557 7 11 10 1 6 58 1 xpt multiple 0 R 
ST 608 7 11 10 1 6 4 1 xpt multiple 1 R 
ST 669 4 11 10 1 6 8 1 aroE multiple 4 R 
ST 838 7 11 10 1 6 8 90 ddl multiple 37 R 
ST 860 40 11 10 1 6 8 1 aroE multiple 2 R 
ST 930 7 11 10 1 6 8 98 ddl multiple 32 R 
ST 933 20 11 10 1 6 8 1 aroE multiple 1 R 
ST 971 7 11 10 1 15 8 1 spi multiple 2 R 
ST 1042 7 11 10 1 6 8 129 ddl one 36 R 
ST 1043 7 11 10 1 86 8 1 spi one 27 R 
ST 1080 7 11 85 1 6 8 1 gki one 1 M 
ST 1184 7 11 10 1 6 8 28 ddl multiple 4 R 
ST 1227 7 11 10 29 6 8 1 recP multiple 7 R 
ST 1271 7 11 41 1 6 8 1 gki multiple 10 R 
ST 1357 7 11 10 1 6 143 1 xpt one 1 M 
ST 1556 7 11 10 12 6 8 1 recP multiple 3 R 
ST 1569 8 11 10 1 6 8 1 aroE multiple 2 R 
ST 1697 7 11 10 77 6 8 1 recP one 1 M 
ST 1864 7 11 10 1 6 8 203 ddl one 27 R 
ST 1893 7 11 10 4 6 8 1 recP multiple 1 R 
ST 1925 7 11 10 1 17 8 1 spi multiple 1 R 
ST 1984 7 62 10 1 6 8 1 gdh multiple 5 R 
ST 2025 88 11 10 1 6 8 1 aroE one 24 R 
ST 2128 7 11 10 5 6 8 1 recP multiple 1 R 
ST 2306 7 11 10 1 6 8 119 ddl multiple 34 R 
ST 2335 7 11 10 1 6 8 229 ddl multiple 35 R 
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ST 2356 7 11 10 1 134 8 1 spi one 1 M 
ST 2405 7 11 62 1 6 8 1 gki multiple 11 R 
ST 2545 7 11 10 1 6 8 241 ddl one 39 R 
ST 2596 16 11 10 1 6 8 1 aroE multiple 1 R 
ST 2616 7 11 10 2 6 8 1 recP multiple 3 R 
ST 2684 7 11 10 10 6 8 1 recP multiple 2 R 
ST 2692 7 11 10 1 11 8 1 spi multiple 7 R 
ST 2722 7 11 10 15 6 8 1 recP multiple 2 R 
ST 2739 7 11 6 1 6 8 1 gki multiple 12 R 
ST 2918 7 11 10 1 6 8 267 ddl one 35 R 
ST 2944 7 11 10 1 6 8 47 ddl multiple 26 R 
ST 2950 7 172 10 1 6 8 1 gdh one 19 R 
ST 2980 7 11 10 1 6 8 27 ddl multiple 3 R 
ST 3119 5 11 10 1 6 8 1 aroE multiple 4 R 
ST 3120 7 2 10 1 6 8 1 gdh multiple 7 R 
ST 3148 7 11 10 1 6 36 1 xpt two 31 R 
ST 3255 7 11 10 1 6 8 54 ddl multiple 35 R 
ST 3424 7 11 10 1 6 8 293 ddl two 35 R 
ST 3425 7 11 10 1 6 8 294 ddl two 33 R 
ST 3634 7 11 10 1 6 49 1 xpt multiple 3 R 
ST 3793 7 11 10 1 6 8 2 ddl multiple 35 R 
ST 3811 7 11 10 1 6 8 315 ddl one 3 R 
ST 3817 7 11 10 1 22 8 1 spi multiple 5 R 
ST 3819 7 11 10 6 6 8 1 recP multiple 3 R 
ST 3825 7 11 10 1 193 8 1 spi one 25 R 
ST 3826 7 11 209 1 6 8 1 gki one 1 M 
ST 3827 7 11 10 1 194 8 1 spi one 1 M 
ST 3830 7 11 10 1 6 275 1 xpt one 1 M 
ST 4024 7 11 10 1 6 8 8 ddl multiple 6 R 
ST 4026 7 11 10 1 6 8 316 ddl one 28 R 
ST 4147 7 149 10 1 6 8 1 gdh one 7 R 
ST 4148 7 217 10 1 6 8 1 gdh one 1 M 
ST 4151 7 11 10 1 6 8 67 ddl multiple 16 R 
ST 4181 7 11 10 1 6 8 343 ddl one 39 R 
ST 4380 15 11 10 1 6 8 1 aroE multiple 2 R 
ST 4388 7 11 1 1 6 8 1 gki multiple 9 R 
ST 4464 7 11 10 1 6 198 1 xpt multiple 34 R 
ST 4573 7 11 10 1 6 8 371 ddl three 2 R 
ST 4575 7 11 10 1 6 8 248 ddl two 32 R 
ST 4612 7 11 10 1 6 8 317 ddl one 51 R 
ST 4618 7 11 10 1 6 8 319 ddl one 27 R 
ST 4623 7 11 10 1 6 314 1 xpt One 38 R 
ST 4964 7 11 10 1 6 76 1 xpt One 1 M 
ST 4969 7 13 10 1 6 75 1 gdh One 1 M 
ST 4971 7 15 10 1 6 75 1 gdh One 2 R 
ST 4973 7 26 10 1 6 75 1 gdh One 7 R 
ST 5458 7 11 10 43 6 75 1 recP One 1 M 
ST 6519 7  11  10  1  6  8  4  ddl multiple 15 R 
ST 6350 7  11  10  108  6  8  1  recP Two 1 R 
Table 3.3.1: Recombination/mutation analysis for SLV’s of Spain9V-3, ST 156 in the 
MLST database.  The allele that differs from that in the expected profile (ST156) is 
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highlighted in yellow. CC – represents the number of clonal complexes observed to 
contain the divergent allele; NC –  number of nucleotide changes observed in the 
divergent allele; R/M – recombination/mutation. 
 
SLVs of the reference Spain9V-3 PMEN are listed in the table above.  MLST allelic 
profile data is continuously being added to the MLST website and this table provides 
the most up to date information as of December 2011.  A total of 95 Spain9V-3 SLV’s 
are present in the database.  Of those 95, only 13 (13.7%) were generated following 
mutation to one of the seven housekeeping genes.  An example of a Spain9V-3  SLV 
generated by mutation and recombination is illustrated below with ST 168 and ST 
265, respectively (figure 3.3.1a).   
 
The two sequence types are taken from table 3.3.1. 
Spain9V-3 aroE gdh gki recP Spi xpt ddl 
Locus 
that 
differs CC NC M/R 
ST156 7 11 10 1 6 8 1  
ST168 7 11 10 1 6 42 1 xpt one 1 M 
ST265 7 34 10 1 6 8 1 gdh multiple 6 R 
Figure 3.3.1a:  ST168 and ST265. An example of a Spain9V-3 SLV generated by 
mutation (M) (ST168) and by recombination (R) (ST265). CC – number of clonal 
complexes observed to contain the divergent allele; NC –  number of nucleotide 
changes observed in the divergent allele; R/M – recombination/mutation. 
 
ST 168 is a SLV of ST 156 as a result of mutation to the xpt locus.  Figure 3.3.1b 
shows that an MLST database query returned an output of only one clonal complex 
containing the xpt allele 42 locus. 
 
Figure 3.3.1b: Presence of xpt allele 42 in the MLST dataset. The allele is present in 
only one clonal complex (id 513, ST168). 
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The sequence of xpt allele 42 was then compared to the sequence of the xpt locus in 
the reference ST156, xpt 8, using the BLAST alignment tool.  The output showed that 
the change from allele 8 to 42 involved a single nucleotide substitution (C>A) (figure 
3.3.1c).  It is therefore predicted that ST 168 is a ST 156 SLV that was generated by 
mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1c:  BLAST alignment of xpt, ST168. A single nucleotide substitution 
(C>A, outlined in red) gives an allele change from allele 8 to allele 42 producing ST 
168.  Query – allele 8, xpt; Subject – allele 42, xpt. 
 
The gdh allele 34 (ST 265, also a SLV of ST 156) was shown to be present in 
multiple clonal complexes in the MLST dataset (figure 3.3.1d). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1d:  database 
query for the presence of gdh 
allele 34 in the MLST 
dataset. The output shows 
that gdh allele 34 is present 
in numerous clonal 
complexes. 
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The sequence of gdh allele 34 was then compared to the sequence of gdh allele 11 in 
the reference ST 156 using the BLAST alignment tool.  The output showed that the 
change from allele 11 to 34 involved 7 nucleotide changes Figure 3.3.1e.  It is 
therefore predicted that ST 265 is a ST 156 SLV that was generated by 
recombination. 
 
 
Figure: 3.3.1e:  BLAST alignment of gdh allele 11 with allele 34. Seven nucleotide 
substitutions (outlined in red) producing ST 265 shows that this allele change was 
generated by recombination.  Query – gdh allele 11; subject – gdh allele 34. 
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3.3.2 England14-9 MLST dataset analysis for recombination/mutation 
England14-9 
aro
E gdh gki 
rec
P spi xpt ddl 
Locus 
that 
differs CC NC M/R 
ST 9 1 5 4 5 5 1 8  
ST 7 1 5 4 1 5 1 8 recP Multiple 2 R 
ST 8 1 5 4 5 17 1 8 Spi Multiple 8 R 
ST 11 1 5 4 5 10 1 8 Spi Multiple 1 R 
ST 13 1 5 4 5 5 27 8 Xpt Multiple 4 R 
ST 14 1 5 4 5 5 1 14 Ddl Multiple 4 R 
ST 15 1 5 4 5 5 3 8 Xpt Multiple 1 R 
ST 24 1 5 4 5 5 1 24 Ddl Multiple 2 R 
ST 622 1 5 4 5 5 78 8 Xpt One 5 R 
ST 984 56 5 4 5 5 1 8 aroE One 1 M 
ST 1161 1 5 4 5 90 1 8 Spi One 1 M 
ST 1246 1 5 4 5 5 1 43 Ddl Multiple 1 R 
ST 1298 1 5 4 5 9 1 8 Spi Multiple 9 R 
ST 1563 8 5 4 5 5 1 8 aroE Multiple 1 R 
ST 1592 1 5 4 74 5 1 8 recP One 1 M 
ST 1687 1 5 4 76 5 1 8 recP one 1 M 
ST 1691 1 5 4 5 5 1 176 Ddl One 1 M 
ST 1775 1 5 4 5 5 1 39 Ddl Multiple 2 R 
ST 1817 1 5 4 18 5 1 8 recP Multiple 1 R 
ST 2436 1 5 4 5 5 4 8 Xpt Multiple 4 R 
ST 2437 1 5 4 5 5 6 8 Xpt Multiple 4 R 
ST 2498 1 5 4 5 5 1 233 Ddl One 1 M 
ST 2654 1 5 4 5 6 1 8 Spi Multiple 4 R 
ST 2922 1 5 4 5 5 20 8 Xpt One 3 R 
ST 3102 110 5 4 5 5 1 8 aroE One 1 M 
ST 3190 1 5 4 5 5 1 280 Ddl One 1 M 
ST 3451 1 5 183 5 5 1 8 Gki Two 16 R 
ST 3719 1 197 4 5 5 1 8 Gdh One 1 M 
ST 3720 1 5 4 5 5 262 8 Xpt One 1 M 
ST 3737 1 5 4 5 5 1 311 Ddl One 1 M 
ST 3833 1 5 4 5 5 276 8 Xpt One 1 M 
ST 3882 1 5 4 5 5 248 8 Xpt Two 1 R 
ST 3898 1 5 8 5 5 1 8 Gki One 3 R 
ST 4297 1 5 4 5 5 299 8 Xpt One 1 M 
ST 4359 1 5 4 5 5 1 352 Ddl One 1 M 
ST 4711 1 5 4 12 5 1 1 recP One 5 R 
ST 4714 1 5 4 5 5 1 318 Ddl One 1    M 
ST 5744 1 5 4 5 5 1 360 Ddl One 4 R 
ST 6047 1  5  4  5  5  320  8  Xpt One 1 M 
ST 6054 7  5  4  5  5  1  8  aroE Multiple 3 R 
ST 6126 1  5  4  5  263  1  8  spi One  1 M 
 Table 3.3.2: Recombination/mutation analysis for SLV’s of England14-9 in the MLST 
database, ST9. The allele that differs from that in the expected profile (ST9) is 
highlighted in yellow. CC – number of clonal complexes that contain the divergent 
allele; NC; nucleotide changes observed in the divergent allele; R/M – recombination 
or mutation. 
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A total of 40 England14-9 SLVs were present in the MLST database (table 3.3.2).  
Interestingly there was a relatively high proportion of mutation, with 17 out of 40 
(42.5%) SLVs generated as a result of mutation to one of the seven housekeeping 
genes.  
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3.3.3 Taiwan19F-14 MLST dataset analysis for recombination/mutation 
Taiwan19F-14 aroE gdh gki recP spi xpt ddl 
Locus 
that 
differs CC NC M/R 
ST 236 15 16 19 15 6 20 26  
ST 237 15 16 19 15 6 20 1 ddl Multiple 7 R 
ST 271 4 16 19 15 6 20 26 aroE Multiple 2 R 
ST 283 15 16 19 15 6 20 50 ddl multiple 29 R 
ST 299 15 16 19 2 6 20 26 recP multiple 3 R 
ST 351 15 16 19 15 6 20 6 ddl multiple 6 R 
ST 352 15 16 19 15 6 20 42 ddl multiple 31 R 
ST 651 15 5 19 15 6 20 26 gdh multiple 5 R 
ST 652 15 16 19 15 6 86 26 xpt one 1 M 
ST 712 15 16 19 15 6 20 106 ddl multiple 31 R 
ST 763 15 16 19 5 6 20 26 recP multiple 4 R 
ST 925 15 16 19 15 6 20 19 ddl multiple 6 R 
ST 926 15 16 19 15 6 20 14 ddl multiple 5 R 
ST 986 57 16 19 15 6 20 26 aroE one 1 M 
ST 1170 15 16 19 15 6 20 131 ddl two 27 R 
ST 1392 15 16 19 15 6 20 156 ddl one 31 R 
ST 1408 15 16 19 15 6 20 61 ddl multiple 34 R 
ST 1428 15 16 19 15 6 20 102 ddl multiple 40 R 
ST 1432 2 16 19 15 6 20 26 aroE multiple 2 R 
ST 1460 6 16 19 15 6 20 26 aroE multiple 3 R 
ST 1583 15 16 19 15 6 20 71 ddl multiple 10 R 
ST 1657 15 16 19 15 6 20 97 ddl multiple 37 R 
ST 1834 15 16 19 15 15 20 26 spi multiple 2 R 
ST 1937 8 16 19 15 6 20 26 aroE multiple 2 R 
ST 1942 15 16 19 15 6 20 208 ddl two 22 R 
ST 1943 15 16 19 15 6 179 26 xpt two 27 R 
ST 1945 15 74 19 15 6 20 26 gdh multiple 1 R 
ST 2116 15 16 19 15 6 20 125 ddl multiple 35 R 
ST 2320 15 16 19 15 6 193 26 xpt one 1 M 
ST 2321 15 16 19 15 6 20 226 ddl one 2 R 
ST 2322 15 16 19 15 6 20 228 ddl one 26 R 
ST 2323 7 16 19 15 6 20 26 aroE multiple 2 R 
ST 2694 15 16 19 1 6 20 26 recP multiple 2 R 
ST 2698 15 16 19 15 6 20 253 ddl one 9 R 
ST 2890 15 16 19 4 6 20 26 recP multiple 1 R 
ST 2920 1 16 19 15 6 20 26 aroE multiple 3 R 
ST 2967 15 16 19 15 6 228 26 xpt one 8 R 
ST 2993 15 16 4 15 6 20 26 gki multiple 10 R 
ST 2998 15 16 53 15 6 20 26 gki multiple 2 R 
ST 3141 15 16 19 15 6 20 5 ddl multiple 4 R 
ST 3182 15 16 176 15 6 20 26 gki one 1 M 
ST 3259 15 16 19 15 6 40 26 xpt multiple 5 R 
ST 3587 15 16 19 15 6 20 297 ddl two 36 R 
ST 3606 11 16 19 15 6 20 26 aroE multiple 1 R 
ST 3625 15 12 19 15 6 20 26 gdh multiple 3 R 
ST 3760 15 16 19 15 6 20 154 ddl multiple 32 R 
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ST 4235 143 16 19 15 6 20 26 aroE one 5 R 
ST 4251 15 16 19 10 6 20 26 recP multiple 2 R 
ST 4311 15 16 19 6 6 20 26 recP multiple 3 R 
ST 4365 15 16 19 15 6 20 355 ddl one 27 R 
ST 4414 15 16 19 15 6 20 4 ddl multiple 18 R 
ST 4471 15 16 14 15 6 20 26 gki one 25 R 
ST 4472 15 16 2 15 6 20 26 gki one 11 R 
ST 5052 15 29 19 15 6 20 26 gdh one 5 R 
ST 5160 15 65 19 15 6 20 26 gdh one 2 R 
ST 5650 15 16 19 15 6 20 396 ddl one 35 R 
ST 6682 15  16  19  15  6  25  26 xpt multiple 2 R 
ST 6792 15  16  19  15  17  20  26  spi multiple 2 R 
Table 3.3.3: Recombination/mutation data analysis for SLVs of clone Taiwan19F-14 in 
the MLST database.  The allele that differs from that in the expected profile (ST236) 
is highlighted in yellow. CC – number of clonal complexes that contain the divergent 
allele; NC; nucleotide changes observed in the divergent allele; R/M – recombination 
or mutation. 
 
Of the 57 Taiwan19F-14 SLVs included in the MLST dataset (table 3.3.3), only 4 had 
arisen by mutation to one of the seven housekeeping genes compared to 53 by 
recombination. 
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3.3.4 Summary of R/M data 
Table 3.3.4:  Summary of the MLST R/M database analysis.  Number of mutation 
(M) and recombination (R) events in the total MLST SLV population (total) for each 
clone with the resulting percentage mutation. 
 
 
The rate of mutation Vs recombination is summarised in table 3.3.4 Interestingly, 
clone England14-9 displayed a significantly higher percentage mutation compared 
Spain9V-3 (p = 0.0006) and compared to Taiwan19F-14 (p = <0.0001).  No significant 
difference was observed between the amount of mutation identified between clones 
Spain9V-3 and Taiwan19F-14 (p = 0.3189). 
 
Clone M:R (total) % Mutation 
Spain9V-3 13:82 (95) 13.7 
England14-9 17:23 (40) 42.5 
Taiwan19F-14 4:53 (57) 7 
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3.3.5 Analysing recombination and mutation as independent variables 
Table 3.3.5: frequency of mutation and recombination events among isolates of the 
three clones of interest submitted to the MLST database.  Only isolates with the ST 
predicted to represent the clone founder and single locus variants of that ST were 
included. 
 
Mutation and recombination events were analysed as independent variables by 
calculating the total number of isolates (founding ST and SLVs of founder) entered on 
the database for each clone (including multiple isolates of the same ST [entered by 
different groups]) and then determining the frequency of absolute 
mutation/recombination events (table 3.3.5).  This differs from the previous method of 
measuring the proportion of SLVs that are recombination and mutation events.  A 
total of 476 Spain9V-3 isolates, 388 England14-9 isolates and 418 Taiwan19F-14 
isolates have been entered onto the MLST database which include 285, 155 and 199 
SLVs, respectively.  Clone England14-9 showed the highest frequency mutation of all 
three clones (4.4 x 10-2), furthermore this clone had the lowest frequency 
recombination (6 x 10-2).   
 
The difference in mutation frequency between Spain9V-3 and England14-9 was not 
statistically significant (p = 0.2411).  However there was a significant difference in 
the occurrence of mutation between clones England14-9 and Taiwan19F-14 (p = 
0.0053).  The frequency of mutation in England14-9 was also significantly higher than 
for the other two clones together.  The recombination values for England14-9 were 
statistically different from both Spain9V-3 (p = <0.0001) and Taiwan19F-14 (p = 
0.0018). Furthermore, there was no significant difference of recombination between 
Spain9V-3 and Taiwan19F-14 (p = 0.0748).  Examining these events as separate 
Clone Total population of 
MLST isolates 
Number of mutation 
events 
(frequency) 
Number of 
recombinant events  
(frequency) 
Spain9V-3 
 
476 13 
2.7 x 10-2 
82 
1.7 x 10-1 
England14-9 
 
388 17 
4.4 x 10-2 
23 
6 x 10-2 
Taiwan19F-14 
 
418 4 
1 x 10-2 
53 
1.3 x 10-1 
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variables therefore suggests that the absolute frequency of recombination events was 
lower among submitted isolates for England14-9. There may also be a higher 
frequency of mutation in England14-9. 
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3.4 PCR and SmaI restriction enzyme digestion 
 
This part of the project was conducted to determine whether any changes to PFGE 
patterns (PFGE results are described in section 3.6) were due to point mutation in the 
SmaI recognition sequence.  SmaI sites were identified with the use of the Genamics 
Expression programme from the published genome sequences of R6 and TIGR4 in 
addition to the G54 sequence which at the time of analysis was incomplete. 
 
 
Figure 3.4a:  SmaI map of the fully sequenced avirulent laboratory strain R6.  Primers 
were designed to amplify regions surrounding SmaI sites (shown with SmaI site 15 as 
an example).  The resulting amplified product (not to scale) was digested to detect 
presence/absence of the SmaI site.  
 
Primers were designed for the regions surrounding each SmaI site.  Each primer pair 
was designed to give two different sized products upon digestion for clear cut 
analysis.  An example is illustrated in figure 3.4a for smaI site 15. This region was 
amplified in all isolates and run on a 0.9% agarose gel.  Subsequently, each amplified 
product was digested with SmaI to check for the presence/absence of the restriction 
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site.  Some sites were not included in the study for one of two reasons; because they 
failed to amplify or because they were located in rRNA genes. It must also be noted 
that there may be SmaI sites present in either of the three clones in this study that  
were undetected due to absence in all three NCBI reference genomes. The sites used 
in this study are summarised in table 3.4a. 
 
Sma_I site Use in this research Reference genomes that 
contain the site 
1 Within rRNA TIGR4, R6 and G54 
2 Within rRNA TIGR4, R6 and G54 
3 Within rRNA TIGR4, R6 and G54 
4 Failed to amplify TIGR4, R6 and G54 
5 Yes TIGR4, R6 and G54 
6 Yes TIGR4, R6 and G54 
7 Yes TIGR4, R6 and G54 
8 Yes TIGR4, R6 and G54 
9 Failed to amplify TIGR4 
10 Failed to amplify G54 
11 Failed to amplify R6 and TIGR4 
12 Yes TIGR4, R6 and G54 
13 Yes TIGR4 and G54 
14 Yes TIGR4, R6 and G54 
15 Yes TIGR4, R6 and G54 
16 Yes TIGR4 
17 Yes TIGR4 
18 Yes TIGR4, R6 and G54 
19 Yes TIGR4, R6 and G54 
20 Yes TIGR4 
21 Within rRNA TIGR4, R6 and G54 
22 Within rRNA TIGR4, R6 and G54 
23 Within rRNA TIGR4, R6 and G54 
24 Within rRNA R6 and G54 
25 Within rRNA TIGR4, R6 and G54 
26 Within rRNA TIGR4, R6 and G54 
27 Within rRNA TIGR4, R6 and G54 
28 Within rRNA TIGR4, R6 and G54 
29 Within rRNA TIGR4, R6 and G54 
Table 3.4a:  The 29 smaI sites identified in R6, TIGR4 and G54.  Yes – SmaI sites 
that amplified successfully and were used in research.  Some sites failed to amplify 
and some were within rRNA gene sequence so were not used. 
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Out of 429 sites tested, only one SmaI site (SmaI_6 in PN93 1802) was absent due to 
point mutation in the SmaI sequence, which was not identified in other isolates of the 
same clone.  Two other sites were found to be absent; SmaI_7 and SmaI_20 in PN93 
1802 (Spain9V-3) and PN93 1719 (England14-9).  However, these sites were later 
found to be absent in all isolates of Spain9V-3 and England14-9. 
 
The point mutation which abolished SmaI_6 in PN93 1802 is illustrated in figure 3.4b 
and c. This isolate was amplified with primers flanking SmaI site 6 to give a product 
of 1337 bp (figure 3.4b, lane 5).   
 
 
 
 
 
 
 
Figure 3.4b:  Amplification of region surrounding SmaI site 6. The expected product 
size is 1337bp. Lane 5 – contains isolate PN93 1802. L – 100bp ladder; B – no DNA 
control. 
 
The amplified products were then digested with SmaI.  The SmaI site digested 
product yielded two bands of 863bp and 474bp. The SmaI_6 PCR product in isolate 
PN93 1802 however did not digest. A single undigested band is observed at 1337bp.  
(figure 3.4c, lane 5).   
 
 
 
 
 
 
 
Figure 3.4c:  Digestion of the SmaI site 6 PCR product in the same isolates. Lane 5 – 
undigested PN93 1802. The remaining isolates contain SmaI_6 shown by a digested 
PCR product (two bands at 863bp and 474bp).  L – 100bp ladder. 
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This product was subsequently sequenced to confirm loss of SmaI site by mutation 
(figure 3.4d).  Sequencing results showed SmaI site 6 was lost by point mutation to 
the final nucleotide of the SmaI recognition sequence, G>A.  
 
 
 
 
 
 
 
 
 
 
Figure 3.4d: Sequence chromatogram of SmaI_6 site in isolate PN93 1802.  The loss 
of SmaI_6 is confirmed by nucleotide substitution to the last base in the recognition 
sequence CCCGGG (G>A). 
 
Sequencing was conducted with all SmaI sites that appeared to be abolished/created to 
confirm mutation in the SmaI recognition sequence. The two other absent sites 
(SmaI_7 and SmaI_20 in Spain9V-3 and England14-9 isolates) were found to differ in 
each clone.  The nucleotide change that abolished SmaI_7 in Spain9V-3 (CCTGGG) 
was different to that identified in England14-9 (CCCAGG).  An example of the 
SmaI_7 mutation is shown below (figure 3.4e). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4e: 
Sequence 
chromatogram of the 
region surrounding 
SmaI_7 in isolate 
PN93 1802.  The 
abolished SmaI site 
(outlined in black) 
contains a change at 
the third site in the 
SmaI recognition 
sequence CCCGGG 
(C>T). 
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The SmaI_20 mutation also differed between the two clones; CCCGAG was 
identified in the Spain9V-3 isolates and CTCGGG for England14-9 isolates.  An 
example is presented in figure 3.4f. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4f:  Sequence chromatogram of the region surrounding SmaI_20 in isolate 
PN93 1802.  The abolished SmaI site (outlined in black) has a change in the fifth 
nucleotide of the SmaI recognition sequence. 
 
SmaI_20 was also found to be absent in all Taiwan19F-14 isolates.  SmaI site 
restriction digestion results are summarised in table 3.4b.  
 
SmaI site lost Sequence  
 
Clone Isolate 
SmaI_6 
 
cccggA Spain9V-3 PN93 1802 
ccTggg Spain9V-3 All Spain9V-3 
isolates 
SmaI_7 
cccAgg England14-9 All England14-9 
isolates 
cccgAg Spain9V-3 All Spain9V-3 
isolates 
cTcggg England14-9 All England14-9 
isolates 
SmaI_20 
 
 
cTTggg Taiwan19F-14 All Taiwan19F-
14 isolates 
Table 3.4b: Summary of identified nucleotide changes to SmaI sites.  Nucleotide 
substitutions are in capital letters. 
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3.5 Analysis of SmaI sites in S. pneumoniae genomes submitted to 
NCBI 
At the time of this analysis (August 2011) 172 pneumococcal genome projects were 
listed on either NCBI (http://www.ncbi.nlm.nih.gov) or Sanger 
(http://www.sanger.ac.uk); 13 complete genomes were listed on NCBI, 5 additional 
complete genomes were listed on the Sanger website and include 23F, 700669, 
INV200, INV104B and OXC141, 42 were in contigs and the remaining projects were 
either SRA/trace projects or were unknown.  Information of all complete/draft 
genomes (as of August, 2011) are presented in tables 3.5.1a and b.   The 
presence/absence of all 29 SmaI sites (from R6, TIGR4 and G54) were investigated in 
sequences contained in the NCBI and Sanger database.  The sequence that surrounded 
each smaI site from forward to reverse primer was used to BLAST each 
pneumococcal genome on NCBI/Sanger to determine whether the smaI recognition 
sequence was intact.  As before, the sites investigated were only those that were 
present in R6, TIGR4 and G54.  Sites present in any of the 60 genomes that are not 
present in either of the three reference genomes were therefore not detected.    Results 
are presented in table 3.5.1c. 
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3.5.1 Complete sequences, draft sequences and those in progress that 
have been submitted to the NCBI/Sanger website 
Table 3.5.1a:  18 complete genome sequences listed on NCBI/Sanger (as of August 
2011).  Serotype, accession number and year of registration are included. 
 
 
 
 
 
 
 
Genome 
name 
Sequencing centre Serotype Accession 
number 
Date of 
registration 
R6 Eli Lilly and Company No capsule NC_003098 02/2003 
TIGR4 TIGR 4 NC_003028 02/2003 
D39 TIGR 2 NC_008533 10/2007 
G54 Institute for Genome sciences 19F NC_011072 07/2008 
Hungary 
19A-16 
J Craig Venter Institute 19A NC_010380 02/2008 
23F Wellcome Trust Sanger 
Institute 
23F NC_011187 09/2008 
700669 Wellcome Trust Sanger 
Institute 
Not 
specified 
NC_011900 01/2009 
JJA J Craig Venter Institute Not 
specified 
NC_012466 03/2009 
P1031 J Craig Venter Institute Not 
specified 
NC_012467 03/2009 
70585 J Craig Venter Institute Not 
specified 
NC_012468 03/2009 
T19F-14 J Craig Venter Institute 19F NC_012469 03/2009 
TCH8431/19
A 
Baylor College of Medicine 19A NC_014251 03/2009 
CGSP14 Beijing Institute of Genomics 14 NC_010582 04/2009 
INV200 Wellcome Trust Sanger 
Institute 
14 FQ_312029 07/2010 
INV104B Wellcome Trust Sanger 
Institute 
1 FQ_312027 07/2010 
OXC141 Wellcome Trust Sanger 
Institute 
3 FQ_312027 07/2010 
AP200 Istituto di Teconologie 
Biomediche, Consiglio 
Nazionale delle Ricerche 
Not 
specified 
NC_014494 09/2010 
670-6B PATRIC: Patho Systems 
Resource Integration Center 
6B NC_014498 10/2010 
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Genome 
name 
Sequencing centre Serotype Accession Date of 
registration 
TIGR (2) TIGR 4 NZ_AAGY02000
000 
06/2005 
SP9-BS68 Center for Genomic 
Sciences 
9F NZ_ABAB01000
000 
05/2007 
SP14-BS69 Center for Genomic 
Sciences 
14 NZ_ABAD01000
000 
05/2007 
SP11-BS70 Center for Genomic 
Sciences 
11 NZ_ABAC01000
000 
05/2007 
SP3-BS71 Center for Genomic 
Sciences 
3 NZ_AAZZ01000
000 
05/2007 
SP23-BS72 Center for Genomic 
Science 
23F NZ_ABAG01000
000 
05/2007 
SP6-BS73 Center for Genomic 
Sciences 
6 NZ_ABAA01000
000 
05/2007 
SP18-BS74 Center for Genomic 
Sciences 
18C NZ_ABAE01000
000 
05/2007 
SP19-BS75 Center for Genomic 
Sciences 
19F NZ_ABAF01000
000 
05/2007 
1807-00 J Craig Venter Institute Not 
specified 
NZ_ABFT010000
00 
09/2007 
1873-00 J Craig Venter Institute Not 
specified 
NZ_ABFS010000
00 
09/2007 
0288-04 J Craig Venter Institute Not 
specified 
NZ_ABGF01000
000 
10/2007 
3059-06 J Craig Venter Institute Not 
specified 
NZ_ABGG01000
000 
10/2007 
MLV 016 J Craig Venter Institute Not 
specified 
NZ_ABGH01000
000 
10/2007 
SP195 J Craig Venter Institute 9V NZ_ABGE01000
000 
10/2007 
1974 McGill University Not 
specified 
NZ_ABZC01000
000 
11/2008 
1974M2 McGill University Not 
specified 
NZ_ABZT01000
000 
11/2008 
Canada 
19A 
Ontario Agency for Health 
+ Promotion 
19A NZ_ACNU01000
000 
12/2009 
Canada 19F Ontario Agency for Health 
+ Promotion 
19F NZ_ACNV00000
00 
12/2009 
BS397 Center for Genomic 
Sciences 
Not 
specified 
NZ_ABWC01000
000 
08/2010 
BS455 Center for Genomic 
Sciences 
Not 
specified 
NZ_ADHN01000
000 
08/2010 
BS457 Center for Genomic 
Sciences 
Not 
specified 
NZ_ABWB01000
000 
08/2010 
BS458 Center for Genomic 
Sciences 
Not 
specified 
NZ_ABWA01000
000 
08/2010 
SP-BS293 Center for Genomic 9V NZ_ABWU01000 08/2010 
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Table 3.5.1b: Draft assembly genome sequences listed on NCBI or Sanger (as of 
August 2011). 
Sciences 000 
SPN021198 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACH00000000 08/2010 
SPN061370 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACJ01000000 08/2010 
SPN072838 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACI01000000 08/2010 
SPN1041 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACE01000000 08/2010 
SPN7465 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACF01000000 08/2010 
SPNA45 Wellcome Trust Sanger 
Institute 
Not 
specified 
CACG01000000 08/2010 
06-01-
003MEF 
Yale University Not 
specified 
AEGF01000000 09/2010 
ND6012 
 
Yale University 6C AFCA01000000 04/2011 
PT8114 
 
Yale University 6C AFCB01000000 04/2011 
07AR0125 Yale University Not 
specified 
AFBY01000000 04/2011 
BR1064 
 
Yale University 6C AFBZ01000000 04/2011 
GA04375 Institute for Genome 
Sciences 
Not 
specified 
AFAX01000000 04/2011 
GA17545 Institute for Genome 
Sciences 
Not 
specified 
AFGA01000000 05/2011 
GA17570 Institute for Genome 
Sciences 
Not 
specified 
AFGB01000000 05/2011 
GA41301 Institute for Genome 
Sciences 
Not 
specified 
AFGD01000000 05/2011 
GA41317 Institute for Genome 
Sciences 
Not 
specified 
AFGT01000000 05/2011 
GA47368 Institute for Genome 
Sciences 
Not 
specified 
AFGS01000000 05/2011 
GA47901 Institute for Genome 
Sciences 
Not 
specified 
AFGR01000000 05/2011 
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Table 3.5.1c: SmaI site presence (Y) absence (sequence) in NCBI/Sanger database genomes.  N/A – region surrounding the entire SmaI is absent. 
(Serotype). 
SmaI 
site 
INV 
104B 
(Bryant 
et al.) 
R6 
(NC) 
D39 
(2) 
OXC 
141 
(3) 
BS71 
(3) 
TIGR4 
(4) 
TIGR4-
2 
(4) 
BS73 
(6) 
670 
-6B 
(6B) 
ND601
2 
(6C) 
PT8114 
(6C) 
BR 
1064 
(6C) 
BS68 
(9F) 
SP195 
(9V) 
SP- 
BS293 
(9V) 
1 Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y 
2 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
3 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
4 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
5 Y Y Y Y Y Y Y Y Y cgcggg Y Y Y Y N/A 
6 Y Y Y tccggg Y Y Y Y Y cccgga cccgga Y Y Y Y 
7 Y Y Y Y Y Y Y Y Y Y Y Y Y cctggg Y 
8 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
9 N/A N/A N/A N/A N/A Y N/A N/A N/A N/A N/A N/A Y N/A N/A 
10 Y ccaggg ccaggg Y Y ccaggg ccaggg ccaggg ccaggg ccagga ccaggg ccagga Y Y ccaggg 
11 Y Y Y Y Y Y Y Y Y N/A N/A N/A Y Y Y 
12 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
13 Y ccaggg ccaggg Y Y Y Y Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
16 N/A N/A N/A Y Y Y Y N/A Y Y N/A Y N/A N/A N/A 
17 N/A N/A N/A Y Y Y Y N/A Y Y N/A Y N/A N/A N/A 
18 tccggg Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
20 ctcggg ctcggg ctcggg cccgag ctcggg Y Y Y ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg 
21 Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y 
22 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
23 Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y 
24 Y Y Y Y Y cctgag cctgag Y Y cctgag Y cctgag cctgag cctgag Y 
25 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
26 Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y 
27 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
28 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
29 Y Y Y Y Y Y Y Y Y Y N/A Y Y Y Y 
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Table 3.5.1c: SmaI site presence/absence in NCBI/Sanger database genomes.  N/A – region surrounding the entire SmaI site is absent; Y – yes; (Serotype). 
SmaI 
site BS70 
(11) 
CGSP-
14 
(14) 
INV 
200 
(14) 
SP14 
BS69 
(14) 
Hun 
19A-16 
(19A) 
TCH 
8341 
(19A) 
CAN 
19A 
(19A) 
BS74 
(18C) 
G54 
(19F) 
T19F-14 
(19F) 
SP19 
BS75 
(19F) 
CAN 
19F 
(19F) 
23F 
(23F) 
 BS72 
(23F) 
700669 
(?) 
1 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
2 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
3 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
4 Y Y Y Y Y cctggg Y Y Y cctggg Y Y cccgag Y Y 
5 Y N/A Y Y Y Y Y Y Y Y Y Y Y Y Y 
6 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
7 Y cccagg cccagg Y cctggg Y Y Y Y Y Y Y tccgag Y tccgag 
8 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
9 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
10 Y ccaggg ccaggg ccaggg N/A ccaggg N/A ccaggg Y ccagga ccaggg N/A Y N/A N/A 
11 N/A Y Y Y Y Y Y Y ctcggg Y Y Y Y Y Y 
12 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y cctggg Y Y Y Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y cccgag Y Y Y Y Y Y Y Y Y Y 
16 N/A N/A N/A N/A Y N/A Y Y N/A Y N/A Y N/A N/A N/A 
17 N/A N/A N/A N/A Y N/A Y Y N/A Y N/A Y N/A N/A N/A 
18 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
20 ctcggg ctcggg ctcggg ctcggg ctcggg cttggg cttggg ctcggg ctcggg cttggg Y cttggg ctcggg ctcggg ctcggg 
21 N/A Y Y N/A Y Y N/A N/A Y Y N/A N/A Y N/A Y 
22 Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y 
23 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
24 Y Y Y cctgag Y Y Y Y Y Y cctgag Y Y Y Y 
25 Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y 
26 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
27 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
28 Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y 
29 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
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Table 3.5.1c: SmaI site presence/absence in NCBI/Sanger database genomes.  N/A – region surrounding the entire SmaI site is absent; Y – yes;  (Serotype). 
SmaI 
site JJA 
(?) 
1031 
(?) 
70585 
(?) 
AP200 
(?) 
1807-
00 
(?) 
1873-
00 
(?) 
0288-
04 
(?) 
3059-
06 
(?) 
MLV01
6 
(?) 
1974 
(?) 
1974 
M2 
(?) 
BS397 
(?) 
BS455 
(?) 
BS457 
(?) 
BS458 
(?) 
1 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
2 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
3 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
4 Y Y Y Y Y Y cccgag cccgag Y Y Y Y Y Y Y 
5 Y Y Y Y cctggg Y cccgtg Y Y Y Y N/A N/A N/A N/A 
6 Y Y Y Y Y cccgga Y Y Y Y Y Y Y Y Y 
7 cctggg cctggg cctggg Y Y Y Y Y Y Y Y Y cccagg Y Y 
8 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
9 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
10 N/A Y N/A Y ccaggg ccaggg ccaggg ccagga Y ccaggg ccaggg ccaggg ccaggg ccaggg ccaggg 
11 Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y 
12 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y Y Y Y cctggg cctggg Y Y Y Y 
14 Y Y Y Y N/A Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
16 N/A Y Y N/A Y N/A N/A N/A Y N/A N/A N/A N/A N/A N/A 
17 N/A Y Y N/A Y N/A N/A N/A Y N/A N/A N/A N/A N/A N/A 
18 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
20 ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg Y ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg 
21 Y Y Y Y Y Y Y Y Y Y Y N/A N/A N/A N/A 
22 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
23 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
24 Y Y Y Y Y Y Y Y Y cctgag cctgag Y Y Y Y 
25 Y Y Y Y Y Y Y Y Y Y   Y Y Y Y Y 
26 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
27 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
28 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
29 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
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Table 3.5.1c: SmaI site presence/absence in NCBI/Sanger database genomes.  N/A – region surrounding the entire SmaI site is absent; Y – yes; (Serotype).
SmaI 
site 
SPN 
021198 
(?) 
SPN 
061370 
(?) 
SPN 
072838 
(?) 
SPN 
1041 
(?) 
SPN 
74765 
(?) 
SPN 
A45 
(?) 
06.01.0
03.MEF 
(?) 
07AR 
0125 
(?) 
GA 
04375 
(?) 
GA 
17545 
(?) 
GA 
17570 
(?) 
GA 
41301 
(?) 
GA 
41317 
(?) 
GA 
47368 
(?) 
GA 
47901 
(?) 
1 Y N/A Y Y Y Y N/A Y Y Y Y Y Y Y Y 
2 Y N/A Y Y Y Y N/A Y Y Y Y Y Y Y Y 
3 Y Y Y Y cctggg Y Y Y cctggg Y Y Y Y Y Y 
4 Y Y Y Y Y Y cccagg Y cctggg Y Y Y Y Y Y 
5 Y Y Y Y Y N/A Y Y Y Y Y Y Y Y Y 
6 cccgga Y cccgga Y Y Y N/A cccgga cccgga Y Y Y Y cccgga Y 
7 Y Y Y Cctggg Y Y Y Y Y Y cctggg Y Y Y Y 
8 Y Y Y N/A Y Y Y Y Y Y Y Y Y Y Y 
9 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
10 Y ccaggg Y ccgggg ccgggg Y N/A ccagga ccagga ccaggg Y Y ccaggg ccaggg ccaggg 
11 Y Y Y Y Y Y Y N/A Y Y Y Y ctcggg Y Y 
12 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y N/A N/A Y Y Y Y Y 
15 Y Y Y Y Y Y N/A Y Y Y Y Y Y Y Y 
16 Y N/A Y Y N/A Y N/A N/A Y Y N/A Y N/A Y N/A 
17 Y N/A Y Y N/A N/A N/A N/A Y Y N/A Y N/A Y N/A 
18 Y cccgga Y tccggg N/A Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
20 ctcggg ctcggg Ctcggg ctcggg ctcggg ctcggg ctcggg  ctcggg ctcggg Ctcggg ctcggg ctcggg ctcggg ctcggg ctcggg 
21 Y Y Y Y Y Y Y N/A Y Y Y Y Y Y Y 
22 Y Y Y Y Y Y N/A Y N/A Y Y Y Y Y Y 
23 Y Y Y N/A Y Y N/A Y Y Y Y Y Y Y Y 
24 Y Y Y Y Y Y N/A Y Y Y cctgag cctgag Y cctgaa cctgag 
25 Y Y Y Y Y Y N/A Y N/A Y Y Y Y Y Y 
26 Y N/A Y Y Y Y N/A Y Y Y Y Y Y Y Y 
27 Y Y Y Y Y Y Y Y Y Y Y N/A Y Y Y 
28 Y Y Y Y Y Y N/A Y N/A Y Y Y Y Y Y 
29 Y N/A Y Y Y Y N/A Y Y Y Y Y Y Y Y 
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The SmaI sites analysed for the 60 genomes include those tested in Spain9V-3, 
England14-9, and Taiwan19F-14 in addition to sites that could not be investigated 
(those that failed to amplify or reside in rRNA).  As previously mentioned, there are a 
total of 29 smaI sites when collectively analysing sequence information from R6, 
TIGR4 and G54.  In total, 1740 smaI sites across the 60 genomes were investigated.  
Of the 1740 SmaI sites, 143 contained a nucleotide change in the SmaI recognition 
sequence.  A summary of this analysis is presented in table 3.5.1d.  As the ancestral 
relationship for isolates in this database collection are not known the combination of 
recombination and mutation to SmaI site change can not be analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5.1d:  Summary of SmaI site changes observed in the 60 sequenced/draft 
genomes listed on NCBI/Sanger.  SmaI sites 1 though 29 (from R6, TIGR4 and G54) 
are included. None – no change to SmaI site; nucleotide change is indicated by capital 
letter and the number of genomes the change is observed in is in brackets. 
 
SmaI site 
Base substitutions observed that abolished a 
SmaI site (number of genomes observed in) 
1 None 
2 None 
3 ccTggg (2) 
4 ccTggg (3); cccgAg (3); cccAAg  
5 ccTggg; cccgTg; cGcggg  
6 Tccggg; cccggA (8) 
7 ccTggg (7); cccAgg (3); TccgAg (2) 
8 None 
9 None 
10 ccAggg (27); ccAggA (6); ccGggg (2) 
11 cTcggg (2) 
12 None 
13 ccAggg (2); ccTggg (3) 
14 None 
15 cccgAg  
16 None 
17 None 
18 Tccggg (2); cccggA  
19 None 
20 cTcggg (50); cccgAg; cTTggg (4) 
21 None 
22 None 
23 None 
24 ccTgAg (10) 
25 None 
26 None 
27 None 
28 None 
29 None 
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3.5.2 Comparison of SmaI sites in Spain9V-3, England14-9 and Taiwan19F-
14 isolates with database isolates 
To determine if SmaI site results from this study correlated with database information, 
SmaI restriction sites from Spain9V-3, England14-9 and Taiwan19F-14 isolates used in 
this research were compared to database isolates of the same serotype (9V, 14 or 19F)  
(table 3.5.2a).  STs of these database isolates were also determined using BLAST to 
identify the allele sequence and the MLST database to determine the allele number. 
The following database isolates were used.  
 
 
 
 
 
 
 
 
 
 
 
Table 3.5.2b compares the different MLST results observed already in this study 
(section 3.2) with the MLST types of database isolates in table 3.5.2a. All isolates 
were grouped and ordered in terms of similarity to their respective reference clone ST. 
 
Interestingly, there were a number of ST’s that correlated with ST’s identified in this 
study.  The database SP195 genome shared the same ST (ST 156) as 5 Spain9V-3 
isolates, in addition to the reference isolate (table 3.5.2b).   
 
The database INV200 shared the same ST (ST9) as England14-9 isolates (table 
3.5.2b), in addition to the reference isolate.  The England14-9 SLV observed in this 
study (PN94 153, ST 15, refer to section/table 3.2.4) was also seen in one of the 
database isolates (CGSP14, ST 15).  Another SLV was observed in the database that 
presented a change in the same allele (SP-BS293, allele xpt), however the base 
Serotype Strain/isolate 
 
SP-BS293 9V 
SP-195 
SP14-BS69 
CGSP14 
14 
INV200 
G54 
Taiwan19F-14 
SP19 BS75 
19F 
Canada 19F 
Table 3.5.2a:   
Database isolates 
selected for 
comparison with 
isolates used in this 
research 
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changes that occurred were different.  Interestingly, SP-BS293 expresses a different 
capsular type (9V).  One other database genome, SP19-BS75, a TLV of England14-9 
also expresses a different capsule type (19).   
 
Two of the nine database isolates shared equivalent STs to Taiwan19F-14 isolates used 
in this research (3.5.2b).  The database T19F-14 isolate was identified as ST236, as was 
isolates from this study, STP 221 and the reference Taiwan19F-14 isolate.  The SLV 
database isolate Canada19F also shared the same ST as ten Taiwan19F-14 isolates 
from this study (3.5.2b).  G54 was originally included in this analysis as it expressed a 
19F capsule.  MLST analysis however revealed a completely diverse allelic profile.  It 
was not excluded at this point however due to the possibility of similarities with other 
19F isolates in terms of SmaI site presence/absence. 
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 Allelic profile 
Isolate Serotype ST aroE gdh gki recP spi xpt ddl 
Spain9V-3 reference isolate 9V 156 7 11 10 1 6 8 1 
PN93 1029/1454/1802 and PN94 812/926 9V 156 7 11 10 1 6 8 1 
SP195 9V 156 7 11 10 1 6 8 1 
PN93 909/917 and PN94 661 9V 162 7 11 10 1 6 8 14 
England14-9 reference isolate 14 9 1 5 4 5 5 1 8 
PN93 637/872/908/1565/1719 and PN94 62/469/653 14 9 1 5 4 5 5 1 8 
INV 200 14 9 1 5 4 5 5 1 8 
PN94 153 14 15 1 5 4 5 5 3 8 
CGSP14 14 15 1 5 4 5 5 3 8 
SP-BS293 9V 13 1 5 4 5 5 27 8 
PN94 336 14 New 14 5 4 5 5 3 8 
SP19-BS75 19 485 1 5 1 1 1 1 8 
SP14-BS69 14 New 1 5 1 5 10 27 14 
Taiwan19F-14 reference isolate 19F 236 15 16 19 15 6 20 26 
STP 221 19F 236 15 16 19 15 6 20 26 
T19F-14 19F 236 15 16 19 15 6 20 26 
STP 002/003/022/026/028/031/038/110/133/138 19F 271 4 16 19 15 6 20 26 
Canada 19F 19F 271 4 16 19 15 6 20 26 
STP 013 19F New 4 16 19 15 5 20 26 
STP 057 19F New 4 16 19 15 5 20 195 
STP 194 19F New 4 16 19 15 5 20 85 
STP 269 19F New 4 16 19 15 5 New 26 
G54 19F 63 2 5 36 12 17 21 14 
Table 3.5.2b:  Comparison of MLST results from this study with MLST results of database serotype 9V, 14 and 19F isolates. Reference isolates 
used in this study are highlighted in blue.  Database isolates are in bold font.  Allele numbers highlighted in yellow represent divergent alleles of 
the respective reference isolate. 
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Table 3.5.2c: Comparison of SmaI site analysis from Spain9V-3 isolates in this 
laboratory with database isolate SP195 (bold). Dark grey bars represent sites that were 
unsuccessful in amplification; light grey – rRNA sites; N/A – the region surrounding 
the corresponding site is not present at all; bold font – NCBI/sanger database genome; 
S – serotype; ST – sequence type. 
 
Overall SmaI site analysis of Spain9V-3 isolates corresponded with SP195 SmaI site 
data (table 3.5.2c).  Interestingly, the SmaI_20 mutation in SP195 is different when 
compared to the Spain9V-3 isolates investigated in this study.  This suggests that the 
ancestral sequence may have been cccggg and independent nucleotide changes once 
occurred to abolish SmaI_20.  What is more interesting however is that the SmaI site 
20 nucleotide change is equivalent to that observed in England14-9 isolates from this 
S9V-3 
Ref 
PN93 
1029 
PN93 
1454 
PN93 
1802 
PN94 
812 
PN94 
926 
SP 
195 
PN93 
909 
PN93 
917 
PN94 
661 
S 9V S 9V S 9V S 9V S 9V S 9V S 9V S 9V S 9V S 9V 
SmaI 
site 
ST 156 ST 156 ST 156 ST 156 ST 156 ST 156 ST 156 ST 162 ST 162 ST 162 
1       Y    
2       Y    
3       Y    
4       Y    
5 Y Y Y Y Y Y Y Y Y Y 
6 Y Y Y cccggA Y Y Y Y Y Y 
7 cccTgg cccTgg cccTgg cccTgg cccTgg cccTgg ccTggg cccTgg cccTgg cccTgg 
8 Y Y Y Y Y Y Y Y Y Y 
9       N/A    
10       Y    
11       Y    
12 Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y Y 
16 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
17 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
18 Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y 
20 cccgAg cccgAg cccgAg cccgAg cccgAg cccgAg cTcggg cccgAg cccgAg cccgAg 
21       Y    
22       Y    
23       Y    
24       ccTgag    
25       Y    
26       Y    
27       Y    
28       Y    
29       Y    
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study (table 3.5.2d, SmaI site number 20). It is therefore also possible that the SmaI 
site change in SP195 was acquired through recombination.   
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Table 3.5.2d: Comparison of SmaI site analysis from England14-9 isolates in this laboratory with related database isolates (bold). Dark grey bars 
represent sites that were unsuccessful in amplification; light grey – rRNA sites; N/A – the region surrounding the corresponding site is not present at 
all; bold font – NCBI/sanger database genome; S – serotype; ST – sequence type. 
SmaI 
site 
PN93 
872 
ref 
PN93 
637 
PN93 
872 
PN93 
908 
PN93 
1565 
PN93 
1719 
PN94 
62 
PN94 
469 
PN94 
653 
INV 
200 
PN94 
153 
CGSP
14 
SP-
BS293 
PN94 
336 
SP19-
BS75 
SP14-
BS69 
 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 14 S 9V S 14 S 19 S 14 
 ST 9 ST 9 ST 9 ST 9 ST 9 ST 9 ST 9 ST 9 ST 9 ST 9 ST 15 ST 15 ST 13 New 485 New 
1          Y  Y Y  Y Y 
2          Y  Y Y  Y Y 
3          Y  Y Y  Y Y 
4          Y  Y Y  Y Y 
5 Y Y Y Y Y Y Y Y Y Y Y N/A N/A Y Y Y 
6 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
7 cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg cccAgg Y Y Y Y 
8 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
9          N/A  N/A N/A  N/A N/A 
10          ccAggg  ccAggg ccAggg  ccAggg ccAggg 
11          Y  Y Y  Y Y 
12 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y ccTggg 
14 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
16 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
17 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
18 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
20 cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg cTcggg Y cTcggg 
21          Y  Y Y  N/A N/A 
22          Y  Y Y  Y Y 
23          Y  Y Y  Y Y 
24          Y  Y Y  ccTgag ccTgag 
25          Y  Y Y  Y Y 
26          Y  Y Y  Y Y 
27          Y  Y Y  Y Y 
28          Y  Y Y  Y Y 
29          Y  Y Y  Y Y 
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Five of the nine database isolates examined (table 3.5.2d, bold) shared the same or 
similar allelic profiles to England14-9 isolates used in this study.  The SmaI site data 
were compared among these isolates.  The SmaI sites tested in all ST9 isolates 
corresponded with INV200; the base change observed in SmaI_7 and SmaI_20 
(section 3.4) were the same in all isolates.   
 
The two ST15 isolates included one England14-9 isolate from this study (PN94 153) 
and the database isolate CGSP14 (table 3.5.2d). Sites corresponded between both 
isolates apart from SmaI_5 which was present in PN94 153 but not in CGSP14 (table 
3.5.2d).  Interestingly, sequence analysis shows that 185bp of this region that includes 
SmaI_5 is absent in CGSP14.  This region is also absent in database isolate SP-BS293 
that expresses a 9V capsule and has a different ST (ST13).  SP-BS293 differs further  
from both ST15 and ST9 isolates as it contains an in tact SmaI_7. 
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Table 3.5.2e: Comparison of SmaI site analysis from Taiwan19F-14 isolates in this 
laboratory with related database isolates (bold). Dark grey bars represent sites that 
were unsuccessful in amplification; light grey – rRNA sites; N/A – the region 
surrounding the corresponding site is not present at all; bold font – NCBI/sanger 
database genome; S – serotype; ST – sequence type. 
 
 
 
 
 
 
 
SmaI 
site 
T19F-
14 Ref 
STP 
221 
T19F-
14 
STP 
002 
STP 
003 
STP 
022 
STP 
026 
STP 
028 
STP 
031 
STP 
038 
 S 19F S 19F S 19F S 19F S 19F S 19F S 19F S 19F S 19F S 19F 
 ST 236 ST 236 ST 236 ST 271 ST 271 ST 271 ST 271 ST 271 ST 271 ST 271 
1   Y        
2   Y        
3   Y        
4   cctggg        
5 Y Y Y Y Y Y Y Y Y Y 
6 Y Y Y Y Y Y Y Y Y Y 
7 Y Y Y Y Y Y Y Y Y Y 
8 Y Y Y Y Y Y Y Y Y Y 
9   N/A        
10   ccagga        
11   Y        
12 Y Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y Y 
16 Y Y Y Y Y Y Y Y Y Y 
17 Y Y Y Y Y Y Y Y Y Y 
18 Y Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y Y 
20 N N cttggg N N N N N N N 
21   Y        
22   Y        
23   Y        
24   Y        
25   Y        
26   Y        
27   Y        
28   Y        
29   Y        
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Table 3.5.2e: Comparison of SmaI site analysis from Taiwan19F-14 isolates in this 
laboratory with related database isolates (bold). Dark grey bars represent sites that 
were unsuccessful in amplification; light grey – rRNA sites; N/A – the region 
surrounding the corresponding site is not present at all; bold font – NCBI/sanger 
database genome; S – serotype; ST – sequence type. 
 
 
 
All SmaI sites investigated in Taiwan19F-14 isolates correlated with database isolates 
T19F-14 and Canada19F (table 3.5.2e).  SmaI_20 was confirmed as absent in all 
isolates by restriction digestion, however the exact base change is unknown as the 
area surrounding SmaI_20 was not sequenced in these isolates.  Unlike Spain9V-3 and 
England14-9, SmaI sites 7, 16 and 17 were present in Taiwan19F-14 isolates.  This 
correlated with results from database isolates.   
 
110 133 138 
Can 
19F 
STP 
013 
STP 
057 
STP 
194 
STP 
269 G54 
 S 19F S 19F S 19F S 19F S 19F S 19F S 19F S 19F S 19F 
 ST 271 ST 271 ST 271 ST 271 New New New New 63 
1    Y     Y 
2    Y     Y 
3    Y     Y 
4    Y     Y 
5 Y Y Y Y Y Y Y Y Y 
6 Y Y Y Y Y Y Y Y Y 
7 Y Y Y Y Y Y Y Y Y 
8 Y Y Y Y Y Y Y Y Y 
9    N/A     N/A 
10    N/A     Y 
11    Y     ctcggg 
12 Y Y Y Y Y Y Y Y Y 
13 Y Y Y Y Y Y Y Y Y 
14 Y Y Y Y Y Y Y Y Y 
15 Y Y Y Y Y Y Y Y Y 
16 Y Y Y Y Y Y Y Y N/A 
17 Y Y Y Y Y Y Y Y N/A 
18 Y Y Y Y Y Y Y Y Y 
19 Y Y Y Y Y Y Y Y Y 
20 N N N cttggg N N N N ctcggg 
21    N/A     Y 
22    Y     Y 
23    Y     Y 
24    Y     Y 
25    Y     Y 
26    Y     Y 
27    Y     Y 
28    Y     Y 
29    Y     Y 
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3.6 PFGE and SmaI hybridisations   
 
As well as single nucleotide polymorphisms in restriction sites, genetic diversification 
also occurs in the form of genomic rearrangements such as deletions, insertions and 
inversions.  The aim here was to determine what types of genetic events underlie the 
restriction fragment polymorphisms in the three clones.  Genomic DNA (as opposed 
to PCR products of SmaI site regions, section 3.4) from all isolates was digested with 
SmaI followed by PFGE to allow restriction fragment patterns to be compared among 
isolates of each serotype.  Subsequently, the location of each site (i.e. the SmaI 
restriction map) was determined by hybridisation with probes flanking each SmaI site.  
The basis of any polymorphisms were then investigated, concentrating on bands that 
differed from a chosen representative isolate. 
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3.6.1 Analysis of TIGR4 and R6 Sma_I PFGE restriction profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1a:  PFGE SmaI restriction profile of TIGR4 (lane 1) and R6 (lane 2).  L – 
lambda ladder. 
 
R6 and TIGR4 have been used throughout this project as NCBI database reference 
strains.  They were therefore used to create a restriction fragment pattern following 
smaI digestion (figure 3.6.1a).  Full sequence information was available for these two 
strains, so a map was able to be depicted which correlated SmaI digested fragments to 
specific locations within the genome (figure 361b and c), the sizes of fragments on 
either side of each SmaI site are also summarised (table 3.6.1b and c). Some smaller 
fragments however could not be mapped due to their size or absence on the gel.  It 
must be noted that SmaI site numbering is fixed throughout this thesis and 
corresponds to previous sections.  SmaI PFGE fragments however have been 
numbered in this section according to size (and therefore order) for each isolate/strain. 
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3.6.1b:  SmaI restriction map of R6.  Full sequence information allows each fragment in the PFGE gel image (right) to be localised on the map.  
SmaI sites are highlighted in blue. Size of fragments are in bp (green).  Order of fragments on the gel image correspond to the restriction map 
(numbered in black on the gel image and map). 
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Table 3.6.1b:  Size of R6 SmaI digested fragments.  Shows fragment sizes of bands on 
each side of SmaI site (e.g. fragment on either side of SmaI is 199888bp and 925bp). 
 
SmaI site 
 
Fragment 1 
 
 
Fragment 2 
 
1 199888 925 
2 925 24783 
3 24783 104605 
4 104605 55704 
5 55704 15773 
6 15773 30385 
7 30385 5533 
8 5533 241355 
11 241355 91585 
12 91585 340914 
14 340914 296544 
15 296544 224593 
18 224593 101643 
19 101643 140581 
21 140581 3407 
22 3407 925 
23 925 89117 
24 89117 7508 
25 7508 925 
26 925 44680 
27 44680 16320 
28 16320 925 
29 925 199888 
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Figure 3.6.1c:  SmaI restriction map of TIGR4.  Full sequence information allows each fragment in the PFGE gel image to be localised. SmaI 
sites are highlighted in blue. Size of fragments are in bp (green).  Order of fragments on the gel image correspond to the restriction map 
(numbered in black on the gel image and map). 
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Table 3.6.1c:  Size of TIGR4 SmaI digested fragments. Shows fragment sizes of 
bands on each side of SmaI site (e.g. fragment on either side of SmaI is 203234bp and 
925bp).
 
SmaI site 
 
 
Fragment 1 
 
Fragment 2 
1 203234 925 
2 925 23500 
3 23500 96031 
4 96031 62855 
5 62855 48211 
7 48211 5533 
8 5533 75880 
9 75880 208007 
11 208007 92840 
12 92840 288551 
13 288551 62196 
14 62196 310816 
15 310816 223854 
16 223854 1548 
17 1548 10350 
18 10350 101643 
19 101643 121122 
20 121122 58741 
21 58741 3407 
22 3407 925 
23 925 97732 
25 97732 925 
26 925 44770 
27 44770 16321 
28 16321 925 
29 925 203234 
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Band number 
 
 
TIGR4 smaI sites 
 
R6 smaI sites 
1 14/15 12/14 
2 12/13 14/15 
3 15/16 8/11 
4 9/11 15/18 
5 1/29 1/29 
6 19/20 19/21 
7 18/19 18/19 
8 23/25 3/4 
9 (a)3/4   (b)11/12 11/12 
10 8/9 23/24 
11 (a) 4/5   (b)13/14 (c)21/20 4/5 
12 (a) 5/7   26/27 26/27 
13 Not visible 6/7 
Table 3.6.1d: Comparison of band numbers and flanking restriction sites in TIGR4 
and R6.  For example, the SmaI probe surrounding SmaI site 15 (bold) would 
hybridise bands 1 and 3 in TIGR4 and bands 2 and 4 in R6. 
 
 
Table 3.6.1d summarises the flanking SmaI sites that correspond to each band in the 
R6 and TIGR4 map/gel image.   
 
As sequence information was not available for Spain9V-3, England14-9, and 
Taiwan19F-14, localising SmaI fragments was not as straightforward.  Instead, a 
representative isolate was selected for each clone, on the basis of a clearly defined 
SmaI pattern, for hybridisation with SmaI site probe. Probes were constructed using 
PCRs of the regions surrounding each SmaI site (details of probe construction are 
described later in section 3.6.2). This allowed the location of each SmaI site to be 
depicted, identifying correlations between bands on a PFGE gel and flanking SmaI 
sites.  For example, table 3.6.1d above shows that the SmaI site probe surrounding 
SmaI site 15 (bold font) would hybridise to sequence from bands 1 and 3 of TIGR4, 
demonstrating that these bands must be adjacent in the genome and are separated by 
SmaI site 15. In R6, the same probe would hybridise sequence from bands 2 and 4.  
Thus the equivalent restriction fragments could be identified in each clone (prior to 
genome sequence information being available). 
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3.6.2 Clone Spain9V-3 
All eight isolates of Clone Spain9V-3 were digested with SmaI and electrophoresed.  
Results identified isolates that presented differences in restriction pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2a: PFGE of Spain9V-3 isolates.  Lane 1 – PN93 909; lane 2 – PN93 917; 
lane 3 – PN93 1029; lane 4 – PN93 1454; lane 5 – PN93 1802; lane 6 – PN94 661; 
lane 7 – PN94 812; lane 8 – PN94 926.  L – PFGE λ ladder. 
 
The isolate that was selected to be used for SmaI site hybridisations was PN94 661 
(figure 3.6.2a, lane 6) due to the clear restriction profile produced when digesting with 
SmaI.  Furthermore, this isolate displayed the ancestral (drug susceptible) MLST type. 
Bands were named 1 through to 12 in order of size (figure 3.6.2b). 
 
 
 
Chapter 3 
 
 159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2b Representative Spain9V-3 isolate PN94 661. Bands are numbered in 
order of decreasing size.  Band sizes were measured and are noted (kb) on the right of 
each fragment. Bands below 50kb were unable to be sized. 
 
 
 
 
 
SmaI site probes 
constructed 
1 
3 
5 
6 
7 
8 
12 
13 
14 
15 
18 
19 
20 
21 
24 
27  
Probes that were adjacent to large fragments (from 
R6 and TIGR4 analysis section 3.6.1) were then 
chosen to create probes. In total, 16 SmaI site probes 
were constructed (table 3.6.2a) using the PCR 
digoxigenin (DIG) system. An example of this can 
be seen with the construction of the SmaI site 15 
probe (Figure 3.6.2c).  The sequence surrounding the 
SmaI site was amplified with incorporated DIG.  
Successful construction of this probe was confirmed 
when analysing the probe on a 0.9% agarose gel 
with the labelled probe running slower than the 
unlabelled control. Multiple strips of the 
representative isolate were then prepared and used 
for hybridisation with each SmaI probe.   
Table 3.6.2a:  
SmaI site probes 
constructed 
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Figure 3.6.2c: Construction of 
SmaI_15 probe. 
 
(i) Diagrammatic representation of 
probe SmaI_15.  The sequence 
surrounding SmaI site 15 was used 
to construct a probe with the DIG 
system, indicated in red. 
 
(ii) Confirmation of SmaI site 15 
probe construction.  L - 1kb+ 
ladder; lane 2 - Control PCR 
product of region surrounding SmaI 
site 15; lane 1 - DIG incorporated 
SmaI_15 probe. 
  
A 
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Table 3.6.2b:  Summary of SmaI probe hybridisations with chosen Spain9V-3 
representative isolate PN94 661.  The PFGE band and corresponding hybridised SmaI 
site probes are shown. For example, SmaI probes 6, 7 and 8 all hybridised PFGE band 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SmaI site 
Probe 
PFGE 
Band 
Size in rep isolate (kb) 
PN94 661 
Size in R6 
(bp) 
Size in TIGR4  
(bp) 
1 6 135 199888 203234 
3 7 98 104605 96031 
5 10 50 55704 48211 
6 11 50 15773 N/A 
7 11 50 30385 48211 
8 3,11 263, 50 241355, 5533 75880, 5533 
12 2, 12 282, Unknown (<50) 340914, 91585 288551, 92840 
13 2, 9 282, 79 N/A 288551, 62196 
14 1, 9 302, 79 340914, 296544 310816, 62196 
15 1, 4 302, 214 296554, 224593 310816, 223854 
18 4, 7 214, 98 224593, 101643 223854, 101643 
19 5, 7 148, 98 140581, 101643 121122, 101643 
20 5 148 N/A 121122 
21 5 148 140581 58741 
24 8 89 89117 - 
27  12 Unknown (<50) 44680 44770 
Figure 3.6.2d:  Diagram to summarise 
SmaI hybridisations with the 
representative Spain9V-3 isolate PN94 
661.  Single hybridisations are shown 
with a single number (e.g. Only 
SmaI_8 hybridised band 3), double or 
multiple hybridisations are marked 
with a forward slash (e.g. SmaI_19, 
SmaI_20 and SmaI_21 hybridised 
band 5), duplet PFGE bands are 
marked with a comma (e.g. SmaI_12 
and SmaI_27 appear to have 
hybridised band 12, however, they 
have hybridised two different bands 
of similar size which lie in the same 
position. 
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Table 3.6.2b and figure 3.6.2d summarise the hybridisation findings with the chosen 
Spain9V-3 representative isolate PN94 661.  The SmaI site probes used are shown (on 
the left in table 3.6.2b) with the corresponding hybridised PFGE fragment. The size of 
each band is then presented in kb for the Spain9V-3 representative isolate as band sizes 
were approximate.  The exact band sizes from R6 and TIGR4, obtained from 
sequence information are also shown for comparison.  As the band sizes are exact, 
they are presented in bp.  Figure 3.6.2d, is an illustrative figure of SmaI probe 
hybridisations to PN94 661 SmaI digested genomic DNA and correlates with results 
in table 3.6.2b.  A summary of these findings compared to the NCBI database 
reference R6 is illustrated in figure 3.6.2e.   
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Figure 3.6.2e:  Summary of PFGE hybridisations with Spain9V-3 representative isolate PN94 661.  Grey line – NCBI reference genome R6 with 
resulting fragment sizes following SmaI digestion (depicted from sequence information).  Red line – results of SmaI probe hybridisations with 
Spain9V-3 chosen representative isolate PN94 661. Resulting approximate fragment sizes following SmaI digestion and hybridisation are also 
shown.  Fragment size is illustrated in green in bp (R6) and kb (PN94 661). Results from SmaI presence/absence analysis (section 3.4 - 3.5) are 
incorporated in this analysis (blue) for bands that were too small to be identified by hybridisation.  PFGE band numbers for PN94 661 are 
labelled 1 through 12 (black) and correspond with band numbers in table and figure 3.6.2d. 
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Subsequently, the remaining Spain9V-3 isolates were compared to the representative 
PN94 661 isolate to look for divergent band patterns >100kb.  Isolates with divergent 
bands are displayed below.  Multiple hybridisation strips were made for these isolates 
which were hybridised with the appropriate SmaI probes.  Unfortunately, all future 
PFGE attempts with PN94 812 (figure 3.6.2f, lane 7) were unsuccessful so results are 
not included for this isolate. Hybridisation results for isolates that presented divergent 
band patterns (red and green) will be presented individually, followed by an 
illustrative summary of findings (figure 3.6.2m). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2f:  Isolates that were investigated for divergent band pattern 
hybridisations.  PFGE image. Lane 1 – PN93 909; lane 2 – PN93 917; lane 3 – PN93 
1029; lane 4 – PN93 1454; lane 5 – PN93 1802; lane 6 – PN94 661; lane 7 – PN94 
812; lane 8 – PN94 926.  L – PFGE λ ladder.  Bands not present in PN94 661 are 
marked in red.  Bands present in PN94 661 but absent in other isolate/isolates are 
marked in green. 
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Divergent band analysis for isolates PN93 917, PN93 1029, PN93 1802, PN93 909 and 
PN93 1454 
Figure 3.6.2g: PN94 917, PN93 1029, PN93 1802, PN93 909 and PN93 1454. Band 4 
in the Spain9V-3 representative isolate PN94 661 PFGE image (A) was not present in 
isolates PN94 917, PN93 1029 (B), PN93 1802, PN93 909 and PN93 1454 PFGE 
image. (C) Illustrative figure of hybridisation results with divergent isolates 
(hybridisation images not shown). 
 
Band 4 in Spain9V-3 representative isolate PN94 661 hybridised SmaI_15 and SmaI_18., 
suggesting that either SmaI_16 and SmaI_17 were absent or another band was present 
that was of similar size to band 4 (figure 3.6.2g).  Probe construction was attempted for 
SmaI_16 and SmaI_17 but failed.  However, analysis of the Spain9V-3 NCBI submitted 
genome SP195 which is in draft assembly was shown not to contain this region at all 
(refer back to section 3.5.2, table 3.5.2c). This region is also absent in R6 and many 
other NCBI submitted genomes.  Furthermore, amplification of this region was 
successful in Taiwan19F-14 isolates.  SmaI_15 and SmaI_18 therefore hybridised the 
same band (band 4) in PN94 661. 
 
Isolates PN94 917, PN93 1029, PN93 1802, PN93 909 and PN93 1454 did not present a 
band 4, as seen in PN94 661.  In these isolates, SmaI probes 15 and 18 hybridised a band 
of very similar size to band 3.  Band 3 in these isolates is of a higher intensity compared 
to other bands (as shown in the example; figure 3.6.2g - B, band 3).  The increase in band 
size compared to PN94 661 occurred as a result of an insertion (or deletion in PN94 661, 
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depending on which is the ancestral band pattern) as both SmaI_15 and SmaI_18 
hybridised the same fragment.  As SmaI sites on either side of this fragment (SmaI_14 
and SmaI_19, respectively) cut in all divergent isolates, the increase in band size was 
confirmed not to be due to loss of a SmaI site. 
Chapter 3 
 
 167 
Divergent band analysis for isolate PN93 909 
Figure 3.6.2h: PN93 909. Band 1 in the Spain9V-3 representative isolate PN94 661 (A) 
PFGE image was not present in isolate PN93 909 (B) PFGE image.  (C) Illustrative 
figure of hybridisation results with divergent isolate PN93 909. Insertion in band size 
is shown in green. 
 
 
Band 1 in representative isolate PN94 661 which 
hybridised SmaI_14 and 15 (figure 3.6.2h - A) was not 
present in PN93 909 (figure 3.6.2h - B).  A new band 
however (figure 3.6.2h – B, outlined in red) was present 
in PN93 909.  In PN93 909 SmaI_14 and 15 both 
hybridised this band (figure 3.6.2i).  It is therefore evident 
that a genomic rearrangement occurred somewhere within 
SmaI_14 and SmaI_15 that increased the band size  
compared to PN94 661. 
 
 
 
 
 
Figure 3.6.2i: PN93 909 hybridisation with SmaI_14 and SmaI_15. A – PN93 909 PFGE 
gel image; B – PN93 909 Southern blot and hybridised probes. 
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Divergent band analysis for isolate PN93 1454 
Hybridisations to representative isolate PN94 661 showed that as expected, SmaI_12 
hybridised to the same band as SmaI_13 (figure 3.6.2j; indicated in blue, band 2, 
isolate PN94 661).  Similarly, SmaI_14 hybridised to the equivalent band as SmaI_15 
(figure 3.6.2j; indicated in blue, band 1, isolate PN94 661).  A divergent restriction 
profile however was observed for isolate PN93 1454.  Bands 1 and 2 were absent 
(compared to that in PN94 661) and two new bands (labelled 1 and 3, figure 3.6.2j, 
PN93 1454) were observed. This isolate was hybridised with SmaI_12, 13, 14 and 15.  
Results showed that band 1 hybridised SmaI_12 and smaI_14, where as band 3 
hybridised SmaI_13 and SmaI_15, suggesting that an inversion had taken place.  
Hybridisation results are shown in figure 3.6.2k. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3.6.2j:  PN93 1454. Representative isolate PN94 661 hybridised probes 
SmaI_12 and SmaI_13 to band 2 and probes SmaI_14 and SmaI_15 to band 1 (blue).  
A divergent restriction profile is observed in isolate PN931454 (green).  
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Figure 3.6.2k:  Hybridisation results for SmaI_12, _13, _14 and _15 in PN93 1454. 
For each SmaI (12 – 15), the PFGE image is shown (left) next to the resulting 
hybridisation (right). SmaI_12 and SmaI_14 hybridised the same fragment (red).  
SmaI_13 and SmaI_15 also hybridised the same fragment. 
 
 
The fragment size between sites were calculated to further confirm the inversion; 
figure 3.6.2 l(a) presents isolate PN94 661 with total fragment size between sites 12 
and 13 (282kb) and SmaI_14 and 15 (302kb) which totals 584kb.  Similarly the total 
distance between sites 12 and 14 (427kb) in addition to the distance between 13 and 
15 (155kb) totals 582kb (figure 3.6.2 L).  As both are extremely similar it shows that 
no large amount of DNA was inserted or deleted.  Instead an inversion occurred 
which altered the location of SmaI sites without losing any DNA in the process.  The 
exact size of the inversion is unknown however the minimum inversion size would 
span ~225kb, compared to the maximum size of ~650kb. 
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Figure 3.6.2l: PN93 1454 inversion. (a) Region that covers SmaI sites 12 – 15 in 
representative isolate PN94 661; (b) Shows the same region.  The exact location of the 
inversion is unknown. The box presents an example of an area that may have been 
inverted in PN93 1454. (c) The resulting rearrangement of DNA as a result of 
inversion in isolate PN93 1454. 
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Summary of Spain9V-3 results 
 
All SmaI sites were characterised in representative isolate PN94 661, most through 
hybridisation, however a few were characterised by reference to sequenced genomes 
All divergent bands >100kb were analysed and found to represent two  
insertion/deletion events and one inversion of a region of between ~225kb and 650kb. 
SmaI site 6 was absent from isolate PN93 1802 due to loss of a restriction site.  This 
site is flanked by small restriction fragments in the sequenced genomes R6 and 
TIGR4 and it was not possible to visualise the change by PFGE under the conditions 
used here. A summary of findings is presented in figure 3.6.2m. 
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Figure 3.6.2m:  Summary of Spain9V-3 PFGE hybridisations. Fragment size is illustrated in green in bp (R6) and kb (PN94 661). Grey line – 
database genome R6 with resulting fragment sizes following SmaI digestion; red line - Spain9V-3 chosen representative isolate PN94 661 with 
resulting fragment sizes following SmaI digestion. Hybridisation results (PN94 661, red) and order of bands, i.e. band numbers, are shown 
(PN94 661, black).  SmaI sites indicated in red are probes that hybridised to the associated fragment.  SmaI site in purple represents loss of smaI 
site (PN93 1802, SmaI_6).  Blue SmaI sites are those predicted from sequenced genomes.  Isolates in black are Spain9V-3 isolates that displayed 
a divergent band pattern with summary of the difference that occurred; green represents insertion, arrow represents deletion and resulting 
fragment size (black).   
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3.6.3 England14-9 
All ten isolates of England14-9 were digested with SmaI and electrophoresed.  Results 
showed that SmaI restriction patterns differed among some isolates.  Five displayed a 
different band pattern to the England14-9 chosen representative isolate (table 3.6.3a) 
(image shown later). 
 
 
 
 
 
Table 3.6.3a: England14-9 isolates that displayed a divergent restriction band pattern 
(gel image not shown). 
 
The isolate that was selected to be used for England14-9 SmaI site hybridisations was 
PN93 1565 (figure 3.6.3a) due to the clear restriction profile produced when digesting 
with SmaI.  Bands were named 1 through to 14.  Multiple strips of the representative 
isolate were then prepared and used as a basis for hybridisation with the probes that 
were previously constructed for hybridisation with Spain9V-3 isolates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PN93 872 
PN93 908 
PN93 1719 
PN94 336 
PN94 653 
Figure 3.6.3a:  
Representative England14-
9 isolate PN93 1565.  
Bands were numbered 
according to decreasing 
size order (shown in kb 
on the right of each band). 
Bands below 45kb were 
unable to be sized. 
Chapter 3 
 
 174 
Each PN93 1565 strip (as seen in figure 3.6.3b) was used to hybridise a different SmaI 
site probe.  A restriction map was therefore generated, allowing bands in the PFGE 
gel to be assigned as flanked by specific SmaI sites.  Examples of the hybridisation 
results can be seen in figure 3.6.3c. Results are specified in table 3.6.3b and figure 
3.6.3d and summarised in figure 3.6.3e. Where only one band was detected in 
hybridisation, it was considered whether two co-migrating fragments might be 
hybridising and otherwise assumed that the second fragment was too small to be 
retained on the PFGE gel. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.3b: multiple lanes of representative England14-9 isolate PN93 1565 (PFGE 
gel image), used to make multiple strips for hybridisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.3c: PN93 1565 
hybridisations; 
 
The PFGE gel image of PN93 1565 
is shown on the left with examples 
of hybridisations with different SmaI 
probes on the right (gel image is not 
to scale with hybridisation image).  
  
Lane 1 – SmaI_19 hybridised bands 
6 and 7  
Lane 2 – SmaI_24 hybridised band 9 
Lane 3 – SmaI_8 hybridised bands 3 
and 11 
Lane 4 – SmaI_12 hybridised band 1 
and 8 
Lane 5 – SmaI_7 hybridised band 12 
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Table 3.6.3b:  SmaI probe hybridisation results with England14-9 representative 
isolate, PN93 1565 (also summarised below in figure 3.6.3d). Each SmaI site probe is 
shown with the corresponding hybridised PFGE bands.  For example SmaI probe 8 
hybridised PFGE bands 3 and 12 in PN93 1565.  The size is shown in R6 and TIGR4 
for comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SmaI site 
probe 
PFGE 
Band 
Size in rep isolate 
(kb) 
PN93 1565  
Size in R6 
(bp) 
 
Size in TIGR4 
(bp) 
 
1 5 198 199888 203234 
3 7, 13 98, unknown (<45kb) 104305, 24783 96031, 23500 
5 10 60 55704 62855, 48211 
6 12 unknown (<45kb) 30385 N/A 
7 12 unknown (<45kb) 30385 N/A 
8 3, 12 246, (<45kb) 241355, 5533 75880, 5533 
12 1, 8 311, 89 340914, 91585 288551, 92840 
13 1, 10 311, 60 N/A 288551, 62196 
14 2, 10 284, 60 340914, 296544 310816, 62196 
15 2, 4 284, 226 296544, 224593 310816, 223854 
18 4, 7 226, 98 224593, 101643 101643, 10350 
19 6, 7 173, 98 140581, 101643  101643, 121122 
20 6 173 N/A 121222 
21 6 173 140581 58741 
24 9 80 89117 N/A 
27 11 45 44680 44770  
Figure 3.6.3d:  Diagram to summarise 
SmaI hybridisations with SmaI 
representative England14-9 isolate 
PN93 1565.  Single hybridisations are 
shown with a single number (e.g. 
Only smaI_8 hybridised band 3), 
double or multiple hybridisations are 
marked with a forward slash (e.g. 
smaI_19, smaI_20 and SmaI_21 
hybridised band 6), duplet PFGE 
bands are marked with a comma (e.g. 
SmaI_3, appear to have hybridised a 
band of very similar size to SmaI_18 
and 19) 
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Figure 3.6.2e:  Summary of PFGE hybridisations with England14-9 representative isolate PN93 1565.  Grey line – NCBI reference genome R6 
with resulting fragment sizes following SmaI digestion (depicted from sequence information).  Red line – Hybridisations with England14-9 
chosen representative isolate PN93 1565 (SmaI site probes are numbered in red and blue from 1 to 29) with resulting approximate fragment sizes 
following SmaI digestion.  Fragment size is illustrated in green in bp (R6) and red in kb (PN93 1565). Results from SmaI presence/absence 
analysis (section 3.4 – 3.5) were incorporated in this analysis for bands that were too small to be identified by hybridisation.  PFGE band 
numbers for PN93 1565 are labelled 1 through 12 (black). 
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Subsequently, multiple hybridisation strips were made for those isolates that displayed 
a different RFLP pattern to PN93 1565 (figure 3.6.3f) and hybridised with the 
appropriate SmaI probes.  Hybridisation results for isolates that presented divergent 
band patterns (red and green) will be presented individually, followed by an 
illustrative summary of findings (figure 3.6.2m). 
 
Figure 3.6.3f: England14-9 isolates that displayed a divergent band pattern. L – 
PFGE λ ladder; lane 1 – PN93 872; lane 2 – PN93 908; lane 3 – PN93 1719; lane 4 – 
PN94 336; lane 5 – PN94 653. Bands not present in PN93 1565 are marked in red.  
Bands present in PN93 1565 but absent in other isolate/isolates are marked in green. 
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Divergent band analysis for isolates PN93 872 
Figure 3.6.3g: PN93 872. (i) band 6 in the representative isolate PN93 1565 is shown 
on the left PFGE gel image. (A) SmaI digested PN93 872 (PFGE image) with (B) 
hybridisation results for SmaI_19 and SmaI_21.  Diagrammatic representation of band 
size reduction in isolate PN93 872 (black) compared to representative isolate PN93 
1565 (red) (ii).  
 
In representative isolate PN93 1565, band 6 hybridised probes SmaI_19, SmaI_20 and 
SmaI_21, suggesting that SmaI_20 was absent or that two bands of very similar size 
were present.  Restriction digestion and sequencing confirmed that SmaI_20 was in 
fact absent (section 3.4).  In isolate PN93 872 band 6 was ~13kb smaller than in PN93 
1565 (figure 3.6.3g).  This band also hybridised SmaI_19 and SmaI_21 (figure 3.6.3g, 
I, B), therefore ruling out creation of SmaI_20 as a cause of band size reduction.  It is 
therefore evident that a genomic rearrangement occurred in the region between 
SmaI_19 and SmaI_21 (insertion/deletion, depending on which is the ancestral 
sequence). 
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Divergent band analysis for isolate PN93 908 
Figure 3.6.3h: PN93 908. PFGE images (A) are shown for England14-9 representative 
isolate PN93 1565 and PN93 908.  Band 9 from PN93 1565 is missing in PN93 908 
(green outline).  A new band is present in PN93 908 (red outline). Southern blots and 
hybridisation results are shown (B) with a diagrammatic illustration on the right.  
 
Band 9 in England14-9 representative isolate PN93 1565 was missing in PN93 908 
(figure 3.6.3h – PN93 908, green outline).  A new band however was present in PN93 
908 (figure 3.6.3h – PN93 908, red outline). Band 9 in PN93 1565 hybridised probe 
SmaI_24.  Hybridisation in PN93 908 with the same probe revealed that SmaI_24 
hybridised the new band.  This band therefore showed an increase of 53kb.  A 53kb 
increase could not be obtained from loss of SmaI sites 21, 22 and 23 (obtained from 
the England14-9 Sanger database isolate, INV200, sequence information); the amount 
of DNA between SmaI sites 19 to 21, 21 to 22 and 22 to 23 is 171 956bp, 3407bp and 
925bp, respectively, which does not amount to the 53kb increase observed (an 
INV200 SmaI restriction map can be seen in the discussion of this chapter, figure 
3.7.2a). SmaI_24 was shown to digest in all England14-9 isolates which rules out the 
possibility of loss of SmaI_24.  It is therefore evident that a genomic rearrangement 
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has occurred between SmaI_23 and SmaI_24 (insertion or deletion, depending on 
which is the ancestral sequence). 
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Divergent band analysis for PN93 1719 
 
Figure 3.6.3i:  PN93 1719.  PFGE gel images of PN93 1565 and PN93 1719 show 
that a band is present in PN93 1719 (outlined in red) that is absent in PN93 1565. 
Band 11 in PN93 1565 is not present in PN93 1719 (green box). The diagram on the 
right illustrates the difference in the size of the fragment which is flanked by 
SmaI_27. 
 
 
In the representative isolate PN93 1565, probe SmaI_27 hybridised band 11 which 
was missing in isolate PN93 1719 (figure 3.6.3i – PN93 1719, green box).  A new 
band (figure 3.6.3i – PN93 1719, red box) was observed in isolate PN93 1719.  This 
band also hybridised SmaI_27.  Loss of sites on either side of SmaI_27 would not 
equate to the 37kb band increase observed; sequence information from INV200 shows 
that there is 7508bp in between SmaI sites 24 and 25, 925bp between SmaI_25 and 26 
and 16,329bp in between SmaI_27 and 28.  This event is thus said to occur by an 
insertion/deletion event (depending on which sequence is ancestral). 
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Divergent band analysis for PN93 336 
Figure 3.6.3j:  PN93 336. PFGE gel images of PN93 1565 and PN94 336 (left) show 
that a band is present in PN94 336 (outlined in red) that is absent from PN93 1565.  
SmaI_13 and SmaI_14 hybridised this fragment.  These probes hybridised band 10 in 
PN93 1565. A diagrammatic illustration of the band increase is shown on the right. 
 
 
A band was observed in PN94 336 (figure 3.6.3j – PN94 336, outlined in red) that 
was not present in the representative isolate PN93 1565.  Hybridisation with SmaI_13 
and 14 showed that this was in fact the same fragment (figure 3.6.3k).  This band was 
increased by 60kb in PN94 336.  Band 10 therefore appears to be a duplet.  This can 
be seen when looking at the PFGE image of PN93 1565, as band 10 is of higher 
intensity than the band above and below it.  Conversely, in isolate PN94 336, the band 
that still lies in position 10 is of the same intensity as bands above and below.  The 
presence of a duplet sized band coincides with sequence information in INV200; the 
fragment size between SmaI_13 and SmaI_14 is 64 141bp and the size between 
SmaI_4 and SmaI_5 is 62 395bp.  On a PFGE gel both bands would therefore appear 
to reside in the same position. 
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The difference in band size is therefore due to a genomic rearrangement 
(Insertion/deletion, depending on which is the ancestral sequence) between SmaI_13 
and _14 as both were able to hybridise the same fragment (figure 3.6.3k).  Restriction 
digestion showed that both sites also cut, therefore ruling out SmaI site abolishment as 
the cause of band increase. 
 
Figure 3.6.3k: 
Hybridisation results for 
PN94 336 with probes 
SmaI_13 and SmaI_14.The 
PFGE gel image is shown on 
the left with resulting 
hybridisations on the right. 
Both probe can be seen to 
hybridise the same fragment. 
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Divergent band analysis for isolate PN94 653 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.3l:  PN94 653. The PFGE image is shown for isolates PN93 1565 and 
PN94 663.  An illustration of the difference in band size is presented on the right. 
 
 
Band 6 in PN94 653 was 20kb smaller than in representative isolate PN93 1565 
(figure 3.6.3L).  In PN93 1565, Band 6 hybridised probes SmaI_19 and SmaI_21.  
The same hybridisations occurred in PN94 653.  The reduction in band size was not 
due to creation of SmaI_20, as this site did not cut in isolate PN94 653.  A genomic 
rearrangement has thus occurred (insertion/deletion, depending on which sequence is 
ancestral) somewhere between SmaI_19 and SmaI_21.  A deletion in the same region 
occurred in isolate PN93 872, but this is an independent event as band sizes, although 
very similar, are at slightly different positions in the PFGE gel (figure 3.6.3f). 
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Summary of England14-9 hybridisation results 
 
All SmaI sites were characterised in representative isolate PN93 1565, most through 
hybridisation, however a few were characterised by reference to sequenced genomes.  
All divergent bands were analysed and found to represent 5 insertion/deletion events. 
A summary of findings is presented in figure 3.6.3m. 
Chapter 3 
 
 186 
Figure 3.6.3m:  Summary of SmaI probe hybridisations with England14-9 isolates.  Grey line - reference genome R6 with resulting fragment 
sizes following SmaI digestion (depicted from sequence information); red line - England14-9 chosen representative isolate PN93 1565 with 
resulting fragment sizes following SmaI digestion. Hybridisation results (red) and order of bands, i.e. band numbers, on PFGE gel are also 
shown (black).  SmaI sites indicated in red are probes that hybridised to the associated fragment.  Blue SmaI sites are those predicted from 
sequenced genomes/SmaI restriction digestion data.  Isolates in black are England14-9 isolates that displayed a divergent band pattern with 
summary of the difference that occurred; green represents insertion; arrow represents deletion; resulting fragment size are written in black.   
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3.6.4 Taiwan19F-14 
 
All 15 isolates of Taiwan19F-14 were digested with SmaI and electrophoresed.  Results 
showed that two isolates displayed different SmaI restriction patterns among 
Taiwan19F-14 isolates (figure 3.6.4a, i; lane 5 and 11). Unfortunately STP 221 was not 
included in this analysis as multiple PFGE attempts were unsuccessful. 
 
Figure 3.6.4a: PFGE of Taiwan19F-14 isolates. (i) lane 1 – Representative isolate STP 
022; L – Ladder; lane 2 – STP003; lane 3 – STP002; lane 4 – STP013; lane 5 – 
STP028; lane 6 – STP031; lane 7 – STP 026; lane 8 – STP038; lane 9 ; STP057; lane 
10 – STP110; lane 11 – STP269.  Isolates STP133, STP138 and STP194 are not 
shown.  STP221 was not successful. (ii) Representative Taiwan19F-14 isolate STP 
022.  Bands are numbered in order of decreasing size. Band sizes (kb) are shown on 
the left. Fragment sizes below 45kb could not be determined. 
 
The isolate that was selected to be used for SmaI site hybridisations was STP 022 
(figure 3.6.4ai lane 1 and 3.6.4aii;) due to the clear restriction profile produced when 
digesting with SmaI.  Bands were named 1 through to 15.  Multiple strips of the 
representative isolate were then prepared and used as a basis for hybridisation with the 
probes previously constructed. 
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Each STP 022 strip (the PFGE image of which is seen in figure 3.6.4b) was used to 
hybridise a different SmaI site probe thus generating a restriction map and allowing 
bands in the PFGE gel to be assigned as flanked by specific SmaI site.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.4b: PFGE image of multiple lanes of representative isolate STP 022. Each 
STP 022 lane is used to construct a separate hybridisation strip for hybridisation with 
different SmaI site probes. The lambda ladder is shown with fragment size (kb). 
 
 
 
Results of all hybridisations are shown in table 3.6.4a and figure 3.6.4c.  A 
diagrammatic summary compared to R6 is presented in figure 3.6.4d. 
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SmaI 
Probe 
Band Size in rep isolate (kb) 
STP 022 
Size in R6 (bp) Size in TIGR4 
(bp) 
1 4 229 199888 203234 
3 6, 14 178, unknown (<45kb) 104605, 24783 96031, 23500 
5 6, 15 178, unknown (<45kb) 55704, 15773 62855, 48211 
6 13, 15 unknown (<45kb), 
unknown (<45kb) 
30383, 15733 - 
7 13 unknown (<45kb) 30383 48211 
8 2 286 241355 75880 
12 1, 10 315, 92 340914, 91585 288551, 92840 
13 1, 11 315, 74 - 288551, 62196 
14 3, 11 258, 74 340914, 296544 310816, 62196 
15 3, 5 258, 211 296554, 224593 310816, 223854 
18 9, 15  101, unknown (<45kb) 224593, 101643 101643, 10350 
19 7, 9 147, 101 140581, 101643 121122, 101643 
20 7 147 121122 N/A 
21 7 147 140581 58741 
24 8 116 89117 - 
27 12 45 44680 44770 
27 12 45 44680 44770 
Table 3.6.4a: Results for probe SmaI hybridisations with Taiwan19F-14 representative 
isolate STP 022. Each SmaI site probe is shown on the left with the resulting 
hybridised band.  For example, SmaI site 3 probe hybridised PFGE bands 6 and 14 in 
isolate STP 022. The size of each fragment in STP 022 is shown with corresponding 
sizes in R6 and TIGR4 for comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.4c:  Diagram to summarise 
SmaI hybridisations with  
representative Taiwan19F-14 isolate 
STP 022.  Single hybridisations are 
shown with a single number (e.g. 
probe SmaI_1 only hybridised band 
4), double or multiple hybridisations 
are marked with a forward slash (e.g. 
smaI_19, smaI_20 and SmaI_21 
hybridised band 7), duplet PFGE 
bands are marked with a comma (e.g. 
SmaI_18, has hybridised a band of 
very similar size to SmaI_5 and 6). 
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Figure 3.6.4d:  Summary of SmaI probe hybridisations with Taiwan19F-14 representative isolate STP 022.  Grey line – NCBI reference genome 
R6 with resulting fragment sizes following SmaI digestion (depicted from sequence information).  Red line – Hybridisations with Taiwan19F-14 
representative isolate STP 022 with resulting approximate fragment sizes following SmaI digestion.  Fragment size is illustrated in green in bp 
(R6) and red in kb (STP 022). Results from SmaI presence/absence analysis were incorporated in this analysis for bands that were too small to 
be identified by hybridisation.  PFGE band numbers are labelled 1 through 12 (black). 
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Divergent band analysis for isolate STP 028 
Figure 3.6.4e:  STP 028. PFGE image is shown for Taiwan19F-14 representative 
isolate STP 022 and STP 028.  The fragment that hybridised probe SmaI_8 is reduced 
in size in STP 028. An illustration of the difference in band size is presented on the 
right. 
 
 
Band 2 in Taiwan19F-14 representative isolate STP 022 (figure 3.6.4e, STP 022) was 
not present in STP 028 (figure 3.6.4e, STP 028).  Instead a new band was present in 
STP 028 (Figure 3.6.4e, STP 028 outlined in red).  Band 2 in STP 022 hybridised 
probe SmaI_8.  The same probe hybridised the new band present in STP 028.  This 
change was very unlikely to have occurred through creation of a SmaI site; analysis of 
the related fully sequenced T19F-14 and Canada 19F database genomes showed that 
smaI_9 (section 3.5.2, table 3.5.2e, T19F-14 and Canada 19F) and the region 
surrounding this site (data not shown) is not present in either isolate.  SmaI_10 is also 
not present the sequenced database isolates (section 3.5.2, table 3.5.2e).  The entire 
region is not present in Canada 19F and in T19F-14 the site has been abolished by two 
base changes in the SmaI recognition sequence from CCCGGG to CCAGGA. As it is 
highly unlikely that two point mutations would have occurred to create site 10, the 
difference in band size for STP028 is said to have been caused by deletion (or 
insertion, depending on which is the ancestral sequence).  In addition, creation of 
SmaI_10 would lead to a reduction in band size of 55 444bp. 
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Divergent band analysis for STP 269 
Figure 3.6.4f:  STP 269. PFGE image is shown for Taiwan19F-14 representative isolate 
STP 022 and isolate STP 269. SmaI probes 3 and 5 both hybridised band 6 in each 
isolate. A deletion of 16kb was observed in STP 269 band 6.  An illustration of the 
difference in band size is presented on the right. 
 
Band 6 STP 022 (figure 3.6.4f, STP 022) was not present in STP 269.  A new band 
however was observed (figure 3.6.4f, STP 269, red outline).  Band 6 hybridised 
SmaI_3 and SmaI_5 in STP 022.  The new band observed in STP 269 hybridised the 
same probes.  As both SmaI _3 and SmaI_5 probes hybridised the same band in STP 
022 and divergent isolate 269, the possibility that smaI_4 was created by point 
mutation was been ruled out. It is therefore evident that the reduction in fragment size 
occurred because of a deletion (or insertion, depending on which is the ancestral 
sequence). 
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Summary of Taiwan19F-14 hybridisation results 
All SmaI sites were characterised in representative isolate PN93 1565, most through 
hybridisation, however a few were characterised by reference to sequenced genomes.  
All divergent bands were characterised and found to represent two insertion/deletion 
events. A summary of findings is presented in figure 3.6.4g. 
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Figure 3.6.2g:  Summary of Taiwan19F-14 SmaI probe hybridisations.  Grey line - reference genome R6 with resulting fragment sizes following 
SmaI digestion (depicted from sequence information); red line – Taiwan19F-14 chosen representative isolate STP 022 with resulting fragment 
sizes following SmaI digestion (STP 022, red).  Hybridisation results (STP 022, red) and order of PFGE bands, i.e. band numbers, are shown 
(STP 022, black).  SmaI sites indicated in red are probes that hybridised to the associated fragment.  Blue SmaI sites are those predicted from 
sequenced genomes.  Isolates in black are Taiwan19F-14 isolates that displayed a divergent band pattern with a summary of the difference that 
occurred; arrow represents deletion and resulting fragment size (black).   
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3.7 Discussion  
3.7.1 MLST and restriction fragment pattern diversity 
A number of common typing methods are available to study relationships within and 
between different pneumococcal clones.  When this project was initiated, the 
sequencing technology was not as it is today.  Only three pneumococcal genomes 
were available on NCBI, one of which was in assembly.  There are now (as of January 
2012) an astonishing 220 genome projects listed on NCBI/Sanger, 23 of which are 
complete and 115 of which are in contigs.  In light of today’s technology the most 
useful and discriminatory way of assessing clonal relationships would be to sequence 
a set of isolates from each of the three clones.  However, as this was not plausible at 
the time this project was initiated, alternative methods were used. MLST is a method 
that has revolutionised the investigation of bacterial population genetics.  It has the 
advantage of allowing numerous submissions to the database from laboratories 
worldwide and thus provides a powerful means to characterise pathogenic isolates.    
 
Allelic profiles were obtained for all isolates used in this study (Section 3.2).  The 
eight Spain9V-3 isolates used in this investigation were previously confirmed to be 
part of this clone by PFGE analysis.  Five were identified as ST156.  Three isolates 
however were SLVs of Spain9V-3 ST156.  This SLV had previously been identified in 
the MLST database and designated as ST162.  Forty representatives for ST162 are 
currently listed on the database and include isolates from serotypes other than 9V; 4, 
9N, 14, 15B, 15C, 19F and 24.  ST 162 includes ddl allele number 14, as opposed to 
ST156 which includes ddl allele 1.  The three ST162 isolates identified in this study 
coincide with the only three Spain9V-3 isolates that do not display antibiotic 
resistance.  Spain was one of the first countries to report a high incidence of antibiotic 
resistant pneumococci and the major Spanish clones of penicillin resistant 
pneumococci were identified using MLST,  including serotype variants of this clone 
(6B and 14) (Zhou et al., 2000).  Interestingly, within each clone isolates either shared 
an identical allelic profile or differed at only a single locus.  A reference clone, France 
9V-3, that shared the same allelic profile as Spain 9V-3 was identified in addition to 
forty other isolates that were either the same ST or SLVs. Of the forty isolates, twelve 
had the same allele difference at the ddl locus from 1 to 14 (as seen in this study) and 
those isolates were all penicillin susceptible. Furthermore all isolates with ddl allele 1 
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were resistant (Zhou et al., 2000).   ST162 has been assigned as the susceptible 
founder of this clonal complex (CC156) (Spratt et al., 2004).  Therefore, the five 
ST156 isolates observed in this study are likely to have originated from an ancestral 
ST162 isolate having acquired penicillin resistance through recombinational exchange 
in addition to an allele change at the ddl locus. 
 
Of the ten England 14-9 isolates, eight were ST9.  Two were divergent from the 
expected profile, one SLV (ST 15) and one DLV (new ST). Thirty five ST 15 strains 
have been entered on the MLST database and include isolates from serotypes other 
than 14; 19A, 19F and 22F.  The DLV includes the same change as the SLV from 
allele 1 to 3 at the xpt locus in addition to the allele change from 1 to 14 at the aroE 
locus.  The allelic profile of the DLV has not previously been described in the MLST 
database.  The DLV is the only England14-9 isolate that is drug susceptible.  However, 
there does not appear to be any direct link between acquisition of mefA and this 
specific allele change from analysis of database isolate INV200 as the aroE locus is 
not in close proximity to the mef insert. 
 
For the fifteen serotype Taiwan19F-14 isolates, ten were ST271.  As previously 
mentioned ST271 is a known polymorphic variant of clone Taiwan19F-14 (ST236) and 
either ST will therefore not be included as a SLV in regards to 
recombination/mutation data.  Four SLVs however were included in analysis, one was 
previously identified in the MLST database ST1411 (isolate STP194), however this 
ST has only been identified in one other strain.  Three new STs were identified for 
isolates STP013, STP057 and STP269.  Furthermore, STP269 also included a new 
allelic variant of xpt as the point mutation involved had not previously been identified 
(section 3.2). 
 
Overall MLST analysis confirmed membership of clonal complexes (previously only 
deduced from PFGE for Spain9V-3 and England14-9).  The differences identified 
within clones were then analysed in terms of mutation/recombination events 
(discussed later in section 3.7.5). 
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3.7.2 Comparison of PFGE pattern diversity with MLST results and 
database sequenced genomes  
 
Using MLST in conjunction with PFGE increases resolution in detecting genomic 
diversity.  Results do not always correlate suggested to be due to the difference in 
molecular basis of the two techniques (Cochetti et al., 2005). PFGE detects genomic 
rearrangements and although MLST can identify homologous recombination that has 
occurred in housekeeping genes, PFGE (with the use of SmaI) is unable to detect 
point mutations unless they directly affect SmaI sites. A disadvantage of using MLST 
alone in genetic diversification studies is reflected in its inability to discriminate 
isolates of same ST (Hall et al., 2010).  It proved practical to use both techniques in 
this research as some isolates displaying a divergent PFGE profile had the same ST 
and vice versa. Furthermore differences were identified among the clones; clones 
Spain9V-3 and England14-9 presented the most divergence in SmaI restriction 
fragment pattern where as Taiwan19F-14 showed most diversity in MLST.  
  
Five clone Spain 9V-3 isolates PN93 909, PN93 917, PN93 1802, PN94 812 and PN93 
1454 presented divergent PFGE patterns (section 3.6.2) but with regards to allelic 
profiles all penicillin susceptible isolates had the same ST (ST156) as did all 
penicillin resistant isolates (ST162) (section 3.2).  The study described earlier by 
(Gherardi et al., 2007) (Chapter 1, section 1.3.6) presented similar findings for this 
clone.  Eleven PFGE subtypes were identified across 17 Spain9V-3 isolates, however, 
all resistant isolates were ST156 compared to the susceptible isolate, ST664 (Gherardi 
et al., 2007).  Divergence in PFGE type was also identified in the analysis of 9 
serotype 9V isolates (Sener et al., 2006). Four isolates were sequenced for MLST 
(ST156) but all displayed different PFGE patterns.  Sadowy et al had similar findings 
in analysis of twenty five penicillin resistant Spain9V-3 isolates in Poland (Sadowy et 
al., 2007). Ten different PFGE patterns were observed, but all apart from one SLV 
(ST557) were ST156 (Sadowy et al., 2007).  Diversity in PFGE as well as MLST 
however has been identified in this clone. A total of 22 isolates that were ST156 or 
closely related were compared by PFGE (Zemlicková et al., 2006).  The majority of 
isolates fell into one PFGE type and two DLV’s (ST380) also shared the same 
restriction fragment pattern.  In the same study, there were isolates of the same ST 
(either ST156 or ST380) with different PFGE types (Zemlicková et al., 2006).  
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Unfortunately, a SmaI map could not be generated for the Spain9V-3 database isolate 
SP195 as this isolate has not yet been fully sequenced (as of January 2012).  A SP195 
SmaI map would have allowed a comparison to be made with the PFGE SmaI map of 
Spain9V-3 isolate PN94 661. 
 
Five clone England14-9 isolates, PN93 1719, PN93 872, PN93 908, PN94 336 and 
PN94 653 presented differences in restriction fragment pattern (section 3.6.3).  PN94 
336, the DLV, was the only isolate to display a divergent ST as well as a divergent 
restriction profile. Interestingly, this is the only England14-9 isolate to be drug 
susceptible. As already discussed, there does not however appear to be any direct 
association between susceptibility and this ST.  The remaining divergent isolates had 
the same restriction profile. Sa-Leao et al also identified restriction fragment pattern 
and MLST diversity in clone England14-9 (Sá-Leão et al., 2001).  Six England14-9 
isolates were included in a study of thirty eight isolates covering six clones.  Three 
different STs were identified and four different PFGE patterns.  One ST15 isolate 
displayed the same restriction profile as two ST9 isolates, similar to results from this 
study; PN94 153 (ST 15) presented an indistinguishable PFGE pattern from 
representative isolate PN93 1565 (ST 9).   
 
Two clone England14-9 database isolates that were not available for most of the 
duration of this project have now been fully sequenced and a restriction map could 
therefore be constructed (with the Genamics Expression programme) for comparison 
purposes.  The INV200 database isolate correlates in ST with chosen representative 
England14-9 isolate, PN93 1565 in addition to seven other isolates (ST9)  (section 
3.2).  The restriction map constructed for PN93 1565 using SmaI probes was 
comparable with the INV200 restriction map (figure 3.7.2a).  The order of restriction 
fragments can be seen in table 3.7.2a.  There were no new SmaI sites identified in 
either INV200 or CGSP14 that were not present in R6, TIGR4 or G54. 
 
Chapter 3 
 
 199 
Figure 3.7.2a:  SmaI restriction map of INV200.  SmaI sites (blue), fragment sizes in 
bp (green) and band numbers (black) in order of decreasing size are shown. 
 
 
The database isolate CGSP14 was also available to construct a SmaI restriction map 
to compare with PN94 153 (both ST15) (figure 3.7.2b).  PN94 153 however presented 
the same restriction fragment pattern as PN93 1565 and INV200.  The order or size of 
SmaI bands differed in four areas for CGSP14; band 1, band 2, band 7 and band 10 
(refer to table 3.7.2a).    
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Figure 3.7.2b:  SmaI restriction map of CGSP14.  SmaI sites (blue), fragment sizes in 
bp (green) and band numbers (black) in order of decreasing size are presented. 
 
 
The observed differences can be explained.  In INV200 and PN93 1565/PN94 153 
(refer to section 3.6.3, figure 3.6.3d for PN93 1565 SmaI hybridisations) bands one 
and two correspond to SmaI fragments 12/13 and 14/15, respectively, however in 
CGSP14 the opposite is observed (band 1 – 14/15; band 2 – 12/13) (table 3.7.2b).  
The region between SmaI sites 14 and 15 in CGSP14 contains a 189kb inversion.  
Inversions are thought to occur following genomic imbalance through acquisition of a 
large mobile genetic element (discussed in section 3.7.4) which could explain the 
increase in band size between SmaI14 and SmaI15 compared to INV200.  In addition, 
the overall genome size of the two genomes differs as CGSP14 (2210kb) is 116kb 
larger than INV200 (2094kb).   
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Band 7 hybridised SmaI_3 as well as SmaI_18 and SmaI_19 in PN93 1565 (section 
3.6.3, figure 3.6.3d).  In INV200 this was shown to be due to the presence of two very 
similar sized fragments (SmaI_3 and SmaI_4 flanked a 97kb fragment, SmaI_18 and 
SmaI_19 flanked a 100kb fragment) (table 3.7.2a).  In CGSP14 a third band was also 
present at band number 7 flanked by SmaI_4 and SmaI_6 (table 3.7.2a).  SmaI 
restriction site presence/absence analysis of database isolates revealed that this site 
was not present (section 3.5.1, table 3.5.1d). Sequence analysis showed that 185bp of 
this region, containing SmaI_5 in CGSP14 is absent. The absence of this region and 
therefore SmaI_5 therefore created a 100kb fragment and thus explains the 
differences observed in band 7.  This also accounts for differences observed at band 
10 between INV200, PN93 1565 and CGSP14, as for CGSP14 there is no longer a 
fragment that hybridises SmaI_4/5 (table 3.7.2a). 
 
Table 3.7.2a:  Comparison of SmaI digested fragment order and size with England14-9 
representative isolate PN93 1565 and database isolates INV200 and CGSP14.  Band 
numbers 1 through 13 are listed.  SmaI site information is obtained from 
hybridisations with PN93 1565 and from devised restriction maps for INV200 and 
CGSP14 (figures 3.7.2a and 3.7.2b). 
 
 
There was a high degree of MLST diversity in Taiwan19F-14 isolates but only two 
displayed a divergent restriction fragment pattern (section 3.6.4). One of those isolates 
(STP 269) also had a new ST in addition to a previously unidentified allele change.  
The four SLVs however (STP 013, STP 057, STP 194 and STP 221) were of different 
 PN93 1565 INV200 CGSP14 
Band 
no. 
SmaI site 
probes 
Size 
 
Flanking 
SmaI sites 
Size 
 
Flanking 
SmaI sites 
Size 
 
1 12/13 311 12/13 308 14/15 351 
2 14/15 284 14/15 282 12/13 309 
3 8 246 8/11 248 8/11 250 
4 15/18 226 15/18 227 15/18 227 
5 1 198 29/1 201 29/1 206 
6 19/21 173 19/21 172 19/21 188 
7 3, 18/19 98 3/4, 18/19 97, 100 3/4, 4/6, 
18/19 
98, 100, 100 
8 12 89 11/12 91 11/12 92 
9 24 80 23/24 82 23/24 83 
10 5, 13/14 60 4/5, 13/14 62, 64 13/14 63 
11 27 45 26/27 49 26/27 49 
12 6/8 <45 6/8 38 6/8 38 
13 3 <45 2/3 25 2/3 25 
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STs but displayed the same restriction fragment pattern (Section 3.6.4, figure 3.6.4ai).  
Diversity in this clone has been observed in PFGE typing of 143 S. pneumoniae 
isolates (Mavroidi et al., 2007). Of the 143 isolates, 110 were categorised in the 
Taiwan19F-14 clonal complex.  A total of 30 PFGE subtypes were identified 
highlighting PFGE pattern diversity, however a uniform pattern was observed with 
half of the isolates.  MLST analysis revealed seven different ST’s all of which were 
Taiwan19F-14 SLVs belonging to CC271 (Mavroidi et al., 2007). 
 
A SmaI restriction map of the database T19F-14 isolate (which was not available for 
most of the duration of this project) was devised using genamics expression for 
comparison purposes (figure 3.7.2c).  A table to compare the order and size of 
fragments with the representative isolate from this study (STP 022) is illustrated in 
table 3.7.2b. 
 
Figure 3.7.2c: SmaI restriction map of T19F-14.  SmaI sites (blue), Fragment sizes 
(green) and band numbers (black) are presented. 
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A number of regions correlate with my findings, however as the sequenced isolate is 
observed to have a large inversion between smaI sites 12 and 16 (similar to the region 
of inversion observed in the Spain9V-3 isolate used in this study, PN93 1454), 
differences are observed in size and order of certain bands (table 3.7.2b, highlighted 
in yellow).  This inversion can be identified in figure 3.7.2c from the inverted order of 
SmaI sites 13, 14 and 15.  This inversion was not observed in Taiwan19F-14 isolates 
used in this study.  Analysis of the fully sequenced isolate also showed that there were 
no new SmaI sites present that had not already been observed in R6, TIGR4 or G54.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7.2b:  Comparison of SmaI digested fragment order and size with Taiwan19F-
14 representative isolate STP022 and database isolate T19F-14.  Band numbers 1 
through 15 are listed.  SmaI site information is obtained from hybridisations for STP 
022 and from devised restriction maps for T19F-14 (figure 3.7.2c). Bands highlighted 
in yellow are those that do not correlate in size/order between STP 022 and T19F-14. 
 
 
Unfortunately, a restriction map could not be devised for the database isolate 
Canada19F.  Although this is a fully sequenced isolate, sequence information does not 
appear to be available. Canada19F is a SLV of Taiwan19F-14 (ST 271).  Ten of the 
Taiwan19F-14 isolates used in this research are ST271 and a restriction map for 
Canada19F would therefore be very useful for comparison with the ST236 map. 
 
 STP 022 T19F-14 
Band 
no. 
SmaI site 
probes 
Size 
 
Flanking 
SmaI sites 
Size 
 
1 12/13 315 13/16 302 
2 8 286 8/11 274 
3 14/15 258 29/1 222 
4 1 229 12/15 202 
5 15 211 14/15 186 
6 3/5 178 3/5 174 
7 19/21 147 19/21 146 
8 24 116 13/14 137 
9 18/19 101 23/24 116 
10 12 92 18/19 101 
11 13/14 74 11/12 88 
12 27 45 26/27 45 
13 6/7 <45 6/7 31 
14 3 <45 2/3 23 
15 5/6, 18 <45 17/18 10 
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It is clear here and elsewhere that using PFGE in conjunction with MLST is extremely 
valuable in identifying different types of genetic diversity.  The evolution of all three 
clones has been highlighted by both techniques and comparison with sequenced 
database isolates has confirmed SmaI hybridisations and allowed small fragments, 
that would not be visible on a PFGE gel, to be mapped.  The next part of the project 
involved defining the observed changes.  MLST variants were analysed for the 
contribution of mutation and recombination in diversification of ST’s and 
polymorphisms in PFGE variants were investigated for genomic rearrangements and 
SmaI site mutation. 
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3.7.3 Investigation of PFGE polymorphisms 
 
Differences observed in PFGE restriction fragment pattern can occur via two 
mechanisms; point mutation to a restriction site or DNA rearrangements.  SmaI site 
presence/absence was investigated to determine the contribution of point mutation to 
PFGE polymorphisms.  Only 1 of the 504 sites tested (0.2%) were abolished by point 
mutation to the SmaI recognition sequence.  The change however was not visible on a 
PFGE gel as it was associated with one of the smaller fragments.  The two other 
abolished sites that were identified, SmaI_7 and SmaI_20, were present in all other 
isolates of the corresponding clone.  Point mutation has previously been observed to 
contribute little to pneumococcal PFGE restriction fragment pattern difference in 
pneumococci (Hall and Duke, 1998). 
 
 
Among bacteria, genomic rearrangements including insertions, deletions and 
inversions are a prominent feature of genetic diversification and are important in 
shaping the evolution of a given species (Achaz et al., 2003, Tettelin et al., 2001).  
Approximately 5% of the pneumococcal genome is made up of insertion sequences 
that may facilitate genomic rearrangements (Tettelin et al., 2001).  PFGE allows 
genetic changes to be identified and hybridisations define these events. Overall, PFGE 
restriction fragment pattern diversity for isolates of the three clones were shown to be 
created by genomic rearrangement as opposed to point mutation. Isolates of clone 
Spain9V-3 and England14-9 displayed the most rearrangements; three independent 
rearrangements were identified in Spain9V-3 isolates (two insertion/deletions and one 
inversion), five independent rearrangements in England14-9 (five insertion/deletions) 
and two independent rearrangements in Taiwan19F-14 (two insertions/deletions). 
 
Although a significantly higher mutation rate in housekeeping alleles was observed 
for database England14-9 isolates (42.5%) compared to Spain9V-3 and Taiwan19F-14, 
recombination still played an important part in the creation of England14-9 variants 
(57.5%).  Furthermore, five independent rearrangement events were identified in this 
clone.  Overall, results from this study and database analysis therefore suggest that 
this clone evolves largely through both recombination as well as mutation.    A 
number of different mechanisms may lead to the rearrangements observed in these 
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isolates including HGT of mobile elements and homologous recombination of 
previously existing genes.  Mobile elements include IS elements, transposons and 
phages.  The availability of pneumococcal genome sequences has allowed mobile 
elements in to be examined and quantified.                  
 
Insertion sequences are simple transposable elements that do not carry accessory 
genes.  The sequencing of R6 and TIGR4 revealed an astonishing number of insertion 
sequences in the pneumococcal genome (Tettelin et al., 2001, Hoskins et al., 2001). 
Since then numerous other genomes have also revealed similar findings and although 
RD studies have showed differences in the composition of insertion sequences across 
different clones it is also evident that members of the same clonal complex can 
contain differences in the presence of IS elements.  The recent sequencing of a 
serotype 11A (ST62) isolate revealed the presence of 63 insertion elements and 
inactivated derivatives (Camilli et al., 2011).  These 63 elements could be categorised 
as one of eight different IS element families.  Interestingly, investigating these ISs in 
two other database serotype 11A, ST62  isolates (SP11-BS70 and MLV-016), 
revealed that for three of the IS families, the number of elements and insertion sites 
differed (Camilli et al., 2011).  These results showed that isolates of the same clonal 
complex can comprise different copy numbers and insertion sites of the same IS 
element. Findings correlate with this research as all PFGE pattern differences were 
shown to have occurred via independent insertion/deletion events (apart from the 
insertion/deletion event that was identified in five different Spain9V-3 isolates, section 
3.6.2, figure 3.6.2g).  Evidence for IS element diversity has been identified from 
sequencing of the database serotype 14, ST15 isolate CGSP14 (Ding et al., 2009).  As 
already mentioned, an England14-9 SLV (ST15) isolate was identified in this study 
(PN94 153).  CGSP14 was found to contain 80 IS elements and inactivated 
derivatives (Ding et al., 2009) showing that these elements are a prominent feature in 
the diversification of clone England14-9. 
 
The insertion/deletion events identified could also have occurred through horizontal 
gene transfer of transposons.  Multidrug resistance in S. pneumoniae has been related 
to the acquisition of Tn916 family transposons.  The Tn916 family is associated with 
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resistance to tetracycline (tetM), chloramphenicol and erythromycin through 
acquisition of the ermB or MefE gene (Cochetti, 2008).  Differences in the 
composition of Tn916 transposons have been identified in England14-9 isolates 
(Quintero et al., 2011).  Horizontal gene transfer events were evident in this clone, as 
more than one type of transposon was detected.  Seven England14-9, ST15 
erythromycin resistant isolates contained the Tn916 related transposon Tn3972.  
Another erythromycin resistant England14-9 (ST15) isolate was shown to have 
acquired a different Tn916 related transposon.  Interestingly, two DLV’s were 
identified that also presented resistance to tetracycline through acquisition of Tn6002.  
All isolates however were shown to acquire erythromycin resistance through erm(B) 
carriage (Quintero et al., 2011). England14-9 isolates in this study are only resistant to 
erythromycin and a previous study showed that this clone acquired resistance by 
carriage of mefA (Birtles et al., 2004).  It is thus evident that this clone continues to 
evolve and various differences in PFGE patterns in any of the three clones may be 
explained by differences in transposon acquisition.  
 
Pneumococcal bacteriophages were first identified from throat swab samples of 
healthy children in 1975 (Mcdonnell et al., 1975). Phages are now a well know 
component of many pneumococcal genomes.  In a study of 791 clinical isolates, an 
astonishing 76% were found to contain prophages or remnants of prophages (Ramirez 
et al., 1999).  Comparative genomic analysis of ten pneumococcal temperate phages 
highlighted the diversity of these mobile elements as the only genes that appeared to 
be conserved in all genomes were those involved in integration and host lysis.  
Interestingly, there was also evidence of recombination and HGT between the phages 
(Romero et al., 2009).  Other genomes have been identified to contain very similar 
phages.  The sequencing of a serotype 11a, ST62 isolate revealed the presence of 
prophage φSPN_200 (Camilli et al., 2011).  It has a comparable GC% content as S. 
pneumoniae (Camilli et al., 2011) as do other phages (Romero et al., 2009) and the 
likely site of recombination has been identified as a 21bp sequence that is present in 
both the pneumococcal and phage genome.  A very similar phage has been identified 
in other database genomes (Camilli et al., 2011).  The fact that a vast number of 
clinical isolates contain phages in addition to the ability of phages to recombine 
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within their population suggests that differences in PFGE pattern may be attributed to 
the acquisition of these mobile elements.  The Ramirez et al study (that showed 
phages to be contained in 76% of clinical isolates) involved the hybridisation of phage 
probes to SmaI digested genomic DNA.  Interestingly, they identified differences in 
the size of SmaI bands (30kb – 280kb bands) and the number of bands that hybridised 
the phage probe (Ramirez et al., 1999).  Further evidence to support the presence of 
phages as an explanation for PFGE fragment diversity comes from analysis of two 
SP195, Spain9V-3, ST156 isolates.   Both have been identified to contain phages and 
on the basis of genome similarity, these prophages have been categorised into two 
different groups (Romero et al., 2009).   
 
Homologous recombination can involve the recombination of pre-existing genes as 
opposed to the acquisition of new sequences or elements through HGT.   
Pneumococcal genomes may recombine with donor genes that are identical apart from 
the presence of SNPs, however such changes are unlikely to be visible on a PFGE gel.  
Differences in PFGE fragment pattern are more likely attributed to homologous 
recombination that leads to the insertion and/or deletion of entire genes and operons.  
Large scale inversions are also facilitated through homologous recombination of 
repeat regions.  Hybridisation results showed that Spain9V-3 isolate PN93 1454 
contained a large inversion involving SmaI sites 12, 13, 14 and 15.  Large scale 
inversions have been identified elsewhere.  Analysis of the database T19F-14 isolate 
(from previous generation of a SmaI map, section 3.7.2, figure 3.7.2c) also shows the 
presence of a large inversion in the same region (in terms of SmaI sites 13, 14 and 15; 
figure 3.7.3),  although this has not been described in a publication.  Analysis of the 
inversion using the genome comparison tool WebACT 
(http://www.webact.org/WebACT/generate) showed that the inversion was 615kb. An 
inversion that has been described in the literature is that in database genome AP200 
(Camilli et al., 2011). This large scale inversion of 163kb covers the 
replication/termination axis (figure 3.7.3).  The borders of this inversion are thought 
to lie within histidine-triad proteins as this family of proteins present high sequence 
similarity and thus have the ability to facilitate an inversion.  Inversions are said to 
occur following the acquisition of large mobile genetic elements that interrupt the 
balance of the chromosomal architecture, particularly when insertions occur on one 
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side of the replication axis (Ding et al., 2009).  A large scale, 189kb inversion that 
also covers the replication axis has been identified in the database England14-9 SLV 
(ST15) isolate CGSP14 (figure 3.7.3) (Ding et al., 2009).  It was intriguing to find that 
the inversion covered SmaI sites 14 and 15, similar to the region in the database T19F-
14 isolate and PN93 1454 from this study.  Another 19kb inversion was observed in 
CPSP14.  The borders of both inversions (i.e. the four breakpoints) in CGSP14 were 
found to lie in IS elements.  In general, genomic rearrangements are said to be 
common in the genus Streptococcus and similar inversions that cover the replication 
axis have been identified in S. mutants and S. pyogenes (Maruyama et al., 2009). 
 
The correlation of the inversion region in Spain9V-3 isolate PN93 1454 with other 
inversions is presented in figure 3.7.3.  Apart from CGSP14 (location of inversion 
was described in (Ding et al., 2009)), inversions were located and sized using 
WebACT and a SmaI restriction map was generated for each genome using Genamics 
Expression.  R6 has been included as a reference SmaI restriction map as it has been 
used throughout this project. INV200 (England14-9, ST9) has also been included as a 
reference for the SLV, CGSP14.  Construction of SmaI maps revealed that for some 
inversions, the order of SmaI sites was not disrupted. This was the case for England14-
9 isolate CGSP14 compared to INV200 as the two inversions lie within SmaI sites 12-
13 and 14-15, respectively, as opposed to spanning the sites (figure 3.7.3, CGSP14 
compared to INV200).  Similarly, the order of SmaI sites have not been disrupted in 
AP200 (figure 3.7.3; AP200).  However, the inversion does include SmaI_14 and as a 
result the location of SmaI_14 has changed respective to the other genomes (figure 
3.7.3; AP200, SmaI_14).  As with the T19F-14 inversion, the inversion identified in 
PN93 1454 has resulted in inversion of SmaI sites. (figure 3.7.3; T19F-14 and PN93 
1454).  The minimum size of the PN93 1454 inversion is ~225kb (figure 3.7.3 PN93 
1454a), however the maximum possible size is ~650kb, similar to that in T19F-14 
(figure 3.7.3; PN93 1454b). Intriguingly, the region of the PN93 1454 inversion 
correlates with other inversions in terms of spanning the replication axis and 
associated SmaI sites. It is therefore plausible as discussed in other research 
(Maruyama et al., 2009, Ding et al., 2009) that the inversion occurred as an attempt to 
balance the genome following acquisition of a large mobile genetic element. 
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Figure 3.7.3:  Summary of inversions described in database isolates CGSP14, AP200 and T19F-14.  R6 and INV200 are included as references.  
Inversions are underlined in red.  SmaI sites 12 – 15, which cover the general area of inversions are underlined in green.  Representative Spain9V-
3 isolate PN94 661 is included for comparison with the Spain9V-3 isolate PN93 1454 inversion; approximate (a) minimum and (b) maximum size 
of inversion. 
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3.7.4 Correlations of polymorphisms in clones with known regions of 
diversity 
The pneumococcus is composed of a core genome that is essential for viability and an 
accessory genome that includes dispensable areas not common to all members of the 
species.  The core genome is able to evolve through homologous recombination of 
pre-existing genes, however, the accessory genome can diverge through horizontal 
gene transfer of mobile genetic elements and genomic islands. The pneumococcal 
supragenome is therefore said to be much larger than the genome of any single S. 
pneumoniae.  The use of sequencing and microarray technology has allowed 
differences within and between clones to be investigated with greatly increased 
resolution.  Comparison of 17 pneumococcal genomes revealed that an astonishing 
54% of orthologous clusters were dispensable. A number of ‘regions of diversity’ 
(RD) studies using CGH have been conducted to identify genes that are part of the 
accessory genome, i.e. genes that are present or absent in various genomes as a result 
of intra and interspecies variation (as opposed to allelic variation). This section 
summarises the findings of RD microarray studies to allow comparison of the regions 
that were divergent in isolates of the three clones used in this study. Related database 
isolates were also used for comparison.  Spain9V-3, England14-9 and Taiwan19F-14 
related database isolates have been listed in table 3.7.4a for reference purposes (refer 
to section 3.2, table 3.2.4 for serotype, ST and CC details of isolates used in this 
study).   
 
Clone Isolate 
 
 
Accession number Serotype ST CC 
Spain9V-3 SP195 
 
NZ_ABGE01000000 9V 156 156 
England14-
9 
INV200 
 
FQ_312029 14 9 15 
England14-
9 
CGSP14 
 
NC_010582 14 15 15 
Taiwan19F-
14 
T19F-14 
 
NC_012469 19F 236 271 
Taiwan19F-
14 
Canada 19F 
 
NZ_ACNV0000000 19F 271 271 
Table 3.7.4a:  Database isolates used in RD analysis. ST – sequence type; CC – clonal 
complex. 
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Two of the most systematic studies conducted by Silva et al (Silva et al., 2006) and 
Blomberg et al (Blomberg et al., 2009) involved comparative genome hybridisation of 
TIGR4 (oligonucleotides of predicted R6 ORFs  were also included in the Blomberg 
et al study) tested against a number of different isolates/strains.  Some of these 
regions have been identified in other studies (Hakenbeck et al., 2001, Obert et al., 
2006, Tettelin et al., 2001, Embry et al., 2007, Tettelin, 2006).  Table 3.7.4b shows 
the isolates/strains examined across different RD studies.    In total, 41 regions of 
diversity were identified across all strains/isolates investigated (table 3.7.4c) and have 
been named RD1 through RD36 (and for R6, R6_RD1 to R6_RD5) for the purpose of 
this thesis. Alternative RD numbering may be used in other studies as the number of 
genomic areas in which RDs were identified varies across the literature, but these are 
noted in table 3.7.4c. Using Genamics Expression these regions were mapped in 
TIGR4 and R6 (in cases where RDs were not found in TIGR4) (figure 3.7.4a) and 
illustrate areas which are part of the accessory genome. The SmaI sites investigated in 
this project are also located in the RD map. 
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Table 3.7.4b:  Serotypes and where possible ST’s of isolates/strains investigated in 
different RD studies (Silva et al., 2006, Tettelin, 2006, Obert et al., 2006, Blomberg et 
al., 2009). 
 
Serotype  
(strain/isolate) 
ST Reference 
4 (TIGR4) 205 Silva et al, 2006; Tettelin et al, 2006 
N/A (R6) 128 Silva et al, 2006: Tettelin et al, 2006 
2 (D39) 128 Silva et al, 2006 
1 306 Blomberg et al 2009 
1 228 Blomberg et al 2009 
1 304 Blomberg et al 2009 
1 217 Blomberg et al 2009 
1 303 Blomberg et al 2009 
3 180 Silva et al, 2006; Blomberg et al 2009 
3 1826 Blomberg et al 2009 
3 1220 Blomberg et al 2009 
4 205 Blomberg et al 2009 
4 247 Blomberg et al 2009 
4 1222 Blomberg et al 2009 
4 205 Blomberg et al 2009 
6A 37 Silva et al, 2006 
6A Unknown Obert et al, 2006 
6B Unknown Obert et al, 2006 
6B 176 Blomberg et al 2009 
6B 138 Blomberg et al 2009 
7F 191 Blomberg et al 2009 
7F 1828 Blomberg et al 2009 
9V 156 Blomberg et al 2009 
9V 162 Blomberg et al 2009 
9V 838 Blomberg et al 2009 
9V 312 Blomberg et al 2009 
11A 62 Blomberg et al 2009 
14 124 Blomberg et al 2009 
14 307 Blomberg et al 2009 
14 9 Silva et al, 2006; Blomberg et al 2009 
14 1109 Blomberg et al 2009 
14 555 Blomberg et al 2009 
14 709 Blomberg et al 2009 
14 143 Blomberg et al 2009 
14 156 Blomberg et al 2009 
14 Unknown Obert et al, 2006 
15B 199 Blomberg et al 2009 
19A 41 Silva et al, 2006 
19A 75 Silva et al, 2006 
19A 440 Blomberg et al 2009 
19F 162 Blomberg et al 2009 
19F 156 Blomberg et al 2009 
19F 309 Blomberg et al 2009 
19F 425 Blomberg et al 2009 
23F 36 Blomberg et al 2009 
23F 81 Blomberg et al 2009 
35B 558 Blomberg et al 2009 
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RD 
 
RD size  
 
Reference Additional information 
1 9 Silva '06 - RD1, Tettelin'02 - RD1  
2 5.8 Silva '06 - RD2  
3 5.6 Silva '06 - RD3, Tettelin '02 - RD2, Embry '07 - RD2   
4 2 Blomberg '09 - RD5  
5 7.6 Blomberg '09 - RD6  
6 14.2 Silva '06 - RD4, Tettelin '02 - RD3 (T) - Atypical GC 
7 3.3 Silva '06 - RD5  
8 5.3 Blomberg '09 - RD9  
9 5.4 Silva '06 - RD6  
10 12.6 Silva '06 - RD7, Tettelin '02 - RD4  
11 7.1 Silva '06 - RD8  
12 8 Blomberg '09 - RD13  
13 5.6 Silva '06 - RD9  
14 11 Silva '06 - RD10  
15 8 Silva '06 - RD11  
16 4.4 Silva '06 - RD12, Tetellin '02 - RD5, Obert '06 - RD5, Embry '07 - RD5  
17 5.4 Blomberg '09 - RD18  
18 1.7 Silva '06 - RD13  
19 6.2 Blomberg '09 - RD20  
20 7.9 Silva '06 - RD14    
21 11.9 Silva '06 - RD15, Tetellin '02 - RD6, Obert '06 - RD 6 (T) - Highly atypical GC 
22 9.2 Silva '06 - RD16, Tetellin '02 - RD7, Obert '06 - RD7, Embry '07 - RD7 (T) - Atypical GC 
23 5.3 Blomberg '09 - RD26  
24 33.7 Silva '06 - RD17, Obert '06 - RD8, Embry '07 - RD8 RD8a (O) - SP1315 - 1332 IPD; SP1333 - 1351 - IPD 
25 12.1 Silva '06 - RD18,   
26 40.4 Tetellin '06 - RD8 (T) - Atypical GC 
Chapter 3 
 
 215 
27 13.1 Silva '06 - RD19, Tettelin '06 - RD9, Obert '06 - RD9, Embry '07 - RD9  
28 2.7 Blomberg '09 - RD32  
29 1.4 Blomberg '09 - RD33  
30 36.2 Silva '06 - RD20, Tetellin - RD10, Obert '06 - RD10, Blomberg '09 - RD34 Highly atypical GC content (T) 
31 5.3 Silva '06 - RD21  
32 3.2 Silva '06 - RD22, Tettelin '06 - RD11, Embry '07 - RD11 (T) Atypical GC 
33 4.5 Silva '06 - RD23, Blomberg '09 - RD38  
34 3.6 Blomberg '09 - RD39  
35 9.4 Silva '06 - RD24, Tettelin '06 - RD12, Embry '07 - RD12 (T) - Highly atypical GC content 
36 13.4 Silva '06 - RD25, Tettelin '06 - RD13, Embry '07 - RD13, Obert '06 - RD13 (O) - IPD for serotype 6A, Non IPD for serotype 14 
R6_RD1 17.2 Blomberg '09 - RD3  
R6_RD2 16.5 Blomberg '09 - RD23  
R6_RD3 12.2 Blomberg '09- RD24  
R6_RD4 9.4 Blomberg '09- RD30  
R6_RD5 4.3 Blomberg '09- RD36  
Table 3.7.4c: Table to summarise RD nomenclature from microarray studies. (Silva et al., 2006, Embry et al., 2007, Obert et al., 2006, Tettelin, 
2006, Blomberg et al., 2009).  RDs identified across different studies are named RD1 to RD36 (TIGR4) and R6_1 to R6_5 (R6).  Reference in 
which RD was identified are noted with corresponding RD number designated in that study described.  Any additional information is also noted 
with corresponding reference; (O) – Obert et al; (T) – Tetellin et al.  
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Figure 
3.7.4a:  
Illustration 
of RDs 
identified 
from 
microarray 
studies 
(table 
3.7.4c) 
mapped in 
TIGR4 and 
R6.  SmaI 
sites are 
also 
included 
(underlined 
in red). 
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Differences in restriction fragment patterns in clones Spain9V-3, England14-9 and 
Taiwan19F-14 were then compared to the location of known RDs in an attempt to 
identify any correlations. A number of RDs were located in regions that correlated 
with polymorphisms identified in isolates of Spain9V-3 (table3.7.4d), England14-9 
(table 3.7.4e) and Taiwan19F-14 (table 3.7.4f).  RDs that were possibly associated with 
observed differences (genomic rearrangement number 1 through 9 in table 3.7.4d, e 
and f and figure 3.7.4b) were also investigated where possible in sequenced database 
genomes with the aid of BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and 
sequence analyses tool Artemis 
(http://www.sanger.ac.uk/resources/software/artemis/). 
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Table 3.7.4d: Spain9V-3 RDs. Known RDs (from various studies described) are compared to genomic rearrangements (1 to 3) identified in clone 
Spain9V-3 isolates from this laboratory (isolate) in addition to related sequenced database genome SP195. 
 
Clone Genomic 
rearrangement 
no. 
(figure 3.7.4b) 
Isolate Antibiotic 
resistance 
Genomic 
rearrangement 
identified 
SmaI sites 
Flanking the 
GR 
RDs 
within 
flanking 
SmaI sites 
RD size 
 
Amount of RD present in 
database sequenced genome 
        SP195 (ST156) 
1 PN93 909 
PN93 917 
PN93 1029 
PN93 1802 
PN93 1454 
Susceptible 
Susceptible 
Resistant 
Resistant 
Resistant 
49kb insertion 
(or deletion) 
 
15 – 18 RD25 
RD26 
RD27 
R6_RD4 
12.1 
40.4 
13.1 
9.4 
1.6 
30.4 
1.7 
N/A 
2 PN93 909 Susceptible 22kb insertion 
(or deletion) 
14 – 15  RD21 
RD22 
RD23 
RD24 
R6_RD2 
R6_RD3 
11.9 
9.2 
2.3 
33.7 
16.5 
12.2 
2.2 
0.9 
N/A 
8.8 
2.3 
0.9 
 
 
 
 
 
 
 
 
Spain9V-3 
3 PN93 1454 Resistant Inversion 
226kb – 663kb 
 
12 – 15 RD15 
RD16 
RD17 
RD18 
RD19 
RD20 
RD21 
RD22 
RD23 
RD24 
R6_RD2 
R6_RD3 
8 
4.4 
5.4 
1.7 
6.2 
7.9 
11.9 
9.2 
5.3 
33.7 
16.5 
12.2 
8 
N/A 
N/A 
1.7 
6.2 
2.4 
2.2 
0.9 
N/A 
8.8 
2.3 
0.9 
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Table 3.7.4e: England14-9 RDs. Known RDs (from various studies described) are compared to genomic rearrangements (4 to 7) identified in 
clone England14-9 isolates from this laboratory in addition to related sequenced database genomes INV200 and CGSP14. 
 
 
Clone Genomic 
rearrangement 
no. 
(figure 3.7.4b) 
Isolate Antibiotic 
resistance 
Genomic 
rearrangement 
Identified 
SmaI sites 
Flanking the 
GR 
RDs 
within 
flanking 
SmaI sites 
RD size 
 
Amount of RD present  in 
database sequenced genome 
 INV200 (ST9) CGSP14 
(ST15) 
4 PN93 872 
PN94 653 
Resistant 
Resistant 
20kb insertion 
13kb insertion 
(or deletion) 
19 –  21 RD30 
RD31 
RD32 
R6_RD5 
36.2 
5.3 
3.2 
4.3 
31.4 
5.3 
1.5 
2.8 
28.3 
5.3 
0.3 
N/A 
5 PN93 908 Resistant 53kb insertion 
(or deletion) 
23 – 24 RD33 
RD34 
RD35 
4.5 
3.6 
9.4 
4.5 
3.6 
1.1 
4.5 
N/A 
N/A 
6 PN93 1719 Resistant 37kb insertion 
(or deletion) 
26 – 27  None N/A N/A N/A 
 
 
 
 
England14-9 
7 PN94 336 Susceptible 60kb insertion 
(or deletion 
13 – 14 None  N/A N/A N/A 
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Clone Genomic 
rearrangement 
no. 
(figure 3.7.4b) 
Isolate Antibiotic 
resistance 
Genomic 
rearrangement 
identified 
SmaI sites 
Flanking 
the GR 
RDs within 
flanking 
SmaI sites 
RD size 
 
RD presence/absence in database 
sequenced genome 
 T19F-14 
(ST 236) 
Canada19F 
(ST271) 
8 STP269 Resistant 16kb deletion 
(or insertion) 
3 – 5 
 
RD1 
RD2 
RD3 
R6_RD1 
9 
5.8 
5.6 
17.2 
0.9 
5.8 
N/A 
15 
0.9 
5.1 
N/A 
15 
 
 
Taiwan19F-
14 
9 STP028 Resistant 20kb deletion 
(or insertion) 
8 – 11 
 
RD4 
RD5 
RD6 
RD7 
RD8 
RD9 
RD10 
RD11 
RD12 
RD13 
2 
7.6 
14.2 
3.3 
5.3 
5.4 
12.6 
7.1 
8 
5.6 
0.3 
7.4 
3.6 
3.4 
5.3 
N/A 
12.6 
7.1 
N/A 
4.0 
0.3 
7.2 
3.6 
0.5 
N/A 
N/A 
N/A 
7.1kb 
3.9 
N/A 
Table 3.7.4f: Taiwan19F-14 RDs.  Known RDs (from various studies described) are compared to genomic rearrangements (8 and 9) identified in 
clone Taiwan19F-14 isolates in this laboratory (isolate) in addition to related sequenced database genomes T19F-14 and Canada19F. 
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Figure 3.7.4b: Location of RDs in database genomes. The TIGR4 and R6 SmaI restriction map is shown with RDs and areas in which 
polymorphisms were observed in Clones Spain9V-3 (1 – 3, red), England14-9 (4 – 7; green) and Taiwan19F-14 (8 – 9; blue). These regions are also 
highlighted in SmaI restriction maps of related sequenced database genomes for Engand14-9 (INV200 and CGSP14) and Taiwan19F-14 (T19F-
14). The position of each SmaI site is shown (bp) next to each SmaI site. A SmaI map could not be included for the Spain9V-3 genome SP195 as 
it is not yet fully sequenced.  
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3.7.4.1 RDs that correlate with polymorphisms identified in clone Spain9V-3 
Three different genomic rearrangements were identified across Spain9V-3 isolates, 
named genomic rearrangement 1 - 3 (table 3.7.4d, figure 3.7.4b). RDs that may be 
associated with Spain9V-3 genomic rearrangements identified in this study have been 
analysed in the database isolate SP195 in addition to related isolates from the same 
clonal complex (Blomberg et al., 2009) (table 3.7.4.1 below) 
 
3.7.4.1.1 Genomic rearrangement 1 
Five Spain9V-3 isolates contained the same insertion between SmaI_15 and SmaI_18 
which covers RD25 – RD27 in addition to R6_RD4 (table 3.7.4d and figure 3.7.4b – 
genomic rearrangement no.1).  
 
RD25 was fully present in two isolates, both of which were ST162 (table 3.7.4.1) but  
was partially present in the remaining isolates: ST156 isolates and SLV ST 838 
(Blomberg et al., 2009) (table 3.7.4.1).  This correlated with the sequenced database 
genome SP195 which only contained 1.6kb of the 12.1kb RD (table 3.7.4d). 
 
The Blomberg et al study did not investigate RD26, however investigation of RD26 in 
sequenced genome SP195 using BLAST interestingly showed this genome to contains 
30.4kb of the 40.4kb RD.  RD26 is particularly intriguing as it has an atypical GC 
content which is indicative of horizontal gene transfer from another species.   
 
RD 27 contains SmaI sites 16 and 17 (figure 3.7.4a, TIGR4) which are either both 
present or both absent in genomes (discussed further in section 3.7.4.3).  Restriction 
enzyme digestion (section 3.4) showed that these sites were absent in all Spain9V-3 
isolates and RD 27 is therefore unlikely to be present in these isolates.  This is further 
supported by analysis of RD27 in the database Spain9V-3 isolate SP195 as only 1.7kb 
of the 13.1 kb RD is present (table 3.7.4d, RD27, SP195).  This region is also absent 
in CC156 isolates examined by Blomberg (Blomberg et al., 2009) (table 3.7.4.1).   
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Table 3.7.4.1:  CC156 RDs.  (i) Comparison of RDs in CC156 isolates from the Blomberg study (Blomberg et al., 2009) with database isolate 
SP195 (http://www.ncbi.nlm.nih.gov/).  The presence of RD15 – R6_RD4 correlate with regions of polymorphisms identified in Spain9V-3 
isolates in this study (1, 2 or 3).  Yellow – RD present; white – RD is partially present; blue – RD absent; red – RD not examined; (1) - database 
isolate; (2) – isolates investigated in Blomberg study (Blomberg et al., 2009).  (ii) Comparison of RDs with location of inversion in T19F-14 is also 
described for comparison purposes with inversion identified in Spain9V-3 isolate PN93 1454. 
RD RD 
15 
RD 
16 
RD 
17 
RD 
18 
RD 
19 
RD 
20 
RD 
21 
RD 
R6_ 
RD2 
RD 
R6_ 
RD3 
RD 
22 
RD 
23 
RD 
24 
RD 
25 
RD 
26 
RD 
27 
RD 
R6_ 
RD4 
Genomic  
Rearrangement no. 
3 3 3 3 3 3 2/3 2/3 2/3 2/3 2/3 2/3 1 1 1 1 
 Sero 
-type 
ST 
(CC) 
 
(i) Analysis of RD15 – R6_RD4 correlation with genomic rearrangements 1 – 3 in CC156 
Spain9V-3 
(Bryant et 
al.)SP195 
9V 156 (156)                 
ST1569V-1 (2) 9V 156 (156)                 
ST1569V-2 (2) 9V 156 (156)                 
ST1629V (2) 9V 162 (156)                 
ST8389V (2) 9V 838 (156)                 
ST15614-1 (2) 14 156 (156)                 
ST15614-2 (2) 14 156 (156)                 
ST16219F (2) 19F 162 (156)                 
ST15619F-1 (2) 19F 156 (156)                 
ST15619F-2 (2) 19F 156 (156)                 
(ii) Analysis of RD11 – RD17 correlation with inversion in database isolate Taiwan19F-14 and other members of CC271 
Database 
Taiwan19F-14 
19F 236 
(271) 
            
Database 
Canada19F  
19F 271 
(271) 
            
ST23619F (2) 19F 236 
(271) 
            
 
Chapter 3 
 
 225 
R6_RD4 is also within SmaI_15 and SmaI_18.  This region however is absent in 
SP195 in addition to all CC156 isolates described (table 3.7.4.1c) and is therefore 
unlikely to be an RD that is associated with CC156.   
 
In summary, of the four RDs that could correlate with genomic rearrangement 1, 
RD25 and RD26 are potential candidates.  RD26 revealed particularly interesting 
results due to the size (40.4kb), which correlates fairly well with the size of the 
genomic rearrangement (47kb), in addition to the identification of an atypical GC 
content. Correlations could be further defined if full sequence information was 
available for database isolate SP195 as a SmaI restriction map could be compared 
with PFGE fragment maps from this study. 
 
3.7.4.1.2 Genomic rearrangement 2 
Spain9V-3 isolate PN93 909 which is a susceptible isolate, was shown to display an 
insertion of around 22kb (table 3.7.4d and figure 3.7.4b; genomic rearrangement 2).  
The insertion occurred between sites 14 and 15 which includes six RD’6 (table 3.7.4d 
and figure 3.7.4b; RD21 – RD24 in addition to R6_RD2 – R6_RD3).    
 
RD21 and R6_RD2 are partially present in all isolates described (table 3.7.4.1).  
RD21 is particularly interesting as it has a highly atypical GC content, indicative of 
horizontal gene transfer.  R6_RD3 and RD22 were shown to be partially present in 
database isolate SP195 but absent in isolates described by Blomberg et al.  RD22 also 
contains an atypical GC content.  As these regions are variable in different CC156 
isolates, it is possible that they account for the insertion identified in isolate PN93 
909.  RD23 is absent in all isolates and is therefore unlikely to be related to the PN93 
909 polymorphism (table 3.7.4.1). 
 
Interestingly, Blomberg et al found that RD24 is present in ST162 (susceptible) 
isolates but absent in ST156 (resistant) isolates as well as isolate ST838 (unknown) 
(Blomberg et al., 2009) (table 3.7.4.1).  As this RD lies between SmaI sites 14 and 15, 
the ST156 (resistant) and ST162 (susceptible) isolates used in this study would be 
expected to present differences in band sizes between these sites if there was any 
correlation with drug resistance.  However, no obvious difference was observed. 
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Analysis of RD24 in database isolate SP195 showed that only part of the RD was 
present, 8.8kb of the 33.7kb RD24 (table 3.7.4d), meaning that 25kb was absent in 
this isolate.  The absent region of this RD could therefore account for the 22kb 
insertion identified in PN93 909.  Once again, a SmaI restriction map of SP195 would 
allow a direct comparison with Spain9V-3 polymorphisms identified in this study. 
 
Of the six RDs that coincide with the location of genomic rearrangement 2, five are 
potentially related to the 22kb insertion identified in PN93 909. The most comparable 
are RD21 and RD24 due to an atypical GC content and a comparable size, 
respectively. 
 
3.7.4.1.3 Genomic rearrangement 3 
One inversion was identified for an isolate of Spain9V-3 which occurred somewhere in 
between SmaI sites 12 and 15.  Twelve RDs are located within this region, covering 
RDs 15 – 24 in addition to R6_RD2 and R6_RD3 (table 3.7.4d and figure 3.7.4b; 
genomic rearrangement 3).   Interestingly, analysis of the NCBI sequenced genome 
T19F-14 and construction of a SmaI map showed that an inversion was present in the 
same region.  Other sequenced genomes have also presented inversions in this region 
(discussed previously in section 3.7.4).  RDs are often flanked by insertion sequences 
which facilitate recombination. It is therefore possible that the same insertion or 
repeated sequences are common in this region of numerous genomes and correlate 
with RDs identified in this area of the genome.   
 
RD15 and RD19 are present in all isolates (table 3.7.4.1). RD16 and RD23 are absent 
in all isolates (table 3.7.4.1). For the remaining RDs, certain regions are partially 
present/absent (table 3.7.4.1).  As SP195 does not contain a large inversion and there 
is no mention of the presence of inversions in the CC156 isolates from the Blomberg 
study, it seemed more beneficial to analyse these RDs in the sequenced database 
isolate T19F-14 (that contains a large inversion in the same region) and compare it to 
the related database isolate Canada19F (no inversion present) and a ST236 isolate 
from the Blomberg et al study (no reported inversion).  As already mentioned the size 
of the inversion may be anywhere from ~225kb to ~650kb so the identification of 
mobile genetic elements within or flanking this region in T19F-14 that were not present 
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in the other two isolates would be indicative of sequences that may have facilitated 
the large inversion.  
 
RD24 revealed the most fascinating results.  This region is not present in Canada19F 
or ST23619F but is partially present in T19F-14. Although T19F-14 only contains 5.4kb 
of RD24 (33.7kb), the included region contains a repeated transposase which is 
heavily repeated in the area flanking the inversion.  In total, 38kb of the genome is 
composed of this repeated transposon/defected transposon (information obtained 
using artemis http://www.sanger.ac.uk/resources/software/artemis/, genamics 
expression and BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi).  It is therefore very 
likely that these regions are related to the presence of the T19F-14 inversion as they are 
not present in Canada19F and ST23619F.  Interestingly, this repeated transposon is 
also common in CGSP14 and AP200 both of which, as previously discussed (section 
3.7.4), contain inversions in similar regions.  Similar transposon sequences may have 
facilitated the inversion observed in PN93 1454.    
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3.7.4.2 RDs that correlate with polymorphisms identified in clone England14-9 
RDs that may be associated with differences identified in England14-9 isolates in this 
study have been analysed in database isolates INV200 and CGSP14 in addition to 
related isolates from Blomberg et al, ST9-14 (Blomberg et al., 2009) and where 
possible Silva et al (Silva et al., 2006) (table 3.7.4.1b, serotype 14, ST9).  Four 
genomic rearrangements were identified in England14-9 isolates (table 3.7.4e and 
figure 3.7.4b; genomic rearrangements 4 – 7), however only two of these (genomic 
rearrangements 4 and 5) correlated with areas of the genome that contained RDs.  
Overall, RDs appear to be fairly diverse in CC15 members as only RD24 correlated in 
all isolates described (table 3.7.4.2a).   
 
Comparison of correlating RDs in isolates of CC15 
RD RD 
30 
RD 
31 
RD 
R6_ 
RD5 
RD 
32 
RD 
33 
RD 
34 
RD 
35 
Genomic rearrangement 
no. 
 
4 4 4 4 5 5 5 
 Sero 
-type 
ST  
INV200 (Bryant et al.) 14 9        
CGSP14 (Bryant et al.) 14 15        
ST9-14 (2) 14 9        
P11 (3) 14 9        
N16 (3) 14 9        
P33 (3) 14 9        
Table 3.7.4.2:  CC15 RDs. Comparison of RDs in CC15 isolates from the Blomberg 
(Blomberg et al., 2009) and Silva (Silva et al., 2006) studies with database isolates 
INV200 (http://www.sanger.ac.uk/) and CGSP14 (http://www.ncbi.nlm.nih.gov/).  
Yellow – RD present; light blue – majority of RD is present; blue – RD absent; white 
– RD partially present/absent; red – RD not examined; (Bryant et al.)– Database 
isolate; (2) – isolates investigated in Blomberg study; (3) – isolates investigated in Silva 
et al study. 
 
3.7.4.2.1 Genomic rearrangement 4 
Two England14-9 isolates from this research presented independent insertions (13 and 
20kb) between SmaI sites 19 and 21 (table 3.7.4e and figure 3.7.4b; genomic 
rearrangement 4).  This region covered four RDs; RD30, RD31, RD32 and R6_RD5 
(table 3.7.4e, figure 3.7.4b; genomic rearrangement 4).  Figure 3.7.4b shows the 
INV200 and CGSP14 SmaI restriction map against the TIGR4 region of diversity 
map.  The INV200 map showed that the region between SmaI sites 19 and 21 
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correlated with the SmaI restriction fragment pattern obtained for chosen England14-9 
representative isolate PN93 1565 (INV200 SmaI_19 – SmaI_21 – 172kb; PN93 1565 
SmaI_19 – 21 – 173kb) (section 3.7.2, table 3.7.2a).   
 
Although in CGSP14 SmaI sites 19 and 21 (which include RDs 30 – 32 and R6_RD4) 
flanked the same fragment as in INV200 and PN93 1565, generation of a SmaI 
restriction map using Genamics Expression showed that the size of the fragment 
differs in CGSP14 by 16kb  (figure 3.7.2a and 3.7.2b; SmaI_19 – SmaI_21).  It was 
therefore plausible that there was a correlation between the increase in fragment size 
(between SmaI_19 and SmaI_21) observed in PN93 872 or PN94 653 (compared to 
the chosen England14-9 representative isolate, PN94 1565) and the increase in 
fragment size observed in CGSP14 (compared to INV200).  However, no major 
differences in the presence/absence of RD30, RD31, RD32 and R6_RD5 in (INV200 
and CGSP14) that could account for the increase in CGSP14 were identified (Table 
3.7.4.2).  Analysis of RD studies revealed differences in RD32.  The majority of 
RD32 was identified in ST9-14 (Blomberg et al., 2009) (table 3.7.4.2), however this 
was not the case for the three ST9 isolates (P11, N16 and P33)  in the Silva et al study  
(Silva et al., 2006). Silva et al identified three genes in RD32 (named RD22 in Silva et 
al –table 3.7.4c), SP_01828 – SP_01830, predicted to have metabolic functions.  All 
three genes were present in N16, however, only SP_1830 was present in P11 and P33.  
Interestingly, this region was also variable in database isolates INV200 and CGSP14 
but differences in gene presence were observed.  SP_1828 was present and SP_1830 
was absent in both genomes. SP_1829 however was only present in CGSP14.  This is 
an interesting RD as a high amount of diversity can occur between isolates from the 
same CC and even the same ST.  However, as RD32 is only 3.2kb in size, it is 
unlikely to account for the 13kb and 20kb insertion observed in England14-9 isolates 
PN93 872 and PN94 653.  Furthermore, as already discussed RDs30 – 32 could not 
account for the increase in fragment size (between SmaI_19 and SmaI_21) observed 
for CGSP14 compared to INV200.  The RD studies described only investigate a 
certain number of pneumococcal genomes and are not representative of RDs in the 
whole population.  It is therefore likely that the insertions identified in England14-9 
isolates and CGSP14 have not been described and may represent entirely new RDs.  
Sequencing this region in PN93 872 and PN94 653 and comparing it to sequence data 
from the same region in chosen representative isolate PN93 1565 in addition to 
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INV200 and CGSP14 would identify the exact location of insertions and identify any 
possible relationship between them. 
 
3.7.4.2.2 Genomic rearrangement 5 
PN93 908 presented a 53kb insertion between SmaI_23 – 24 (figure 3.7.4b and table 
3.7.4e; genomic rearrangement 5).  Three RDs were identified in this region, RD33, 
RD34 and RD35 (table 3.7.4b and figure 3.7.4b).  RD33 is present in all genomes 
(table 3.7.4.2).  RD34 is present in INV200 and ST9-14 (this region was not described 
in ST9 isolates from Silva et al) (table 3.7.4.2).  RD35 is absent in CGSP14 and ST9-
14 but partially present in INV200 (this region was not described in ST9 isolates from 
Silva et al) (table 3.7.4.2).  The size of these RDs however (which are listed in table 
3.7.4e) are not comparable to the size of the genomic rearrangement observed and are 
therefore unlikely to be related. 
 
3.7.4.2.3 Genomic rearrangement 6 and 7 
PN93 1719 and PN94 336 incurred relatively large insertions between SmaI sites 26 – 
27 and 13 – 14, respectively (table 3.7.4e and figure 3.7.4b; genomic rearrangement 6 
and 7).  No RDs were identified in these regions that could be analysed for 
comparison purposes and may therefore represent new RDs. 
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3.7.4.3 Taiwan19F-14 correlations with known RDs 
RDs that may be associated with differences identified in Taiwan19F-14 isolates in this 
study have been analysed in database isolates T19F-14 and Canada19F in addition to a 
related isolate from Blomberg et al, ST236-19F (Blomberg et al., 2009) (table 3.7.4f).  
Figure 3.7.4b shows the SmaI restriction map for the database T19F-14 isolate 
alongside TIGR4 and R6 SmaI restriction maps with RDs.  Two genomic 
rearrangements were identified (table 3.7.4f and figure 3.7.4b; genomic 
rearrangements 8 and 9).  RDs located within the region of genomic rearrangements 8 
and 9 are presented in table 3.7.4.3.   
 
3.7.4.3.1 Genomic rearrangement 8 
A 16kb deletion was observed in STP269 between SmaI_3 and SmaI_5 which 
includes RD1 – RD3 in addition to R6_RD1 (table 3.7.4f and figure 3.7.4b; genomic 
rearrangement 8).  A SmaI restriction map of the database isolate T19F-14 showed that 
the region between SmaI_3 and SmaI_5 is of a similar size to that identified in 
Taiwan19F-14 chosen representative isolate STP 022 (STP 022 – 178kb; T19F-14 
database isolate – 174kb) (section 3.7.2; table 3.7.2b).  Therefore there was no loss of 
DNA (between SmaI_3 and SmaI_5) in T19F-14 compared to STP 022 that could 
correlate with the deletion observed in STP 269.  A restriction fragment comparison 
could not be made in this region for Canada19F as the sequence was not available to 
devise a map.  However, the RDs could be analysed in both genomes.   
 
RD1 was partially present in both database genomes, however this region was absent 
in the related isolate investigated by Blomberg et al, ST236-19F (table  3.7.4.3).  The 
amount of RD1 present in T19F-14 and Canada19F however is only 0.9kb and the 
difference observed is unlikely to be related to the 16kb deletion identified in STP269. 
RD3 is also unrelated as it is absent in all three genomes (table 3.7.4.3). 
 
RD2 (5.8kb) is present in all genomes and may correlate with the some of the region 
that was deleted in SP269. 
 
The most comparable RD to the observed 16kb deletion is R6_RD1 (17.2kb) which is 
partially present in all three genomes.  Analysis of T19F-14 and Canada194 showed 
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that 15kb of this RD is present which is comparable with the amount of DNA deleted 
in STP 269. 
 
RD2 and R6_RD1 could therefore be related to the insertion observed in STP 269.  A 
restriction map of the fully sequenced Canada19F would enable RDs to be further 
defined. 
 
 
3.7.4.3.2 Genomic rearrangement 9 
STP 028 was identified to contain a 20kb deletion between SmaI_8 and SmaI_11 
(table 3.7.4f and figure 3.7.4b; genomic rearrangement 9).  This region contains RD4 
– RD13.   
 
RD9 is absent in all three genomes and is therefore unlikely to account for the STP 
028 deletion. 
 
RD8, RD11, RD6 and RD12 are present or partially present in T19F-14, Canada19F 
and ST236-19F and may therefore correlate with the deletion.  RD6 is particularly 
interesting as it has a highly atypical GC content.   
 
STP 028 is of ST271 (as is Canada19F) and there are three regions where this isolate 
differs from T19F-14 and ST236-19F (both ST236), RD7, RD10 and RD13.  RD7 is 
present in T19F-14 and ST236-19F but only partially present in Canada19F.  
Furthermore, RD10 and RD13 are present and partially present, respectively, in both 
ST236 isolates but absent in Canada19F.  Interestingly the size of all three RDs is 
comparable to amount of DNA lost in the STP 028 deletion. A restriction map of 
Canada19F would confirm whether the equivalent decrease in fragment size between 
SmaI_8 and SmaI_11 is present, however, the sequence information was 
unfortunately not accessible. 
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Table 3.7.4.3:  CC271 RDs. Comparison of RDs in isolate ST236-19F  from the Blomberg study (Blomberg et al., 2009)  with database isolates  
T19F-14 and Canada19F (http://www.ncbi.nlm.nih.gov/).   Yellow – RD present; light blue – majority of RD is present; blue – RD absent; white 
– RD partially present/absent; red – RD presence/absence not specified in isolate; (Bryant et al.)– Database isolate; (2) – isolates investigated in 
Blomberg study. 
 
 
 
 
 
RD RD1 RD2 R6_ 
RD1 
RD3 RD4 RD5 RD6 RD7 RD8 RD9 RD10 RD11 RD12 RD9 
13 
Genomic rearrangement no. 
 
8 8 8 8 9 9 9 9 9 9 9 9 9 9 
 Sero 
-type 
ST  
T19F-14 (Bryant et 
al.) (Bryant et al.) 
 
19F 236               
Canada19F (Bryant 
et al.) 
 
19F 271               
ST236-19F  (2) 
 
19F 236               
Chapter 3 
 
 234 
3.7.4.3.3 RD27 
A general observation was made with SmaI_16 and SmaI_17 as both are either 
present or absent in all database genomes.   This was also identified in SmaI 
restriction enzyme digestion experiments in isolates of the three clones used in this 
study.  Amplification of this region in isolates of Spain9V-3 and England14-9 was 
unsuccessful, however Taiwan19F-14 isolates were confirmed to contain SmaI_16 and 
SmaI_17.  Analysis of this area in database isolates showed that the entire region 
surrounding both sites (which lie just 1.5kb apart) is absent in those isolates that do 
not contain either site.  RD analysis showed that this region is contained within RD27 
(figure 3.7.4a).  Further analysis revealed that these sites lie within the same gene, 
recP1. RecP1 has a 73% sequence similarity to RecP, one of the seven housekeeping 
genes in MLST.   
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3.7.5 Discussion: the contribution of recombination and mutation in S. 
pneumoniae evolution 
The extent of recombination and mutation was investigated in isolates of the three 
clones. Clonal complexes contain isolates that have indistinguishable MLST allelic 
profiles in addition to those that are allelic variants. MLST data can be used to 
determine whether an allelic polymorphism within a set of clonally related isolates is 
likely to have arisen by recombination or mutation. This provides an estimation of the 
relative contributions each have had in the evolution and dissemination of the clone. 
MLST diversity was examined in two sample sets. The first involved analysing STs in 
isolates from this laboratory, i.e. the SLVs and one DLV (section 3.2). The second 
involved analysing SLVs on a much larger scale by determining the occurrence of 
recombination/mutation in the database submitted isolates (section 3.3). 
 
MLST profiling for isolates in our collection showed that the eight out of ten allele 
changes were caused by recombination This coincides with research conducted by 
Feil et al who showed that the contribution of recombination to the generation of 
novel alleles is much higher than mutation; ten fold for the generation of new alleles 
and fifty fold for individual nucleotides (Feil et al., 2000b). Pérez-Losada et al also 
showed that S. pneumoniae MLST alleles diverge more as a result of recombination 
than mutation (Pérez-Losada et al., 2006). Only two of the ten changes were created 
by mutation, which gave the following percentage mutation for Spain9V-3, England14-
9 and Taiwan19F-14, respectively; 0%, 33.3% and 25%. These percentages however 
were presented for illustrative purposes only as the data set was too small to 
determine if results reflected MLST allele evolution in the true pneumococcal 
population. Conversely, the database sample size was large enough to identify 
significant differences in the contribution of mutation/recombination to the evolution 
of MLST alleles in all three clones. A significantly high occurrence of mutation in 
England14-9 was identified (section 3.3.4). A remarkable 42.5% of England14-9 SLVs 
were found to be created by mutation, which was significantly higher than that of 
Spain9V-3 (p = 0.0006) and Taiwan19F-14 (p = <0.0001). A figure much higher than 
expected and one that significantly exceeds a previously identified contribution of 
mutation of ~10% (Feil et al., 2000b) (described in chapter 1, section 1.3.5.1).  Feil’s 
findings correlate however with results for clones Spain9V-3 and Taiwan19F-14 
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(discussed later). Such a difference in R/M ratio between the clones suggest that 
England14-9 differs from the other two clones significantly in the relative contribution 
mutation and recombination has had on its evolution.  
 
Results from analysis of recombination and mutation as independent variables in 
MLST allele evolution indicated that recombination occurs significantly less 
frequently in clone England14-9 than in Spain9V-3 or Taiwan19F-14.  The frequency of 
mutation also appears to be higher.  However, there may be bias in the MLST 
database population as most research groups now tend only to enter novel variants of 
a clone as opposed to the population studies in which all isolates including 
representatives of existing STs are entered.  Furthermore, research is more frequently 
undertaken on penicillin resistant isolates, which may enrich for recombination-
competent isolates.   
 
An independent way of measuring recombination and mutation as separate events is 
to measure these variables in pneumococcal sample populations described in large 
scale epidemiological studies.  This may be more representative of the true 
pneumococcal population as the MLST data of all isolates from the sample are 
described.  Three large epidemiological pneumococcal studies were identified that 
included isolates from at least two of the three clones and did not select penicillin 
resistant isolates for study (table 3.7.5a) (erythromycin resistance is encoded on 
transposable elements so is not expected to bias the selection of isolates with respect 
to recombination competence). In most cases, only a few isolates of each clone were 
included and results were therefore combined for evaluation. Again, the frequency of 
recombination in clone England14-9 appeared lower, although the difference was less 
and not statistically significant. Overall, frequency of recombination was comparable 
to that seen for the full MLST database, suggesting that over-representation of 
recombination-competent isolates is not a major issue.  England14-9 however evolved 
significantly more by mutation compared to Spain9V-3 (p = 0.0053) and Taiwan19F-14 
(p = 0.0540).   
 
Analysis of data from published epidemiological studies ensures that a representative 
sample of the population is analysed.  A disadvantage is that the sample size is so 
much smaller than for all isolates submitted to the MLST database that differences 
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seen may be due to chance.  Both strategies suggest that increased mutation and lower 
recombination may contribute to the lower R/M ratio of England14-9 compared to 
other clones investigated.  However mutation frequency and mutation rate for two 
England14-9 isolates was no higher than for other clinical isolates, including Spain9V-3 
(Henderson-Begg and Hall personal communication).  It is therefore likely that a low 
rate of recombination accounts for the R/M ratio observed for England14-9.  This is 
supported by limited penicillin resistance in this clone and transformation deficient 
isolates observed in this laboratory. 
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Table 3.7.5a: Occurrence of recombination and mutation within three clones of interest from published pneumococcal population studies. Each 
allelic variant was determined to represent either a recombination or mutation event according to the method of Fiel et al (Feil et al., 2000b) and 
is described in section 3.2. No allelic variant was observed in more than one study. 
 
 Total 
number of 
isolates 
investigated 
Total 
number 
MLST 
typed 
Spain9V- 
3 
 
England14-
9 
Taiwan19F-
14 
Criteria for isolate 
selection 
Country Reference 
No. of isolates 542 542 54 67 n/a 
Recombination  5/54 5/67 n/a 
Mutation  1/54 10/67 n/a 
Invasive, elderly patients, 
submitted to HPA 
UK and 
Wales 
(Pichon et al., 
2009) 
No. of isolates 110 110 4 4 41 
Recombination  2/4 1/4 3/41 
Mutation  0/4 1/4 1/41 
Erythromycin resistant 
isolates 
Asia (Ko and Song, 
2004) 
No. of isolates 2200 60 n/a 3 1 
Recombination  n/a 1/3 1/1 
Mutation  n/a 1/3 0/1 
Macrolide/erythromycin 
resistant isolates 
Norway (Littauer et al., 
2005) 
No. of isolates 33 33 8 10 15 
Recombination  3/8 1/10 3/15 
Mutation  0/8 0/10 1/15 
Invasive, PMEN clones England and 
New 
Zealand 
This study 
Total number 
of isolates 
 66 84 57  
Total 
recombination 
 10 
(1.5 x 10-1) 
8 
(9.5 x 10-2) 
7 
(1.2 x 10-1) 
 
Total 
mutation 
 1 
(1.5 x 10-2) 
12 
(1.4 x 10-1) 
2 
(3.5 x 10-2) 
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3.7.5.1 Investigation of transformation gene defects in clone England14-9 
A bias against recombination for clone England14-9 was identified in the laboratory in 
this project.  In chapter 4 (section 4.1 to 4.3) the inactivation of dinB in different 
genetic backgrounds is described. Attempts were also made to inactivate dinB in 
England14-9 isolates, but no transformants were obtained.  To further explore the 
transformation efficiency of the clones, additional experiments were conducted to 
transform isolates with a rifampicin resistant variant of rpoB.  Rifampicin resistant 
mutants of R6 had previously been selected and sequenced to confirm the location of 
the resistance mutation within rpoB.  A 1.1kb fragment including the mutation was 
amplified and used to transform isolates of clones Spain9V-3, Enland14-9 and 
Taiwan19F-14. Three transformation experiments were conducted with each clone and 
results are shown below in table 3.7.5.1. 
 
 
 
 
 
Table 3.7.5.1: Frequency of transformants to rifampicin resistance in clones Spain9V-
3, England14-9 and Taiwan19F-14. 
 
As with the dinB construct, clone England14-9 failed to transform the rifampicin 
resistance allele on all three occasions.  Based on the number of colonies detected, 
this suggested that the frequency of recombination is at least 100 fold lower for 
England14-9 than for the other two clones. 
 
In S. pneumoniae, transcription of genes involved in transformation is controlled by 
quorum sensing which is activated upon increasing levels of competence stimulating 
peptide (CSP) in the surrounding media (Håvarstein et al., 1995) (described in section 
1.2).  The inability of clone England14-9 to transform could be due to incompatibility 
of the CSP variant used or defects in genes associated with competence (presented in 
figure 3.7.5.1a), DNA uptake or recombination and will now be discussed.  Since 
completion of the main work in this project, complete genome sequences have 
Spain9V-3 
 
England14-9 Taiwan19F-14 
4.62 x 10-08 
 
0 6.01 x 10-08 
 
3.59 x 10-08 
 
0 4.20 x 10-08 
 
4.69 x 10-08 
 
0 5.83 x 10-08 
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become available for two isolates from the England14-9 clone, CGSP14 and INV200.  
In addition, an incomplete genome sequence is available for an isolate named PN93 
872, isolated in the UK (named England14-9 on NCBI, project number 
PRJNA180292, but will be referred to by its isolate name in this thesis to avoid 
confusion with other England14-9 isolates described).  It is therefore possible to 
explore potential genetic causes of low transformation frequency by comparison with 
transformable S. pneumoniae R6. 
 
CGSP14 and INV200 are both multi-resistant isolates of clone England14-9 (Ding et 
al., 2009). Both have resistance determinants acquired through conjugative 
transposons which do not rely on the host machinery to uptake DNA. However, only 
CGSP14 has acquired penicillin resistance through recombination.  This genome has a 
PBP profile similar to Spain23F isolates, indicative of HGT with this clone (Ding et 
al., 2009).  INV200 and PN93 872 on the other hand are penicillin susceptible. 
Furthermore, PN93 872 is an isolate used in this project which was observed to be 
transformation deficient. A BLAST of pbp gene sequences (pbp1a, pbp2b and pbp2x) 
from susceptible R6 revealed high similarity (99%) to sequences in INV200 as well as 
PN93 872.  In addition to penicillin susceptibility, INV200 and PN93 872 are related 
by sharing the ancestral MLST ST, ST9.  CGSP14 conversely is of ST15, a SLV of 
ST9.  Most  England14-9 isolates, including those used in this study are only resistant 
to erythromycin (Birtles et al., 2004, Sogstad et al., 2007, Smith et al., 2006, Sá-Leão 
et al., 2001) and MLST database results support a low occurrence of recombination.  
It is possible that any genetic defects in transformation observed in INV200 and PN93 
872 would not be present in CGSP14.  Any differences identified in competence or 
recombination gene sequences between INV200/PN93 872 and CGSP14 may 
therefore explain transformation incompetence in this clone. 
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Figure 3.7.5.1a: Competence genes that may be defected in clone England14-9.  (A) 
Process of competence. (B) Products of comAB operon, comCDE operon and comX 
operon.  CSP, encoded by comC, in the surrounding media is recognised by the 
receptor ComD.  This initiates phosphorylation of ComE which in turn induces 
expression of early transformation genes from operons comAB, comCDE and comX.  
The product of comX then initiates transcription of late transformation genes. These 
genes were investigated in database clone England14-9 isolates as possible causes of 
transformation deficiency. 
 
3.7.5.2 Polymorphisms in genes associated with competence  
Quorum sensing can be initiated by different types of CSP and to date six have been 
recognised in pneumococci (Whatmore et al., 1999).  Of all six types, CSP-1 and 
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CSP-2 are more commonly identified and the former is produced by the majority of 
isolates (Pozzi et al., 1996). In most cases, isolates that recognise CSP-1 carry comC1 
and those that recognise CSP-2 carry comC2 (Pozzi et al., 1996). Initiation of 
transformation in this study was thus performed by supplementing transformation 
media with CSP-1 and failure of England14-9 isolates to transform was possibly due to 
recognition of a different CSP type. There is 50% sequence homology between CSP-1 
and CSP-2, however the difference in sequence occurs in the central region which 
confers specificity. The sequence of CSP-1 and CSP-2 were used to BLAST INV200, 
CGSP14 and PN93 872. As results showed that all three genomes possess comC1 and 
therefore produce CSP-1, it is likely that England14-9 isolates in this study also 
produce the same CSP.  
 
The CSP receptor, ComD specifically recognises its cognate CSP type. Isolates will 
therefore not respond to the presence of alternative CSPs (Pozzi et al., 1996, Ramirez 
et al., 1997). There are four allelic variants of the ComD receptor; comD1, cmD2, 
comD3 and comD4 (Iannelli et al., 2005). In most cases, comC1-comD1 and comC2-
comD2 are cognate, however two additional allelic combinations have been 
described; comC1-comD3 and comC1-comD4 (Iannelli et al., 2005) (figure 3.7.5.2, 
A). Moreover, there is evidence that cross-induction with both CSP types can occur in 
isolates carrying ComD2 or ComD3 (Iannelli et al., 2005) (figure 3.7.5.2, B). BLAST 
showed that a fully intact ComD1 receptor was present in CGSP14, INV200 and 
PN93 872 which eliminates the possibility of an alternative or defected ComD as the 
cause of failed transformation.    
 
Following CSP recognition, the ComD receptor triggers phosphorylation of the 
response regulator, ComE which is then able to activate transcription of early 
transformation genes from all three operons (figure 3.7.5.1a) (Pestova et al., 1996). 
ComE deletion has been shown to disrupt competence and response to CSP (Pestova 
et al., 1996), however the presence of intact ComE in all three database genomes 
means it is unlikely to be the cause of failed transformation in clone England14-9 
isolates (table 3.7.5.2a).  Furthermore a protein-protein BLAST shows 100% amino 
acid homology with transformable R6 (table 3.7.5.2a). 
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Figure 3.7.5.2:  Variants of CSP and its receptor. (A) Four allelic variants of the CSP receptor ComD exist; ComD1 (D1), ComD2 (D2), ComD3 
(D3) and ComD4 (D4).  CSP-1 is recognised by three of the allelic variants, compared to CSP-2 (green) which is only recognised by ComD2.  
(B) Cross competence induction by both CSP types has been demonstrated in isolates that carry ComD2 or ComD3 receptors. 
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One of the genes initiated by phosphorylated ComE is comX which encodes an 
alternative sigma factor (Lee and Morrison, 1999).  This sigma factor recognises a 
specific sequence known as the combox, located upstream from the start site of genes 
required for DNA uptake and transformation (Campbell et al., 1998).  S. pneumoniae 
possess two copies of comX, comX1 and comX2 (Lee and Morrison, 1999). A protein 
BLAST of both copies showed 99% amino acid homology with R6 for all three 
isolates (table 3.7.5.2a).  An amino acid change at position 92 from isoleucine to 
serine was identified (table 3.7.5.2b, comX1 and comX2).  However this change was 
also present in multiple other sequenced genomes and is thus very unlikely to cease 
transformability of clone England14-9 (table 3.7.5.2b, comX1 and comX2). 
 
In summary it can be concluded that the England14-9 clone is predicted to respond to 
the standard CSP, CSP-1 and no defects are apparent in genes involved in 
competence. 
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Table 3.7.5.2a:  Investigation of genes involved in competence, DNA uptake and recombination as the cause of defective transformation in 
isolates of clone England14-9.  The gene, gene product and function is presented.  All protein-protein BLASTs were conducted with protein 
sequence from R6 (gene id in R6 is shown).  The results for protein-protein homology are presented for England14-9 sequenced database isolates 
CGSP14 and INV200 in addition to draft sequence PN93 872 (872).  
  
Gene 
 
Protein 
 
Function 
R6 
genome 
reference 
Protein-protein BLAST 
homology with R6 
 872 CGSP14 INV200 
comC1 CSP-1 Quorum sensing spr2043 100% 100% 100% 
comD1 Histidine kinase CSP-1 receptor spr2042 100% 100% 100% 
comE Response regulator Initiates transcription of early genes  spr2041 100% 100% 100% 
comA Transporter Process and export of CSP spr0043 99% 100% 99% 
comB Transporter Process and export of CSP spr0044 99% 99% 99% 
comX1 Sigma factor Transcription initiation of late transformation genes spr0013 99% 99% 99% 
Competence 
comX2 Sigma factor Transcription initiation of late transformation genes spr1819 99% 99% 99% 
celA DNA binding protein Binds donor DNA spr0856 93% 98% 93% 
celB Transmembrane protein DNA entry spr0857 96% 98% 96% 
cglA ABC transporter Exports cglCDEFG products through membrane  spr1864 99% 99% 99% 
cglB ABC transporter Exports cglCDEFG products through membrane spr1863 99% 99% 99% 
cglC Transmembrane protein Cell wall channel spr1862 97% 93% 97% 
cglD Transmembrane protein Cell wall channel spr1861 96% 96% 96% 
cglE Transmembrane protein Cell wall channel spr1860 100% 100% 100% 
cglF Transmembrane protein Cell wall channel spr1859 96% 96% 96% 
cglG Transmembrane protein Cell wall channel spr1858 95% 95% 95% 
cflA Helicase  DNA entry spr2013 99% 99% 99% 
 
 
 
 
 
 
DNA Uptake 
cflB Competence protein Unknown spr2012 99% 99% 99% 
ssbB Binding protein Binds and protects donor strand spr1724 100% 100% 100% Recombination 
recA Rec protein Facilitates synapsis between donor and chromosomal 
DNA 
spr1757 99% 99% 99% 
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 Gene 
 
Genome Amino acid change Amino acid 
position 
Presence in 
other genomes 
comA CGSP14/INV200/ 
PN93 872 
Iso > Met 674 Multiple 
Thr > Ala 102 
Ser > Thr 286 
Iso > Val 311 
Thr > Ala 335 
comB CGSP14/INV200/ 
PN93 872 
Asp > Tyr 360 
Multiple 
comX
1 
CGSP14/INV200/ 
PN93 872 
Iso > Ser 92 Multiple 
Competence 
comX
2 
CGSP14/INV200/ 
PN93 872 
Iso > Ser 92 Multiple 
Leu > Ser 54 
Val > Ser 55 
Ser > Thr 56 
Asn > Lys 61 
Leu > Ser 143 
CGSP14 
Iso > Thr 149 
Multiple 
Gln > His 35 
Deletion; Lys, Glu, 
Lys, Glu 
62 
Ala > Ser 132 
Val > Ala 133 
Thr > Ala 137 
Leu > Ser 139 
Ala > Ser 181 
Gly > Ala 199 
celA 
INV200/PN93 872 
Thr > Ala 210 
None, 
93% homology 
in 9 sequenced 
genomes 
including R6 
Val > Iso 96 
Ala > Ser 108 
Asp > Asn 109 
Iso > Ala 112 
Lys > Thr 174 
Arg > Gly 210 
Phe > Leu 326 
Ala > Thr 354 
Thr > Val 393 
Thr > Ala 431 
Ser > Arg 432 
Thr > Ala 462 
Lys > Gly 484 
Cys > Ser 489 
Leu > Phe 477 
His > Tyr 481 
DNA uptake 
 
celB CGSP14 
Ser > Thr 537 
Multiple 
Table 3.7.5.2b: Amino acid changes identified in competence, DNA uptake and recombination proteins.  
Identified from a protein BLAST of R6 amino acid sequences with England14-9 database isolates CGSP14, 
INV200 and PN93 872.  Multiple – set of amino acid changes present in multiple sequenced genomes, none – set 
of amino acid changes not identified in any other sequenced genome.  Bold font – unique amino acid changes. 
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 Tyr > His 709  
Ser > Pro 9 
Iso > Leu 10 
Iso > Phe 46 
Phe > Ser 49 
Gly > Ser 54 
Iso > Leu 58 
Iso > Leu 59 
Val > Leu 68 
Val > Iso 96 
Ala > Ser 108 
Tyr > His 117 
Ala > Thr 130 
His > Tyr 135 
Glu > Asp 136 
Gly > Glu 138 
Asp > Asp 156 
Iso > Val 181 
Asn > Asp 253 
Ala > Thr 281 
Val > Iso 320 
Phe > Leu 326 
Val > Iso 353 
Ser > Arg 355 
Pro > His 377 
Thr > Val 393 
Val > Ala 403 
Thr > Ala 442 
Trp > Cys 443 
Lys > Arg 463 
Thr > Ala 465 
Cys > Ser 468 
Leu > Phe 476 
Tyr > Asp 519 
Lys > Glu 523 
Met > Ala 529 
Ser > Thr 537 
 
INV200/PN93 872 
Asp > Glu 559 
None 
96% homology 
with R6 and 
numerous 
other genomes 
His > Gln 83 CGSP14 
Iso > Met 85 
Multiple 
Thr > Ala 18 
cglA 
INV200/PN93 872 
His > Gln 83 
Multiple 
Thr > Iso 6 
Val > Ala 68 
Ala > Thr 88 
DNA uptake 
 
cglB CGSP14 
Val > Iso 249 
None 
Table 3.7.5.2b: Amino acid changes identified in competence, DNA uptake and recombination proteins.  
Identified from a protein BLAST of R6 amino acid sequences with England14-9 database isolates CGSP14, 
INV200 and PN93 872.  Multiple – set of amino acid changes present in multiple sequenced genomes, none – set 
of amino acid changes not identified in any other sequenced genome.  Bold font – unique amino acid changes. 
Chapter 3 
 
 248 
Val > Thr 3 
Ala > Thr 23 
Val > Iso 184 
Glu > Asp 68 
 INV200/PN93 872 
Ser > Thr 74 
Multiple 
Arg > Ser 76 
Ala > Gly 80 
Ala > Val 89 
Lys > Asn 93 
His > Tyr 96 
CGSP14 
Asp > Thr 97 
Multiple 
Val > Iso 19 
cglC 
INV200/PN93 872 
Arg > Ser 76 
Multiple 
Glu > Gly 3 
Gly > Ser 34 
Ser > Ala 41 
Met > Thr 78 
CGSP14 
Iso > Leu 79 
Multiple 
Val > Ala 13 
Gly > Ser 15 
Ser > Ala 33 
Ser > Ala 63 
Met > Thr 70 
cglD 
INV200/PN93 872 
Iso > Leu 71 
Multiple 
CGSP14/PN93 872 Leu > Met 1 Multiple 
Ala > Thr 20 
Val > Ala 49 
Asn > Asp 87 
Arg > Ser 91 
Val > Ala 105 
Arg > Glu 106 
Arg > His 115 
His > Arg 117 
CGSP14 
Lys > Glu 134 
Multiple 
Val > Ala 67 
Gly > Ser 79 
Asn > Asp 95 
Arg > Ser 97 
Val > Ala 121 
Arg > Glu 122 
Arg > His 131 
His > Arg 133 
cglF 
INV200/ PN93 872 
Lys > Glu 152 
Multiple 
Val > Iso 34 
Val > Ala 60 
DNA uptake 
 
cglG CGSP14/INV200/P
N93 872 
Phe > Val 68 
Multiple 
Table 3.7.5.2b: Amino acid changes identified in competence, DNA uptake and recombination proteins.  
Identified from a protein BLAST of R6 amino acid sequences with England14-9 database isolates CGSP14, 
INV200 and PN93 872.  Multiple – set of amino acid changes present in multiple sequenced genomes, none – set 
of amino acid changes not identified in any other sequenced genome.  Bold font – unique amino acid changes. 
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Gly > Ser 82 
Arg > Thr 86 
Asp > Ser 90 
  
Val > Ala 123 
 
Met > Thr 217 CGSP14 
Ala > Glu 318 
Multiple 
Thr > Iso 46 
Met > Thr 217 
cflA 
INV200/PN93 872 
Ala > Glu 318 
None 
 
cflB CGSP14/INV200/ 
PN93 872 
Leu > Phe 62 Multiple 
Re- 
combination 
recA CGSP14/INV200 Pro > Thr 325 Multiple 
 
 
 
 
 
Table 3.7.5.2b: Amino acid changes identified in competence, DNA uptake and recombination proteins.  
Identified from a protein BLAST of R6 amino acid sequences with England14-9 database isolates CGSP14, 
INV200 and PN93 872.  Multiple – set of amino acid changes present in multiple sequenced genomes, none – 
set of amino acid changes not identified in any other sequenced genome.  Bold font – unique amino acid 
changes. 
Chapter 3 
 
 250 
3.7.5.3 Polymorphisms in genes associated with DNA uptake and recombination 
The pneumococcal cgl operon consists of seven late competence genes, cglA, B, C, D, 
E, F and G, all of which are thought to form a structure which allows DNA to come 
into contact with the cell wall receptor, celA  (Dubnau, 1999).  CelA and celB genes 
are then responsible for binding and transport of exogenous DNA, followed by 
degradation of a single strand by the nuclease EndA (Lacks and Greenberg, 1976, 
Dubnau, 1999, Provvedi and Dubnau, 1999).  Studies have shown that mutations in 
any of these genes decrease transformability (Bergé et al., 2002, Pestova et al., 1996, 
Pestova and Morrison, 1998).   
 
All of the above genes were shown to contain differences when compared to R6 and 
ranged from 93% - 99% amino acid homology (table 3.7.5.2a).  The majority of 
differences were also present in multiple sequenced pneumococcal genomes and are 
unlikely to cause transformation problems in clone England14-9 (table 3.7.5.2b).  
Three CGSP14 CglB changes were not present in any other genome (table 3.7.5.2b, 
CGSP14, CglB, bold font), however polymorphisms were conservative amino acid 
changes and located outside conserved regions.  Furthermore CGSP14 is presumed to 
be transformation competent, so the observed changes were unlikely to contribute to 
loss of transformation in this clone.  A number of INV200/PN93 872 CelA and CelB 
amino acid changes were not present in any other genome (table 3.7.5.2b, 
INV200/PN93 872, celA and celB, bold font). The potential significance of changes in 
CelA and CelB is discussed in the following section (section 3.7.5.4).   
 
The cfl operon is also important in DNA uptake and contains two genes; cflA and cflB.  
CflA knock out mutants show a significant reduction in transformability. Although 
mutants are able to bind DNA, they are unable to incorporate it (Lee et al., 1999, 
Bergé et al., 2002).  The function of pneumococcal CflB is yet to be elucidated, 
however in Bacillus subtilis the mutated homologue ComFA reduces transformability 
to only 10% (Dubnau, 1991b).  A protein-protein BLAST of R6 CflA with CGSP14, 
INV200 and PN93 872 showed that CGSP14 contains two amino acid changes which 
are present in multiple other fully sequenced genomes (table 3.7.5.2b, cflA).  INV200 
and PN93 872 have a third amino acid change (threonine > isoleucine) not identified 
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in any other genome but it is not in a conserved region and is therefore unlikely to be 
significant. 
 
Following DNA uptake the late competence gene ssbB is thought to be involved in 
recombination initiation and protection of the incoming strand.  SsbB knock out 
mutants show reduced transformability to only 3% (Campbell et al., 1998).  RecA 
promotes synapses between the donor DNA and chromosome.  Following mismatch 
repair the DNA then recombines into the chromosome. These genes are unlikely to be 
causative of transformation problems as the SsbB protein from CGSP14, INV200 and 
PN93 872 showed 100% homology with R6 and the single amino acid difference in 
RecA was present in multiple other genomes.  
 
Other rec genes involved in recombination: recD, recF, recG, recJ, recN, recO, recR, 
recU, recX, radA, radC, rarA and ruvB are all present and intact in draft genome 
PN93 872 (L. Hall, personal communication) and are thus unlikely to be the cause of 
failed transformation in England14-9 isolates. 
 
3.7.5.4 Potential significance of polymorphisms in CelA and CelB 
Loss of function mutations, such as a frameshift or the introduction of a premature 
stop codon were not identified in CGSP14, INV200 or PN93 872 competence or 
transformation genes.  A number of polymorphisms were identified but most were 
shared with sequenced transformable genomes.  However polymorphisms identified 
in INV200 and PN93 872 CelA and CelB were not identified in other genomes 
including CGSP14. Unique changes were localised to determine whether they were 
situated within conserved domains as identified by the conserved domain function of 
BLAST.   
 
CelA is part of an operon consisting of three different open reading frames.  It is a 
membrane protein thought to be essential for binding and transport of DNA. 
Insertional mutagenesis of celA in S. pneumoniae and B. subtilis has been shown to 
reduce transformation (Inamine and Dubnau, 1995, Bergé et al., 2002).  In B. subtilis, 
two mutants were created. An internal 44 amino acid deletion caused a twofold 
reduction in transformation and a partial decrease in its capability to bind DNA.  
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Conversely, a 22 C-terminal residue amino acid deletion ceased DNA binding and 
resulted in a 107 decrease in transformability (Inamine and Dubnau, 1995, Bergé et 
al., 2002).  Similar results were observed in S. pneumoniae (Berge et al., 2002). These 
results suggest that maintaining the structure of the C-terminus is particularly 
important. 
 
In this analysis, a four amino acid deletion was identified in the N-terminal region of 
INV200 and PN93 872 CelA (figure 3.7.5.4a). This deletion was in frame and did not 
occur in a conserved region however an impact on structure and reduced 
transformation can not be ruled out. Furthermore, this deletion is not present in the 
presumed transformable England14-9 isolate CGSP14 and may therefore be a 
candidate to explain transformation deficiency.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.5.4a: Comparison of celA nucleotide sequence between R6 and INV200.  
Twelve nucleotides are deleted in INV200 (-) that are present in R6 (green highlight).  
Nucleotide changes that resulted in amino acid changes in INV200 are highlighted in 
yellow. 
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The remaining six amino acid changes were not significant changes according to 
BLOSUM (Henikoff and Henikoff, 1992) and none of the changes were located in 
highly conserved regions. 
 
CelB is the third gene on the operon that also contains celA. Disruption of this gene 
leads to a 100 fold decreased rate of transformation (Pestova and Morrison, 1998).  
Through comparison with homologues in other species such as B. subtilis, N. 
gonorrhoeae and H. influenzae, it is thought to act as an aqueous channel which 
allows internalisation of DNA (Draskovic and Dubnau, 2005, Pestova and Morrison, 
1998, Facius and Meyer, 1993). Null mutations in this gene cause DNA transport to 
cease, however the ability to bind DNA remains (Hahn et al., 1993, Dubnau, 1997).  
Gene sequences from other species and investigation into CelB topology shows that it 
is a large hydrophobic protein made up of seven transmembrane regions. As a result, 
there are also a number of hydrophilic regions including a large hydrophilic domain at 
N- and C-terminus of the protein (Draskovic and Dubnau, 2005, Dubnau, 1997).   
 
Several unique changes were identified in INV200 and PN93 872 CelB (table 
3.7.5.2b), most of which were not significant changes according to BLOSUM 
(Henikoff and Henikoff, 1992).  There are three conserved domain regions in CelB, 
one of which is partly illustrated in figure 3.7.5.4b.   
Figure 3.7.5.4b: Conserved domain output of CelB.  Three regions are conserved in 
CelB, one of which is partly shown above. Highly conserved regions (red) and 
conserved regions (blue) between amino acids 99 and 160 in R6 (underlined in black) 
as well as other organisms (gi’s).  Amino acids outlined in black and numbered 
correspond to changes seen in PN93 872/INV100 (shown in purple). 
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Amino acid changes 117 to 156 (that correspond with table 3.7.5.2b, celB, 
INV200/PN93 872) are presented in figure 3.7.5.4b.  Conserved amino acid changes 
are shown in red and non-conserved changes in blue.  The majority of changes were 
not well conserved.  Although amino acid changes 117 and 156 were in conserved 
regions, the change from tyrosine to histidine and asparagine to aspartic acid, 
respectively, were seen in other organisms (underlined in grey) and are therefore not 
considered to have a significant effect on CelB structure. A significant change was 
identified with a -3 value according to BLOSUM (amino acid position 519, tyrosine > 
aspartic acid). By comparison with B. subtilis sequences using BLAST, the location of 
the change in INV200 and PN93 872 could be compared to sequence and topology 
information of the CelB homologue in B. subtilis.  According to the conserved domain 
BLAST function it is not in a conserved region however the same amino acid 
sequence is present in B. subtilis and the change is situated in the C-loop which is 
thought to be part of the extracellular region of the DNA channel, shown in figure 
3.7.5.4c (adapted from Draskovic and Dubnau, 2005).  It is therefore possible that an 
amino acid change in this region with a -3 BLOSUM classification could affect the 
secondary structure of the channel and thus inhibit the transport of DNA into the cell.  
Furthermore, the celB gene occupies the same operon as celA which carries the four 
amino acid deletion and act together to bind and transport DNA into the cell. 
 
In conclusion, competence/recombination genes were investigated in the penicillin 
resistant England14-9 sequenced isolate CGSP14 that is presumed to be transformable 
proficient and compared to transformation deficient England14-9 isolate PN93 872, as 
well as INV200 (which is penicillin susceptible and of the ancestral ST and is 
therefore also assumed to be defective in transformation). The most potentially 
exciting finding is the deletion in INV200 and PN93 872 celA.  The fact that this 
deletion was not identified in CGSP14 or other transformable sequenced genomes 
suggests that this may be causative of structural problems with CelA.  This protein 
acts together with the DNA channel CelB and the significant amino acid change 
identified here may contribute to the potential inability to bind and transport DNA. 
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Figure 3.7.5.4c: The DNA channel and C-loop of CelB. Adapted from Draskovic and Dubnau, 2005.  (A) The C-terminal end of CelB protein 
that also shows the C-loop (blue outline). This region contains a severe (-3, BLOSUM) amino acid change from tyrosine to aspartic acid at 
position 519 in INV200.  The equivalent amino acid in B. subtilis is shown (Y>D). (B) Graphic illustration of CelB as a DNA channel and the 
location of the C-loop as an extracellular component of CelB. 
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In order to investigate significance of these observations, isogenic mutants could be 
created in transformable genomes such as CGSP14 or R6 to delete the same four 
amino acids that are deleted in INV200 and PN93 872. Transformation efficiency 
could then be compared to the parent isolate. 
 
Isolates from various serotypes have demonstrated low or non-transformability under 
laboratory conditions elsewhere (Pozzi et al., 1996) and some isolates belong to well 
recognised clones (Henriques-Normark et al., 2008).  An intriguing observation is that 
clonal clusters with low transformability are very rarely penicillin resistant 
(Henriques-Normark et al., 2008, Pozzi et al., 1996).  This suggests that clones or 
isolates with low transformability may not have access to the gene pool that is 
available for those that are readily transformable.   
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3.7.6 The contribution of recombination and mutation to bacterial evolution 
 
A number of bacterial species, including  S. pneumoniae, Neisseria gonorrhoeae and 
Haemophilus influenzae have long been known to be naturally transformable, while 
others such as E. coli and Staphylococcus aureus are considered not to develop 
competence (Sparling, 1966).  Such variation has important implications in the 
evolution of bacteria and is expected to lead to differences in the contribution of 
recombination to genetic variation.    
 
The R/M ratio was developed as a measure of the contribution each mechanism has 
had in the evolution of variant MLST alleles.  This has been analysed in a number of 
different bacterial species.  As with this project, SLVs were scored to have evolved by 
mutation or recombination in the same way as was conducted by Feil et al (see section 
3.2 for description).  A summary of R/M findings across the literature is presented in 
table 3.7.6a.   
 
Similar to S. pneumoniae, N. meningitidis is a common resident of the nasopharynx 
and can cause invasive disease by entering the blood and CSF (Peltola, 1983). H. 
pylori on the other hand is responsible for chronic gastritis, ulcers and cancer.  Both 
species share a naturally transformable trait with the pneumococcus and frequently 
engage in horizontal gene transfer during mixed colonisation (Yazdankhah and 
Caugant, 2004, Brugger et al., 2010, Nedenskov-Sorensen et al., 1990, Smeets et al., 
2003, Salaun et al., 1998).  The estimated pneumococcal recombination to mutation 
ratio (R:M) in the generation of SLVs (S. pneumoniae: 8.9:1 – 10:1) (Feil et al., 
2000b, Feil et al., 2001) was found to be approximately two to three times higher than 
that identified in N. meningitidis (3.6:1 – 4.75:1) (Feil et al., 1999) and around 1.5 
times higher than in H. pylori (6.7:1) (Falush et al., 2001) and C. jejuni (6.95:1) (Yu 
et al., 2012).  H. pylori is said to be one of the most freely recombining species to the 
extent that linkage equilibrium can be generated between alleles at different loci 
(Achtman et al., 1999, Alm et al., 1999, Suerbaum et al., 1998).  As a result clonal 
descent can be difficult to detect (Suerbaum et al., 1998, Salaun et al., 1998, Go et al., 
1996). One would thus expect a much higher contribution of recombination to the 
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Table 3.7.6a: Summary of recombination/mutation (R/M) ratio studies across the literature. The per allele (probability that the allele change is 
due to recombination) and per site (probability that a single site will change because of recombination) R/M ratios are presented across a number 
of different bacterial species.  
 
 
Organism 
 
 
Disease Naturally 
transformable 
Per allele R:M 
ratio 
Per site R:M ratio Reference 
 
 
 
Streptococcus pneumoniae 
 
Pneumonia, meningitis, 
septicaemia, otitis media 
 
Yes 8.9:1 - 10:1 45:1 - 61:1 (Feil et al., 2000b, Feil et 
al., 2001) 
Neisseria meningitidis 
 
 
Meningitis Yes 3.6:1 - 4.75:1  80:1 - 100:1 (Feil et al., 1999) 
Helicobacter  pylori 
 
Chronic gastritis, ulcers 
and cancer 
 
Yes 6.7:1 76:1 (Falush et al., 2001) 
(supplementary material) 
Campylobacter jejuni  Gastroenteritis 
 
 
Yes 6.95:1 
 
N/A (Yu et al., 2012) 
Staphylococcus aureus 
 
Pneumonia, endocarditis, 
septicaemia, bone/joint 
infections 
No 6.5:1 24:1 (Feil et al., 2001) 
Staphylococcus epidermis 
 
Infection in 
immunocomprimised 
individuals 
No 2.5:1 10:1 (Miragaia et al., 2007) 
Salmonella enterica 
 
Salmonellosis 
 
 
No 1.14:1 N/A (Didelot et al., 2011) 
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observed R/M ratio. However this species also has a very high mutation rate which 
would alter the relative contribution of both events in the generation of SLVs.  This 
may be accounted for by the lack of a mutSLH-like repair system in H. pylori (Tomb 
et al., 1997, Alm et al., 1999).  
  
Surprisingly, Staphylococcus aureus was shown to have an R/M ratio comparable to 
H. pylori (table 3.7.6a), even though this species is not naturally transformable and 
there is evidence of clonal structure in the emergence of methicillin resistant strains 
(Musser and Kapur, 1992).  R/M ratios for this species have been calculated as 6.5:1, 
and the importance of recombination is also apparent from lack of congruence 
between gene trees (Feil et al., 2001). Feil et al (2001) suggest that horizontal gene 
transfer is mediated by phage transduction in S. aureus. By contrast the contribution 
of recombination to MLST allele diversity in Staphylococcus epidermis was found to 
be low with an R/M ratio of 2.5:1 (Miragaia et al., 2007). In Salmonella enterica, 
which is known to be highly clonal, recombination and mutation were estimated to 
have a nearly equal contribution to polymorphism (R/M – 1.14:1) (Didelot et al., 
2011). 
 
The per site R/M ratio was also analysed in both Feil studies.  That is, the relative 
probability that a single nucleotide site will change as a result of recombination or 
mutation.  Although S. pneumoniae showed a higher allele R/M ratio, interestingly the 
per site ratio for N. meningitidis (80 – 100:1) (Feil et al., 1999)  and H. pylori (76:1) 
(Falush et al., 2001) was higher than in S. pneumoniae (45 – 61:1) (Feil et al., 2000b, 
Feil et al., 2001).  This is believed to reflect differences in sequence diversity within 
and between different species. Compared to N. meningitidis, recombination was 
concluded to be more significant in S. pneumoniae as it occurs more frequently, 
however, a higher incidence of sequence divergence in housekeeping genes of N. 
meningitidis can account for the increased per site R/M (Zhou et al., 1997).  Around 
four fold more polymorphisms can be introduced from recombinational exchange of 
housekeeping alleles in N. meningitidis than in S. pneumoniae. These genes 
commonly have a mosaic structure resulting from both inter and intra-species 
recombination at MLST loci for N. meningitidis (Zhou et al., 1997).  Studies have 
shown that every third nucleotide in H. pylori housekeeping genes is polymorphic 
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(Achtman et al., 1999)  which would account for a higher per site R/M ratio in this 
species. 
 
The per site ratio was also determined for the three pneumococcal clones used in this 
study for comparison with other species and is shown in table 3.7.6b.  
 
 
 
Spain9V-3 England14-9 Taiwan19F-14 
Per site R:M ratio 
 
(1084:13) 
83.4:1 
(88:17) 
5.2:1 
(685:4) 
171.3:1 
Table 3.7.6b: Recombination to mutation per site ratios for MLST SLVs analysed 
from data in section 3.3.  Per site R:M ratio – the number of nucleotides changed as a 
result of recombination (R) and mutation (M) in each divergent allele for SLV’s from 
clones Spain9V-3, England14-9 and Taiwan19F-14.  R/M figures are presented in 
brackets with the resulting ratios underneath.  
 
Interestingly, the clone England14-9 per site ratio (5.2:1, table 3.7.6b) in addition to 
the per allele ratio (section 3.3) was similar to that of non transformable and highly 
clonal bacteria such as S. epidermis and S. enterica (table 3.7.6a). The per site ratios 
particularly highlight the impact that recombination has had on sequence divergence 
within each clone.  Multi drug resistant clones Spain9V-3 and Taiwan19F-14 show high 
levels of recombination and are therefore likely to contain higher sequence divergence 
in MLST allele. Conversely, the low level of recombination in clone England14-9 
reflects higher MLST allele sequence similarity and therefore a low R/M per site 
ratio.  
 
Although Feil’s method has provided interesting R/M data for various species it is 
also evident that this method may have limitations, for example, given the relatively 
low R/M ratios for H. pylori (table 3.7.6a).  A potential flaw in this method is the 
correct scoring of a true mutation event.  Alleles that have a single nucleotide change 
not observed anywhere else in the dataset are regarded to have arisen by mutation, 
however, it is possible that the nucleotide change was generated by recombination 
with an isolate not present in the database.  Conversely, two independent but identical 
mutations, present in different isolates would be scored as recombinants, but could 
have arisen in different lineages by chance.  Alleles that contain two mutations are 
Chapter 3 
 
 261 
also scored as recombinants but it is possible for two independent mutations to arise 
in one allele.  There is also the possibility of mutation hotspots affecting results.  
Mutation hotspots are genomic areas which tend to mutate more often than by chance.  
The presence of a hotspot within an MLST allele could result in misinterpretation of 
mutation as recombination. 
 
Alternative methods to determine the contribution of recombination in the evolution 
of bacterial species have also been utilised.  Multilocus enzyme electrophoresis was 
used extensively before the introduction of MLST to study population structure of 
numerous bacterial species by comparing electrophoretic mobilities of housekeeping 
enzymes.  Isolation of identical MLEE types from different geographic locations 
revealed the clonality and limited recombination of many bacterial species, including 
E. coli (Selander and Levin, 1980, Selander, 1987).  This method also showed that 
naturally transformable species have higher variability in MLEE type than non-
transformable bacteria (Selander et al., 1987 , Selander, 1987).  O’Rourke et al were 
the first to illustrate a bacterial species with a freely recombining background 
(O'Rourke and Stevens, 1993). The index of association (IA) identifies linkage 
equilibrium by determining the non-random association between alleles at different 
loci (Smith et al., 1993). Frequent recombination events cause linkage equilibrium 
and the expected IA value is zero or a value significantly close to zero (which 
represents free recombination).  Conversely, populations that are clonal are expected 
to have an IA value that differs significantly from zero (Smith et al., 1993).  A set of 
Neisseria gonorrhoea isolates collected between 1963 and 1989 were used for IA 
analysis and revealed a value not significantly different from zero (-0.16 ± 0.17) 
(O'Rourke and Stevens, 1993).  Subsequently, N. meningitidis was shown to have a 
freely recombining population structure by the same method (0.21  ± 0.08) (Smith et 
al., 1993), as was S. pneumoniae (-0.04 ± 0.23) (Hall et al., 1996).  Campylobacter 
jejuni, a naturally transformable gastrointestinal species had a comparable IA value 
with other competent species (0.42 ± 0.05).  Interspecies recombination occurs 
frequently in this organism, creating strain diversity (Suerbaum et al., 2001, Fitzgerald 
et al., 2001).  Surprisingly Haemophilus influenzae, also naturally transformable, had 
an IA value significantly different from zero (1.25 ± 0.18) (Smith et al., 1993) similar 
to the clonal Salmonella typhimurium (1.22 ± 0.33).  Although naturally 
transformable, the mechanism in which this organism incorporates DNA is more 
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specific than some naturally competent species such as S. pneumoniae, as it requires 
the presence of specific DNA uptake sequences (Mell et al., 2012). Furthermore the 
isolates investigated were of H. influenzae type B, which is known to be relatively 
clonal (Urwin et al., 1995) Interestingly there is also a high level of congruence 
between gene trees in H. influenzae supporting the MLEE evidence of a limited level 
of recombination (Feil et al., 2001).  Therefore in general IA values across the 
literature correlate well with an organisms ability to recombine based on other 
methods.  Results are summarised against R/M results in table 3.7.6c.  
 
Although this method estimates how far organisms are from free recombination or 
clonality, it has been criticised for its inability to measure the rate at which 
recombination occurs (McVean et al., 2002). Comparison between genes and or 
species is therefore problematic (McVean et al., 2002).  Recombination and mutation 
rates can be estimated as separate variables using a standard coalescent approach as 
conducted by Perez-Losada et al (Pérez-Losada et al., 2006).    This approach assumes 
large Fisher-Wright populations, no selection or migration (McVean et al., 2002).  A 
total of 91 housekeeping gene sequences from sixteen bacterial species were 
examined.  The population recombination (ρ) and population mutation (Θ) rate was 
identified using the coalescent approach (McVean et al., 2002) and some results are 
presented in table 3.7.6c for comparison.  Species that had a population recombination 
ρ = >50 were considered highly recombinant and those ≤15 rarely recombinant.  H. 
pylori had the highest recombination rate followed by S. pneumoniae. In contrast to 
findings by Feil et al which showed a surprisingly similar R/M ratio for H. pylori and 
S. aureus, the population recombination (ρ) for the two species was completely 
incomparable (99.2 and 5.1, respectively), placing S. aureus among the rarely 
recombinant species along with E. coli and S. epidermis (Pérez-Losada et al., 2006) 
(table 3.7.6c).  Interestingly, C. jejuni was also included in this category (ρ = 2.2), a 
finding which does not correlate with its natural competence and IA value.  
Furthermore, investigation of mutation and recombination rate in over 1000 C. jejuni 
isolates revealed that recombination is the dominant force in its evolution (Wilson et 
al., 2009).  The discrepancies between different methods suggest that further 
investigation is required to fully understand the role of recombination in some species. 
Our finding of low recombination in one clone of S. pneumoniae suggest that 
mechanisms  of   evolution  may  vary   among different  groups within  species,  such   
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Table 3.7.6c: Comparison of recombination and mutation data from naturally competent and non naturally competent bacterial species. Data obtained 
from numerous studies, referenced in brackets, presents recombination to mutation  ratios (R/M), index of association (IA) and population 
recombination (ρ)/population mutation (Θ) rate. N/A – not analysed in the corresponding study.  The presence of an SOS response system to repair 
severe DNA damage in organisms is also noted.  
Organism 
 
 
Naturally 
trans. 
SOS 
repair  
system 
 
Per allele R:M ratio Index of association 
IA 
Population recombination 
(ρ) 
Population Mutation 
(Θ) 
Streptococcus 
pneumoniae 
 
Yes No 8.9:1 - 10:1 
(Feil et al., 2000b, Feil et 
al., 2001) 
-0.04 ± 0.23 
(Hall et al., 1996) 
71.5 
(Pérez-Losada et al., 2006) 
18.99 
(Pérez-Losada et al., 2006) 
Neisseria 
meningitidis 
Yes No 3.6:1 - 4.75:1 
(Feil et al., 1999) 
0.21 ± 0.08 
(Smith et al., 1993) 
58.6 
(Pérez-Losada et al., 2006) 
23.56 
(Pérez-Losada et al., 2006) 
Helicobacter  
pylori 
Yes No 6.7:1 
(Falush et al., 2001) 
N/A 99.2 
(Pérez-Losada et al., 2006) 
23.04 
(Pérez-Losada et al., 2006) 
Haemophilus 
influenzae 
Yes Yes N/A 1.25 ± 0.18  
(Smith et al., 1993) 
42.9 
(Pérez-Losada et al., 2006) 
14.27 
(Pérez-Losada et al., 2006) 
Campylobacter 
jejuni 
Yes No 6.95:1 
(Yu et al., 2012) 
0.42 ± 0.05 
(Suerbaum et al., 2001) 
2.2 
(Pérez-Losada et al., 2006) 
25.63 
(Pérez-Losada et al., 2006) 
Neisseria 
gonorrhoea 
Yes No N/A -0.16 ± 0.17 
(O'Rourke and Stevens, 
1993) 
N/A N/A 
Staphylococcus 
aureus 
No Yes 6.5:1 
(Feil et al., 2001) 
N/A 5.1 
(Pérez-Losada et al., 2006) 
22.59 
(Pérez-Losada et al., 2006) 
Staphylococcus 
epidermis 
No Yes 2.5:1 
(Miragaia et al., 2007) 
N/A 1.2 
(Pérez-Losada et al., 2006) 
7.72 
(Pérez-Losada et al., 2006) 
Salmonella 
enterica 
No Yes 1.14:1 
(Didelot et al., 2011) 
N/A N/A N/A 
Salmonella 
typhimurium 
No Yes N/A 1.22 ± 0.33 
(Smith et al., 1993) 
N/A N/A 
Escherichia 
coli 
No Yes N/A N/A 0 
(Pérez-Losada et al., 2006) 
29.31 
(Pérez-Losada et al., 2006) 
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that the selection of isolates to investigate could have influenced the outcome of these 
studies. 
 
There are clearly advantages and disadvantages present in the various methods 
described and conflicting results can be obtained by using different methods to 
analyse the same species. Perhaps the most useful method is by comparing full 
genome sequences. The sequencing technology today allows a vast number of 
genomes to be sequenced in a relatively short period of time. Analysing multiple 
genome sequences of a single lineage in a bacterial species increases the detection of 
true events, as polymorphisms that are acquired through horizontal gene transfer can 
be distinguished from those that arise from base substitutions. Recently, 240 Spain23F-
1 isolates were sequenced and mapped against a reference pneumococcal isolate 
(Croucher et al., 2011). A total of 39107 polymorphic sites were observed that 
included 57736 SNPs. The majority, 88% (50720), were acquired through 
recombination. The Spain23F-1 clone was the first to be included on the PMEN 
database and has had worldwide success. It is likely that the high level of 
recombination in this lineage aided its ability to acquire multiple drug resistance and 
continually evade vaccine pressure. These values however are reflective of only one 
clone and potential future sequencing projects across a number of clones will reveal 
interesting differences in clonal evolution.  
3.7.6.1 Recombination in antibiotic resistance genes 
The significance of recombination in pneumococci was originally discovered due to 
its role in penicillin resistance (Dowson et al., 1989, Dowson et al., 1993)   However, 
the contribution of recombination and mutation has had to pneumococcal evolution is 
mainly investigated with the use of housekeeping genes. Housekeeping genes are 
necessary for viability and are thus present in the entire pneumococcal population. 
Furthermore, variants are presumed to be neutral with regards to selection. These 
genes are therefore useful to measure and compare events that have created variants 
by random chance.  No systematic analysis of recombination and mutation has been 
conducted for chromosomal genes involved in resistance.  However, the linkage of 
ddl to the penicillin resistance gene PBP2b provides an opportunity to explore the 
impact of selection for resistance and estimate whether recombination rates in 
antibiotic resistance genes is higher than in housekeeping genes.  Evidence suggests 
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that this locus has evolved further than other MLST loci due to its linkage (Feil et al., 
2000a), which suggests a higher recombination rate in resistance genes. Table 3.7.6.1 
shows MLST database analysis from this study in the format of total mutation and 
recombination events for each locus.  In Spain9V-3 and Taiwan19F-14, recombination 
at the ddl locus is clearly higher than in other MLST loci.  This is not the case for 
clone England14-9, in line with the limited amount of penicillin resistance in this 
clone.  
 
Clone 
 
Spain9V-3 England14-9 Taiwan19F-14 
 Total M:R Total M:R Total M:R 
MLST locus  
aroE 9 0:9 4 2:2 9 1:0 
Gdh 10 2:8 1 1:0 6 0:6 
Gki 7 2:5 2 0:2 4 1:3 
recP 13 2:10 7 2:4 6 0:6 
Spi 15 2:13 5 2:3 2 0:2 
Xpt 13 5:8 11 4:7 6 2:0 
Ddl 28 0:28 11 6:5 23 0:23 
Table 3.7.6.1: Comparison of mutation and recombination events in each MLST 
allele, that resulted in a SLV. This data is analysed from the mutation Vs 
recombination database analysis (section 3.3). Total – total number of isolates that 
had a change at the specified MLST locus; M:R – the amount of mutation (M) and 
recombination (R) in the generation of each SLV. 
 
The selection for antibiotic resistance is therefore clearly influencing the pattern of 
evolution but as penicillin resistance can not occur by single point mutation this may 
not apply to other resistances involving modification of target genes within the 
genome. 
 
In contrast to penicillin resistance, fluoroquinolone resistance can be acquired by the 
accumulation of single point mutations in genes that code for DNA gyrase (gyrA and 
gyrB) and topoisomerase IV (parC and parE) (Gonzalez et al., 1998, Perichon et al., 
1997, Pan et al., 1996, Pan and Fisher, 1996).  This makes it impossible to apply the 
method of Feil to distinguish recombination from mutation events since the 
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occurrence of the same mutation in different clonal complexes could result either by 
independent selection of the same mutation, or by recombination. Although inter-
species recombination was estimated to be 106 times more likely to cause resistance 
than mutation in vitro (Tankovic et al., 1996), this does not appear to be reflected in 
the true pneumococcal population. Analysis of 71 ciprofloxacin resistant isolates 
revealed that only one contained sequences divergent from pneumococcal resistance 
genes (Bast et al., 2001b), suggesting that inter-species recombination at these loci is 
rare. Isolation of numerous isolates in succession from a single infected patient 
showed that mutation can occur during treatment with fluoroquinolones and results in 
differences in the level of resistance (de la Campa et al., 2003).  In this situation 
recombination is unlikely as suitable donors would rarely be present. Genetic 
variability in a population generally provides evidence for acquisition of resistance by 
mutation.   
 
One study investigated intra-chromosomal recombination in the acquisition of 
fluoroquinolone resistance by measuring evolution through branching incongruence 
(horizontal gene transfer) or congruence in a diverse set of pneumococcal isolates that 
had been MLST typed (Stanhope et al., 2005).  Housekeeping genes in addition to 
four fluoroquinolone target genes were sequenced and aligned on the basis of 
homology in 60 clinical isolates.  The majority of isolates were thought to have 
acquired resistance by clonal dissemination, however sequences in 3 – 10% of isolates 
(depending on locus) were indicative of intra-species horizontal gene transfer 
(Stanhope et al., 2005).  However these authors did not attempt to estimate the 
number of independent mutation events leading to clonally disseminated resistance 
genes. 
 
Resistance to sulphonamide can also be acquired by a single genetic event leading to 
3 or 6 base pair duplications in the gene encoding dihydropteroate synthase (Maskell 
et al., 1997). Among six resistant isolates originally investigated there were five 
different duplications, suggesting that de novo mutation is a common mechanism for 
the acquisition of resistance in this case (Maskell et al., 1997).    
 
In conclusion, the direct measurement of recombination in the ddl locus suggests that 
recombination rates are higher in the development of resistance to penicillin than in 
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the evolution of housekeeping alleles, but this may not be the case for resistance 
mechanisms that can be generated by single mutations.    
3.7.7 Recombination as a means of genomic variation and DNA repair 
A number of methods to investigate the contribution of recombination and mutation to 
bacterial evolution have been adopted.  From this analysis it is clear that S. 
pneumoniae as a species evolves largely through recombination, and the significantly 
lower occurrence of recombination in clone England14-9 is highly uncommon, 
especially for globally successful pneumococcal clones.  To understand why 
recombination is so important to pneumococcal evolution, the potential benefits to the 
organism of this mechanism need to be discussed.  There are two main functions of 
recombination, as a means for genetic variation and a mechanism for DNA repair.  It 
is intriguing that many of the pathogen species demonstrated to evolve extensively by 
recombination appear to lack the SOS response mechanism (described in section 
1.4.1.4), by which genetic variation is generated during repair of double-strand DNA 
breaks with error-prone polymerases. No homologue of the LexA repressor that is 
central to the SOS response can be identified in the genomes of S. pneumoniae, N. 
meningitidis, N, gonorrhoeae H. pylori or C. jejuni, whereas it is present in H. 
influenzae and S. aureus as well as E. coli, S. enterica and S. epidermis (table 3.7.6c).  
 
In order to adapt to a constantly changing environment, bacteria need to demonstrate a 
certain level of genomic flexibility.  The ability of pneumococci along with other 
naturally competent species to incorporate genes horizontally allows adaptation to 
different environments at a faster rate compared with that through repeated mutation 
(Levin and Cornejo, 2009). The ecological niche and location of horizontal gene 
transfer for pneumococci is the nasopharynx, a site also inhabited by other naturally 
transformable bacteria such as H. influenzae and N. meningitidis. An advantage of 
transformability may be a greater evolutionary potential of recombination compared 
to mutation during mixed colonisation with other strains of the same species, and with 
related species. Clearly recombination has been beneficial in the acquisition of 
antibiotic resistance, as discussed above. Similarly, although the environment for H. 
pylori is extremely different from organisms that reside in the nasopharynx, it is 
known to participate in HGT during mixed colonisation in the gut (Smeets et al., 
2003, Salaun et al., 1998) and has developed drug resistance in much the same way 
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(Pot et al., 2001). The gastroenteric pathogen C. jejuni also acquired antimicrobial 
resistance through intra (de Boer et al., 2002, Oyarzabal et al., 2007) and inter species 
recombination (Oyarzabal et al., 2007), again presumably during mixed colonisation 
that is likely to occur in the animal host. In addition to the possibility of acquiring 
resistance to antibiotics, a number of virulence factors are also acquired by horizontal 
gene transfer, perhaps the most important of which in pneumococci is the ability to 
switch capsules.   
 
It has been argued that recombination may have evolved to act as a response to DNA 
damage, and is an alternative mechanism by which to repair double-strand breaks.  
The environment of S. pneumoniae makes it susceptible to constant oxidative damage 
which is known to cause lesions in DNA (Cooke et al., 2003). Pneumococci 
themselves produce large amounts of hydrogen peroxide (Pericone et al., 2000), even 
though they do not have an SOS response.  It has been proposed that the induction of 
competence can instead act as a DNA response mechanism, known as the X state 
(Claverys et al., 2006) in which competent pneumococcal cells trigger lysis of non-
competent cells (Guiral et al., 2005, Håvarstein et al., 2006, Steinmoen et al., 2003). 
This was shown in an experiment when mitomycin C in addition to other antibiotics 
induced fratricide in pneumococcal cells (Prudhomme et al., 2006). H. pylori and C. 
jejuni reside in the hostile gut environment.  A relatively recent study showed that 
DNA damage in H. pylori induces competence (Dorer et al., 2010).  Species that have 
a low recombination rate may perhaps not face the same environmental pressures as 
naturally competent bacteria.  S. aureus for example is commonly found on the skin 
and is therefore less exposed to the immune system. 
 
Recombination may act as a response to severe DNA damage in S. pneumoniae, 
leading to a much higher occurrence of recombination compared to mutation.  
However, as clone England14-9 is mainly transformation deficient it seems unlikely 
this is the only mechanism of repair. Although S. pneumoniae lack a typical SOS 
response, they do posses a DNA polymerase, PolIV (encoded by dinB), which is part 
of the E. coli SOS response and capable of repairing double-strand breaks.  As 
discussed, dinB knock out isolates show increased sensitivity to DNA damaging 
agents (chapter 4) suggesting a role for this polymerase in DNA repair.  It is therefore 
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possible that the action of PolIV compensates for lack of recombination in clone 
England14-9.  
 
In terms of recombination as a method of generating variation, it is evident that 
Spain9V-3 and Taiwan19F-14 fit into this hypothesis. Both have recombined frequently 
to generate multi resistance, virulence factors and capsule switch variants.  
Furthermore, the appearance of multi resistant England14-9 isolates is becoming more 
common.  The global success of England14-9 isolates that are only erythromycin 
resistant however suggests that recombination is not the sole mechanism in successful 
evolution.  Interestingly, this clone was observed to have similar per site allele r/m 
ratios with species that are not naturally transformable such as S. epidermis and the 
frequency of mutation from MLST and epidemiological study analysis appears to be 
higher for this clone.  At some point in the evolution of England14-9, transformation 
deficient clones may have had a selective advantage.  Although variation can increase 
bacterial fitness, it can also be costly.  A high mutation rate in this clone may have 
caused the selection of recombination deficient clones, or it may have increased as a 
result of ceased recombination.   
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4.0 Investigation of dinB 
 
The cell continuously experiences various types of damage, such as chemical damage, 
oxidative damage, UV damage and spontaneous DNA alterations.  This can lead to 
single or double stranded breaks in the DNA, mispairing or base deletion. Pathways, 
such as BER and MMR are in place to repair incorrect or mismatched nucleotides. 
Double strand breaks in DNA lead to disruptions in the replicative machinery and the 
cell is then in a state of emergency.  In E. coli, a process known as the SOS response 
is initiated at times when the cell can benefit from error prone polymerases 
incorporating nucleotides at the lesion site in an attempt to rescue the cell.  Although 
recombination has been suggested to act as a response to severe DNA damage, the 
significantly low occurrence of recombination in clone Englad14-9 MLST alleles, in 
addition to the observation of transformation deficient Englad14-9 isolates in this 
laboratory indicates that other DNA repair mechanisms are in place. S. pneumoniae 
contain one of three polymerases seen in the E. coli SOS response, DNA polymerase 
IV, encoded by the dinB gene.  Knock out mutants of dinB in E. coli are shown to be 
sensitive to DNA damaging agents and no experiment has been conducted to 
determine the effect of dinB deletion on the pneumococcal genome. The aim of this 
part of the project was to create isogenic dinB mutants to investigate the role of DNA 
polymerase IV in S. pneumoniae. 
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4.1 Cloning of dinB  
The experimental approach was to disrupt the dinB locus by insertion of the 
tetracycline resistance insert, tetM.  Cloning of the dinB knock out mutant was carried 
out by Stephanie Henderson-Begg which will be described in this section. All further 
work on dinB (Section 4.2 onwards) was carried out by myself.  DinB was cloned into 
the pGEM®-3Z cloning vector (Promega) using a fusion PCR cloning kit which 
works by amplifying the dinB gene with primers that contain sequence homology to 
the vector insertion site and an In-Fusion enzyme which captures the DNA ends and 
fuses the PCR product to the vector.  
 
The dinB gene was initially amplified from R6 resulting in a 2173bp product that 
covered the entire open reading frame and some flanking sequence (figure 4.1a, A).  
The primers used were designed to contain 15bp sequence homology (at the 3’ and 5’ 
end) to the vector insertion site (figure 4.1a, A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1a:     Cloning of dinB into the pGEM®-3Z cloning vector.  A: the dinB PCR 
product (blue), amplified (by Stephanie Henderson-Begg: SHB) with primers that 
contain sequence homology to the vector at both ends of the PCR product (orange). B: 
location of pGEM®-3Z insertion site for dinB is in the lacZ gene (orange). The 
pGEM®-3Z cloning vector also contains the ampicillin resistance gene for selection. 
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The plasmid to be used for cloning, pGEM®-3Z, was extracted from the E. coli host 
JM109 with use of the Qiagen plasmid extraction kit and linearised by digestion with 
SmaI.  The homologous regions of the dinB product were then fused to the vector 
insertion site using the BD In-FusionTM cloning kit (BD Biosciences Europe, 
Erembodegem-Dorp, Belgium). E. coli cells transformed with plasmid were selected 
by growth on media containing ampicillin. Plates were also supplemented with the β-
galactosidase (encoded by lacZ) substrate X-gal to identify dinB incorporated 
plasmids.  A non functional β-galactosidase caused by successful insertion of dinB 
results in the presence of white colonies.  Blue colonies appear when functional β-
galactosidase is able to cleave X-gal.  
 
Plasmids were extracted from colonies that contained the desired insert and linearised 
with HincII.  The presence of dinB was further confirmed by PCR.  The tetracycline 
resistance gene, tetM, was then amplified producing a 3082bp product. DinB was 
disrupted by insertion of tetM through restriction enzyme digestion with XhoI (figure 
4.1b).   
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Figure 4.1b: The tetracycline resistance gene, tetM, was amplified (by Stephanie Henderson-Begg: SHB) with tetM forward (tetM_FP) and 
reverse (tetM_RP) primers producing a 3082bp product to be inserted into dinB (A).  The dinB gene (contained in lacZ of the pGEM®-3Z 
cloning vector) was inactivated by insertion of tetM through restriction enzyme digestion with XhoI, resulting in the dinB knock out construct 
(B).  
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4.2 Transformation of dinB 
 
The work conducted from this section onwards was carried out by myself.  The dinB 
construct (inactivated dinB with the tetM insertion) was amplified from the linearised 
plasmid with primers designed using the primer 3 programme 
(http://frodo.wi.mit.edu/primer3/) and transformed into three different genetic 
backgrounds; the laboratory strain R6, the R6 related mismatch repair deficient 
laboratory strain CP1015 and an isolate from the internationally recognised clone 
Greece6B-22, PN94 361 (details in section 4.4).  Isogenic mutant names used 
throughout this thesis are listed below in table 4.2. 
 
 
 
 
 
 
Table 4.2:  Designated names for isogenic dinB mutants. DinB wild type: wild type 
gene.  DinB mutant: dinB gene inactivated with tetM (dinBΔ).  Designated name: 
name given throughout the thesis for each isolate/strain. 
 
Colonies that were shown to contain the transformed construct by presence of growth 
on plates containing tetracycline were selected and grown in BHI broth for genomic 
extraction.  DinBΔ was confirmed by amplification. The wild type product (from R6)                             
was confirmed as 1.01kb and dinBΔ was 4.1kb (figure 4.2a). A diagrammatic 
representation of the construct is presented in figure 4.2b. 
 
 
 
 
 
 
 
Isolate/strain 
 
DinB  Designated name 
DinB wild type R6:dinB R6 
DinB mutant R6:dinBΔ 
DinB wild type CP1015:dinB CP1015  
DinB mutant CP1015:dinBΔ 
DinB wild type PN94361:dinB PN94 361 
DinB mutant PN94361:dinBΔ 
 
Figure 4.2a: Confirmation 
PCR of inactivated dinB 
gene (i.e. tetM insertion) in 
CP1015, PN94 361 and R6. 
L; 1kb ladder; dinB – wild 
type dinB (1.01kb product); 
R6:dinBΔ, CP1015:dinBΔ 
and PN94361:dinBΔ – dinB 
knock out mutants (4.1kb 
PCR product).  
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Figure 4.2b:  Location of primers used to confirm replacement of dinB with dinBΔ (containing tetM). Blue – dinB; red – tetM. PCRs; wild type 
dinB PCR – 1017bp compared to dinBΔ PCR – 4124bp.  PCR product A (dinB-TET) and B (TET-dinB) confirm location of the insert and are 
1662bp and 1671bp, respectively (described in section 4.3). RS – restriction site XhoI. 
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4.3 Verification of dinBΔ  
 
To confirm and analyse the exact location of the tetracycline resistance gene, two 
pairs of primers were designed to contain sequence from both genes (dinB and tetM) 
at the 5’ and 3’ end of the tetM gene (figure 4.3).   
 
 
 
 
 
Figure 4.3: Primer design for confirmation and location of the tetM insertion. Primer 
pairs A and B are illustrated in black and were designed to contain sequence from 
both dinB and tetM to confirm presence and insertion site of tetM. FP – forward 
primer; RP – reverse primer. 
 
 
Primer pair A (figure 4.3 – A FP, A RP) was designed to amplify part of the dinB 
sequence with the 5’end of the tetM insert (dinB-TET).  Primer pair B (figure 4.3 – B 
FP, B RP) was designed to amplify the 3’end of the tetM insert with part of the dinB 
sequence (TET-dinB). 
 
4.3.1 dinB-TET (primer pair A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.1a:  PCR using primer pair 
A (dinB-TET: figure 4.3) to 
amplify region in CP1015, 
PN94 361 and R6 dinB knock 
out mutants (dinBΔ).  L – 1kb 
ladder; control – no DNA 
control; CP1015:dinBΔ, 
R6:dinBΔ and 
PN94361:dinBΔ – dinB knock 
out mutants. 
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DinB-TET PCR products were confirmed to be 1662bp (figure 4.3.1a).  Sequencing 
showed that tetM was inserted 198bp downstream of the dinB initiation codon in all 
three isolates/strains (figure 4.3.1b).  
 
Figure 4.3.1b: A sequence chromatogram example of PCR product A (dinB-TET: 
figure 4.3) from CP1015 (1) dinB knock out mutant (dinBΔ). PN94 361 and R6 
dinBΔ sequence is also shown (2) and (3). The 5’ end of the tetM insert is shown (red) 
following dinB sequence (blue) and the XhoI restriciton site (black). 
 
4.3.2 TET-dinB (primer pair B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2a:  PCR using primer pair B 
(TET-dinB: figure 4.3) to amplify 
region in CP1015, PN94 361 and R6 
dinB knock out mutants (dinBΔ).  L – 
1kb ladder; CP1015:dinBΔ, R6:dinBΔ 
and PN94361:dinBΔ – dinB knock out 
mutants. 
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Amplification and sequencing of TET-dinB further confirmed dinBΔ (4.3.2a). 
Analysis of both sequence sets (figure 4.3.1b and 4.3.2b) also confirmed that tetM 
inserted into dinB with no overall loss of dinB sequence in all three isolates/strains. 
 
Figure 4.3.2b: A sequence chromatogram example of PCR product B (TET- dinB) 
from CP1015 dinB knock out mutant (dinBΔ).  PN94 361 and R6 dinBΔ sequence is 
also shown (2) and (3). The 3’ end of the tetM insert is observed (red) to precede dinB 
sequence (blue) and XhoI restriction site (black). 1 – PN94361:dinBΔ; 2 – 
CP1015:dinBΔ; 3 – R6:dinBΔ. 
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4.4 Investigating the effect of polIV on mechanisms of genome 
evolution 
It was previously identified that clone England14-9 isolates in this laboratory are 
transformation deficient and are therefore likely use repair mechanisms other than 
recombination to respond to severe DNA damage.  The role of dinB in S. pneumoniae 
was thus investigated. As already mentioned, dinB knock out mutants were created in 
three different backgrounds; the hypermutable laboratory strain CP1015 originates 
from strain Rx (a daughter strain of the clinical serotype 2 isolate, D39) crossed with 
DNA from an isolate that is streptomycin resistant (Morrison et al., 1983).  CP1015 is 
defective in mismatch repair as it contains a C:G – A:T transversion at nucleotide 
1953 of the hexB gene.  This creates a premature termination codon in the HexB 
protein which renders it non-functional (Bergé et al., 2002).  A clinical isolate from 
clone Greece6B-22 was also used, PN94 361. PN94 361 is a serotype 6B isolate that 
has been well characterised in this laboratory.  It contains no polymorphisms for the 
well conserved Hex residues and is transformable on addition of CSP. Finally, the 
avirulent laboratory R6 strain (another daughter strain of the serotype 2 isolate D39) 
was used, only in the investigation of DNA damaging agents (section 4.7). 
 
The following sections investigate the effect of dinBΔ on mutation frequency, 
mutation spectrum and resistance to DNA damage.   
 
Isolate/strain 
 
Construct 
name 
Genotype 
(dinB/hex) 
PN94361:dinB dinB+/hex+ PN94 361 
PN94361:dinBΔ dinB-/hex+ 
CP1015:dinB dinB+/hex- CP1015 
CP1015:dinBΔ dinB-/hex- 
R6:dinB dinB+/hex+ R6 
R6:dinBΔ dinB-/hex+ 
Table 4.4: DinB/hex genotype of isogenic dinB knock out mutants used in this project.  
 
 
 
 
 
 
 
 
Chapter 4 
 
 281 
4.5 Mutation frequency to Rifampicin resistance 
Preliminary experiments showed that the tetM insertion was unstable.  To maintain 
mutant selection, tetracycline was included in all plates for dinBΔ isolates/strains.  To 
ensure reliability of results each mutation frequency experiment was done in triplicate 
and the result was taken as the average count (viable count/mutation frequency) 
across all three plates. This was conducted twenty times for each of the four 
genotypes (PN94361:dinB, PN94361:dinBΔ, CP1015:dinB, CP1015:dinBΔ).  
Mutation frequencies are included in appendix II.  Results are presented below.  
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4.5.1 Comparison of PN94361:dinB and PN94361:dinBΔ mutation 
frequency results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.1:  Mutation frequency results for twenty PN94361:dinB and twenty 
PN94361:dinBΔ isolates. Each dot represents an individual mutation frequency. The 
median is shown by a black like. 
 
 
Mutation frequency results for PN94 361 are presented in figure 4.5.1.  Results 
analysed using the Mann Whitney U test showed that there was a significant 
difference observed between mutation frequencies for PN94361:dinB and 
PN94361:dinBΔ  (P = 0.0165).  The median value for PN94361:dinB was 4.02 x 10-08 
compared to 1.45 x 10-08 for PN94361:dinBΔ. 
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4.5.2 Comparison of CP1015:dinB and CP1015:dinBΔ mutation 
frequency results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.2:  Mutation frequency results for twenty CP1015:dinB and twenty 
CP1015:dinBΔ isolates. Each dot represents an individual mutation frequency. The 
median is shown by a black like. 
 
 
 
CP1015 Mutation frequency results are shown in figure 4.5.2.  As with 
PN94361:dinBΔ, CP1015:dinBΔ showed a significant decrease in mutation frequency 
compared to CP1015:dinB (P = 0.0028). The median value for CP1015:dinB was 4.92 
x 10-07 compared to 1.74 x 10-07 for CP1015:dinBΔ. 
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4.6 Mutation spectrum 
 
Rifampicin resistance is acquired through mutation to the rpoB gene which encodes 
the β-subunit of RNA polymerase.  In E. coli, rpoB gene mutations can be categorised 
into one of three clusters. Clusters I and II contain most rpoB mutations and are 
positioned at amino acids 505 – 532 and amino acids 560 – 572, respectively.  Cluster 
III contains only one known mutation at position 687 (Iwakura et al., 1973, Jin and 
Gross, 1988). The S. pneumoniae rpoB gene is 3651bp long compared to 4029bp in 
E. coli.  It must therefore be noted that the positioning of the amino acids will differ 
between the two organisms (Padayachee and Klugman, 1999).   In S. pneumoniae the 
majority of mutations are identified in cluster I.  Those not present in cluster I or II 
are identified in what is known as S. pneumoniae cluster III, a cluster that is different 
from the E. coli cluster III (Padayachee and Klugman, 1999). 
 
This part of the project investigates the rpoB gene mutation spectrum in CP1015 and 
PN94 361 (dinB and dinBΔ). Primers were designed to amplify the region that is 
known to contain most rpoB mutations, cluster I (figure 4.6a, highlighted in yellow). 
The amplified products were then sent for sequencing and compared.  The sequencing 
results are presented in the following figures (figures 4.6b, c, d and e) and summarised 
in table 4.6.1.   
 
Figure 4.6a: Region of rpoB gene amplification.  Sequence highlighted in pink - 
forward and reverse primers.  Sequence highlighted in yellow  - cluster I. 
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Figure 4.6b:  CP1015:dinB rpoB mutation spectrum.  RpoB wild type sequence is shown at the top (WT).  Base changes are highlighted in yellow. 
Sequence with no highlight represents high quality sequence. The quality of green highlighted sequence is lower and was confirmed by 
comparison with reverse sequence (not shown). 
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Figure 4.6c:  CP1015:dinBΔ rpoB mutation spectrum sequencing results.  RpoB wild type sequence is shown at the top (WT).  Base changes are 
highlighted in yellow. Sequence with no highlight represents high quality sequence. The quality of green highlighted sequence is lower and was 
confirmed by comparison with reverse sequence (not shown). 
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Figure 4.6d:  PN94361:dinB rpoB mutation spectrum. RpoB wild type sequence is shown at the top (WT).  Base changes are highlighted in yellow. 
Sequence with no highlight represents high quality sequence. The quality of green highlighted sequence is lower and was confirmed by 
comparison with reverse sequence (not shown). 
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Figure 4.6e:  PN94361:dinBΔ rpoB mutation spectrum. RpoB wild type sequence is shown at the top (WT).  Base changes are highlighted in 
yellow.  Sequence with no highlight represents high quality sequence. The quality of green highlighted sequence is lower and was confirmed by 
comparison with reverse sequence (not shown). 
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4.6.1 Analysis of mutation spectrum 
 
To ensure that each rifampicin mutant represented a separate mutation event, a 10-6 
dilution of thawed starter culture (containing ~5 x103 cells/ml) was used to inoculate 
BHI broth cultures.  This was likely to eliminate the presence of any pre-existing 
mutants.  In addition, experiments were not all conducted at the same time.  The total 
number of sequences obtained were as follows; CP1015:dinB – 28; CP1015:dinBΔ – 
28; PN94361:dinB – 12; PN94361:dinBΔ – 22.  Results are summarised below in 
table 4.6.1. 
 
Table 4.6.1:  Summary of rpoB sequencing results.  Double mutants are not included 
in the final number of transitions and transversions. 
 
There was no difference in mutation type between the hypermutable isolates 
CP1015:dinB and CP1015:dinBΔ.  Of the 28 CP1015:dinB isolates sequenced, 23 
were transitional changes, none were transversional changes and 5 were double 
mutants.  Of the 28 CP1015:dinBΔ isolates sequenced, 23 base changes were also 
transitions.  One transversion was also identified in addition to 4 double mutant 
changes. 
 
There did however appear to be a difference in mutation type for PN94 361 isolates.  
PN94361:dinBΔ presented mainly transitional changes (17 transitions:4 
transversions), however PN94361:dinB presented an equal number of transitions and 
transversions (6 transitions:6 transversions). One rifampicin resistant mutant derived 
from PN94361:dinBΔ did not present a base change and the mutation must have 
Mutation CP1015 
:dinB 
CP1015 
:dinBΔ 
PN94361 
:dinB 
PN94361 
:dinBΔ 
C:G – T:A 7 10 6 16 
C:G – A:T  1 3 2 
C:G – G:C   1  
T:A – G:C     
T:A – C:G 16 13  1 
T:A – A:T   2 2 
None    1 
[CA] – [TG] 4 2   
[CA] – [AG] 1 2   
Sample size 28 28 12 22 
Double mutants 5 4   
TRANSITIONS  23 23 6 17 
TRANSVERSIONS 0 1 6 4 
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therefore occurred elsewhere in rpoB.  It most likely occurred in one of the other 
clusters.   
 
One feature that was not identified across the whole PN94 361 dataset, in contrast to 
the CP1015 dataset was the presence of double mutants.   
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4.7 DNA damaging agents 
 
Although S. pneumoniae does not display a typical SOS response, it does contain one 
of the well conserved error prone polymerases known to be involved in SOS activity, 
DNA polymerase IV.  This low fidelity enzyme repairs double strand breaks in an 
attempt to rescue the cell following severe damage.  As previously discussed, Bjedov 
et al investigated the effect of dinB deletion in E. coli following exposure to alkylating 
agents (refer to introduction section 1.4.4) and found that knock out mutants were 
much more sensitive to EMS, MMS and MNNG.  This part of the project investigates 
whether similar effects are observed in S. pneumoniae dinB knock out mutants, using 
a method adopted from Bjedov et al (Bjedov et al., 2007) 
 
Iso-Sensitest plates containing 5% horse blood were made which contained one of 
three agents (EMS, MMS and NQO) at varying concentrations.  PN94 361, CP1015 
and R6 dinB and dinBΔ stocks were grown to an OD620 0.4.  Ten fold serial dilutions 
were then made up to 10-6 and individually spotted onto plates.  Dilutions were also 
spotted onto control plates with no agent.  Plates were incubated overnight and 
analysed for the cut off point at which colony growth had been visibly first affected in 
size/number.   To ensure reliability of results, each DNA damaging agent experiment 
was conducted at least twice for all concentrations.  Tetracycline was also added to 
plates for PN94361:dinBΔ, CP1015:dinBΔ and R6:dinBΔ to ensure that the tetM 
insert was not lost.   
 
DNA damaging agents results are presented in the three following sections according 
to the agent used (data for experiments are presented in appendix II.2). Results are 
summarised in graphs and an example of each is shown.  Summary results for all 
three isolates/strains are presented at the end of each section.   
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4.7.1 Sensitivity to EMS 
4.7.1.1 PN94361:dinB and PN94361:dinBΔ results 
PN94361:dinB and PN94361:dinBΔ EMS sensitivity results are shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.1.1a: PN94 361 EMS sensitivity results.  Blue dots –  PN94361:dinB; red 
dots –PN94361:dinBΔ ; y axis – dilution 1st visibly effected by EMS; U – unaffected; 
N – no growth; x axis – different concentrations of EMS (%).   
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Figure 4.7.1.1b: Sensitivity of PN94361:dinB (left) and PN94361:dinBΔ (right) 
isolates to different concentrations (%) of  EMS. Serial dilutions (up to 10-6) of 
untreated controls for each are shown at the top followed by serial dilutions of each 
isolate (up to 10-6) onto EMS plates of different concentrations (0.15 – 0.6% EMS).  
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4.7.1.2 CP1015:dinB and CP1015:dinBΔ results 
 
CP1015:dinB and CP1015:dinBΔ EMS sensitivity results are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.1.2a: CP1015 EMS sensitivity results.  Blue dots –  CP1015:dinB; red dots 
– CP1015:dinBΔ; y axis – dilution 1st visibly effected by EMS; U – unaffected; N – 
no growth; x axis – different concentrations of EMS (%).   
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Figure 4.7.1.2b: Sensitivity of CP1015:dinB (left) and CP1015:dinBΔ (right) isolates 
to different concentrations (%) of  EMS.  Serial dilutions (up to 10-6) of untreated 
controls for each are shown at the top followed by serial dilutions of each isolate up to 
10-6 onto EMS plates of different concentrations (0.15 – 0.6% EMS).  
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4.7.1.3 R6:dinB and R6:dinBΔ results  
 
R6:dinB and R6:dinBΔ EMS sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.1.3a: Summary of R6 EMS sensitivity results.  Blue dots –  R6:dinB; red 
dots – R6:dinBΔ; y axis – dilution 1st visibly effected by EMS; U – unaffected; N – 
no growth; x axis – different concentrations of EMS (%).   
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Figure 4.7.1.3b: sensitivity of R6:dinB (left) and R6:dinBΔ (right) isolates to different 
concentrations (%) of  EMS.  Serial dilutions (up to 10-6) of untreated controls for 
each are shown at the top followed by serial dilutions of each isolate up to 10-6 onto 
EMS plates of different concentrations (0.15 – 0.6% EMS).  
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4.7.1.4 Summary of EMS sensitivity results  
 
Table 4.7.1.4 summarises EMS sensitivity results for PN94 361, CP1015 and R6. 
 
 
Table 4.7.1.4: Summary of EMS sensitivity results.  Dilution 1st effected by EMS . U 
– unaffected by EMS (for controls – unaffected in growth); N – no growth; exp no. – 
experiment number; dinB – dinB wild type; dinBΔ – dinB mutant. 
 
 
dinB/dinBΔ EMS 
conc. 
Exp 
No. 
Dilution 1st effected by EMS in isolate/strain 
 PN94 361 CP1015 R6 
1 U U U 
2 U U U 
3 U U U 
4 U U U 
dinB 
 
5 U U U 
1 U U U 
2 U U U 
3 U U U 
1 U U U 
dinBΔ 
No 
agent 
5 U U U 
1 U U U 
2 U U U 
dinB 
 
3 U U U 
1 10-4 U U 
2 U U U 
dinBΔ 
0.15% 
3 U U U 
1 U U U 
2 10-6 10-6 10-6 
dinB 
 
3 10-6 U U 
1 10-5 10-3 10-4 
2 10-4 10-3 10-3 
dinBΔ 
0.3% 
3 10-5 10-4 10-3 
1 10-4 10-3 10-4 dinB 
 2 10-4 10-3 10-4 
1 10-2 10-1 10-2 dinBΔ 
0.35% 
2 10-2 10-1 10-2 
1 10-3 10-2 10-2 dinB 
 2 10-3 10-2 10-2 
1 N N N dinBΔ 
0.4% 
2 N N N 
1 N N N dinB 
 2 N N N 
1 N N N dinBΔ 
0.6% 
2 N N N 
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Overall, dinBΔ isolates/strains were considerably more sensitive to the effects of 
EMS than dinB isolates/strains. In general, the concentration at which growth was 
inhibited was comparable across all three strains. In each case 0.35% and 0.4% EMS 
showed the most differentiation between dinB and dinBΔ.  PN94 361 isolates were 
the least sensitive compared to CP1015 and R6.  CP1015 isolates displayed the 
highest sensitivity and in some cases were 10-fold more sensitive.   
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4.7.2 Sensitivity to MMS 
4.7.2.1 PN94361:dinB and PN94361:dinBΔ results 
PN94361:dinB and PN94361:dinBΔ MMS sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.2.1a: Summary of PN94 361 MMS sensitivity results.  Blue dots –  
PN94361:dinB; red dots – PN94361:dinBΔ; y axis – dilution 1st visibly effected by 
MMS; U – unaffected; N – no growth; x axis – different concentrations of MMS (%).   
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Figure 4.7.2.1b: Sensitivity of PN94361:dinB (left) and PN94361:dinBΔ (right) 
isolates to different concentrations (%) of  MMS. Serial dilutions (up to 10-6) of 
untreated controls for each are shown at the top followed by serial dilutions of each 
isolate up to 10-6 onto MMS plates of different concentrations (0.005 – 0.03% MMS).  
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4.7.2.2 CP1015:dinB and CP1015:dinBΔ results 
 
CP1015:dinB and CP1015:dinBΔ MMS sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.2.2a: Summary of CP1015 MMS sensitivity results.  Blue dots –  
CP1015:dinB; red dots – CP1015:dinBΔ; y axis – dilution 1st visibly effected by 
MMS; U – unaffected; N – no growth; x axis – different concentrations of MMS (%).   
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Figure 4.7.2.2b: Sensitivity of CP1015:dinB (left) and CP1015:dinBΔ (right) isolates 
to different concentrations (%) of  MMS. Serial dilutions (up to 10-6) of untreated 
controls for each are shown at the top followed by serial dilutions of each isolate up to 
10-6 onto MMS plates of different concentrations (0.005 – 0.03% MMS).  
. 
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4.7.2.3 R6:dinB and R6:dinBΔ results 
 
R6:dinB and R6:dinBΔ MMS sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.2.3a: Summary of R6 MMS sensitivity results.  Blue dots –  R6:dinB; red 
dots – R6:dinBΔ; y axis – dilution 1st visibly effected by MMS; U – unaffected; N – 
no growth; x axis – different concentrations of MMS (%).   
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Figure 4.7.2.3b: Sensitivity of R6:dinB (left) and R6:dinBΔ (right) isolates to MMS.  
Serial dilutions (up to 10-6) of untreated controls for each are shown at the top 
followed by serial dilutions of each isolate up to 10-6 onto MMS plates of different 
concentrations (0.005 – 0.03% MMS).  
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4.7.2.3 Summary of MMS sensitivity results  
Table 4.7.2.3: Summary of MMS sensitivity results.  Dilution 1st affected by MMS is 
shown. U – unaffected by MMS (for controls – unaffected in growth); N – no growth; 
exp no. – experiment number. 
 
Isolate/ 
Strain 
MMS 
Conc. 
Exp 
No. 
        Dilution 1st effected by MMS in isolate/strain 
 PN94 361 CP1015 R6 
1 U U U 
2 U U U 
3 U U U 
4 U U U 
dinB 
 
5 U U U 
1 U U U 
2 U U U 
3 U U U 
4 U U U 
dinBΔ 
No 
agent 
5 U U U 
1 U U U 
2 U U U 
dinB 
 
3 U U U 
1 U U U 
2 U U U 
dinBΔ 
0.005% 
3 U U U 
1 U U U 
2 U U U 
3 10-6 U U 
dinB 
 
4 U U U 
1 10-6 10-4 U 
2 10-5 10-5 U 
3 10-5 10-5 10-5 
dinBΔ 
0.01% 
4 10-5 10-5 10-5 
1 10-3 10-4 10-5 
2 10-4 10-5 10-6 
3 10-3 10-5 10-6 
4 10-3 10-4 10-5 
5 10-3 10-3 10-3 
dinB 
 
6 10-3 10-3 10-5 
1 10-1 10-1 10-1 
2 10-1 N 10-1 
3 N 10-1 10-2 
4 N N 10-1 
5 N 10-1 N 
dinBΔ 
0.02% 
6 N 10-1 10-2 
1 10-1 10-1 10-1 dinB 
 1 10-1 10-1 N 
2 N N N dinBΔ 
0.03% 
2 N N N 
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Overall, dinBΔ isolates/strains were considerably more sensitive to the effects of 
MMS than dinB isolates/strains.  The concentration that showed the most 
differentiation between dinB and dinBΔ was 0.02% and 0.03% MMS.  In general, the 
concentration at which growth was inhibited was comparable across all three strains. 
In contrast to EMS sensitivity results, R6 and CP1015 appeared to be less sensitive to 
MMS than PN94 361.   
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4.7.3 Sensitivity to NQO 
4.7.3.1 PN94361:dinB and PN94361:dinBΔ results 
PN94361:dinB and PN94361:dinBΔ NQO sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.3.1a: Summary of PN94 361 NQO sensitivity results.  Blue dots –  
PN94361:dinB; red dots – PN94361:dinBΔ; y axis – dilution 1st visibly effected by 
NQO; U – unaffected; N – no growth; x axis – different concentrations of NQO (%).   
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Figure 4.7.3.1b: Sensitivity of PN94361:dinB (left) and PN94361:dinBΔ (right) 
isolates to NQO.  Serial dilutions (up to 10-6) of untreated controls for each are shown 
at the top followed by serial dilutions of each isolate up to 10-6 onto NQO plates of 
different concentrations (0.3 – 0.6% NQO).  
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4.7.3.2 CP1015:dinB and CP1015:dinBΔ results 
 
CP1015:dinB and CP1015:dinBΔ NQO sensitivity results are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.3.2a: Summary of CP1015 NQO sensitivity results.  Blue dots –  
CP1015:dinB; red dots – CP1015:dinBΔ; y axis – dilution 1st visibly effected by 
NQO; U – unaffected; N – no growth; x axis – different concentrations of NQO (%).   
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Figure 4.7.3.2b: Sensitivity of CP1015:dinB (left) and CP1015:dinBΔ (right) isolates 
to NQO. Serial dilutions (up to 10-6) of untreated controls for each are shown at the 
top followed by serial dilutions of each isolate up to 10-6 onto NQO plates of different 
concentrations (0.3 – 0.6% NQO).  
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4.7.3.3 R6:dinB and R6:dinBΔ results 
 
R6:dinB and R6:dinBΔ NQO sensitivity results are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.3.3a: Summary of R6 NQO sensitivity results.  Blue dots –  CP1015:dinB; 
red dots – CP1015:dinBΔ; y axis – dilution 1st visibly effected by NQO; U – 
unaffected; N – no growth; x axis – different concentrations of NQO (%).   
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Figure 4.7.3.3b: Sensitivity of R6:dinB (left) and R6:dinBΔ (right) isolates to NQO.  
Serial dilutions (up to 10-6) of untreated controls for each are shown at the top 
followed by serial dilutions of each isolate up to 10-6 onto NQO plates of different 
concentrations (0.3 – 0.6% NQO).  
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4.7.3.4 Summary of NQO sensitivity results  
 
Isolate/ 
Strain 
NQO 
conc. 
Exp 
no. 
              Dilution 1st effected by NQO in isolate/strain 
 PN94 361 CP1015 R6 
1 U U U 
2 U U U 
3 U U U 
4 U U U 
dinB 
 
5 U U U 
1 U U U 
2 U U U 
3 U U U 
4 U U U 
dinBΔ 
No 
agent 
5 U U U 
1 U U U dinB 
 2 U U U 
1 10-6 U U dinBΔ 
0.3% 
2 10-6 U U 
1 U U U 
2 10-6 U U 
dinB 
 
3 U U U 
1 10-5 U 10-6 
2 10-4 10-6 U 
dinBΔ 
0.4% 
3 10-4 U 10-6 
1 10-4 U 10-6 dinB 
 2 10-4 U 10-6 
1 N 10-1 10-1 dinBΔ 
0.5% 
2 N 10-1 10-1 
1 10-1 10-1 10-1 dinB 
 2 N 10-1 10-1 
1 N N N dinBΔ 
0.6% 
2 N N N 
Table 4.7.3.4:Summary of NQO sensitivity results.  Dilution 1st effected by NQO.  U 
– unaffected by NQO (for controls – unaffected in growth); N – no growth; exp no. – 
experiment number; dinB – dinB wild type; dinBΔ – dinB mutant. 
 
 
As with EMS and MMS, dinBΔ isolates/strains were considerably more sensitive to 
the effects of NQO than dinB isolates/strains and 0.5% NQO produced the largest 
observable difference between dinB and dinBΔ. The concentration at which growth 
was inhibited was comparable across all three strains. As with MMS sensitivity, R6 
and CP1015 appeared to be less sensitive to NQO than PN94 361.   
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4.7.4 The effect of DNA damaging agents on clones Spain9V-3, 
England14-9 and Taiwan19F-14 
 
Results from this study showed that dinBΔ is more sensitive to DNA damaging agents 
than dinB isolates/strains.  As Spain9V-3 isolates are natural dinB mutants, sensitivity 
to EMS and MMS was tested among two isolates. Sensitivity to these agents was also 
examined in two isolates from clones England14-9 and Taiwan19F-14 for comparison.  
Unfortunately, due to time limitation NQO sensitivity experiments were not 
conducted. 
 
The isolates used were as follows; Spain9V-3 isolates - PN94 661 and PN93 1029; 
England14-9 isolates - PN94 336 and PN94 653; Taiwan19F-14 isolates - STP110 and 
STP133.  Three different concentrations of EMS were tested; 0.3%, 0.35% and 0.4%.  
Three concentrations were also used for MMS; 0.01%, 0.02% and 0.03%.  An 
example of each is illustrated in figure 4.7.4. Results are summarised in table 4.7.4.1 
(EMS results) and 4.7.4.2 (MMS results). 
Figure 4.7.4:    EMS and MMS sensitivity results for isolates of clone Spain9V-3, 
England14-9 and Taiwan19F-14 Serial dilutions (up to 10-6) of untreated controls for 
each are shown at the top followed by serial dilutions of each isolate up to 10-6 onto 
EMS and MMS plates of different concentrations (%).  
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4.7.4.1  The effect of EMS on  Spain9V-3, England14-9 and Taiwan19F-14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.4.1a: Summary of Spain9V-3, England14-9 and Taiwan19F-14 EMS 
sensitivity results.  Red squares – Spain9V-3; green dots – England14-9: purple dots –   
Taiwan19F-14; y axis – dilution 1st visibly effected by EMS; U – unaffected; N – no 
growth; x axis – different concentrations of EMS (%).   
 
 
Results are illustrated in figure 4.7.4.1 and table 4.7.4.1. At 0.35% and 0.4% Spain9V-
3 isolates were more sensitive to EMS than isolates of clones England14-9 and 
Taiwan19F-14. 
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Table 4.7.4.1: Spain9V-3, England14-9 and Taiwan19F-14 sensitivity results to different 
concentrations of EMS.  Dilution 1st effected by EMS refers to the dilution at which 
colony growth is visibly effected in size/number compared to untreated control (no 
agent); U – unaffected by EMS (for controls – unaffected in growth). 
 
Isolate Clone EMS concentration Dilution  
1st 
effected 
PN94 661 U 
PN93 1029 
9V 
U 
PN94 336 U 
PN94 653 
14 
U 
STP 110 U 
STP 133 
19F 
 
 
No agent 
U 
PN94 661 10-6 
PN93 1029 
9V 
U 
PN94 336 10-6 
PN94 653 
14 
U 
STP 110 U 
STP 133 
19F 
 
 
0.3% 
10-6 
PN94 661 10-2 
PN93 1029 
9V 
10-2 
PN94 336 10-3 
PN94 653 
14 
10-3 
STP 110 10-3 
STP 133 
19F 
 
 
0.35% 
10-3 
PN94 661 10-1 
PN93 1029 
9V 
10-1 
PN94 336 10-2 
PN94 653 
14 
10-2 
STP 110 10-2 
STP 133 
19F 
 
 
0.4% 
10-2 
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4.7.4.2  The effect of MMS on  Spain9V-3, England14-9 and Taiwan19F-14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.4.2: Summary of Spain9V-3, England14-9 and Taiwan19F-14 MMS 
sensitivity results.  Red squares – Spain9V-3; green dots – England14-9: purple dots –   
Taiwan19F-14; y axis – dilution 1st visibly effected by MMS; U – unaffected; N – no 
growth; x axis – different concentrations of MMS (%).   
 
 
Results are illustrated in figure 4.7.4.2 and table 4.7.4.2.  At 0.02% and 0.03%, 
Spain9V-3 isolates were markedly more sensitive to MMS than isolates of clones 
England14-9 and Taiwan19F-14. 
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Table 4.7.2.b: Spain9V-3, England14-9 and Taiwan19F-14 sensitivity results to different 
concentrations of MMS.  Dilution 1st effected by MMS refers to the dilution at which 
colony growth is visibly affected in size/number compared to untreated control (no 
agent); U – unaffected by MMS (for controls – unaffected in growth); N – no growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolate Clone MMS conc. Dilution  
1st 
effected 
PN94 661 U 
PN93 1029 
9V 
U 
PN94 336 U 
PN94 653 
14 
U 
STP 110 U 
STP 133 
19F 
 
 
No agent 
 
U 
PN94 661 10-5 
PN93 1029 
9V 
10-6 
PN94 336 U 
PN94 653 
14 
U 
STP 110 U 
STP 133 
19F 
 
 
0.01% 
10-6 
PN94 661 10-2 
PN93 1029 
9V 
10-2 
PN94 336 10-6 
PN94 653 
14 
10-6 
STP 110 10-6 
STP 133 
19F 
 
 
0.02% 
10-5 
PN94 661 N 
PN93 1029 
9V 
10-1 
PN94 336 10-3 
PN94 653 
14 
10-4 
STP 110 10-2 
STP 133 
19F 
 
 
0.03% 
10-2 
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4.8 Mutation frequency following exposure to a DNA damaging agent 
 
It is argued that polIV can act in an error prone or error free manner in order to correct 
lesions in DNA.  Mutation frequency results from this research suggest that in S. 
pneumoniae, polIV acts in an error prone manner as a decline in mutation frequency is 
observed in dinBΔ.  Although knocking out dinB in both the clinical isolate and 
hypermutable laboratory strain resulted in a significant decrease in mutation 
frequency, this experiment was conducted to determine if exposure to a DNA 
damaging agent would alter the mutation frequency in any way.  Due to time 
limitation only CP1015 isolates were examined. 
 
CP1015:dinB and CP1015:dinBΔ cultures were grown to OD ~0.25.  They were split 
in two equal volumes and experimental cultures were exposed to 4% NQO for one 
hour.  This concentration was selected as it was not lethal to dinBΔ but still presented 
a slight difference in sensitivity between dinB and dinBΔ.  Apart from the addition of 
NQO, control cultures were treated the same as experimental cultures and plated as 
normal. Mutation frequency data is shown in appendix II (II.2). 
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Figure 4.8:  Mutation frequency post NQO exposure.  CP1015:dinBΔ – dinB wild 
type untreated control; CP1015:dinB NQO – dinB wild type treated, NQO; 
CP1015:dinBΔ control – dinB knock out mutant untreated control; CP1015:dinBΔ 
NQO – dinB knock out mutant, NQO. 
 
 
Figure 4.8 shows the results for the mutation frequency experiments following 
exposure to NQO. In total 5 independent mutation frequency experiments were 
obtained for isolates/strains exposed to NQO (figure 4.8 - NQO) and 5 were obtained 
for isolates/strains that were untreated controls (figure 4.8 - control) for both 
CP1015:dinB and CP1015:dinBΔ.  
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No significant difference in mutation frequency was observed between CP1015:dinB 
control and CP1015:dinB NQO (P = 0.2222).  Similarly, no significant difference was 
observed between CP1015dinBΔ control and CP1015dinBΔ NQO (P = 0.0952).  
Although not statistically significant, there appears to be a slight change in median 
mutation frequency (figure 4.8).  A slight increase was observed in CP1015:dinB 
NQO cultures (median – 3.76 x 10-07) compared to CP1015:dinB control cultures 
(median – 2.39 x 10-07).  Similarly, a slight decrease was observed with CP1015dinBΔ 
NQO cultures (median – 4.7 x 10-08) compared to CP1015dinBΔ controls (median – 
8.18 x 10-08).  Lack of a significant difference may be due to sample size.  Only five 
separate mutation frequencies were obtained for each control and experimental 
genotype compared to twenty in the previous mutation frequency experiment.   
 
A significant difference was however observed between CP1015:dinB NQO and 
CP1015:dinBΔ NQO (P = .0079).  
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4.9 Hydrogen peroxide 
 
The natural metabolism of S. pneumoniae leads to the production of large amounts of 
hydrogen peroxide (H2O2).  This is known to be an important pneumococcal virulence 
factor.  The amount of hydrogen peroxide produced by S. pneumoniae is deleterious 
to other organisms that also share the respiratory tract (Pericone et al., 2000, Selva et 
al., 2009).  In E. coli, the damage caused by hydrogen peroxide has been shown to 
initiate proteins involved in the SOS response.  Although S. pneumoniae produce 
relatively high amounts of hydrogen peroxide, they appear to be resistant to its 
deleterious effects.  The aim of this part of the project was to use dinB isogenic 
mutants to investigate whether this gene is involved in the tolerance of damage caused 
by H2O2.   
 
Cultures at ~ OD620 0.4 were exposed to various concentrations of H2O2 for 30 
minutes and spotted in triplicate on Iso-Sensitest blood agar plates with or without 
tetracycline, at a dilution of 1 x 104.  Two separate experiments were conducted.  Both 
experiments tested CP1015, PN94 361 and R6 dinB isogenic mutants simultaneously.  
Preliminary experiments were conducted to determine the range of H2O2 
concentrations tested in each isolate/strain.  This range differed between PN94 361, 
CP1015 and R6. 
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4.9.1 PN94 361 H2O2 sensitivity results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9.1: H2O2 sensitivity results for PN94361:dinB and PN94361:dinBΔ. Isolates 
are spotted in triplicate onto plates at a dilution of 10-4 following exposure to different 
concentrations of H2O2 (mM). Untreated controls (no H2O2 exposure) are shown at 
the top. 
 
Table 4.9.1:  H2O2 sensitivity results for PN94 361 dinB isogenic knock out mutants. 
++ over 100 colonies; + under 100 colonies.  
 
 
 H2O2 concentration (mM) 
Exp 
no. 
Isolate Untreated 
control 
 
20 
 
40 
 
80 
 
160 
++ + 8 2 1 
++ + 10 1 1 
PN94361:dinB 
++ + 9 7 2 
++ 12 - - - 
++ 10 - - - 
1 
PN94361:dinB
Δ 
++ 10 - - - 
++ + 9 2 - 
++ + 14 2 - 
PN94361:dinB 
++ + 19 3 - 
++ + - - - 
++ + - - - 
2 
PN94361:dinB
Δ 
++ + - - - 
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Four different H2O2 concentrations were examined. Figure 4.9.1 shows the results for 
experiment 2 and results for both experiments are shown in table 4.9.1.  Both 
experiments showed that PN94376:dinBΔ was more sensitive to H2O2 than 
PN94361:dinB. 
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4.9.2 CP1015 H2O2 sensitivity results 
Figure 4.9.2: H2O2 sensitivity results for CP1015:dinB and CP1015:dinB.  Isolates are 
spotted in triplicate onto plates at a dilution of 10-4 following exposure to different 
concentrations of H2O2 (mM). Untreated controls (no H2O2 exposure) are shown at 
the top. 
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 H2O2 concentration (mM) 
Exp 
no. 
Isolate Untreated 
control 
 
2 
 
4 
 
6 
 
8 
 
10 
 
12 
 
14 
++ ++ ++ ++ ++ ++ - - 
++ ++ ++ ++ ++ ++ - - 
CP1015:dinB 
++ ++ ++ ++ ++ ++ - - 
++ ++ ++ - - - - - 
++ ++ ++ - - - - - 
1 
CP1015:dinBΔ 
++ ++ ++ - - - - - 
++ ++ ++ ++ 12 - - - 
++ ++ ++ ++ 19 - - - 
CP1015:dinB 
++ ++ ++ ++ 10 - - - 
++ ++ ++ 1 - - - - 
++ ++ ++ - - - - - 
2 
CP1015:dinBΔ 
++ ++ ++ - - - - - 
Table 4.9.2:  H2O2 sensitivity results for CP1015 dinB isogenic knock out mutants. ++ 
over 100 colonies; + under 100 colonies; - no growth. 
 
 
 
The concentrations used for PN94 361 isolates were too toxic for CP1015 isolates. 
Figure 4.9.2 presents the results for experiment 1 and results for both experiments are 
shown in table 4.9.2. CP1015:dinBΔ was more sensitive to H2O2 than CP1015:dinB. 
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4.9.3 R6 H2O2 sensitivity results 
Figure 4.9.3: H2O2 sensitivity results for R6:dinB and R6:dinBΔ. Isolates are spotted 
in triplicate onto plates at a dilution of 10-4 following exposure to different 
concentrations of H2O2 (mM). Untreated controls (no H2O2 exposure) are shown at 
the top. 
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Table 4.9.3: H2O2 sensitivity results for R6 dinB isogenic knock out mutants. ++ over 
100 colonies; under 100 colonies; - no growth. 
 
Figure 4.9.3 shows results for experiment 1.  Results from both experiments showed 
that R6:dinBΔ was more sensitive to H2O2 than R6:dinB (figure and table 4.9.3) 
 H2O2 concentration (mM) 
Exp 
no. 
Isolate/strain Untreated 
control 
 
5 
 
10 
 
15 
 
20 
 
25 
 
30 
 
35 
 
40 
++ ++ ++ ++ ++ ++ ++ - - 
++ ++ ++ ++ ++ ++ ++ - - 
R6:dinB 
++ ++ ++ ++ ++ ++ ++ - - 
++ ++ ++ ++ 3 - - - - 
++ ++ ++ ++ 4 - - - - 
1 
R6:dinBΔ 
++ ++ ++ ++ - - - - - 
++ ++ ++ ++ ++ + 8 - - 
++ ++ ++ ++ ++ + 5 - - 
R6:dinB 
++ ++ ++ ++ ++ + 4 - - 
++ ++ ++ ++ - - - - - 
++ ++ ++ ++ 2 - - - - 
2 
R6:dinBΔ 
++ ++ ++ ++ - - - - - 
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4.10 Discussion 
 
This section investigated the effect of PolIV on mechanisms of genome evolution.  
The SOS response is adopted by numerous bacteria in response to severe DNA 
damage.  Although it has been proposed that competence can be induced as a 
mechanism of DNA repair (Claverys et al., 2000), the majority of England14-9 isolates 
are transformation deficient.  The worldwide success of this clone would suggest that 
other mechanisms have been adopted to respond to severe DNA damage. DNA 
polymerase IV is the only polymerase found in S. pneumoniae that is part of the SOS 
response in E. coli.  The role of DNA polymerase IV in S. pneumoniae has not 
previously been investigated.  The aim of this part of the project was therefore to 
investigate the effect of PolIV on mutation and DNA repair by creating isogenic dinB 
knock out mutants in three different genetic backgrounds, CP1015, R6 and PN94 361. 
 
Preliminary experiments suggested that the dinBΔ construct was unstable and all 
future experiments were grown in the presence of tetracycline to ensure mutant 
selection.  It appeared dinBΔ had lost the tetM insertion on numerous post 
experimental amplifications of the construct as the wild type PCR was observed.  
Release of the tetM insert would require homologous recombination within the dinBΔ 
construct.  Intra-chromosomal homologous recombination is known to cause 
deletions, inversions, duplication and translocations (Smith, 1989).  Astonishingly, 
around 5% of the pneumococcal genome is made up of repeat regions with the 
potential to facilitate recombination within the genome (Martin et al., 1992, Oggioni 
and Claverys, 1999). Intra-chromosomal recombination can be categorised into three 
distinct types: site specific recombination, homologous recombination and illegitimate 
recombination (Michel, 1999, Smith, 1988).  The latter two require a certain degree of 
homology between repeated regions to facilitate recombination. Homologous 
recombination however can occur between repeats that are not in close proximity in 
the genome where as illegitimate recombination occurs between closely repeated 
regions (Michel, 1999, Smith, 1988).  DinB experiments in this project involved the 
exposure of DNA damaging agents so there may be a selective advantage to revert to 
wild type to enable the potential repair of strand breaks. 
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The probability of an intra-chromosomal recombination occurring is dependent on the 
amount of homology between repeats.  The longer the repeat region, the more likely it 
is that recombination will occur.  RecA dependent recombination normally requires at 
least 25bp identical sequence, although deletions can occur between very short 
repeats, at least in E. coli (Shen and Huang, 1986, Albertini et al., 1982).  The tetM 
insert was incorporated into the dinB gene by restriction enzyme digestion with XhoI. 
Sequence analysis to previously confirm the presence of tetM shows that there are no 
homologous regions on either side of the XhoI site (section 4.3; figure 4.3.1b and 
4.3.2b).  As a result, no terminal overlapping sequence or repeat regions were present 
to facilitate homologous recombination and excise tetM.  Furthermore, functional 
dinB could only be reconstituted by an accurate recombination event that maintained 
the reading frame on excision. It is therefore more likely that some wild type dinB 
isolates were able to withstand growth on tetracycline and out grow dinBΔ isolates 
over the course of numerous experiments in the absence of tetracycline, despite steps 
taken to subculture the initial mutants to purify at the time of construction. 
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4.10.1 Mutation frequency versus mutation rate and mutation spectrum 
Mutation frequency and mutation rate can be used to analyse the amount of mutation 
that occurs in Streptococcus pneumoniae, however there is conflicting opinion on 
which method is more suitable. The term mutation rate refers to a per generation 
estimation of the amount of mutation in a cell. The mutation frequency provides a 
sample of the bacterial population at a specific time including a reflection of the 
mutation rate in addition to the population history before the administration of 
selection (Martinez and Baquero, 2000).   
 
The mutation frequency method has been considered flawed due to the presence of 
‘jackpot cultures’ in which mutations arise early in culture growth producing a high 
mutant progeny which skews results (Pope et al., 2008).  This was first observed in 
the classic fluctuation experiments conducted by Luria and Delbruck who 
demonstrated that bacteriophage sensitive cultures of E. coli can become 
bacteriophage resistant in the presence of excess bacteriophage T1 (Luria and 
Delbruck, 1943).  Large fluctuations in mutant numbers led authors to determine that 
the quantity of mutants present in culture is dependent on how early the mutant arises. 
Therefore, those mutations that occur early in culture produce a distortion in results 
(Luria and Delbruck, 1943). It is consequently argued that mutation rate is a more 
reliable method in antibiotic research (Pope et al., 2008).  However, it also argued that 
this problem can be overcome by following steps to minimise the likelihood of pre-
existing mutants prior to mutation frequency experiments (Hall and Henderson-Begg, 
2006). A standardised innoculum must be determined in which a known number of 
colony forming units (usually in the range of 102 – 104) are used from a characterised 
starter culture.  This allows pre-existing mutants to be quantified and minimised (Hall 
and Henderson-Begg, 2006).  It is also important to use the median mutation 
frequency in analysis to avoid bias from jackpot cultures (Henderson-Begg et al., 
2010a, Drake, 1991).  Mutation frequency was originally chosen for ease of 
comparison as most studies that investigated the effect of knocking out dinB in other 
organisms used this method. 
 
Both mutation frequency and mutation rate of rifampicin resistant mutants however 
were assessed in dinB and dinBΔ cultures.   
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4.10.1.1 Mutation frequency 
Mutation frequencies were examined by determining the frequency of rifampicin 
resistant colonies in isogenic dinB mutants CP1015 and PN94 361, following 
exponential culture growth. In E. coli as many as sixty-nine different rpoB mutations 
give rise to rifampicin resistance, covering all six types of base substitutions 
(Garibyan et al., 2003). The use of resistance to this antibiotic is thus a practical assay 
to test for mutation frequency and mutation spectrum and is applicable to diverse 
bacterial species (Garibyan et al., 2003). 
 
To ensure the absence of pre-existing mutants in the experimental innoculum, a 10-6 
dilution of the starter culture (containing around 5 x 103 cfu/ml) was used to inoculate 
broths.  Mutation frequency experiments aim to investigate the frequency of 
spontaneous mutants.  The presence of a pre-existing mutant would therefore distort 
results. The median mutation frequency from twenty independent mutation 
frequencies was used for analysis as opposed to the mean due to the possible presence 
of “jack-pot” cultures where a resistant mutant arises early in the growth phase 
(Drake, 1991).   
 
4.10.1.1.2 The effect of dinBΔ 
CP1015:dinBΔ strains (median mutation frequency – 1.74 x 10-07) presented a 
significantly lower mutation frequency (P = 0.0028) compared to CP1015:dinB 
(median mutation frequency – 4.92 x 10-07). Similarly, there was a significant 
difference (P = 0.0165) in PN94 361 isolates with a reduced mutation frequency in 
PN94361:dinBΔ (median mutation frequency – 1.45 x 10-08) compared to 
PN94361:dinB (median mutation frequency – 4.02 x 10-08).  The amount of decrease 
in median values for both dinB knock out mutants was similar.  PN94361:dinBΔ 
presented a 2.77 fold reduction in median mutation frequency, compared to 
CP1015:dinB which presented a 2.83 fold reduction in median mutation frequency. 
 
Results from this research and evidence elsewhere suggest a role for DNA polymerase 
IV in TLS (discussed in section 4.10.2), however the reduced mutation frequency in 
dinBΔ also suggests that PolIV is active during normal growth and not just in 
conditions of stress. In E. coli, induction of the SOS response leads to a ten-fold 
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increase in expression levels of dinB.  However, dinB is still expressed at high levels 
in undamaged cells at ~250 copies (Kim et al., 2001). 
 
Strauss et al examined the effect of dinB deletion in E. coli (Strauss et al., 2000). A 
number of genetic backgrounds were examined to determine the rate of base 
substitutions and frameshifts, including deletion of dnaE (a subunit of DNA 
polymerase III) and mutS (the pneumococcal hexA homologue).  A significant 
mutation frequency reduction in dinB knock out strains (dinB-/mutS+/dnaE+) 
compared to wild type strains (dinB+/mutS+/dnaE+) was observed for both 
frameshifts and base substitutions (Strauss et al., 2000).  On the basis of experimental 
findings, Strauss et al suggested that spontaneous mutations are in part caused by 
PolIV in both dnaE wild type and defective strains (Strauss et al., 2000).  The finding 
of a reduced mutation frequency in E. coli dinB mutants has also been observed by 
Jacob et al (Jacob and Eckert, 2007). Moyano et al looked at the effect of dinB 
deletion in P. aeruginosa (Moyano et al., 2007a).  P. aeruginosa colonises the 
respiratory tract and is a major cause of mortality in cystic fibrosis.  A significant 
reduction in mutation frequency was observed for dinB mutant strains compared to 
wild types (Moyano et al., 2007b).  These findings suggest that PolIV may be 
responsible for some replication errors opposite normal bases. 
 
 
Part of this project also involved determining whether mutation frequency would alter 
following exposure to a DNA damaging agent.  Control and experimental CP1015 
dinB and dinBΔ cultures were treated the same apart form the addition of NQO (in 
experimental cultures).  Although there was not a significant difference in mutation 
frequencies with and without exposure to NQO, there was a significant difference 
between dinB and dinBΔ, with a reduced mutation frequency in dinBΔ.  Compared to 
untreated controls, there did appear to be a slight increase in mutation frequency for 
CP1015:dinB cultures exposed to NQO and a slight decrease in mutation frequency 
for CP1015:dinBΔ exposed to NQO.  The lack of significance may be due to sample 
size.  Due to time limitation only twenty mutation frequencies were obtained, five 
separate mutation frequencies for each of the four conditions (CP1015:dinB and 
CP1015:dinBΔ, with and without NQO).  In general however, these results still 
correlate with a reduced mutation frequency for dinB knock out mutants. 
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In general, there is evidence to support a role for S. pneumoniae PolIV in normal 
growth in addition to stress response.  However, there is also conflicting evidence 
from other studies. Mycobacterium tuberculosis possess two Y-family polymerases 
encoded by dinB1 (Rv1537) and dinB2 (Rv3056) (Cole et al., 1998). A study 
conducted by Kana et al showed that mutant and wild type dinB1 and dinB2 
backgrounds showed similar spontaneous mutation rates to rifampicin (Kana et al., 
2010). It is not necessarily the case that dinB will perform the same function in 
different organisms. Conflicting evidence nevertheless has also been identified in E. 
coli. Kuban et al investigated the effect of E. coli dinB deletion in a mismatch repair 
deficient background on mutation frequency and identified no difference between 
dinB wild type and mutants (Kuban et al., 2004).  It is therefore clear that the role of 
dinB in spontaneous mutation is still elusive. 
 
4.10.1.1.2 The effect of hexΔ 
The main aim of this chapter was to investigate the effect on dinB deletion on 
mutation and later DNA repair (next section), however it was also interesting to 
observe the effect of dinB deletion in a mismatch repair deficient background 
(CP1015). Overall, the mutation frequencies for CP1015 isolates were 10 fold higher 
than that of PN94 361 isolates. It must be noted that an isogenic background was not 
created for the hex mutant, however comparisons could still be made with PN94 361 
hex wild type isolates.  Hypermutators display an increased rate of mutation across the 
entire genome due to damaged repair mechanisms or a higher frequency of incorrect 
nucleotide incorporation.  As CP1015 isolates are Hex MMR mutants, an overall ten 
fold increase in mutation frequency can be accounted for.   Other research conducted 
to determine the mutation frequency in antibiotic resistant and susceptible 
pneumococcal isolates also presented similar results for CP1015 (dinB wild type) 
isolates with an increased mutation frequency compared to non-hypermutable clinical 
isolates (Henderson-Begg et al., 2010b).  A 4 – 10 fold increase in mutation frequency 
for pneumococcal Hex mutants has been reported in other studies (Negri et al., 2002, 
Tiraby et al., 1973, Tiraby and Sicard, 1973, Morosini et al., 2003).  
 
As already mentioned, Strauss et al examined the effect of  E. coli dinB deletion in a 
number of genetic backgrounds including the mismatch repair Mut (homologous to 
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pneumococcal Hex) deficient background (Strauss et al., 2000).  In general and 
comparable to findings from this study, mutS deficient backgrounds presented a 
significantly higher mutation frequency when compared to mutS wild type 
backgrounds (in both dinB+ and dinB-). Another comparable finding to this research 
is observed in the Moyano et al study already described (Moyano et al., 2007b). In P. 
aeruginosa mutS knock out strains, the frequency of mucoid variant mutations 
increased compared to wild type strains (mutS+). However, dinB-/mutS- double knock 
out mutants presented a significant decrease in the presence of mucoid variants 
compared to dinB+/mutS- strains (Moyano et al., 2007a). 
 
4.10.1.2 Mutation rate 
Two general methods are available to test for mutation rate: mutation accumulation 
and fluctuation analysis.  Mutation accumulation is based on the growth of culture 
exponentially and will include the growth of pre-existing mutants in addition to the 
presence of newly generated mutations.  This leads to a constant increase in the 
mutation fraction per cell generation and the difference can be measured over time. 
Fluctuation analysis, designed by Luria and Delbruck, involves inoculating a small 
number of cells into parallel cultures and allowing them to grow exponentially (Luria 
and Delbruck, 1943).   Each culture is then plated on selective medium to determine 
the number of mutants present.  The total number of cells is determined by plating 
dilutions on non-selective media (Luria and Delbruck, 1943).  Although mutation rate 
is mostly calculated from the total number of colonies arising in culture following 
inoculation with a single colony, various modifications have been developed that 
allows mutation rate to be determined from results already obtained in this study.  The 
Jones median estimator uses median values from mutation frequency data to calculate 
the rate (Jones et al., 1994). 
 
The mutation rate for PN94361:dinBΔ (4.07 x 10-08) was ~2 fold lower than that for 
PN94361:dinB (7.45 x 10-08).  Similarly, the mutation rate for CP1015:dinBΔ (1.88 x 
10-07) was ~2 fold lower than for CP1015:dinB 4.57 x 10-07).  As a result, this 
coincides with mutation frequency results and does not alter conclusions from those 
experiments. 
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4.10.1.3 rpoB mutation spectrum 
Analysis of rpoB mutation spectrum was examined in PN94 361 and CP1015 isogenic 
mutants.  Similar results were obtained for hex deficient CP1015:dinB and 
CP1015:dinBΔ  isolates with a majority of transitional changes.  The majority of 
PN94361:dinBΔ mutations were transitional changes, however PN94361:dinB 
isolates had an equal amount of transitional and transversional changes.  This is likely 
to be due to differences in genetic background.  The pneumococcal Hex system is 
known to repair transitions more efficiently than transversions.  Knocking hex out 
therefore causes an increase in the occurrence of transitional mutations (Humbert et 
al., 1995).   Another difference in mutation type for Hex deficient CP1015 and PN94 
361 isolates was the occurrence of T:A – C:G transitions.   Sixteen and thirteen of 
these changes were observed for CP1015:dinB and CP1015:dinBΔ mutations, 
respectively.  However only one of these changes was observed for PN94 361 
mutations (PN94361:dinBΔ). 
 
The finding of an increased occurrence of transversional changes in PN94361:dinB 
compared to PN94361:dinBΔ was also identified previously in this laboratory by 
Stephanie Henderson-Begg (unpublished data); the transition to transversion ratio 
observed was 1:18 for PN94 361 and 9:4 for PN94 361 dinB knock out isolates.  DinB 
has been identified to promote transversions in P. aeruginosa (Sanders et al., 2006).  
However the commonly promoted transversion was CG – AT transversion as opposed 
to T:A – A:T, CG – G:C and C:G – A:T for PN94361:dinB in this study.  Inactivation 
of dinB in E. coli demonstrated an increase in the proportion of AT – GC and GC – 
AT transitions in addition to a decrease in AT – TA transversions (Wolff et al., 2004).  
Some of these findings were comparable to results from this study and work 
conducted previously in this laboratory.  CP1015:dinBΔ and PN94361:dinB both had 
an increased number of GC – AT transitions and as already mentioned, unpublished 
data conducted by Stephanie Henderson-begg showed a considerable decrease in 
transversions in PN94361:dinBΔ .   In summary, differences in mutation spectrum are 
apparent in different organisms and even divergent genetic backgrounds within the 
same organism.  Knocking dinB out in S. pneumoniae appears to increase the 
presence of C:G  - T:A transitional changes in both CP1015:dinBΔ and 
PN94361:dinBΔ and decrease the number of transversions in PN94361:dinBΔ. 
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4.10.2 DNA damaging agents – EMS, MMS and NQO 
In E. coli, polIV has been shown to play an important role in bypassing lesions with 
low fidelity that would otherwise stall the replication fork.   This part of the 
investigation aimed to determine whether the S. pneumoniae dinB gene is also 
involved in repair following exposure to various DNA damaging agents.  Ten fold 
dilutions of R6, CP1015 and PN94 361 dinB and dinBΔ isolates were plated onto agar 
containing either EMS, MMS or NQO (in addition to tetracycline to select for dinB 
mutants). Untreated dilutions of dinB and dinBΔ were used as a control.  For all three 
strains/isolates used (R6, CP1015 and PN94 361) dinBΔ displayed increased 
sensitivity to DNA damaging agents compared to their isogenic dinB strains/isolates.   
 
4.10.2.1 The effect of DNA damaging agents on PN94 361, CP1015 and R6 
S. pneumoniae cells lacking dinB presented a marked sensitivity to NQO.  In bacteria 
as well as mammals, NQO acts as a mutagen and carcinogen causing various lesions, 
some of which are responsible for double strand breaks (Galiègue-Zouitina et al., 
1985).  The most common lesion identified is that caused at the N2 position of 
guanine (N2-dG adduct) (Menichini et al., 1989) which blocks replication (Xu et al., 
2007). Results from this study show that dinB reduces the effects of NQO. In E. coli , 
cells that lack dinB also display increased sensitivity to NQO (Williams et al., 2010).  
Ten fold dilutions of dinB wild type and mutant E. coli showed that mutant strains 
were generally two orders of magnitude more sensitive to NQO (Williams et al., 
2010).  In this study, dinBΔ isolates/strains ranged from four to six orders of 
magnitude more sensitive at 0.5% NQO.  Further evidence for a role of E. coli  dinB 
in TLS of NQO lesions comes from other studies where dinB mutant strains show a 
marked sensitivity to this agent (Jarosz et al., 2009, Jarosz et al., 2006b, Gutierrez et 
al., 2011).  These findings are not limited to bacteria. The dinB homologue in yeast, 
rev1 displayed increased sensitivity to NQO when mutated (Wiltrout and Walker, 
2011). NQO is known to predominantly create the same lesions (N2-dG adducts) as 
nitrofurazone (NFZ) and additional evidence to support findings of increased 
sensitivity of dinB mutants can thus come from studies using NFZ. In E. coli, a 
number of studies have shown that dinB mutants are significantly more sensitive to 
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NFZ than wild types (Benson et al., 2011, Jarosz et al., 2009, Jarosz et al., 2006b, 
Gutierrez et al., 2011). 
 
Results from this research also suggest that S. pneumoniae polIV can perform TLS on 
lesions that occur as a result of alkylation.  Alkylation can cause DNA damage from 
diverse exogenous sources in both prokaryotes and eukaryotes (Singer and 
Kuśmierek, 1982).  EMS and MMS are both alkylating agents.  All three dinBΔ 
isolates/strains (R6:dinBΔ, CP1015:dinBΔ and PN94361:dinBΔ) were more sensitive 
to EMS and MMS compared to dinB wild type strains/isolates.  Bjedov et al showed 
that E. coli dinB mutants were sensitive to alkylating agents MMS, EMS and MNNG 
in a alka tag deficient background (Bjedov et al. 2007).  As with this research, 
varying concentrations were used to test ten fold serial dilutions of culture. Increases 
in agent concentration resulted in increased sensitivity of the dinB mutant. Evidence 
for a role of polIV in the repair of alkylating lesions has also been identified in other 
studies. Recent research in E. coli showed that dinB knock out mutants complemented 
with various plasmid-borne dinB variants presented differences in the levels of 
sensitivity to MMS (Benson et al., 2011).  The highest level of sensitivity to MMS 
was observed with dinB mutant cells that received an inactive dinB variant (Benson et 
al., 2011). Gutierrez et al also showed that dinB knock out models of E. coli display 
enhanced sensitivity to MMS  compared to wild type E. coli (Gutierrez et al., 2011).   
 
Further evidence to support a general role of polIV in TLS comes from studies using 
other agents that block the replicative machinery.  E. coli PolIV is able to bypass N2-
(1-carboxyethyl)-2_-deoxyguanosine lesions caused by Methylglyoxal (Lorenz and 
Wackernagel), a byproduct of the glycolysis pathway (Yuan et al., 2008).  It has also 
been shown to efficiently bypass acrolein mediated N2-N2-gunine interstrand DNA 
crosslinks (ICLs) (Kumari et al., 2008).  Around the same time Minko et al also 
demonstrated that E. coli  polIV in addition to its human homologue polK accurately 
bypasses N2-N2-guanine ICLs (Minko et al., 2008).  Furthermore these findings are 
apparent in other organisms; S. enterica dinB mutants were shown to be sensitive to 
DNA damage from bile salts (Prieto et al., 2006) and the human homologue polK has 
also been observed to perform TLS (Fischhaber et al., 2002, Takenaka et al., 2006). 
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4.10.2.2 The effect of DNA damaging agents on Spain9V-3, England14-9 and 
Taiwan19F-14 
 
Plenty of evidence from E. coli studies has been published, much since the initiation 
of this project.  This study is the first to investigate the effect of dinB deletion in S. 
pneumoniae and has shown that S. pneumoniae polIV reduces the killing effect of 
DNA damaging agents.  In addition, this work is consistent with findings in E. coli 
and other organisms.  The next part of this project therefore involved testing the 
effects of DNA damaging agents on two Spain9V-3 isolates (natural dinB mutants) and 
comparing them to dinB wild type isolates of clone England14-9 and Taiwan19F-14.  
Sensitivity to NQO was not investigated due to time limitation. 
 
Spain9V-3 isolates were more sensitive to EMS and MMS compared to other isolates.  
In general, isolates were one order of magnitude more sensitive to EMS than isolates 
from clones England14-9 and Taiwan19F-14.  MMS results were more diverse but 
Spain9V-3 isolates were one to three orders of magnitude more sensitive to MMS.  A 
comparison of results from isolates of clones Spain9V-3, England14-9 and Taiwan19F-
14 with isolates from clone Greece6B-22 (PN94361:dinB and PN94361:dinBΔ) 
showed that PN94361:dinBΔ was the most sensitive isolate to the effects of EMS and 
MMS, followed by the natural dinB mutant Spain9V-3 isolates (figure 4.10.2.2).  In 
general, all concentrations of EMS and MMS apart from the lowest concentration 
(which showed a slight difference for dinB mutants) demonstrated that wild type dinB 
isolates (PN94361:dinB and isolates of England14-9 and Taiwan19F-14) were more 
resistant to killing than dinB mutants (PN94361:dinBΔ and isolates of Spain9V-3) 
(figure 4.10.2.2).  
 
PN94 361 and CP1015 isolates/strains used were isogenic dinB mutants and the 
observed difference in sensitivity was therefore solely due to the effect of dinB alone.  
Although the natural mutant dinB clone Spain9V-3 did show increased sensitivity to 
DNA damaging agents compared to other clones, we can not be certain that the 
observed results were due the effect of dinB alone. Furthermore, to obtain a reliable 
data set this experiment would ideally be repeated at least once more.   
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With regards to dinB mutants only (Clone Spain9V-3 isolates and Greece6B-22 isolate 
PN94361:dinBΔ), PN94361:dinBΔ was more sensitive to killing by EMS and MMS 
than the natural dinB isolates of clone Spain9V-3.  It is plausible that this clone has 
adapted other mechanisms to repair severe DNA damage.  The worldwide success of 
Spain9V-3 would suggest that alternative mechanisms have been utilised.  Jean-Pierre 
Claverys has proposed that the induction of competence is a mechanism of response 
to damage in pneumococci, referred to as the X state (Claverys et al., 2006). 
Interestingly, competent pneumococci are capable of triggering lysis of cells that are 
not displaying competence, therefore releasing their genetic content to the 
extracellular environment, a mechanism referred to as fratricide (Guiral et al., 2005, 
Håvarstein et al., 2006, Steinmoen et al., 2003).   Claverys et al investigated the effect 
of mitomycin C on the com regulon (Claverys et al., 2006).  This antibiotic had 
previously been identified to induce the SOS response in E. coli (Kim and Oh, 2000).  
By fusing luciferase to competence genes, they were able to monitor activity during 
growth following exposure to various mitomycin C levels.  Certain levels of 
mitomycin C stimulated expression, demonstrating that competence is induced in 
pneumococcal cells following severe stress (Claverys et al., 2006).  It is not 
uncommon to find that bacterial species respond differently to damage. It is therefore 
plausible that S. pneumoniae are able to repair severe damage through competence 
induction in addition to inducing high levels of DNA repair associated polymerases.  
Differences have been observed in the response of E. coli and B. subtilis to severe 
damage as double stranded breaks were identified to initiate SOS induction in almost 
all E. coli, but only in a small proportion of B. subtilis (Simmons et al., 2009).  
Although B. subtilis is able to initiate the SOS response, only 8 SOS regulated genes 
are orthologous between the two species and only three of those eight genes are 
associated with the repair of double strand breaks (Au et al., 2005).  B. subtilis 
therefore illustrates the use of different mechanisms to repair severe DNA damage 
and represents an interesting intermediate between E. coli and S. pneumoniae.   
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Figure 4.10.2.2:    Comparison of Spain9V-3, England14-9, Taiwan19F-14 and Greece6B-22 EMS and MMS sensitivity results.  Squares – dinBΔ; 
circles – dinB; red – Spain9V-3; green – England14-9: purple –   Taiwan19F-14; blue – Greece6B-22 ; y axis – dilution 1st visibly effected by 
MMS; U – unaffected; N – no growth; x axis – different concentrations of MMS (%).   
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4.10.3 DNA damaging agents – hydrogen peroxide 
Hydrogen peroxide is produced in relatively high quantities by S. pneumoniae, yet 
there does not appear to be an obvious mechanism to protect itself from DNA damage 
caused by H202.  In E. coli , the effects of hydrogen peroxide have been known to 
initiate the SOS response (Goerlich et al., 1989).  This is also true of S. aureus (Selva 
et al., 2009).  It therefore seemed possible that the S. pneumoniae dinB gene may be 
important in dealing with the continual effect of this damaging agent.  This part of the 
project investigated the effect of H2O2 on dinB isogenic mutants.  The sensitivity of 
CP1015, PN94 361 and R6 dinB isogenic mutants to H2O2 was tested simultaneously, 
however due to time limitation, only two experiments were conducted.  To obtain a 
reliable dataset, this experiment would need to be repeated additional times.  It would 
also be interesting to test H2O2 sensitivity in clones Spain9V-3 England14-9 and 
Taiwan19F-14. 
 
4.10.3.1 The effect of dinBΔ 
Both experiments showed that dinBΔ isolates/strains were more sensitive to H2O2 
than dinB isolates/strains.  Unlike the DNA damaging agents previously described 
(EMS, MMS and NQO) which mainly cause lesions that stall replication, oxidative 
damage is known to create the most varied types of DNA damage (Farr and Kogoma, 
1991, Demple and Harrison, 1994) and thus requires the use of different DNA repair 
mechanisms (discussed in section 4.3.7.4.2).  However there is evidence that E. coli 
polIV bypasses lesions caused by reactive oxygen species (ROS) that block 
replication.  Incubation of E. coli polIV with oligonucleotides containing various 
changes showed that polIV bypassed certain lesions with high efficiency (Hori et al., 
2010).  Interestingly, it was most efficient at bypassing oxodA lesions, a lesion that is 
similar to N2-dG (that causes double strand breaks) (Hori et al., 2010).  Conversely, 
polIV bypassed 7,8-dihydro-8-oxoguanine (8-oxoG) with very low efficiency, a small 
non-bulky lesion that does not stall replication and is primarily repaired by BER 
(Shibutani et al., 1991).  Results from this study may reflect the ability of S. 
pneumoniae polIV to bypass H2O2 lesions that stall replication. 
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4.10.3.2 The effect of HexΔ 
In general, the Hex deficient strain CP1015 was more sensitive to H2O2 than PN94 
361 and R6. This would be expected as MMR is involved in the repair of some lesions 
caused by oxidative damage (Ni et al., 1999).  Interestingly, this was not observed  
when investigating the effects of chemical agents.  This may be due to diversity in the 
types of DNA damage caused by H2O2.  Chemical agents used in this research mainly 
produce lesions that stall replication.  However, as already mentioned, oxidative 
damage creates the most varied types of DNA damage (Farr and Kogoma, 1991, 
Demple and Harrison, 1994).  Evidence suggests that hydrogen peroxide does not 
directly damage DNA.  Rather, it is thought to damage DNA by the formation of ·OH 
radicals through the fenton reaction (Imlay et al., 1988) producing a vast array of 
oxidative base lesions (Bjelland and Seeberg, 2003, Demple and Harrison, 1994).  
Different types of DNA damage lead to initiation of various repair mechanisms.  Most 
oxidative damage is in fact repaired by base-excision repair (BER), a mechanism that 
tends to repair modified bases (Dizdaroglu, 2005).  Nucleotide excision repair 
however is likely to repair tandem lesions created by H2O2 (Kuraoka et al., 2000, 
Brooks et al., 2000).  In S. cerevisiae,  E. coli mismatch repair homologues MSH2 and 
MSH6 have been identified to repair certain base modifications (Ni et al., 1999).  
MMR has also been demonstrated as a repair mechanism of oxidative damage in E. 
coli (Wyrzykowski and Volkert, 2003).  This is likely to account for the marked H2O2 
sensitivity observed in CP1015 strains.  Further evidence comes from the observation 
that oxidative damage mainly creates 7,8-dihydro-8-oxoguanine (8-oxoG) (Opresko et 
al., 2005, Hah et al., 2007), a small non-bulky lesion that does not stall replication and 
is primarily repaired by BER (Shibutani et al., 1991).  In E. coli, the MMR system has 
been shown to remove this commonly found lesion (Wyrzykowski and Volkert, 
2003).  
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5.0 Summary discussion  
 
Investigation of the three clones revealed new findings in genomic diversity and 
differences in mechanisms of evolution.  New ST’s and MLST allele sequences were 
identified in some isolates and these sequences have been submitted to the MLST 
database.  A number of genomic rearrangements were observed, the most interesting 
of which was a large inversion that correlated with the location of inversions 
identified in other studies.  Intriguingly, these inversions were found to lie across the 
replication axis and have been suggested to occur following acquisition of a large 
mobile element in an attempt to balance the genome (Ding et al., 2009). A number of 
known RDs were found to correlate with the location of polymorphisms identified in 
all three clones by SmaI probe hybridisation.  A number of these regions are expected 
to account for the observed polymorphisms and some, such as RD 27, have been 
confirmed to account for identified differences between the three clones.  
 
The extent to which these clones diverge by recombination compared to mutation 
showed that pneumococcal clones generally differentiate through recombination. The 
most interesting aspect of this part of the project however was the finding that MLST 
alleles of clone England14-9 evolve significantly less through recombination 
compared to clones Spain9V-3 and Taiwan19F-14.  Interestingly, this clone was 
observed to have similar R/M ratios to clonal bacteria that are not naturally 
transformable.   To the best of our knowledge there has been no prior publication on 
the rate of recombination and mutation in these clones, however, they are known not 
to be part of the hyper recombinant group of strains identified by Hanage et al. 
(Hanage et al., 2009)  (personal communication). Recombination and mutation were 
investigated as independent variables to determine if it was a reduced recombination 
or increased mutation rate that caused a significantly different R/M ratio in this clone. 
Analysis of entries to the MLST database suggested that although mutation rate was 
somewhat elevated, a significantly reduced recombination rate was the major factor.  
Conversely, analysis of these variables in large scale epidemiological studies 
suggested that mutation was more significant in differences observed for clone 
England14-9, but the number of isolates included in this analysis was much smaller.    
Laboratory experiments further demonstrated that England14-9 isolates were 
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transformation deficient (this thesis), while there was not evidence of elevated 
mutation rates measured in vitro (Henderson-Begg and Hall personal 
communication). Taken together with the rare incidence of penicillin resistance in 
England14-9, it can be concluded that this clone has a significantly reduced rate of 
recombination compared to the other clones investigated, and the species as a whole.  
 
Since the start of this project an extraordinary number of sequenced genomes have 
become available for analysis on NCBI. The existence of a draft genome sequence of 
a transformation deficient isolate (PN93 872) of England14-9, in addition to the fully 
sequenced INV200 (also presumed to be transformation deficient) allowed 
investigation of possible competence/recombination gene defects.   The most 
potentially exciting finding was a four amino acid deletion in CelA, involved in the 
binding and transport of DNA.  This deletion was not present in other transformable 
genomes, nor in CGSP14, a rare penicillin resistant isolate of clone England14-9 that 
is postulated to be transformable.  
 
Recombination is known to be involved in the generation of genomic variation and 
repair of severe DNA damage.  Intriguingly, bacterial species that evolve largely 
through recombination appear to lack a typical SOS response as seen in E. coli. S. 
pneumoniae reside in the nasopharynx and are therefore under the constant threat of 
oxidative damage.  Moreover, S. pneumoniae themselves produce a large amount of 
hydrogen peroxide.  The lack of recombination in England14-9 in addition to the 
global success of this clone indicates that another mechanism is adopted to respond to 
severe DNA damage.   
 
Although S. pneumoniae lack a typical SOS response (Gasc et al., 1980), they do 
however possess DNA polymerase IV (encoded by dinB) which is an error-prone 
polymerase and part of the SOS response in E. coli.  This polymerase is highly 
important for the repair of double strand breaks in E. coli but has not previously been 
investigated in S. pneumoniae.  Isogenic dinB mutants were therefore created to 
investigate the role of polIV in S. pneumoniae. Mutation frequency experiments 
demonstrated a reduced mutation frequency for dinB mutants, suggesting that polIV 
appears to be active under normal growth and not just under conditions of exposure to 
a DNA damaging agent.  This has been supported by other evidence of a reduced 
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mutation frequency in E. coli dinB mutants (Strauss et al., 2000, Jacob and Eckert, 
2007, Moyano et al., 2007b) although conflicting evidence has also been reported 
(Kana et al., 2010, Kuban et al., 2004).  This project was the first to demonstrate that 
S. pneumoniae dinB mutants are more sensitive to DNA damaging agents compared 
to wild type isolates.  In E. coli, polIV attempts to rescue the cell and repair adducts 
that stall the replication machinery.   Much of the literature on the function of polIV 
in E. coli, which provides evidence for a role in TLS is recent and was published after 
the data was obtained for this project (Benson et al., 2011, Jarosz et al., 2009, Jarosz 
et al., 2006b, Gutierrez et al., 2011, Williams et al., 2010).  The recent work on dinB 
thus help to interpret results from this study.  The DNA damaging agents used here, 
which have also been used in other studies, create breaks that can stall replication.   
The observed increased sensitivity of dinB knockout mutants to these agents indicate 
that pneumococcal PolIV is involved in a TLS repair mechanism similar to that of E. 
coli.  Further evidence to support a function in TLS was obtained by the finding that 
isolates of clone Spain9V-3, a natural dinB mutant, were also more sensitive to DNA 
damaging agents than isolates of dinB wild type clones England14-9 and Taiwan19F-
14.  The global success of clone Spain9V-3 however does suggest the induction of 
competence can substitute as a repair mechanism in this clone, identified previously 
as a pneumococcal repair device by Claverys (Claverys et al., 2006).  
 
S. pneumoniae is able to withstand high levels of H202 despite not producing proteins 
that are known to withstand and combat oxidative stress (Hoskins et al., 2001, Tettelin 
et al., 2001).  In E. coli the effects of H202 have been shown to initiate the SOS 
response (Goerlich et al., 1989).  This is also the case for S. aureus (Selva et al., 
2009).  DinB isogenic mutants in this research were exposed to various levels of H202 
to determine if PolIV is involved in the repair of oxidative damage.  Overall, results 
illustrated that dinB mutants were more sensitive to H2O2 than wild type 
isolates/strains. This suggests that there may be a role for S. pneumoniae PolIV in the 
repair of oxidative damage.  In addition CP1015 (hex-) isolates were more sensitive to 
H2O2 compared to PN94 361 and R6.  This is supported by the finding in other 
organisms that MMR is involved in the repair of certain oxidative lesions (Ni et al., 
1999).   
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The pneumococcal supragenome provides an extensive gene pool for pneumococci to 
experiment with different combinations of gene sequences.  Recombination within 
and between species has certainly created variation of selective advantage, from 
antibiotic resistance and virulence factors to capsule switch variants which allow 
isolates to evade the pressure of the conjugate vaccine.  Although most England14-9 
isolates lack the ability to recombine, dinB results from this study suggest that this 
clone has been able to withstand severe DNA damage through the function of PolIV, 
where as Spain9V-3 is more likely to respond to severe damage through 
recombination.  This highlights the plasticity of the pneumococcal genome and the 
remarkable ability of this organism to evolve through constant selective pressures.  
Organisms which utilise more than one repair mechanism have been observed 
elsewhere. Bacillus subtilis for example is able to initiate an SOS response but can 
also become competent (Simmons et al., 2009, Grossman, 1995).  Competence 
however is only initiated in around 10% of B. subtilis isolates in culture (Smits et al., 
2005) which may be to preserve the SOS mechanism as a response to severe DNA 
damage in the remaining B. subtilis population (Claverys et al., 2006).  
 
Future work on the investigation of dinB could aim to identify the exact nature and 
role of PolIV in S. pneumoniae.  It seems likely from comparison of results in this 
study with studies in E. coli and other organisms that S. pneumoniae PolIV is 
involved in TLS of adducts that stall replication, however, this is yet to be confirmed.  
Although dinB mutants display increased sensitivity to DNA damaging agents, the 
exact mechanism of DNA repair by PolIV in pneumococci is yet to be elucidated.  
The relative contributions of PolIV in the repair of severely damaged DNA compared 
to mechanisms such as competence induction is unknown. 
 
The pneumococcal genome is highly adaptable and differences in the rate and 
mechanisms of evolution are apparent in different lineages.  The ability of this 
organism to transfer genetic material to other pneumococci in addition to other related 
species has lead to a number of pneumococcal clones expanding with worldwide 
success.  Many pneumococcal lineages have acquired drug resistance, some of which 
are resistant to multiple antimicrobial agents. Even the appearance of multiple 
resistant isolates of clone England14-9 is becoming more common and reports of 
capsule switching variants are on the rise.  The sequencing technology available today 
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allows a large number of genomes to be sequenced in a relatively short period of time.  
A study by Croucher et al that involved sequencing of 240 Spain23F-1 ST81 isolates 
revealed the ability of pneumococci to rapidly evolve in response to clinical 
intervention (Croucher et al., 2011).   Astonishingly, 700 recombination events, the 
evolution of resistance to a number of different antimicrobial agents and ten capsule 
switch events in the ST81 lineage were identified (Croucher et al., 2011).  It would be 
extremely useful to sequence isolates of clone Spain9V-3, England14-9 and Taiwan19F-
14 to investigate the evolution of each lineage as it has spread.  The total number of 
polymorphisms could be identified and those introduced by recombination could be 
determined as opposed to investigating the relative contribution of 
recombination/mutation in MLST alleles or restriction sites.  The genomic 
rearrangements identified in this study in addition to any other rearrangements that 
were not detected by PFGE of SmaI digested fragments could be located and defined. 
This would also present the ability to distinguish horizontally acquired sequences with 
those that were acquired vertically.  Regions of diversity common or specific to each 
clone could also be determined and the exact nature of those regions could be defined.  
In summary, the sequencing technology available today will greatly increase 
understanding of the way pneumococci and different lineages within this organism 
evolve.  This information will be vital in the future control of S. pneumoniae.   
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Appendix I – Buffers and Solutions 
I.1 General buffers  
1 TE Buffer 
10 mM Tris-HCl 
1 mM EDTA 
 
10x TBE 
1 M Tris-HCl 
1 M Boric acid 
2 mM EDTA 
10% Sodium Dodecyl Sulphate (SDS) 
SDS  
Dissolved in dH2O at 68ºC  
pH 7.2  
6 DNA Loading Dye for Agarose Gel Electrophoresis 
50% (v/v) Glycerol 
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene cyanol 
 
 
I.2 PFGE buffers and solutions 
PETT IV Buffer 
10 mM Tris-HCl (pH 7.6)  
1 M NaCl  
EC Lysis Buffer 
6 mM Tris-HCl  
1 M NaCl  
100 mM EDTA  
0.5% Brij-58  
0.2% Sodium deoxycholate  
0.5% N-Lauroyl sarcosine  
Dissolved in 100 ml dH2O with gentle heat 
Made up to 400 ml and filter sterilised in 20 ml aliquots.  
Stored at -20C.   
Before use, 1 mg/ml (final conc.) lysozyme and 20 g/ml (final conc.) of heat-treated 
RNase was added. 
ESP Buffer 
0.5 M EDTA   
1% N-Lauroyl sarcosine  
0.5 mg/ml (final conc.) Proteinase K was added prior to use. 
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I.3 Southern hybridisation buffers and solutions 
Denaturation Solution 
0.5 M NaOH  
1.5 M NaCl  
Dissolved in dH2O. 
 
Neutralisation Solution  
0.5 M Tris-HCl (pH 7.0)  
3 M NaCl  
Dissolved in dH2O 
pH 7.0. 
 
20 SSC (Standard Saline Citrate)  
3 M NaCl  
0.3 M Trisodium citrate  
Dissolved in dH2O 
pH 7.0  
Transfer Solution 
20 SSC 
pH 7.0 
 
 
I.4 DIG buffers and solutions 
Washing Buffer 
Maleic Acid buffer 
0.3% v/v Tween 20 
Blocking Solution 
10% v/v blocking reagent (kit-stored in freezer) 
90% v/v maleic acid buffer. 
Prepared freshly for each hybridisation 
heated to 37oC to dissolve 
 
Stringency Wash  
2 SSC  
0.1% SDS  
 
Detection Buffer 
0.1 M NaCl  
pH 9.5  
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I.5 Transformation buffers and solutions 
Supplements 
 0.1M CaCl2  
 0.5M K2HPO4   
 20% glucose  
 8% Bovine Serum Albumin (BSA)  
 
CAT Medium 
10 g Casitone (pancreatic digest of caneium)  
5 g Tryptone 
4 g Yeast extract 
5 g NaCl (sodium chloride) 
1 L ultra pure water 
Autoclave at 121C (15 pounds per square inch) for 20 minutes. 
 
TM medium 
300ml CAT medium 
10 mL K2HPO4 
3 mL glucose 
1.5 mL 0.1 M calcium chloride 
7 mL bovine serum albumin (8% solution) 
pH 7 
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Appendix II 
Appendix II.1 Mutation frequency data 
PN94361:dinB mutation frequency results  
 
No. 
 
Viable count 
 
 
Mutation frequency 
 
Mutants/ml 
 
1 
 
1.57 x 1008 0 0 
2 
 
1.20 x 1008 5.56 x 10-08 6.66 
3 
 
8.33 x 1007 4.00 x 10-08 3.33 
4 
 
1.23 x 1008 4.05 x 10-08 5 
5 
 
1.13 x 1008 2.65 x 10-07 30 
6 
 
1.03 x 1008 3.23 x 10-08 3.33 
7 
 
8.00 x 1007 2.08 x 10-08 1.66 
8 
 
7.67 x 1007 4.35 x 10-08 3.33 
9 
 
1.28 x 1008 0 0 
10 
 
1.77 x 1008 5.66 x 10-08 10 
11 
 
1.43 x 1008 4.65 x 10-08 6.66 
12 
 
1.13 x 1008 0 0 
13 
 
5.67 x 1007 2.94 x 10-08 1.66 
14 
 
1.13 x 1008 4.41 x 10-08 5 
15 
 
7.00 x 1007 7.14 x 10-08 5 
16 
 
1.20 x 1008 2.78 x 10-08 3.33 
17 
 
1.30 x 1008 2.56 x 10-08 3.33 
18 
 
7.67 x 1007 1.09 x 10-07 8.33 
19 
 
1.10 x 1008 0 0 
20 
 
8.00 x 1007 6.25 x 10-08 5 
Table II.1A: Results for 20 independent PN94361:dinB mutation frequencies.
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PN94361:dinBΔ mutation frequency results 
 
No. 
 
Viable count 
 
 
Mutation frequency 
 
Mutants/ml 
 
1 
 
1.07 x 1008 4.69 x 10-08 5 
2 
 
1.07 x 1008 1.56 x 10-08 1.66 
3 
 
1.07 x 1008 6.25 x 10-08 6.66 
4 
 
1.00 x 1008 1.67 x 10-08 1.66 
5 
 
1.30 x 1008 2.56 x 10-08 3.33 
6 
 
1.40 x 1008 0 0 
7 
 
7.67 x 1007 2.17 x 10-08 1.66 
8 
 
8.67 x 1007 1.92 x 10-08 1.66 
9 
 
8.00x 1007 4.17 x 10-08 3.33 
10 
 
7.67 x 1007 2.17 x 10-08 1.66 
11 
 
1.17 x 1008 5.71 x 10-08 6.66 
12 
 
1.33 x 1008 0 0 
13 
 
1.37 x 1008 1.22 x 10-08 1.66 
14 
 
1.23 x 1008 1.35 x 10-08 1.66 
15 
 
1.23 x 1008 0 0 
16 
 
1.27 x 1008 0 0 
17 
 
1.20 x 1008 0 0 
18 
 
1.60 x 1008 1.04 x 10-08 1.66 
19 
 
2.27 x 1008 0 0 
20 
 
2.77 x 1008 0 0 
Table II.1B: Results for 20 independent PN94361:dinBΔ mutation frequencies.
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CP1015:dinB mutation frequency results 
 
 
No. 
 
Viable count 
 
 
Mutation frequency 
 
Mutants/ml 
 
1 
 
3.63 x 1008 7.20 x 10-07 261.6 
2 
 
6.77 x 1008 6.03 x 10-07 408.3 
3 
 
4.63 x 1008 9.57 x 10-07 443.3 
4 
 
3.87 x 1008 4.48 x 10-07 173.3 
5 
 
5.87 x 1008 6.19 x 10-07 363.3 
6 
 
7.60 x 1008 7.46 x 10-07 566.6 
7 
 
6.03 x 1008 7.07 x 10-07 426.6 
8 
 
5.20 x 1008 7.18 x 10-07 373.3 
9 
 
7.50x 1008 5.36 x 10-07 401.6 
10 
 
5.20 x 1008 6.83 x 10-07 355 
11 
 
6.20 x 1008 8.33 x 10-08 26.6 
12 
 
5.47 x 1008 1.74 x 10-07 95 
13 
 
6.10 x 1008 1.67 x 10-07 101.6 
14 
 
7.00 x 1008 1.27 x 10-07 78.3 
15 
 
6.10 x 1008 1.09 x 10-07 66.6 
16 
 
5.93 x 1008 2.84 x 10-07 168.3 
17 
 
9.50 x 1008 1.96 x 10-07 186.6 
18 
 
5.83 x 1008 3.7.29 x 10-07 226.6 
19 
 
7.77 x 1008 1.44 x 10-07 111.6 
20 
 
8.70 x 1008 1.48 x 10-07 128.6 
Table II.1C: Results for 20 independent CP1015:dinB mutation frequencies 
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CP1015:dinBΔ mutation frequency results 
 
 
No. 
 
Viable count 
 
 
Mutation frequency 
 
Mutants/ml 
 
1 
 
6.70 x 1008 3.01 x 10-07 201.6 
2 
 
8.27 x 1008 2.26 x 10-07 186.6 
3 
 
2.50 x 1008 4.00 x 10-07 100 
4 
 
5.33 x 1008 2.75 x x10-07 146.6 
5 
 
7.50 x 1008 3.24 x 10-07 243.3 
6 
 
4.20 x 1008 6.79 x 10-07 285 
7 
 
3.20 x 1008 2.97 x 10-07 95 
8 
 
7.77 x 1008 2.00 x 10-07 155 
9 
 
5.30 x 1008 3.71 x 10-07 196.6 
10 
 
3.23 x 1008 2.89 x 10-07 93.3 
11 
 
6.10 x 1008 1.04 x 10-07 63.3 
12 
 
9.30 x 1008 9.32 x 10-08 86.6 
13 
 
9.63 x 1008 7.09 x 10-08 68.3 
14 
 
9.43 x 1008 9.01 x 10-08 85 
15 
 
8.13 x 1008 6.97 x 10-08 56.6 
16 
 
4.90 x 1008 1.16 x 10-07 56.6 
17 
 
7.07 x 1008 1.49 x 10-07 105 
18 
 
7.00 x 1008 5.00 x 10-08 35 
19 
 
7.53 x 1008 8.63 x 10-08 65 
20 
 
7.87 x 1008 1.23 x 10-07 96.6 
Table II.1D: Results for 20 independent CP1015:dinBΔ mutation frequencies 
. 
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Appendix II.2 DNA damaging agents: PN94 361, CP1015 and R6 
 
No agent control 
 
Isolate/ 
Strain 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 
1 +++ +++ +++ ++ 7 1 
2 +++ +++ +++ ++ 5 1 
3 +++ +++ +++ ++ 6 2 
4 +++ +++ +++ ++ 10 1 
PN94361 
:dinB 
 
5 +++ +++ +++ ++ 9 1 
1 +++ +++ +++ ++ 14 3 
2 +++ +++ +++ ++ 11 1 
3 +++ +++ +++ ++ 10 2 
4 +++ +++ +++ ++ 9 1 
PN94361 
:dinBΔ 
 
5 +++ +++ +++ ++ 8 1 
1 +++ +++ +++ ++ 16 1 
2 +++ +++ +++ ++ + 2 
3 +++ +++ +++ ++ + 5 
4 +++ +++ +++ ++ + 3 
CP1015 
:dinB 
 
5 +++ +++ +++ ++ + 1 
1 +++ +++ +++ ++ + 4 
2 +++ +++ +++ ++ + 3 
3 +++ +++ +++ ++ + 4 
4 +++ +++ +++ ++ + 2 
CP1015 
:dinBΔ 
 
5 +++ +++ +++ ++ + 2 
1 +++ +++ +++ ++ + 3 
2 +++ +++ +++ ++ + 2 
3 +++ +++ +++ ++ + 2 
4 +++ +++ +++ ++ + 1 
R6 
:dinB 
 
5 +++ +++ +++ ++ + 3 
1 +++ +++ +++ ++ + 3 
2 +++ +++ +++ ++ + 2 
3 +++ +++ +++ ++ + 1 
4 +++ +++ +++ ++ + 1 
R6 
:dinBΔ 
 
5 +++ +++ +++ ++ + 1 
Table II.2A: No agent control counts. +++ confluent growth; ++ >100 colonies; + 20 
– 100 colonies. 
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EMS 
 
Isolate/ 
Strain 
EMS  
conc. 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ 12 1 U 
2 +++ +++ +++ ++ 11 3 U 
PN94361 
:dinB 
3 +++ +++ +++ ++ 8 1 U 
1 +++ +++ +++ ++* - - 10-4 
2 +++ +++ +++ ++ 17 1 U 
PN94361 
:dinBΔ 
 
 
0.15% 
3 +++ +++ +++ ++ 8 3 U 
1 +++ +++ +++ ++ 8 1 U 
2 +++ +++ +++ ++ 5 - 10-6 
PN94361 
:dinB 
3 +++ +++ +++ ++ 4 - 10-6 
1 +++ +++ +++ ++  +* - 10-5 
2 +++ +++ +++ ++* - - 10-4 
PN94361 
:dinBΔ 
 
0.3% 
3 +++ +++ +++ ++ - - 10-5 
1 +++ +++ +++ ++* 2* 1* 10-4 PN94361 
:dinB 2 +++ +++ +++ ++* 1* - 10-4 
1 +++ +++* ++* - - - 10-2 PN94361 
:dinBΔ 
 
0.35% 
2 +++ +++* ++* - - - 10-2 
1 +++ +++ ++*  - - - 10-3 PN94361 
:dinB 2 +++ +++ ++* - - - 10-3 
1 - - - - - - N PN94361 
:dinBΔ 
 
0.4% 
2 - - - - - - N 
1 - - - - - - N PN94361 
:dinB 2 - - - - - - N 
1 - - - - - - N PN94361 
:dinBΔ 
 
0.6% 
2 - - - - - - N 
Table II.2B: PN94 361 sensitivity results to different concentrations of EMS.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by EMS; N – no growth; * 
- colony size/colony growth severely affected and very faint but still present. 
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Table II.2C: CP1015 sensitivity results to different concentrations of EMS.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by EMS; N – no growth; * 
- colony size/colony growth severely and very faint affected but still present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolate/ 
Strain 
EMS  
Conc. 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 3 U 
2 +++ +++ +++ ++ + 5 U 
CP1015 
:dinB 
 3 +++ +++ +++ ++ + 3 U 
1 +++ +++ +++ ++ + 9 U 
2 +++ +++ +++ ++ + 1 U 
CP1015: 
dinBΔ 
 
 
 
0.15% 
3 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 1 U 
2 +++ +++ +++ ++ + - 10-6 
CP1015 
:dinB 
 3 +++ +++ +++ ++ + 4 U 
1 +++ +++ +++* ++* - - 10-3 
2 +++ +++ +++* ++* - - 10-3 
CP1015: 
dinBΔ 
 
 
0.3% 
3 +++ +++ +++ ++* - - 10-4 
1 +++ +++ ++ + - - 10-3 CP1015 
:dinB 2 +++ +++ ++ + - - 10-3 
1 +++* +++* - - - - 10-1 CP1015: 
dinBΔ 
 
0.35% 
2 +++* +++* - - - - 10-1 
1 +++ +++* - - - - 10-2 CP1015 
:dinB 2 +++ +++* - - - - 10-2 
1 - - - - - - N CP1015: 
dinBΔ 
 
0.4% 
2 - - - - - - N 
1 - - - - - - N CP1015 
:dinB 2 - - - - - - N 
1 - - - - - - N CP1015: 
dinBΔ 
 
0.6% 
2 - - - - - - N 
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Table II.2D: R6 sensitivity results to different concentrations of EMS.  +++ confluent 
growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st effected 
refers to the 1st dilution at which colony growth is visibly effected in size/number 
compared to untreated control; U – unaffected by EMS; N – no growth; * - colony 
size/colony growth severely affected and very faint but still present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolate/ 
Strain 
EMS  
conc. 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + 3 U 
R6:dinB 
 
3 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 2 U 
2 +++ +++ +++ ++ + 2 U 
R6:dinBΔ 
 
0.15% 
3 +++ +++ +++ ++ + 3 U 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + - 10-6 
R6:dinB 
 
3 +++ +++ +++ ++ + 1 U 
1 +++ +++ +++ ++* - - 10-4 
2 +++ +++ ++* - - - 10-3 
R6:dinBΔ 
 
 
0.3% 
3 +++ +++ ++* - - - 10-3 
1 +++ +++ +++ ++* +* - 10-4 R6:dinB 
 2 +++ +++ +++ ++* +* - 10-4 
1 +++ ++ +* - - - 10-2 R6:dinBΔ 
 
0.35% 
2 +++ ++ +* - - - 10-2 
1 +++ +++* +++* - - - 10-2 R6:dinB 
 2 +++ +++* ++* - - - 10-2 
1 - - - - - - N R6:dinBΔ 
 
0.4% 
2 - - - - - - N 
1 - - - - - - N R6:dinB 
 2 - - - - - - N 
1 - - - - - - N R6:dinBΔ 
 
0.6% 
2 - - - - - - N 
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MMS 
 
Isolate/ 
Strain 
MMS 
Conc. 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 1 U 
2 +++ +++ +++ ++ 7 1 U 
PN94361 
:dinB 
 3 +++ +++ +++ ++ 4 1 U 
1 +++ +++ +++ ++ 7 2 U 
2 +++ +++ +++ ++ + 1 U 
PN94361 
:dinBΔ 
 
 
0.005% 
3 +++ +++ +++ ++ 5 1 U 
1 +++ +++ +++ ++ 9 1 U 
2 +++ +++ +++ ++ 10 2 U 
3 +++ +++ +++ ++ 7 - 10-6 
PN94361 
:dinB 
 
4 +++ +++ +++ ++ 7 1 U 
1 +++ +++ +++ ++ 2 - 10-6 
2 +++ +++ +++ ++ - - 10-5 
3 +++ +++ ++ ++ - - 10-5 
PN94361 
:dinBΔ 
 
 
 
 
0.01% 
4 +++ +++ ++ ++ - - 10-5 
1 +++ +++ ++ ++ - - 10-3 
2 +++ +++ +++ ++* - - 10-4 
3 +++ +++ ++ 7 1 - 10-3 
4 +++ +++ ++ ++ - - 10-3 
5 +++ +++ +++* 12 - - 10-3 
PN94361 
:dinB 
 
6 +++ +++ ++ 17 - - 10-3 
1 ++ + - - - - 10-1 
2 ++ + - - - - 10-1 
3 - - - - - - N 
4 - - - - - - N 
5 - - - - - - N 
PN94361 
:dinBΔ 
 
 
 
 
 
 
0.02% 
6 - - - - - - N 
1 ++* - - - - - 10-1 PN94361 
:dinB 1 ++* 5* 1* - - - 10-1 
2 - - - - - - N PN94361 
:dinBΔ 
 
0.03% 
2 - - - - - - N 
 
Table II.2E: PN94 361 sensitivity results to different concentrations of MMS.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the 1st dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by MMS; N – no growth; 
* - colony size/colony growth severely affected and very faint but still present. 
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Isolate/ 
Strain 
MMS 
Conc. 
Exp 
No. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 2 U 
2 +++ +++ +++ ++ + 5 U 
CP1015 
:dinB 
 3 +++ +++ +++ ++ + 9 U 
1 +++ +++ +++ ++ + 3 U 
2 +++ +++ +++ ++ + 2 U 
CP1015: 
dinBΔ 
 
 
0.005% 
3 +++ +++ +++ ++ + 7 U 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + 2 U 
3 +++ +++ +++ ++ + 5 U 
CP1015 
:dinB 
 
4 +++ +++ +++ ++ + 6 U 
1 +++ +++ +++ ++* - - 10-4 
2 +++ +++ +++ ++ +* 3* 10-5 
3 +++ +++ +++ ++ +* - 10-5 
CP1015: 
dinBΔ 
 
 
 
 
0.01% 
4 +++ +++ +++ ++ +* - 10-5 
1 +++ +++ +++ ++* +* - 10-4 
2 +++ +++ +++ ++ +* 5* 10-5 
3 +++ +++ +++ ++ +* 4* 10-5 
4 +++ +++ +++ ++* + - 10-4 
5 +++ +++ ++ + +* 5* 10-3 
CP1015 
:dinB 
 
6 +++ +++ ++ + +* 2* 10-3 
1 +++* ++* - - - - 10-1 
2 - - - - - - N 
3 +++* +++* ++* - - - 10-1 
4 - - - - - - N 
5 ++ - - - -  10-1 
CP1015: 
dinBΔ 
 
 
 
 
 
 
0.02% 
6 ++ ++* - - - - 10-1 
1 +++* - - - - - 10-1 CP1015 
:dinB 2 ++ - - - - - 10-1 
1 - - - - - - N CP1015: 
dinBΔ 
0.03% 
2 - - - - - - N 
 
Table II.2F: CP1015 sensitivity results to different concentrations of MMS.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the 1st dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by MMS; N – no growth; 
* - colony size/colony growth severely affected and very faint but still present. 
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Isolate/ 
Strain 
MMS 
Conc. 
Exp 
no. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 1 U 
2 +++ +++ +++ ++ + 6 U 
R6:dinB 
 
3 +++ +++ +++ ++ + 5 U 
1 +++ +++ +++ ++ + 2 U 
2 +++ +++ +++ ++ + 6 U 
R6:dinBΔ 
 
 
0.005% 
3 +++ +++ +++ ++ + 4 U 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + 2 U 
3 +++ +++ +++ ++ + 1 U 
R6:dinB 
 
4 +++ +++ +++ ++ + 3 U 
1 +++ +++ +++ ++ + 2 U 
2 +++ +++ +++ ++ + 2 U 
3 +++ +++ +++ ++ +* - 10-5 
R6:dinBΔ 
 
 
 
 
0.01% 
4 +++ +++ +++ ++ +* - 10-5 
1 +++ +++ +++ ++ 5 1 10-5 
2 +++ +++ +++ ++ + 2* 10-6 
3 +++ +++ +++ ++ + - 10-6 
4 +++ +++ +++ ++ +* 4* 10-5 
5 +++ +++ ++ + 3 - 10-3 
R6:dinB 
 
6 +++ +++ +++ ++ +* 5 10-5 
1 +++* - - - - - 10-1 
2 +++* - - - - - 10-1 
3 +++ ++* - - - - 10-2 
4 + - - - - - 10-1 
5 - - - - - - N 
R6:dinBΔ 
 
 
 
 
 
 
0.02% 
6 +++ ++* - - - - 10-2 
1 +++* ++* - - - - 10-1 R6:dinB 
 2 - - - - - - N 
1 - - - - - - N R6:dinBΔ 
0.03% 
2 - - - - - - N 
Table II.G: R6 sensitivity results to different concentrations of MMS.  +++ confluent 
growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st effected 
refers to the 1st dilution at which colony growth is visibly effected in size/number 
compared to untreated control; U – unaffected by MMS; N – no growth; * - colony 
size/colony growth severely affected and very faint but still present. 
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NQO 
 
Isolate/ 
Strain 
NQO 
conc. 
Exp 
no. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ 10 1 U PN94361 
:dinB 2 +++ +++ +++ ++ 8 1 U 
1 +++ +++ +++ ++ 10 - 10-6 PN94361 
:dinBΔ 
0.3% 
2 +++ +++ +++ ++ 9 - 10-6 
1 +++ +++ +++ ++ + 1 U 
2 +++ +++ +++ ++ 7 - 10-6 
PN94361 
:dinB 
3 +++ +++ +++ ++ 12 1 U 
1 +++ +++ +++ ++ 4* - 10-5 
2 +++ +++ +++ ++ - - 10-4 
PN94361 
:dinBΔ 
0.4% 
3 +++ +++ +++ ++ - - 10-4 
1 +++ +++ +++ ++* +* - 10-4 PN94361 
:dinB 2 +++ +++ +++ ++* - - 10-4 
1 - - - - - - N PN94361 
:dinBΔ 
0.5% 
2 - - - - - - N 
1 ++ - - - - - 10-1 PN94361 
:dinB 2 - - - - - - N 
1 - - - - - - N PN94361 
:dinBΔ 
0.6% 
2 - - - - - - N 
 
Table II.2H: PN94 361 sensitivity results to different concentrations of NQO.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the 1st dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by NQO; N – no growth; 
* - colony size/colony growth severely affected and very faint but still present. 
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Isolate/ 
Strain 
NQO  
Conc. 
Exp 
no. 
10-1 10-2 10-3 10-4 10-5 10-6 1st 
dilution 
effected 
1 +++ +++ +++ ++ + 2 U CP1015 
:dinB 2 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 7 U CP1015: 
dinBΔ 
 
0.3% 
2 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + 3 U 
CP1015 
:dinB 
3 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 4 U 
2 +++ +++ +++ ++ + - 10-6 
CP1015: 
dinBΔ 
 
 
 
0.4% 
3 +++ +++ +++ ++ + 2 U 
1 +++ +++ +++ ++ + 1 U CP1015 
:dinB 2 +++ +++ +++ ++ + 2 U 
1 ++ + - - - - 10-1 CP1015: 
dinBΔ 
 
0.5% 
2 +++* - - - - - 10-1 
1 +++* - - - - - 10-1 CP1015 
:dinB 2 ++ + - - - - 10-1 
1 - - - - - - N CP1015: 
dinBΔ 
0.6% 
2 - - - - - - N 
 
Table II.2I: CP1015 sensitivity results to different concentrations of NQO.  +++ 
confluent growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st 
effected refers to the 1st dilution at which colony growth is visibly effected in 
size/number compared to untreated control; U – unaffected by NQO; N – no growth; 
* - colony size/colony growth severely affected and very faint but still present. 
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Isolate/ 
Strain 
NQO  
Conc. 
Exp.  
no 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution 
1st 
effected 
1 +++ +++ +++ ++ + 2 U R6:dinB 
2 +++ +++ +++ ++ + 3 U 
1 +++ +++ +++ ++ + 5 U R6:dinBΔ 
 
0.3% 
2 +++ +++ +++ ++ + 1 U 
1 +++ +++ +++ ++ + 2 U 
2 +++ +++ +++ ++ + 1 U 
R6:dinB 
3 +++ +++ +++ ++ + 1 U 
1 +++ +++ +++ ++ + - 10-6 
2 +++ +++ +++ ++ + 2 U 
R6:dinBΔ 
 
 
 
0.4% 
3 +++ +++ +++ ++ + - 10-6 
1 +++ +++ +++ ++ + - 10-6 R6:dinB 
2 +++ +++ +++ ++ + - 10-6 
1 +++*  - - - - 10-1 R6:dinBΔ 
 
0.5% 
2 +++*  - - - - 10-1 
1 +++* - - - - - 10-1 R6:dinB 
2 +++* - - - - - 10-1 
1 - - - - - - N R6:dinBΔ 
 
0.6% 
2 - - - - - - N 
 
Table II.2J: R6 sensitivity results to different concentrations of NQO.  +++ confluent 
growth; ++ >100 colonies; + 20 – 100 colonies; - no growth; dilution 1st effected 
refers to the 1st dilution at which colony growth is visibly effected in size/number 
compared to untreated control; U – unaffected by NQO; N – no growth; * - colony 
size/colony growth severely affected and very faint but still present. 
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Appendix II.3 DNA damaging agents: Spain9V-3, England14-9 and 
Taiwan19F-14 
  
Isolate/ 
Strain 
Clone 10-1 10-2 10-3 10-4 10-5 10-6 
PN94 661 +++ +++ +++ ++ 15 2 
PN93 1029 
Spain9V-3 
+++ +++ +++ ++ 14 3 
PN94 336 +++ +++ +++ ++ 12 2 
PN94 653 
England14-9 
+++ +++ +++ ++ 12 1 
STP110 +++ +++ +++ ++ 15 5 
STP133 
Taiwan19F-14 
+++ +++ +++ ++ 13 3 
 
Table II.3A: Isolates from clones Spain9V-3, England14-9 and Taiwan19F-14. No agent 
control counts. 
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EMS 
 
Isolate Clone EMS 
conc. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution  
1st 
effected 
PN94 661 +++ +++ +++ ++ 6 - 10-6 
PN93 1029 
9V 
+++ +++ +++ ++ 9 4 U 
PN94 336 +++ +++ +++ ++ + - 10-6 
PN94 653 
14 
+++ +++ +++ ++ + 1 U 
STP 110 +++ +++ +++ ++ + 1 U 
STP 133 
19F 
 
 
0.3% 
+++ +++ +++ ++ + - 10-6 
PN94 661 +++ ++ + - - - 10-2 
PN93 1029 
9V 
+++ ++ + - - - 10-2 
PN94 336 +++ +++ +* - - - 10-3 
PN94 653 
14 
+++ +++ ++* - - - 10-3 
STP 110 +++ +++ +* - - - 10-3 
STP 133 
19F 
 
 
0.35% 
+++ +++ ++* - - - 10-3 
PN94 661 ++ - - - - - 10-1 
PN93 1029 
9V 
++ - - - - - 10-1 
PN94 336 +++ ++ + - - - 10-2 
PN94 653 
14 
+++ ++ - - - - 10-2 
STP 110 +++ ++ ++ - - - 10-2 
STP 133 
19F 
 
 
0.4% 
+++ ++ ++ - - - 10-2 
 
Table II.3B: Isolates from clones Spain9V-3, England14-9 and Taiwan19F-14. 
Sensitivity results to different concentrations of EMS.  +++ confluent growth; ++ 
>100 colonies; + 20 – 100 colonies; - no growth; dilution 1st effected refers to the 1st 
dilution at which colony growth is visibly effected in size/number compared to 
untreated control; U – unaffected by EMS; N – no growth; * - colony size/colony 
growth severely affected and very faint but still present. 
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MMS 
 
Table II.3C: Isolates from clones Spain9V-3, England14-9 and Taiwan19F-14. 
Sensitivity results to different concentrations of MMS.  +++ confluent growth; ++ 
>100 colonies; + 20 – 100 colonies; - no growth; dilution 1st effected refers to the 1st 
dilution at which colony growth is visibly effected in size/number compared to 
untreated control; U – unaffected by MMS; N – no growth; * - colony size/colony 
growth severely affected and very faint but still present. 
 
 
Isolate Clone MMS 
conc. 
10-1 10-2 10-3 10-4 10-5 10-6 Dilution  
1st 
effected 
PN94 661 +++ +++ +++ ++ + - 10-5 
PN93 1029 
9V 
+++ +++ +++ ++ + 1* 10-6 
PN94 336 +++ +++ +++ ++ + 2 U 
PN94 653 
14 
+++ +++ +++ ++ + 1 U 
STP 110 +++ +++ +++ ++ + 1 U 
STP 133 
19F 
 
 
0.01% 
+++ +++ +++ ++ + - 10-6 
PN94 661 +++ ++ + - - - 10-2 
PN93 1029 
9V 
+++ ++ + - - - 10-2 
PN94 336 +++ +++ +++ ++ + 1* 10-6 
PN94 653 
14 
+++ +++ +++ ++ + - 10-6 
STP 110 +++ +++ +++ ++ + - 10-6 
STP 133 
19F 
 
 
0.02% 
+++ +++ +++ ++ 4 2 10-5 
PN94 661 - - - - - - N 
PN93 1029 
9V 
+ 11 - - - - 10-1 
PN94 336 +++ +++ ++* 5 - - 10-3 
PN94 653 
14 
+++ +++ +++ ++* - - 10-4 
STP 110 +++ ++ 10 2 - - 10-2 
STP 133 
19F 
 
 
0.03% 
+++ ++ 9 3 - - 10-2 
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Appendix II.4 Mutation frequency results post NQO exposure 
 
 
 
 
CPWT 
Control 
Viable count 
 
CPWT 
Control 
Mutation 
frequency 
CPWT 
Control 
Mutants/ml 
CPWT 
Viable count 
Post NQO 
 
CPWT 
Mutation 
frequency 
Post NQO 
CPWT 
Mutants/ml 
Post NQO 
 
1 5.23 x 1008 
 
3.97 x 10-07 198.3 4.37 x 1008 5.11 x 10-07 223.3 
2 4.53 x 1008 
 
2.39 x 10-07 108.3 5.23 x 1008 3.31 x 10-07 173.3 
3 8.70 x 1008 
 
2.32 x 10-07 201.6 8.836 x 1008 3.7.4 x 10-07 275 
4 
 
8.80 x 1008 2.37 x 10-07 208.5 6.40 x 1008 5.86 x 10-07 375 
5 5.50 x 1008 
 
4.24 x 10-07 233.3 3.90 x 1008 3.76 x 10-07 146.6 
 CPM 
Control 
Viable count 
 
CPM 
Control 
Mutation 
frequency 
CPM 
Control 
Mutants/ml 
CPM 
Viable count 
Post NQO 
 
CPM 
Mutation 
frequency 
Post NQO 
CPM 
Mutants/ml 
Post NQO 
 
1 9.47 x 1008 
 
9.51 x 10-08 90 5.87 x 1008 1.42 x 10-08 8.3 
2 7.53 x 1008 
 
7.74 x 10-08 58.3 3.50 x 1008 9.52 x 10-08 33.3 
3 5.30 x 1008 
 
8.18 x 10-08 43.3 6.03 x 1008 4.70 x 10-08 28.3 
4 6.53 x 1008 
 
1.15 x 10-07 75 5.30 x 1008 5.35 x 10-08 28.3 
5 7.00 x 1008 
 
8.10 x 10-08 56.6 4.13 x 1008 3.63 x 10-08 15 
Table II.4: Viable counts, mutants/ml and mutation frequency results for 
CP1015:dinB and CP1015:dinBΔ.  
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